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Abstract 
 
The current treatment of nasopharyngeal carcinoma (NPC), a tumour common in southern 
Chinese people, is dependent on chemo/radiosensitivity. Patients with early stages of the 
disease are usually chemo and radiosensitive with 5 years survival rates of 90% whereas, 
patients with late-stages of the disease or relapse have between 20-70% survival rates. 
These statistics indicate a need for a treatment to improve the overall survival rates in NPC 
patients, especially for those with relapse. Immunotherapy is a prime candidate for such 
treatment due to its association with Epstein-Barr Virus (EBV) infection, expression of 
EBV antigens in NPC tumour cells and the presence of EBV-specific T cells at the tumour 
site. More importantly, studies in other EBV-associated diseases strongly indicated that 
CD8+ T cell based immunotherapy targeting EBV antigens could control EBV infection 
and also tumour regression in some patients, however, most patients show poor tumour 
response rate due to ineffective maintenance of EBV-specific CD8+ T cells. Studies have 
also shown that CD4+ T cells are important in the control of viral infection by maintaining 
an effective CD8+ T cell response and as effectors in its own right. CD4+ T cell responses 
to EBV antigens have only been studied in the Caucasian population and not in Chinese 
people where NPC incidence is high. This thesis work was prompted with these points in 
mind. In this thesis, the screening in 25 Caucasian donors (24 donors are EBV-seropositive 
and 1 donor was EBV-seronegative at the time of this study) for T cell responses (CD8+ 
and CD4+) against the predicted BART products and BARF1 protein. The BART and 
BARF1 transcripts are expressed in NPC tumour cells, but their expression as proteins have 
never been identified until Kienzle et al (1998) reported the finding of CD8+ T cell 
response to one of the products encoded by the BART transcript, BARF0. In this study, no 
CD8+ or CD4+ T cell responses were detected against the BART products or to BARF1 
protein, and concluded that if responses do exist, they are probably rare responses and 
would have little or no immunotherapeutic value. The attention of this thesis work was then 
shifted to studying an EBV protein that is uniformly identified in NPC tumour cells, 
Epstein-Barr virus nuclear antigen (EBNA) 1. CD4+ T cell response against EBNA1 has 
been studied in the Caucasian population, however, little is known about CD4+ T cell 
xix 
epitopes presented by HLA alleles in Chinese people. In this study, CD4+ T cell responses 
in 78 healthy Chinese EBV carriers were analyzed and found marked focusing of epitopes 
in the EBNA1 C-terminal region, including a DP5-restricted epitope recognized by almost 
half of the donors tested. More importantly, EBNA1-specific CD4+ T cell clones to this 
DP5-restricted epitope could recognize EBNA1-expressing, DP5-positive target cells. 
However, further studies are required to determine the role of these EBNA1-specific CD4+ 
T cells in T cell based therapy. 
xx 
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Introduction 
 
 
 
 
 
 
 
 
 
 
 
 
Section 1.1 
Viruses linked to human cancers 
1 
1.1: Viruses linked to human cancers 
 
In the last 40 years, considerable evidence has linked several infectious agents, especially 
viruses, to human cancers, (Parkin, 2002). Table 1.1 summarises the key associations 
between viruses and human cancer and the global incidence of virus-associated tumours, 
estimated to be >12% of total cancer burden worldwide. Summarised briefly, the overall 
picture is as follows: evidence for a causal association is strongest where viral genetic 
information is not only consistently retained in every cell of an individual tumour, but is 
also being expressed as viral proteins. There are four examples of this type.   
 
Certain types of the human papilloma virus (HPV), especially HPV types 16 and 18, are 
associated with cervical cancer, a disease which accounts for around 5% of global cancer 
burden (Parkin, 2006).  In every tumour specimen, HPV DNA fragments can be detected 
integrated into the host genome with the E6 and E7 genes still intact. Furthermore, 
expression of viral proteins E6 and E7 is consistently found in tumour cells (Pagano et al, 
2004).  The relevant HPV types are sexually transmitted and widespread in human 
populations. The incidence of cervical cancer differs between developing (7.7%) and 
developed countries (1.7%), this lower incidence in developed countries being largely due 
to the introduction of screening programmes.  
 
As will be discussed later in detail, Epstein - Barr virus (EBV), a gamma herpesvirus, is 
associated with several human malignancies, together constituting around 1% of global 
cancer burden (Parkin, 2006). EBV infection is very common worldwide, with >95% of the 
world population are EBV-carriers. While the incidence of one EBV-associated tumour, 
Hodgkin Lymphoma (HL), a malignancy of Hodgkin/Reed Sternberg cells (HRS), is 
similar in all parts of the world, but this is not true of other tumours. For example, Burkitt 
lymphoma (BL), a type of B cell lymphoma, has a very high incidence rate in many parts of 
equatorial Africa and in New Guinea where malarial infection is holoendemic, compared 
with BL incidence worldwide. Therefore in some way malarial infection, combined with 
EBV, is thought to contribute to tumour development (Pagano et al, 2004). Another  
Table 1.1: Viruses linked to human cancer 
This table was adapted from Cancer Research UK (2006) CancerStats – Infectious Agents and Cancer 
(info.cancerresearchuk.org/ cancerstats)
3 
example, nasopharyngeal carcinoma (NPC), an epithelial cancer, is relatively rare on a 
world scale (0.7% of all cancers per year), but has moderately high incidence in certain 
North African countries and in Inuit people. More importantly, the tumour is common in 
South East Asia, and exceptionally common in Southern Chinese people. This observed 
geographical isolation of NPC incidences possibly indicates potential genetic susceptibility 
or environmental factors which may play a part in promoting tumour development. In all 
cases of EBV – positive malignancies, EBV episomal DNA and the expression of EBV 
latent proteins could be detected in the tumour cells, with different EBV - associated 
tumours expressing different patterns of viral latent cycle proteins. 
 
The Kaposi Sarcoma Herpes Virus (KSHV) is associated with several human malignancies, 
together accounting for <1% of global cancer burden (Parkin, 2006). The best known 
association is with a tumour of endothelial cell origin, Kaposi Sarcoma (KS). There are four 
major forms of this tumour: (1) classic form of KS is mainly seen in elderly men of 
Mediterranean and Eastern European descent, possibly indicating genetic susceptibility but 
also reflecting the fact that KSHV incidence is higher in such populations than in Northern 
Europe. (2) Endemic KS, an aggressive from of KS, prevalent in certain parts of Africa 
before the HIV epidemic. (3) KS is relatively common among acquired immunodeficiency 
syndrome (AIDS) patients and is considered an AIDS-defining condition in human 
immunodeficiency virus (HIV)-positive carriers. A high incidence of KS is observed in 
Africa, where KSHV infection is common and where the epidemic of human 
immunodeficiency virus (HIV)/AIDS is severe. (4) KS occurs in rare organ transplant 
patients who are naturally KSHV-infected and receiving immunosuppressive therapy. 
KSHV viral DNA and KSHV encoded proteins could be detected in >95% of all KS lesions 
(Pagano et al, 2004).  
 
Primary effusion lymphoma (PEL) is a very rare B cell tumour, typically seen in heavily 
immunocompromised HIV-infected individuals, particularly among homosexual cohorts in 
which KSHV has become endemic. This may reflect that sexual behaviour plays a part in 
the development of the disease. To date, all cases of PEL analysed are positive for KSHV 
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DNA. Multicentric Castleman’s disease (MCD), another B cell proliferative condition, is 
observed in both AIDS and non-AIDS associated cases. In most, if not all, AIDS-associated 
MCD cases KSHV DNA could be detected in the tumour cells, while only approximately 
50% of non-AIDS associated cases have detectable KSHV DNA.  
 
 The Human T Lymphotropic Virus type 1 (HTLV 1), the first human retrovirus to be 
discovered, is associated with Adult T-cell Leukaemia (ATL). ATL is a rare cancer, in 
global scales, accounting for 0.03% of the global cancer burden. However, ATL is seen at 
higher frequency in southern Japan where HTLV1 infection is relatively common and 
where in 3-5% of infected individuals would develop ATL over their life-time. 
Transmission of the virus from one individual to another is via HTLV1-infected T cells and 
not ‘free’ virus, thus HTLV1 has low levels of transmission to contacts but can be passed 
from mother to child in breast milk. In every case of ATL, proviral HTLV1 DNA can be 
detected integrated into the host genome. However, integration sites differ between ATL 
patients, and it is thought that the HTLV1-encoded Tax protein plays a role in 
lymphomagenesis. 
 
In contrast to the above examples where viral gene expression in tumour cells is thought to 
actively contribute to the malignant process, the association between hepatitis viruses and 
hepatocellular carcinoma (HCC) is thought to be indirect. HCC is among the most common 
cancer in the world, with 42.5% of cases in developed countries and 92% in developing 
countries associated with hepatitis B or C virus (HBV or HCV) infection respectively. On a 
global scale, HBV infection is the major factor in the development of HCC, with the 
prevalence of HBV and incidence of HCC following the same geographical pattern of 
distribution. Prospective studies have shown that HBV carriers have 10-100 fold increased 
risk of HCC, while parallel studies with HCV are still on-going. In HBV-associated HCC, 
the HBV DNA is consistently integrated into the host genome. However the position of 
integration into the cellular genome shows no consistent pattern, no particular fragment of 
viral DNA is consistently retained and no particular viral antigens are consistently 
expressed. HBV, a DNA virus, and HCV, an RNA virus, naturally infects and replicate in 
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hepatocytes. This could activate virus-specific and non-specific cellular responses in the 
host which may contribute to liver injury and hence to chronic stimulation of liver 
regeneration. The continual cell turnover that results puts the regenerating population at 
risk of oncogenic change. In the case of HBV, integration of viral DNA adds a second 
contributory factor, since integration is potentially mutagenic and the resultant genomic 
instability could facilitate the oncogenic process. 
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1.2: Immune strategies targeting virus-associated malignancies 
 
1.2.1: Prophylactic vaccines 
Considering the impact of these virally-associated tumours on the global cancer burden, it 
is important to look at immune strategies to reduce that burden. Ideally, prophylactic 
vaccination, using a vaccine that protects the naïve healthy host against initial viral 
infection, would be the most direct way to achieve this. As an example, prophylactic 
vaccines have been developed to protect against primary HPV infection, a bivalent vaccine 
targeting HPV types 16 and 18 and a quadrivalent vaccine targeting HPV types 6, 11, 16, 
18.  They act by inducing a neutralising antibody response against the major capsid protein, 
L1, in the vaccinated individuals (Garcia and Saslow, 2007). Ongoing clinical trials 
demonstrate nearly 100% protection from persistent infection (Koutsky et al, 2002). 
Currently studies are underway to vaccinate large numbers of naïve healthy young girls 
against HPV infection. Possibly within 20 years time, a decline in HPV transmission would 
begin to be reflected in a falling incidence of new HPV-associated tumours. This would 
constitute formal proof of a causal association between viral infection and tumourgenesis. 
 
As a second example, the HBV vaccine was developed around 20 years ago, using the viral 
surface antigen, HbS, to induce a neutralizing antibody response. For example, Galimska 
(2000) reports the effectiveness of the HBV vaccination programme in Poland. The 
vaccination programme started in 1993, where all newborns and people at high risk to HBV 
infection were vaccinated, these included, medical workers, medical students, people with 
HBV-infected partners, people with chronic liver disease and patients undergoing surgery. 
In total, around 3.7 million people or 10% of  Poland’s population where vaccinated 
between 1993 to1997. In the early 1990s, prior to HBV vaccination, HBV incidence in 
Poland was around 40 per 100,000 (or 13,296 cases of recorded HBV infected individuals a 
year), whereas in 1997, HBV incidence in Poland was around 12.7 per 100,000 (or 4896 
cases/year). In a period of four years, a considerable decline in HBV incidence was noted. 
This shows that the HBV vaccine is effective at providing HBV naïve individuals 
protection against HBV infection (Galimska, 2000). In a separate study in Taiwan, Chien et 
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al (2006) reports a 10 year study of the HBV vaccine which started in July 1984. Between 
July 1984-June 1986, all newborns born to high risk HBV-positive mothers where 
vaccinated with the HBV vaccine and Hepatitis B immunoglobulin (HBIG). The 
programme was further extended in 1987 to include the vaccination of preschool children 
(who have not yet received the vaccination during birth) and to susceptible medical 
personnel. From 1988 to 1990, the vaccination programme was extended even further to 
include elementary school children. Prior to the vaccination programme, >90% of the 
general population <40 years of age were infected with HBV, with 15-20% of cases are 
chronic HBV infection. Several seroepidemiological studies were carried out as a ‘follow-
up’ of the vaccination trial. Prior to the vaccine trial, the prevalence of Hepatitis B surface 
antigen (HBsAg) detected in children under the age of 5 in 1984 was 9.3% which dropped 
to 2% in 1989. This study demonstrated an effective protection (78%) in majority of HBV-
negative children. Subsequent studies in 1992 and 1994 showed effective protection in 
HBV-negative young children reaching 85% and 87% respectively. In addition to HBV 
transmission, the incidence of HCC in children has also dropped significantly. The 
incidence of HCC in children between the ages of 6-14 was 0.7 per 100,000 between the 
years 1981-1986, and between 1986-1990 was 0.57 per 100,000 and 1990-1994 was 0.36 
per 100,000. Thus the vaccination programme clearly demonstrates the potential efficacy of 
prophylactic vaccination as a strategy to reduce cancer incidence. It also served to directly 
link HBV infection in the causation of HCC. 
 
Prophylactic vaccines for the other virally-associated cancers have yet not been developed 
despite extensive research. This reflects the fact that different agents have different 
biologies and generating truly sterile immunity is easier in some systems than in others. 
 
1.2.2: Therapeutic vaccines 
Facing with the current situation, with viruses for which no prophylactic vaccines is 
available, an alternative approach would be a therapeutic vaccine, given to patients with the 
tumour and aiming to boost the host cellular immune response against viral antigens that 
are expressed in the tumour. Therapeutic vaccines are still at an early stage of development 
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and aim to exploit the specificity and power of the CD8+ and CD4+ T cell responses that 
normally act to control infections against intracellular pathogens such as viruses. CD8+ T 
cells are important because they recognize endogenously expressed antigens in the context 
of Human Leukocyte Antigen (HLA) class I molecules (HLA I). Such T cells are known to 
have cytotoxic functions and so, if specific for viral antigens expressed in tumours, should 
in theory recognize and kill HLA class I-positive tumour cells. CD4+ T cells, on the other 
hand, usually recognize exogenously acquired antigens in the context of HLA II molecules. 
These T cells are known to produce cytokines which ‘help’ sustain CD8+ T cell responses. 
However recent studies suggest that, in some cases, CD4+ T cells can also recognize 
endogenously expressed antigens in HLA II-positive target cells, although the mechanism 
underlying this phenomenon is still under investigation.  
 
The present thesis was undertaken with these general points in mind. The specific virus to 
be studied is Epstein-Barr virus, and the work was prompted by the possibility of 
developing a therapeutic vaccine against one particular EBV-associated tumour, 
nasopharyngeal carcinoma. Although the cellular response to EBV infection has been 
studied, information has largely come from work in Caucasian individuals and not on 
Chinese populations which are at highest risk of this tumour. The next section of the thesis 
reviews current understanding of how antigens are presented to T cells and the role of 
human leukocyte antigen (HLA) complex in that process. This is central to the theme of the 
thesis work since differences in HLA polymorphism between Caucasians and Chinese 
populations will influence T cell responsiveness.  
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1.3.0: Antigen processing and presentation to T cells 
The adaptive immunity is elicited when antigen-specific cells are activated upon antigen 
recognition. Activation of T cells occur via the T cell receptor (TCR) recognition of 
antigenic peptide presented by HLA molecules that are displayed on the surface of infected 
cells or antigen presenting cells (APC). APC are specialised cells which processes antigens 
and display them through HLA class I or II molecules to T cells.  
 
1.3.1: Antigen Presenting Cells (APC) 
This section reviews the importance of profession APCs in the role of generating an 
effective adaptive immunity against pathogens. Much of the understanding in the role of 
APC came from study of dendritic cells (DCs). DCs play an important role in bridging the 
innate and adaptive immunity. The activation of adaptive immunity is initiated during 
innate response. This is achieved by the recognition of pathogen-associated molecular 
patterns (PAMPs) that signals through pattern recognition receptors, the toll-like receptors 
(TLR). TLR is a family of receptors that are expressed at the surface and within the 
cytoplasm and endosomal membranes of DCs (Hochrein and O’Keeffe, 2008). There are 
currently 13 mammalian TLRs identified and these receptors are capable of recognising 
distinct bacterial, fungal and viral patterns. For example, TLR3 (double stranded RNA), 7 
(single stranded RNA), 8 (single stranded RNA) and 9 (CpG DNA) recognises genomic 
patterns (Diebold et al, 2004; Heil et al, 2004; Lund et al, 2004; Tabeta et al, 2004; 
Ahmad-Nejal et al, 2002). TLR2 (human cytomegalovirus glycoproteins gH and gB) and 
TLR4 (fusion protein of respiratory syncytial virus) recognises envelope proteins. In terms 
of innate immunity, TLR recognition of pathogen components leads to MyD88 – NFkB 
signalling and ultimately leading to inflammatory response (Doherty and Arditi, 2004). In 
addition, in the context of adaptive immunity, MyD88 signalling also upregulate the 
expression of CD80 and CD86 molecules which ‘flags’ HLA-pathogen complexes on the 
cell surface. T cells that interact with the HLA-pathogen complex, and express surface 
molecules CD28 or CTLA-4, would get the appropriate costimulatory signal for the 
activation of adaptive immunity.  
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In addition to recognition of pathogen components by the TLRs and the activation of 
adaptive immunity, APCs are also capable of processing antigens to be presented to CD8+ 
and CD4+ T cells of the adaptive immune system through HLA I and HLA II molecules 
respectively. These sections would be discussed separately. 
 
1.3.2: Presentation of endogenously expressed antigens to CD8+ T cells 
Every protein is subjected to continuous turnover and is degraded, at rates reflected by the 
half-life of the protein. In addition, recently synthesised proteins that are misfolded or 
abnormal (defective ribosomal products (DRiPs) are rapidly degraded. DRiPs account for 
30% of all synthesised proteins in the cell (Princiotta et al, 2003). Proteins that are targeted 
for degradation are tagged with a small protein called ubiquitin (Ciechanover, 2006). 
Ubiquitinated proteins are then targeted by a multifunctional protease complex called 
proteasome which cleaves peptide bonds, in an ATP-dependent manner, generating peptide 
fragments. Two forms of proteosomes exist; (1) constitutive proteosomes are expressed in 
healthy cells, and (2) ‘immunoproteosomes’ are expressed by interferon gamma (INF-γ) or 
tumour necrosis factor alpha (TNF-α) stimulated cells and in primary and secondary 
lymphoid organs. In immunproteosomes, the active proteosome subunits are replaced by 
‘immuno’ subunits (Lmp2, Lmp7 and MECL-1) to form immunoproteosomes (Duan et al, 
2006). These immunoproteosomes are speculated to be more effective in generating HLA I 
antigenic peptides, however, certain HLA I antigenic peptides could only be generated by 
the constitutive proteasome (Duan et al, 2006).  
 
In the endoplasmic reticulum (ER), newly synthesised HLA I α-chain is associated with a 
membrane bound chaperone protein, calnexin, which facilitates the correct folding of the 
molecule. ERp57, a thiol oxidoreductase was found to be associated with calnexin and 
calreticulin which was demonstrated to form disulphide bonds in protein folding (Zhang 
and Williams, 2006). β2-microglobulin (β2-m), calreticulin and tapasin then displaces 
calnexin forming a calreticulin-tapasin-HLA I complex. This complex, when the peptide-
binding cleft is unoccupied, is unstable and is retained in the ER. Antigenic peptide is 
acquired through association of the protein complex and with transporters associated with 
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antigen processing (TAP). TAP is a heterodimer consisting of two proteins, TAP1 and 
TAP2, which has a high affinity to transport peptide fragments that are typically 8-10 
amino acids in length into the ER (Romisch, 1994). Association of the protein complex 
with TAP would bring the HLA I molecule in close proximity to receiving transported 
antigenic peptides. Upon high affinity binding of antigenic peptide, the HLA class I 
molecule become stable and dissociates from the complex. The HLA I/antigenic peptide 
loaded complex is then transported to the cell surface membrane for presentation via the 
Golgi. 
 
1.3.3: Presentation of exogenously acquired antigens to CD8+ T cells 
Traditionally it was believed that antigens presented to CD8+ T cells are entirely derived 
from endogenously expressed proteins. However, while this remains essentially true for 
most cell types, it has been shown in DCs, macrophages, B lymphocytes, neutrophils and 
endothelial cells that they could acquire and present exogenously derived antigens to CD8+ 
T cells (Basta and Alatery, 2007). This process is termed ‘cross-priming’. Exactly how 
“cross-priming” is achieved remains hotly debated. It has been suggested that exogenously 
derived antigens are acquired by DCs, either by phagocytosis or macropinocytosis of 
apoptotic vesicles generated from dying infected or tumour cells (Rock and Shen, 2005; 
Winau et al., 2004; Chen et al., 2004), and then processed for HLA I molecule 
presentation. Donohue et al (2006) demonstrated that antigens of the cross-priming 
pathway are a separate pool of antigens from the direct-priming pathway. This is because 
antigens that are processed in the classical pathway are mainly derived from DRiP. DRiPs 
are ‘short-lived’ proteins that could only be visualised by inhibiting their rapid degradation 
shortly after their synthesis. Whereas, antigens that are processed by cross-priming do not 
require on-going synthesis to prime naïve CD8+ T cell responses. Possibly these proteins 
are more stable or they are stabilised by heat shock proteins (HSP), since inhibitors to 
HSP90 (geldanamycin and herbimycin A) would inhibit cross-priming in vitro (Basta et al, 
2005). There are several proposed pathways, based on evidence using inhibitors of 
processing machineries, which may suggest the possible routes in which exogenously 
acquired proteins could be processed and presented to CD8+ T cells. 
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One such pathway is TAP and proteasome-independent (Storni and Bachmann, 2004; 
Kurotaki et al, 2007). This involves processing of internalised antigens through the 
endocytic pathway using the same mechanism as generating peptides for the HLA class II 
molecules and also endosomal proteases, cathepsin (Kurotaki et al, 2007). This is supported 
by the evidence that TAP-defective cell line, RMA-S, are capable of presenting HLA-I 
restricted epitopes to CD8+ T cells possibly through association with heat shock protein 
(Schirmbeck and Reimann, 1994). In another study, Schirmbeck et al (1995) demonstrated 
that lysosomal inhibitors (chloroquine, NH4Cl, primaquine, or leupeptin) would block 
TAP-defective T2 cell lines from presenting HLA I-restricted antigens to CD8+ T cells, 
whereas, proteosomal inhibitors (cycloheximide or brefeldin A) did not. Loading of 
peptides generated by lysosomal enzymes possibly takes place in the late endosomal 
compartments involving recycling HLA I molecules (Hochman et al., 1991; Gromme et al., 
1999; Kurotaki et al, 2007). However, other studies have shown that newly synthesised 
MHC class I molecule may also be directly involved where the late endosomal 
compartment may have fused with the rough endoplasmic reticulum (RER), since RER 
derived membrane could be found in the endosomal membrane. In addition, RER derived 
enzymes could also be found in the endosomal compartment (De Bruijn et al., 1995; 
Gagnon et al, 2002). 
 
Another suggested pathway, the TAP and proteosome-dependent pathway, was proposed 
that internalised antigens are transported into the cytoplasm where they are processed by 
the proteasome and then transported by TAP into the ER for HLA I presentation (Burgdorf 
and Kurts, 2008).  The evidence came from study by Isenman and Dice (1993) where they 
demonstrated that radiolabelled peptide fragments internalised into the lysosome can make 
their way into the cytosol. In another experiment,  Norbury et al (1995) showed that 
exogenous derived proteins may also possibly gain access into the cytosol where it is 
processed by the proteasome, since, proteosomal inhibitors (Brefeldin A and gelonin) 
would inhibit HLA-I presentation of internalised proteins. The mechanism involving the 
transfer of exogenously acquire proteins from the endocytic compartments to the cytoplasm 
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is not fully understood. Reis e Sousa and Germain (1995) argues that exogenous proteins 
possibly escape into the cytoplasm as a result of phagocytic overload leading to loss of 
phagosome membrane integrity, since increasing concentration of exogenous protein would 
lead to leaking of the protein into the cytosol. However, Norbury et al (1995) and Isenman 
and Dice (1993) showed that the lysosomal membrane integrity is still intact.  
 
These experiments clearly show that there may be more than one possible route in which 
cross-priming can occur. Possibly some proteins are processed by the TAP-independent 
pathway, whereas, other proteins are processed by the TAP-dependent pathway. More 
importantly, these experiments strong support the presence of an alternative pathway in 
which antigens that escape the classical pathway are still processed and presented to CD8+ 
T cells. 
 
1.3.4 MHC class II presentation of exogenous antigen 
Peptides that are displayed through the HLA II molecule generally are derived from 
proteins acquired exogenously by APCs either through phagocytosis, endocytosis or 
micropinocytosis (Pillay et al, 2002). Each organelle of the endocytic pathway plays an 
important role in the processing of internalised substances. The first organelle, the early 
endosome, is the sorting station. This compartment has a slightly acidic environment, with 
a pH range of 6.3-6.5, which facilitates the dissociation of antigens that may be bound to 
receptors. The receptors are then recycled, whereas, the antigens are transported by 
endosome carrier vesicles to the late endosome (Killisch et al, 1992) or the early endosome 
may directly fuse with the late endosome (Jahraus et al, 1998). The late endosome is the 
main site of proteolysis (Tjelle et al, 1996). This organelle contains approximately 20% of 
the hydrolase pool which operate under acidic pH (pH 5.0-5.5). At this stage, most 
antigenic proteins are digested into peptide fragments which may have two possible fates. 
Antigen-derived peptides may be transported to the HLA II containing compartment (HIIC) 
where it is then loaded onto the HLA II molecule and exported to the plasma membrane for 
presentation to CD4+ T cells. Alternatively, the late endosome may fuse with the lysosomal 
compartment where the antigen is further digested into smaller fragments (Rocha and 
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Neefjes, 2008). Enzymes in the lysosomal compartment are activated in acidic pH between 
4.5-5.0. The lysosomal compartment, which contains the majority of the hydrolase pool, 
only accounts for 20% of the total proteolysis that takes place inside a cell. It has been 
suggested that the lysosomal compartment may serve to be a storage compartment for 
hydrolases, that can be called upon when needed, such as during phagocytosis when large 
amounts of foreign substances are engulfed by the cell (Tjelle et al, 1996). Finally, antigen-
derived peptide fragments are then transported to the HIIC for loading onto HLA II 
molecules for presentation.  
 
Newly synthesised HLA class II αβ dimers are associated with a protein called invariant (Ii) 
chain in the ER (Brown et al, 1993). Ii has three major functions; (1) the folding of the α 
and β chains (Bikoff et al, 1993; Viville et al, 199), (2) the Class II-associated invariant 
chain peptide (CLIP) of Ii blocks the HLA class II peptide-binding cleft preventing 
inappropriate loading with peptides in the ER (Roche and Cresswell, 990), (3) the re-
direction of the HLA class II molecules from the trans-golgi network (TGN) into the 
endosomal/lysosomal pathway for peptide loading, specifically to the HIIC (Bakke and 
Dobberstein, 1990; Roche et al, 1993).  
 
The HIIC is the primary site where the HLA II molecule is loaded with antigenic peptide. 
The exact definition of an HIIC compartment is debatable, but several essential components 
are required for the loading of the HLA II molecule. The HIIC compartment is a late 
endosome-like compartment (Rocha and Neefjes, 2008) which has the feature of an acidic 
pH (Ziegler and Unanue, 1982) containing key enzymes cathepsin S and L, and a non-
classical class II molecule HLA-DM (Honey and Rudensky, 2003). Within the HIIC 
compartment, Ii is broken down by cathepsin S and L leaving the CLIP section still intact 
and bound to the peptide-binding cleft of the HLA class II molecule. Inhibition of cathepsin 
S and L would subsequently prevent HLA II peptide loading (Riese and Chapman, 2000) 
and cell surface expression (Neefjes and Ploegh, 1992). Replacement of the CLIP by 
processed antigen-peptide requires a low acid pH and is regulated by a non-classical class II 
molecules, HLA-DM. HLA-DM is a dedicated chaperone (the only known function is its 
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interaction with HLA II molecules) which stabilises the HLA II molecule that is devoid of 
peptide, preventing aggregation and support peptide exchange until a high affinity peptide 
is bound (Sloan et al, 1995; Densin et al, 1996).  
 
Peptide loading of HLA II molecules has also been observed in other compartments of the 
endocytic pathway, and including, the plasma membrane (Moss et al, 2007) which has a 
neutral pH, absence of cathepsin S and L, and absence of antigen preparation. This can 
occur when the HLA-DM along with the HLA II molecule is transported to the plasma 
membrane via the HIIC compartment (Wubbolts et al, 1996), then loading of the HLA II 
molecule can occur in the plasma membrane. More importantly, the HLA-DM molecule 
contains a classical tyrosine-based internalisation motif which signals the internalisation of 
the HLA-DM molecule into the endocytic pathway. Therefore, loading of HLA II 
molecules therefore could take place in every endocytic compartment. 
 
1.3.5 MHC class II presentation of endogenously expressed antigen 
As described above, HLA class II molecules predominantly present peptides derived from 
uptake of exogenous antigens. However, analysis of natural ligands eluted from the HLA 
class II molecule revealed a relatively large proportion of these ligands are of the 
cytoplasm, nucleus and mitochondrial origin (Rammensee et al., 1999; Zhou and Blum, 
2004). This indicated that endogenously synthesised proteins are be processed and 
presented to CD4+ T cells. More importantly, the absence of these endogenously 
synthesised antigens within the endocytic pathway (Trombetta and Mellman, 2005) 
suggested the mechanism for the processing of endogenously expressed antigens do not 
involve the endocytic pathway, but possibly through some form of intracellular sorting, a 
phenomenon call autophagy.  
 
Autophagy is a process where cellular components are transported to the lysosome for 
degradation. In most cells, autophagy occurs at a low baseline rate and this is increased in 
response to nutrient starvation (Strawbridge and Blum, 2007). There are three types of 
autophagy, microautophagy, macroautophagy and chaperone-mediated autophagy. 
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Research in microautophagy is still in its early stages. Microscopy studies in yeast system 
have shown that during cell starvation the cytosol and organelles are directly internalised 
by invagination of the lysosomal membrane (Roberts et al, 2003). More importantly, 
inhibition of Tor with rapamycin would enhance microautophagy, possibly indicating a 
similar pathway is used in the control of microautophagy to that of macroautophagy. 
 
The understanding in the mechanism of macroautophagy is more defined. Macroautophagy 
is a process whereby the cytosol and organelles are engulfed by a membrane of unknown 
origin into a specialised compartment called the autophagosome (Yorimitsu and Klionsky, 
2005). Autophagosome formation is enhanced during periods of starvation. Studies in yeast 
models indicated, when cells have excess nutrient, phosphatidylinositol 3-kinase (PI3K) is 
activated leading to downstream activation of Tor, and Tor phosphorylates Atg13 resulting 
in the dissociation from Atg1 and inhibition of macroautophagy. Inhibitors of PI3K, such as 
Wortmannin and 3-methyladenine (3-MA) would result in decreased HLA class II 
presentation of endogenously expressed bacterial cytoplasmic antigen (Nimmerjahn et al, 
2003). Alternatively, inhibition of Tor with rapamycin or its analogue CCI-779 would 
enhance macroautophagy (Klionsky, 2005). These autophagosomes contain one or more 
intravesicular membranes which, when fused with the lysosomes and early endosomes 
(Berg et al., 1998), would render its contents susceptible to breakdown and processing in 
the MHC class II pathway. Paludan et al (2005) demonstrated that by inhibiting 
acidification of the lysosome would lead to build up of whole unprocessed endogenously 
expressed viral proteins in the lysosome, suggesting proteolysis of endogenously expressed 
antigens takes place in the lysosome and not in the cytoplasm before HLA class II molecule 
loading. 
 
Chaperone-mediated autophagy (CMA) is a selective process of antigen transfer from the 
cytoplasm to the lysosome by specialised proteins, heat shock cognate protein (HSC) and 
HSP. It was noted by Dengjel et al (2005) that during the period of cell starvation there is 
an accumulation HSC-70, which is a key chaperone protein in CMA. HSC-70 transfers 
endogenously expressed proteins from the cytosol into the lysosome through interaction 
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with the lysosome-associated membrane transporter (LAMP)-2a, since overexpression of 
LAMP-2a or HSC-70 would lead to enhanced CMA (Zhou et al, 2005). Whereas, 
diminished expression of HSC-70 would result in reduced CMA induced CD4+ T cell 
response. In addition to HSC-70, Rajagopal et al (2006) demonstrated in mouse models that 
the inhibition of HSP-90 with geldanamycin would lead to a dose-dependent reduction in 
the presentation of endogenously expressed antigens by CMA. 
 
The phenomenon of autophagy remains true for many endogenously expressed antigens, 
however, Taylor and Rickinson (2007) demonstrated that not all endogenously expressed 
antigens enter the HLA class II processing pathway through autophagy. In their 
experiments using lymphoblastoid cell lines (LCL), a B cell line immortalised by EBV 
expressing GFP-tagged endogenously expressed antigens, reported to be susceptible to 
autophagy, could be inhibited by 3-MA. However, 3-MA was unable to inhibit presentation 
of some endogenously expressed viral antigens in these LCLs, since these LCLs were able 
to induce antigen-specific CD4+ T cell responses (Taylor and Rickinson, 2007). More 
importantly, they demonstrated the transfer of antigens from a ‘donor’ cell to a ‘recipient’ 
cell through a process similar to acquiring exogenous antigen (endocytic pathway). In this 
particular experiment, the donor cells are described as cells expressing the relevant antigens 
but do not have the relevant HLA II molecules to present these antigens to antigen-specific 
CD4+ T cells. The recipient cells, in this case B cells, do not express the relevant antigens 
but do have the relevant HLA II molecules to present antigens to antigen-specific CD4+ T 
cells. When the donor cells were cultured with the recipient cells, the recipient cells 
induced antigen-specific CD4+ T cell responses. Antigen transfer does not require direct 
donor-recipient cell contact, since culturing recipient cells in filtered (cell free) donor cell 
media could also induce antigen-specific CD4+ T cell responses.  
 
These experiments clearly show that endogenously expressed antigens could gain access to 
the HLA II processing pathway and be presented to CD4+ T cells. Some antigens gain 
access possibly through autophagy, while other endogenously expressed antigens are 
picked up and treated as exogenously acquired antigens. The central message from these 
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reviews is that both endogenously expressed and exogenously acquired antigens can gain 
access to the HLA I and II processing pathway and presented to CD8+ and CD4+ T cells.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Section 1.4 
Epstein-Barr Virus 
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1.4.0 History of Epstein – Barr Virus  
The study leading to the discovery of Epstein – Barr virus (EBV) was initiated in the 
1950’s where Denis Burkitt, an Irish surgeon working in Uganda, noted an unusual cancer 
of the jaw specifically affecting children (Burkitt, 1958). This cancer, now known as 
Burkitt’s lymphoma (BL), was substantially found to occur throughout equatorial Africa 
and its distribution mirrored very clearly to that of holoendemic malaria (Burkitt, 1962). 
These observations, originally leading to speculations, that a vector-borne agent may be 
responsible for the disease led ultimately to the discovery by electron microscopy of a 
herpesvirus-like particle in a BL-derived cell line (Epstein et al, 1964). This virus proved to 
be antigenically different to the then known human herpesviruses and was subsequently 
named as Epstein-Barr virus after the discoverers. 
 
Despite the geographic restriction over BL incidence, seroepidemiological studies, 
demonstrated that EBV infection is very common throughout all human populations with 
>90% adults seropositive (Henle et al, 1969). Clearly, therefore, its association with BL 
was complex since only very few infected individuals develop the tumour. Forty years on, 
although we understand many aspects of EBV biology, still the pathogenesis of EBV 
associated tumours, now including BL, Hodgkin’s Disease (HD), post-transplant 
lymphoproliferative disease (PTLD), acquired immunodeficiency syndrome-related central 
nervous system lymphomas (AIDS-CNSL) and nasopharyngeal carcinoma (NPC), remains 
unresolved.  
 
1.4.1 EBV infection in vitro: B cell entry 
The understanding of EBV infection in vitro came from studies of EBV interaction with its 
natural host, B cells. One of the most abundant viral glycoprotein expressed on the surface 
of the viral envelope is gp350/220, which is responsible for high affinity binding of the 
virus to B cell surface protein, the complement receptor type2 (CR2). The natural ligand of 
CR2 is the C3dg component of complement binding (Fingeroth et al, 1984; Fingeroth et al, 
1988). The gp350/220 CR2 binding site has a very similar amino acid sequence to that of 
C3dg CR2 binding site. Synthetic peptides correlating to the C3dg CR2 binding site would 
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inhibit gp350/220-CR2 binding (Nemerow et al, 1989). Studies using recombinant EBV 
virus lacking gp350/220 show reduced efficiency of these viruses to infect B cells, thus 
suggesting that gp350/220 is the dominant, but not the only route in which EBV could 
infect B cells (Janz et al, 2000). In addition, antibodies targeting gp350/220 and soluble 
forms of CR2 could neutralised virus infection of B cells (Moore et al, 1991; Tanner et al, 
1988).  
 
Complex formation of gp350/220 with CD21 would initiate receptor mediated endocytosis 
of the virus (Tanner et al, 1987) into a low pH compartment, but low pH is not required 
(Miller and Hutt-Fletcher, 1992). In addition, EBV requires glycoproteins gH, gL, gB and 
gp42 for efficient fusion and penetration (Backovic et al, 2007; McShane and Longnecker, 
2004). The exact role of these glycoproteins in fusion is unclear, but studies show that they 
are essential component in fusion of the viral envelope with the host membrane leading to 
penetration of the virus into the host. The glycoprotein gL serves as a chaperone for gH, 
and these two glycoproteins exist as a noncovalently bound complex. In studies with 
recombinant gH-null viruses, gL is not expressed, but more importantly the virus retains the 
ability to bind B cells but is unable to mediate B cell fusion (Molesworth et al, 2000). 
Likewise, recombinant viruses with gB deleted would also prevent B cell infection (Lee 
and Longnecker, 1997). 
 
Glycoprotein gp42 associates noncovalently with gHgL and has been shown to interact 
with HLA class II molecule which functions to mediate viral entry into B cellss.  
Monoclonal antibodies (MAbs) against gp42 or HLA II molecules would inhibit viral 
infection (Li et al, 1997).This finding was supported in a model using recombinant viruses 
with gp42 deleted are unable to infect B cells. Infection in B cells could be restored when a 
soluble gp42 is introduced that could re-associates with gHgL. However when a soluble 
truncated gp42 that could bind to HLA class II molecules but not re-associated with the 
gHgL complex was introduced, it demonstrated to still inhibit B lymphocytes infection. 
This finding suggests gp42 is vital to B lymphocytes infection and must associate with the 
gHgL complex (Wang et al, 1998).  
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1.4.2 EBV infection in vitro: Epithelial cell entry 
EBV infection of epithelial cells is more complicated than in B cells, since CR2 is 
expressed at low levels on some epithelial cells in culture. However, Fingeroth et al (1999) 
demonstrated using culture epithelial cells expressing low level cell surface CR2, EBV 
infection can occur. However, it is still uncertain whether epithelial cells express CR2 in 
vivo since monoclonal antibodies used in these studies cross-reacted with unrelated 
epithelial cell proteins (Young et al, 1989).  
 
In addition to the CR2 dependent mechanisms of infection by EBV, three CR2-independent 
mechanisms have been proposed. The first mechanism came from evidence that the EBV 
virus when coated with gp350/220-specific IgA antibody would bind to the IgA receptor 
(Sixbey and Yao, 1992). It is suggested that the route of infection might be related to the 
IgA receptor, since cells expressing IgA receptor are more susceptible to EBV infection 
induced by EBV-specific IgA. The second mechanism came from the observation that EBV 
derived from B cells expressing gHgL complex can bind to epithelial cells while gH-null 
recombinant viruses loose this ability (Molesworth et al, 2000). In addition, monoclonal 
antibodies against gH is able reduce EBV binding to epithelial cells. These observations 
suggest that epithelial cells express a receptor, which is yet to be identified and is termed 
the gHgL receptor, which is used by EBV to bind to epithelial cells. Finally, EBV express a 
membrane protein, encoded by the BMRF2 open reading frame, which has been 
demonstrated to bind integrin that are expressed on the surface of polarised epithelial cells 
(Tugizov et al, 2003).  
 
Fusion of EBV in nonpolarised epithelial cells takes place at neutral pH and does not 
appear to require endocytosis (Miller and Hutt-Fletcher, 1992). Studies using gp42-null 
recombinant viruses and monoclonal antibodies specific for gp42 do not affect epithelial 
cell infection, which is expected since epithelial cells do not constitutively express HLA II 
molecules (Wang et al, 1998). However, association of gp42 with the gHgL complex would 
inhibit epithelial cell fusion. More importantly, Wu et al (2005) identified gH-specific 
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monoclonal antibodies that specifically inhibit epithelial cell fusion but do not inhibit B cell 
fusion. This indicated that the mechanism for gHgL complex mediated fusion in B cells is 
different from that of epithelial cell fusion. Stoichiometric analysis of virion glycoprotein 
composition confirms this findings showing the expression of two kinds of complexes, the 
gHgLgp42 and the gHgL complex, on the EBV envelope. In addition, Wu et al (2005) was 
able to show, by making different gH chimeras by joining EBV gH with gH homologue 
from rhesus lymphocrytovirus, that certain chimeras preferentially mediate fusion with B 
cells, others preferentially mediate fusion with epithelial cells, and then there are those that 
would mediate fusion with neither cell types. These results suggested that gH important fo 
fusion in both B cells and epithelial cells, but differs in the way which fusion is triggered. 
In addition to the gHgL complex, epithelial cell fusion also requires gB expressed at a 
higher protein level than seen with B cell infection (Oda et al, 2000). How the process of 
fusion takes place still remains to be determined.  
 
1.4.3 The EBV genome 
The EBV genome is a double-stranded linear DNA that is approximately 184 kb in length 
encoding approximately 100 genes. EBV was the first herpesvirus to have its genome 
completely sequenced (Baer et al, 1984). The EBV genome was sequenced from the B95.8 
EBV strain that was broken into fragments of variable sizes using various endonuclease, 
and the Bam HI endonuclease notation will be used in this thesis to refer to the EBV 
genome. The different Bam HI fragments were sorted in descending order of fragment size, 
A to Z. Individual DNA fragments were than cloned into Escherichia coli, sequence and 
paste together. Open reading frames (ORFs), genes and sites of transcription or RNA 
processing are usually referred to Bam HI (B) fragments, fragment size (A-Z), direction of 
promoter or ORF (L, left; R, right), whether it is a promoter (P) or ORF (F), and follow by 
a number indicating which ORF is being referred to; e.g BARF1 would be Bam HI - 
fragment A - Rightward - ORF – 1 (first ORF). 
 
The B95.8 EBV genome is approximately 172kb and, in comparison to wild type strain, has 
an approximate 12 kb deletion in the Bam HI A region of the genome. This deleted region 
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was later sequenced from the Raji virus strain (Parker et al, 1990). At both ends of the 
DNA are terminal repeats (TR) that are approximately 0.5kb in length. In latently infected 
cells, the EBV genome is circularized, and the TR ends are joined together where the 
LMP2 exons are also encoded. 
 
1.4.4 Latent Genes 
During latency infection, latent genes are expressed; these include the EBERs, BART 
transcripts, EBNAs and LMPs. The functions of these genes are summarized to give a 
general idea of their role in EBV-associated diseases. 
 
1.4.4.1 EBERs 
There has been considerable progress in understanding the function of Epstein-Barr virus 
(EBV)-encoded small nonpolyadenylated RNAs (EBERs) in EBV infection. EBER1 and 
EBER2 are the most abundant viral transcripts in latently EBV-infected cells (Lerner et al, 
1981; Rymo, 1979). The EBERs have been demonstrated to associate with cellular proteins 
La (Lerner et al, 1981), ribosomal protein L22 (Toczyski et al, 1994) and double-stranded 
RNA activated protein kinase (Clemens et al, 1994). This association with cellular proteins 
may function to control expression or inhibition of cellular genes that may play a role in 
maintenance of EBV-infected cells (Kitagawa et al, 2000; Yang et al, 2004; Takada, 2000). 
Swaminathan et al (1991) demonstrated in their EBER negative recominbinant virus model 
that EBERs are not essential for immortalization of B lymphocytes or for the replication of 
the virus. However, Yajima et al (2005) demonstrated in their EBER negative recombinant 
virus models that EBERs do play a critical role in improving the efficiency of B-cell 
transformation. 
 
1.4.4.2 BART transcripts 
The BARTs have the potential to encode for three polypeptides A73, RPMS1 and BARF0. 
To date, there is no substantial evidence showing that these polypeptides are ever 
expressed. However, many groups have tried to understand the biological functions of these 
polypeptides by transfection models. Inspection of the amino acid composition of RMPS1 
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ORF showed the presence of an amino acid sequence WWP, which is rarely found in 
protein sequences, but is also found in the EBV EBNA2 sequence (Smith et al, 2000). This 
WWP motif in EBNA2 is important in EBNA2 for the binding to cellular protein CBF1. 
RPMS1 was demonstrated to interact and regulate the functions of cellular proteins CBF-1, 
NotchIC and CIR (Smith et al, 2000) which may be important in the life-long persistent 
infection of the virus (Zhang et al, 2001). More importantly, interaction of RPMS1 with 
Notch seems to favour proliferation of epithelial cells. BARF0 was also demonstrated to 
bind to Notch and directs the protein for proteosomal degradation (Thornburg et al, 2004). 
These studies demonstrated, if RPMS1 or BARF0 really exist, the regulation of Notch is 
important in EBV biology since Notch appears to have tumor suppressor function in several 
cell types such as keratinocytes and squamous cell carcinomas (Weng and Aster, 2004).  
 
A73 was demonstrated to bind to several cellular proteins; RACK1 (receptor for activated 
C kinase), KIAA0547 (protein of no known function), β5-integrin, and a protein which 
could not be identified in EBML, Genbank or the EST databse (Smith et al, 2000). It was 
shown that RACK1 interacts with Src and Lck and inhibiting their activity, resulting in 
reduced growth rate in NIH 3T3 cells (Chang et al, 1998). The exact role of A73 in EBV 
biology is yet to be determined, but possibly A73 functions to modulate the activity of 
these cellular proteins and contribute to the development of EBV tumours. 
 
1.4.4.3 EBNA 1 
EBNA 1 is the only viral protein which is expressed in all different forms of latency and is 
absolutely required for episomal maintenance of the viral genome in proliferating cells by 
ensuring segregation at each cell division (Yates et al., 1985). The B95.8 EBV strain of 
EBNA 1 is a 641 amino acid nuclear protein. The protein has a high proline content and 
consists of four components: (1) 89 amino acid Arg-rich N-terminal, (2) gly-ala repeat 
domain between amino acids 90-327, (3) a second Arg-rich region between amino acids 
328-386 which contains a nuclear localization sequence between amino acids 379-386, and 
(4) a C-terminal domain between amino acids 387-641 which can bind DNA and dimerise 
(Oddo et al, 2006).  
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EBNA1 binds specifically to two clusters of sites within the EBV plasmid origin of latent 
DNA replication (OriP). OriP is a 1.7 kbp cis-acting region of the EBV genome and 
contains two clusters of EBNA1 binding sites, the family of repeats (FR) and the dyad 
symmetry elements (DS). The FR and DS contain multiple copies of high affinity binding 
sites, the FR contain 20 tandem copies of a 30bp element and the DS contain 4 copies of 
the repeat, and these copies of repeats are separated by 980bp of spacer DNA (Ambinder et 
al, 1991; Chen et al, 1993). In addition, EBNA1 can also bind to three different promoters 
located in Bam HI- C, Q and W with different affinities, and the binding of EBNA1 to these 
promoters plays an important role in the maintenance of latent EBV infection. 
 
1.4.4.4 EBNA-2, -3s and -LP 
EBNA2 is a key transactivator of gene expression of both viral (LMP1 and 2) and human 
genes (CD21 and CD23) through interaction with RBP-Jκ. EBNA2 is important in B 
lymphocyte transformation because mutant viruses that carry the EBNA2 deletion are 
transformation incompetent (Rabson et al, 1982; Sixbey et al, 1991).  
 
Recombinant viruses with an EBNA3 gene deletion showed that EBNA3B is not essential 
in latent infection of primary B lymphocytes, LCL outgrowth, cell survival or lytic virus 
replication (Tomkinson and Kieff, 1992). While EBNA3A and EBNA3C are critical for the 
transformation of B lymphocytes and survival.  
 
EBNA-LP appears to interact with EBNA2 in a cooperative manner to induce cellular or 
viral gene expression (Peng et al, 2004; Sinclair et al, 1994). However molecular genetic 
analysis showed that full length EBNA-LP is not an absolute requirement for B lymphocyte 
transformation because LCL could be generated from EBV with deleted EBNA-LP 
(P3HR1/633 EBV). However, EBNA-LP deficient LCL seems to grow poorly but growth 
could be restored by transfecting with a vector expressing wild type EBNA-LP. 
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1.4.4.5 LMP-1 and -2 
The LMPs are membrane bound proteins. LMP1 and LMP2 have very distinct biological 
functions. LMP1 is a potent transforming protein activating a range of cellular transcription 
factors, such as, NF-κB (Wu et al., 2005). These transcription factors complement the role 
of EBNA2 in the transformation of B cells. LMP2 expression was demonstrated to 
influence signaling pathways linked to cell adhesion and motility, a possible role in the 
migration of cancer cells (Allen et al., 2005; Pegtel et al., 2005). 
 
The B95.8 EBV strain LMP1 is a 386 amino acid consisting of three domains: (1) a 20 
amino acid arginine and proline rich N-terminus that is located in the cytoplasm, (2) six 20 
amino acid α-helical transmembrane segments joined together by five 8-10 amino acid 
reverse turns, and (3) a 200 amino acid C-terminus rich in acidic residues also located 
within the cytoplasm (Eliopoulos and Young, 2001). LMP1 is a relatively unstable protein 
with a short half-life of less than 2 hours but is converted to a more stable cytoskeleton-
associated form. LMP1 also aggregates either with itself or other cellular membrane 
proteins (i.e. vimentin) to form a large, non-covalently linked membrane complex. Much of 
the understanding of LMP1 function came from studies in the ability of EBV recombinants 
carrying specific mutated LMP1 to transform primary B lymphocytes into LCLs. Several 
important functional properties had been identified from such experiments: (1) the N-
terminal tail of LMP1 contains sequences which hold the protein in the correct orientation 
for aggregation and oligomerization, (2) the cytoplasmic C-terminus of LMP1 is 
responsible for signal transduction leading to B cell transformation and phenotypic changes 
(Eliopoulos and Young, 2001). Biochemical studies of the mechanism that underlies the 
transformation ability of LMP1 showed that the protein could activate the NFκB pathway 
through interaction with the cellular protein tumor necrosis factor (TNF) receptor-
associated factor (TRAF)-1, -2 and -3 and TNFR-associated death domain proteins, 
TRADD and RIP. This type of signaling is similar to that seen with human CD40 in the 
activation of NFκB. 
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The LMP2s are two integral membrane proteins, LMP-2A (497 amino acids) and -2B (378 
amino acids). Both proteins are structurally similar with an N-terminus cytoplasmic domain 
(LMP2A not 2B) followed by 12 integral membrane segments joined together by short 
reverse turns and a 27 amino acid C-terminus (Miller et al, 1994). LMP2A N-terminal 
domain directly interacts with cellular proteins, the src family tyrosine kinases (syk, fyn 
and lyn) and inhibits B cell receptor signaling, preventing activation of EBV replication 
(Caldwell et al, 2000). Studies of EBV infected epithelial cell models suggest that LMP2A 
and 2B may have other roles in these cell types different from that observed in infected B 
cells (Allen et al., 2005). EBV infected epithelial cells were observed to have increased cell 
adhesion and motility. However, the mechanism is still yet to be elucidated but there is 
evidence which suggests that tyrosine kinases may play a role (Scholle et al., 2000).  
 
1.4.5.1 Lytic cycle antigens 
Viral gene expression in lytic cycle follows a temporal and sequential order. The immediate 
early genes are expressed followed by the early genes and then the late genes. In vitro 
infection of B lymphocytes usually results in latency type infection and models of studying 
lytic infection usually requires inducing latently infected cells into lytic cycle (Amon et al, 
2005). Viral immediate early gene expression is induced directly by signal transduction of 
the B cell receptor. Two immediate early mRNAs have been identified for EBV, encoding 
the proteins BZLF1 and BRLF1. BZLF1 appears to be the major immediate early gene 
product in EBV. BZLF1 plays a dominant role in the switch from latent cycle to productive 
infection (Flemington and Speck 1990; Lieberman and Berk 1990). BZLF1 is a 34 to 38kD 
DNA-binding protein related to the basic leucine-zipper family of transcription factors with 
some sequence homology to c-Fos. BZLF1 has been shown to bind to several early gene 
promoters and cellular gene promoters, as well as the lytic origin of replication. BZLF1 
further activates its own expression by binding to its own promoter and also activates 
transcription of BRLF1 (Speck et al, 1997). BRLF1 is also a transcription factor, and 
together with BZLF1 would activate most of the early genes.   
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Lytic cycle replication of EBV DNA requires several early gene products; BALF5, 
BMRF1, BALF2, BBLF4, BSLF1 and BBLF2/3 (Fixman et al, 1995). BALF5 encodes a 
DNA polymerase catalytic subunit (Tsurumi et al, 1993), BMRF1 encodes the DNA 
polymerase accessory subunit (Tsurumi, 1993), BALF2 encodes a single-stranded DNA-
binding protein (Tsurumi et al, 1998), and the proteins encoded by BBLF4, BSLF1 and 
BBLF2/3 encode a protein complex, predicted from sequence comparison with herpes 
simplex virus type 1 (HSV-1) genes, to act as helicase, primase and helicase-primase 
associated proteins (Fixman et al, 1995). These proteins are believed to work together to 
replicate the EBV genome. Finally, proteins identified as late lytic genes encode for viral 
structural proteins, such as that of the glycoproteins gp350/220, gH, gL, and gp42 that are 
expressed on the viral envelope, and also the viral capsid proteins. 
 
1.4.5.2 BARF1 
BARF1 is a lytic cycle antigen, and it will be described in more detail in this section of the 
thesis because its expression can also be found in latency type infection. An x-ray 
crystallography study of BARF-1 showed that BARF-1 has a sequence and structural 
homology similar to human CD80 (Tarbouriech et al., 2006). Human CD80 (expressed on 
the surface of antigen presenting cells) interacts with CD152 or CD28 (expressed on the 
surface of T cells) either by emitting inhibitory or activating signals. Stockbine et al (1998) 
observed the binding of BARF-1 to human colony-stimulating factor 1 (hCSF1) thus 
inhibiting T cell differentiation. This may suggest that BARF-1 play an important role in 
regulating the host immune response to enhance EBV infection. More recently, Wange et al 
(2006) reported that cancer cells transfected with BARF-1 are more tolerant to 
chemotherapy drugs, such as taxol, suggesting a role for BARF-1 with anti-apoptotic 
function.  
 
1.4.6 Early events in EBV infection 
Once the virus has entered the host, the process leading to capsid dissolution and genome 
transport to the nucleus is not known. However, in almost all EBV-infected cells the EBV 
linear genome becomes a covalently closed circular EBV episome (Adams, 1987; Lindahl, 
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1976). There is evidence suggesting the transcription factor Sp1 (and maybe with the help 
of other proteins) may play an important role in circularisation of the EBV genome by 
binding and joining the TR (Sun et al, 1997). Inhibitors of DNA, RNA and protein 
synthesis added to cells at the time of viral infection will inhibit genome circularisation at 
least suggesting that active cell macromolecular synthesis is necessary to aid the 
circularisation process (Sinclair and Farrell, 1995).  
 
The virus can undergo two types of infections, lytic and latent. Lytic infection usually takes 
place in epithelial cells in vivo resulting in active replication, a process where viruses are 
produced and are released from the infected cell (Sixbey et al, 1983). Lytic cycle infection 
normally takes place in the oropharynx where a high viral load can be found in saliva 
(Gerber et al, 1972; Yao et al, 1985). Latent infection of B lymphocytes in vitro will result 
in circularisation of the EBV genome into episomes, expression of viral latent genes and 
immortalising the B lymphocyte. 
 
1.4.7 Latency gene expression 
Latent gene expression varies between different types of human malignancies. Figure 1.4.1 
shows three models of latent infections, Latency I, II and III, that roughly describes the 
transcription pattern of the different human malignancies. The latency III gene expression 
comes from observation of in vitro transformed B lymphocyte lines (LCL) (Henderson et 
al., 1977). The latency III transcription pattern includes the expression of (1) EBV early 
region (EBER) RNAs 1 and 2, (2) the Bam H1A RNAs (BARTs), a family of spliced 
polyadenylated transcripts with the potential of encoding 3 polypeptides (BARF0, A73 and 
RPMS1), (3) EBV nuclear proteins (EBNA) 1, 2, 3A, 3B, 3C and LP expression through 
the Wp/Cp promoter, and (4) three spliced Bam HI N RNAs encoding latent membrane 
proteins (LMP) 1, 2A and 2B. Latency I was first described in EBV-positive BL cells with 
the characteristics of expression of; EBERs; BARTs; silencing of the Wp/Cp promoter and 
activation of the FQp promoter. This shift in promoter usage only initiates EBNA1 
expression and all other EBNAs are not expressed; silencing of the LMP promoters in the  
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Figure 1.4.1: The patterns of EBV latent gene transcripts in the three forms of 
latency. 
This Figure was taken from Kief and Rickinson (2001, p.2399). The genomic positioning 
of the exons is shown (top) on a linear map of the viral genome. It is important to note that 
the viral genome is circularized in latently infected cells through fusion of the terminal 
repeats (TR), and the LMP2 transcripts are spliced across this region. The transcripts are 
displayed in the correct orientation relative to one another with promoters (pennants), 
noncoding RNAs (white) and mRNAs (black). 
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Bam HI N region. Latency II was first recognised in EBV-positive Hodgkin Disease (HD) 
to express EBERs, BARTS, silencing of Wp/Cp promoter and activation of the FQp 
promoter for the expression of EBNA1, activation of one or more LMP promoter and 
BARF1 protein expression. 
 
 1.4.8 EBV infection in vivo 
B cells are the primary target cells for EBV infection and establishment of latency. More 
importantly, EBV infection in B cells is usually non-productive, thus infection of B cells 
does not explain the successful spread of the virus in the human population. However,  
EBV can also infect epithelial cells, and studies in AIDS patient with oral hairy leukoplakia 
show that EBV undergo massive lytic replication and sheds virus from the epithelium of 
the lateral part of the tongue (Greenspan et al, 1985). It was believed that what was seen in 
HIV infected individual was an amplification of the situation in healthy non-HIV-infected 
EBV-infected individuals. But, this is not the case, since the EBV virus was not detectable 
from exfoliated epithelial samples collected from patients with infectious mononucleosis 
and from healthy individuals (Karajannis et al, 1997; Niedobitek et al, 1997). However, 
EBV lytic cycle antigen BZLF1 was detected in B cells and plasma cells, which suggested 
that the life cycle of EBV is restricted to B cells in vivo (Niedobitek et al, 1997). Laichalk 
and Thorley-Lawson (2005) showed that when memory B cells differentiate into plasma 
cells, EBV lytic cycle is activated through activation of BZLF1 promoter. However, the 
actual number of plasma cells that is producing EBV is minimal and does not correspond to 
the viral load found in saliva. 
 
In a study by Shannon-Lowe et al (2005), the authors showed that when epithelial cell lines 
were directly cultured in cell-free recombinant EBV, expressing GFP, only <1 in 104 
epithelial cells were GFP-positive, this is termed direct infection. Whereas, when the same 
epithelial cell lines were cocultured with freshly prepared B cells coated with the same 
virus preparation, up to 25% of epithelial cells were GFP-positive. In addition, when the 
same experiment was repeated using a recombinant EBV with BZLF1-deleted but still 
expressing GFP, efficient epithelial cell infection was observed. This indicated that 
32 
infection of epithelial cells is not secondary to B cell infection, since the efficiency of 
infection by replication-deficient recombinant EBV was the same as that of wild type, but 
is a direct transfer from the B cell surface to the epithelial cells. This is termed transfer 
infection. Using different epithelial target cells (including cultures of normal 
nasopharyngeal epithelium) in the same experiments, Shannon-Lowe et al (2005) 
demonstrated efficient EBV infection in these epithelial cells, but was unable to infect 
normal fibroblasts, endothelial cells or primary T cells. They also demonstrated using 
different CR2-expressing donor cells (including EBV-negative Akata-BL, BJAB B cell 
lines, primary B cells and primary T cells) that primary B cells was the optimal donor cell 
type in transfer infection. Interestingly, glutaraldehyde fixation of B cells prior to exposure 
to EBV did not affect EBV binding but severely reduces transfer infection of their donor 
epithelial cells. This indicated that transfer infection requires active participation of the 
donor cell. Time course experiments, using monoclonal antibody staining for gp350 and 
fluorescence insitu hybridisation (FISH) using sensitive EBV DNA probe to detect for 
DNA containing EBV viral particle on the surface of B cells, showed that infected primary 
B cells is capable of transfer infection around 6 hours postinfection and remained 
competent to do so in up to 2 days. More importantly, EBV retained on the B cell surface 
was the source of transfer infection. 
 
In studies using recombinant EBVs that lack gp350, gH, gp42 or BILF2 glycoprotein and 
recombinant EBV expressing low levels of gB, Shannon-Lowe et al,(2005)showed several 
important points: (1) gp350 is required for virus binding and transfer infection, and 
interestingly, gp350-null recombinant EBV consistently gave rate of direct infection 
equivalent to that seen in transfer infection, (2) as expected, gp42 is required for B cell 
infection, through interaction with HLA II molecule, but is not required in transfer 
infection, and (3) gH and gB are essential for EBV infection of B cells and epithelial cells. 
 
Finally, Shannon-Lowe et al (2005) demonstrated, using confocal microscopy study and 
MAbs staining of CR2, gp350 and FISH staining of EBV DNA, that  B cells at 24 hours 
post EBV infection would form conjugates with epithelial cells. More importantly, CR2 
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and gp350 accumulates at the junction where there was cell-cell contact. These data suggest 
that gp350 may possible inhibit direct infection of epithelial cells, and infection of 
epithelial cells is made possible when gp350 is bound to the B cell exposing the viral ligand 
to the epithelial receptor.  
 
Persistent infection is achieved by infection of circulating naïve B cells. These EBV-
infected naïve B-cells show a latency type III growth program. The EBV-infected naïve B-
cells enter the germinal center where they proliferate and clonally expand, and therefore 
increase the EBV-infected B-cell pool. The germinal center infected cells show a latency 
type II EBV gene expression pattern (Thorley-Lawson, 2001). The EBV-infected germinal 
center cells differentiate into memory B-cells and functions as the long-term reservoir for 
EBV. Most of the EBV-infected memory B-cell population that circulates in the periphery 
do not show any EBV gene expression (termed latency type 0), but a small population of 
these EBV-infected memory B-cells would show a latency type I EBV gene expression 
pattern.  
 
The next section of this thesis will review some of the current understanding of immune 
responses to EBV infection, specifically antibody responses and T cell responses to EBV 
antigens. This will set a theme for later sections of this thesis when reviewing the current 
immunotherapeutic strategies that are being studied in the treatment of EBV diseases. 
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1.5 Immune responses to EBV infection 
 
1.5.1 Antibody responses to EBV antigens 
Henle et al (1968) first observed that infectious mononucleosis (IM) was associated with 
EBV seroconversion, and that IM patients would first develop IgM and IgG antibodies 
specific for viral capsid antigens (VCA), non-structural early antigens and membrane 
antigens. Evans et al (1983) showed in transmission studies in monkeys and in man that 
EBV infection would lead to production of heterophile antibodies and IM. This study 
provided a causal association between EBV infection and IM. 
 
Interestingly, a sero-epidemiological study conducted over a period of 9 years in Uganda, 
where Denis Burkitt reported a high incidence of Burkitt’s lymphoma (BL), showed that 
EBV-positive individuals who had high serum antibody titres against VCA  compared to 
the mean control group are 30 times more likely to develop BL (de-Thé et al, 1978). This 
provided a causal link between EBV infection and development of BL. With the discovery 
of early antigens and the differentiation between early antigens that could be found in the 
cytoplasm and the nucleus (‘diffuse’ – D) and early antigens that could only be detected in 
the cytoplasm (‘restricted’ - R) components, Henle et al (1971) showed that different EBV 
diseases would have a different antibody profile. For example, most BL patients gave high 
antibody titres to EA-R.  Sero-epidemiological study was also conducted on other 
suspected EBV diseases, such as in Hodgkin’s disease (HD) patients have elevated 
antibody titres against VCA, EA-D and EA-R antigens (Mueller et al, 1989) and in 
nasopharyngeal carcinoma (NPC), high IgG and IgA antibody titres could be detected 
against VCA, EA (especially EA-D), EBNA and ZEBRA (Desgranges et al, 1977). 
Especially for NPC, antibodies to EA-D and EBV-specific IgA antibody titres is a 
characteristic of the disease (Henle and Henle, 1976) 
 
 
 
35 
1.5.2 CD8+ T cell responses to EBV antigens 
Studies in IM patients showed that these individuals have an expanded CD8+ T cell 
numbers. Most of these CD8+ T cells are lytic antigen specific (Callan et al., 1998) and 
accounts for approximately 25% of total CD8+ T cell population. CD8+ T cells directed at 
latent antigens can also be detected, but it is comparably much lower than responses against 
lytic antigens (Callan et al., 1998; Hislop et al., 2002). CD8+ T cell responses to lytic 
antigens are poorly understood considering that there are ~70 lytic antigens and fewer than 
20 of these antigens have been studied. However, of the antigens studied to date, there 
seems to be a clear immunodominance in CD8+ T cell responses to the immediate early 
antigens (BZLF1 and BMRF1), and some of the early lytic antigens and the weakest 
responses to the late lytic antigens (Pudney et al, 2005). This may be due to impairment of 
the HLA II presentation pathway, as Keating et al (2002) demonstrated by FACS analysis. 
In their experiment, Keating et al (2002) showed, when latently infected cells (BL cell line 
Ag876 and B cell line (LCL)) were induced to go into lytic infection, that there was a 
decline in HLA I molecule staining by 5-fold and a 40-50% reduction in HLA II molecule 
staining relative to the latently infected cells. They also showed by monoclonal antibody 
staining for the presence of BZLF1 that these cells were in lytic infection. More 
importantly, downregulation of HLA I molecules happen early on during lytic infection, 
since the decrease in HLA molecules in late lytic cycle (by staining for VCA) and in early 
lytic cycle (by staining for presence of BZLF1) was approximately the same, 5-fold lower 
than seen in latently infected cells. These data suggests that CD8+ T cell responses to the 
immediate early antigens are strong mainly because at this stage of infection the MHC class 
I presentation pathway is still intact, but as the virus infection progresses onto early and late 
gene expression, the MHC class I presentation pathway becomes impaired. 
 
Phenotype studies of these CD8+ T cell populations show that lytic antigen specific CD8+ T 
cells are of the late CD28-/CD27- differentiation phenotype (Hislop et al., 2001) whereas, 
latent antigen specific CD8+ T cells are of the early CD28+/CD27+ differentiation 
phenotype also frequently expressing CCR7, a homing marker for secondary lymphoid 
organs (Appay et al., 2002; Hislop et al., 2001).  
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As for CD8+ T cell responses to the latent antigens, a hierarchy of responses was also 
observed. The EBNA3s (EBNA3A, -3B and -3C) are the dominant CD8+ T cell responses 
(Steven et al., 1996) followed by LMP2 responses (Khanna et al., 1992). Whereas, CD8+ T 
cell responses to LMP1, measured by IFN-γ ELISpot assay (Meij et al., 2002), and EBNA1 
(Lee et al., 2004) are less frequent. Approximately 10% (5/50) of healthy Caucasian donors 
have detectable HLA-A2 restricted responses against 2 LMP1 epitopes (LMP1 125-133 and 
LMP1 159-167) whereas responses to other LMP1 epitopes are less frequent (Meij et al., 
2002). While, approximately 50% of the Caucasian population is HLA-A2 positive this 
clearly shows that only a minority of the Caucasian population responds to LMP1. On the 
other hand, responses to LMP2 are much more frequent, with more than 40% (12/28) of 
healthy Caucasian donors tested against LMP2 synthetic peptides had detectable CD8+ T 
cell responses against two HLA-A2 restricted epitopes (LMP2 356-364 and LMP2 426-
434). In addition, of the 12 LMP2 epitopes identified, 4 are also HLA-A2 restricted 
epitopes (Meij et al., 2002).  
 
EBNA1 was first thought to be an immune evasive protein which prevents proteasome 
degradation through its gly-ala repeat domain (Levitskaya et al., 1995; Levitskaya et al., 
1997). And the gly-ala repeat domain was found to downregulate its own protein 
expression and therefore reduces the chances of being detected by the immune system (Yin 
et al., 2003). More importantly, earlier work failed to detect EBNA1-specific CD8+ T cell 
responses by cytotoxicity assay. These data led to the assumption that EBNA1-specific 
CD8+ T cell responses are not present in the T cell repertoire. Even with these immune 
evasive strategies, EBNA1 does not fully escape detection by CD8+ T cells in studies using 
LCL models. EBNA1-specific CD8+ clones could be generated from EBV-immune donors 
with the capacity to recognize naturally infected target cells using IFN-γ as readout (Blake 
et al., 1997; Blake et al., 2000; Lee et al., 2004). More importantly, these IFN-γ producing 
EBNA1-specific CD8+ T cells are capable of inhibiting outgrowth of LCLs. However, these 
clones are unable to recognize Burkitt’s lymphoma cells or TAP-deficient cells (T2) which 
suggest that processing of EBNA1 for CD8+ T cell recognition is through the conventional 
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proteosome/TAP-dependant pathway. This was confirmed using inhibitors of proteosomal 
function which would abolish LCL recognition by these clones (Lee et al., 2004; Tellam et 
al., 2004). 
 
Immune responses to the BamH1A rightward transcripts (BARTs) are poorly studied 
mainly because there is no substantial evidence to date which suggests that any of the 
predicted BART polypeptides are ever expressed at the protein level. But the main reason is 
because much of the work concerned with T cell responses has been focused on the well 
known EBV antigens (the LMPs and EBNAs).  
 
However, CD8+ T cell responses to BARF0 (one of the predicted BART polypeptides) have 
been studied (Kienzle et al., 1998) mainly initiated by the use of rabbit anti-serum which 
detected the expression of the product at the protein level (Fries et al., 1997). However, this 
same rabbit antiserum was later found to cross-react with cellular proteins (Kienzle et al., 
1999). Therefore to date, it is still uncertain whether BARF0 is expressed at the protein 
level. However, in the study by Kienzle et al (1998), they showed that an HLA-A2 
(LLWAARPRL) restricted BARF0-specific CD8+ T cell clones could be generated from a 
single healthy virus carrier and, demonstrated that these clones have the capacity to kill an 
EBV-negative BL line overexpressing BARF0 using a vector but not naturally infected BL 
line. This suggested that possibly BARF0 is expressed naturally at very low levels thus 
evading detection by the immune system rather than immune evasion of the proteosome 
degradation pathway since, the epitope LLWAARPRL is processed for presentation when 
BARF0 is overexpressed in a EBV-negative BL line (DG75, HLA-A2 positive BL cell 
line). More importantly, Kienzle et al (1998) demonstrated, using the BARF0 peptide, that 
BARF0 peptide-specific CD8+ T cell response could be detected in HLA-A2 positive EBV 
seropositive individuals but not in HLA-A2 positive EBV seronegative individuals. In 
addition, BARF0-specific CD8+ T cells were capable of killing BARF0 peptide loaded 
target cells. These data strongly suggest that BARF0-specific CD8+ T cells do exist, since 
it could be detected only in EBV-seropositive but not in EBV-seronegative individuals. 
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1.5.3 CD4+ T cell responses to EBV antigens 
CD4+ T cell responses to EBV have not been studied until quite recently mainly because 
EBV specific CD4+ responses never reach the high frequency of EBV specific CD8+ 
responses (Amyes et al., 2003; Precopio et al., 2003), and there was an assumption that 
they were not as important as CD8+ T cells as effectors. But this was an assumption and not 
a fact. 
 
Evidence supporting the importance of CD4+ T cells in the role for controlling persistent 
infection came from studies in MHC class II knockout (KO) mice models (Cardin et al., 
1996). Respiratory challenge of the MHC class II KO mice with murine gammaherpesvirus 
68 (MHV-68) leads to productive infection of the virus in both lungs and adrenal epithelial 
cells. But primary infection is effectively controlled by CD8+ T cells and the virus develops 
persistent infection in lymph node and splenic B cells. However, over time, the control of 
persistent infection deteriorates due to progressive loss of CD8+ T cells in the absence of 
CD4+ T cell responses measured by increase of viral load in the lung, development of 
wasting and early death in MHC class II KO mice. This experiment clearly shows that 
CD4+ T cell responses are important in the control of persistent infection, probably as 
‘helper’ cells in maintaining an efficient CD8+ T cell response, humoral response or as 
direct control. 
 
In addition to ‘helper’ function of CD4+ T cells, in vitro studies of EBV-specific CD4+ T 
cells lines and clones suggest a more direct role for CD4+ T cells in the control of 
persistent infection (MacArther et al, 2007; Landais et al, 2004; Adhikary et al, 2006). 
MacArther et al (2007) demonstrated using EBV-specific CD4+ T cell lines, generated by 
reactivation of cord blood with irradiated autologous LCLs, in coculture assays would 
inhibit the growth of autologous LCLs. Furthermore, inhibition of LCL growth is 
dependent on the effector:target (E:T) ratio and inhibition of LCL growth is observed when 
E:T>2:1. Interestingly, E:T > 16:1 would lead to elimination of LCL growth. Transwell 
studies demonstrated that cell-cell contact is necessary for LCL growth inhibition, since 
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CD4+ T cell lines coculture with LCLs on one of the membrane does not inhibit LCL 
growth on the other side of the membrane.  
 
MacArther et al (2007) also demonstrated in chromium release assays that their CD4+ T 
cell lines could kill autologous LCLs, however, the mechanism of cytotoxicity was slow 
and maximum kill was achieved only in a 24 hour assay compared to NK cell killing of 
LCLs which takes 5hours. FACS analysis of these CD4+ T cell lines showed a small 
proportion of CD4+ T cells stained for granzyme B and granulysin which suggests that 
only a small proportion of cells mediate killing and this is possibly mediated through 
granzyme B and granulysin.  
 
Interestingly, EBV-specific CD4+ T cell lines were demonstrated to reduce the efficiency 
of virus transformation of B cells, but this is only achievable at a high EBV-specific CD4+ 
T cell line: B cell ratio of 10:1. Whereas, at low T cell:B cell ratio (1:1) the efficiency of 
virus transformation doubles. This indicated that possibly majority of the noncytotoxic T 
cells help with virus transformation, and reflected by increase in CD4+ T cell: B cell ratio, 
that the minority of cytotoxic T cells dominate the response and reduces the efficiency of 
virus transformation (MacArther et al, 2007). These studies demonstrated that CD4+ T 
cells play an important role, both as helper cells and effector cells, in the control of 
persistent and productive EBV infection. 
 
Several groups have identified CD4+ T cell responses to several lytic antigens (BZLF1, 
BMLF1 and BHRF1) (Precopio et al., 2003; Amyes et al., 2003; Landais et al., 2004), of 
which, the HLA-DR0401 restricted (BHRF1 122-133) CD4+ T cell clones were 
demonstrated to have direct effector functions further suggesting the role of CD4+ T cells in 
controlling EBV replication (Landais et al., 2004). Adhikary et al (2006) also demonstrated 
that BZLF1, BLLF1 and BALF4 –specific CD4+ T cells were cytolytic and capable of 
inhibiting proliferation and outgrowth of LCL cells. Thus, in addition to control of 
persistent infection, these studies demonstrate a role for CD4+ T cells in the control of lytic 
infection in vitro. 
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In vivo studies of EBV-specific CD4+ T cell responses in AIDS patients with primary CNS 
lymphoma supports the importance of CD4+ T cells in the protective role against EBV-
diseases (Gasser et al, 2007). In this report, Gasser et al (2007) studied PBMC samples 
from six patients that were obtained 0.5-4.7 years prior diagnosis of primary CNS 
lymphoma and 16 PBMC samples from HIV individuals who did not develop primary CNS 
lymphoma. They assessed the PBMC samples for EBV-specific CD4+ T cell responses by 
IFN-γ ELISpot assay using EBV peptides restricted through the HLA types of the samples 
or EBV-infected B cell lysates to stimulate EBV-specific CD4+ T cell IFN-γ response. 
Their results showed that 1/6 of the patients and 13/16 of the controls had detectable EBV-
specific CD4+ T cell response. This suggested that, in the absence of CD4+ T cells would 
lead to primary CNS lymphoma. Whereas, the control group had EBV-specific CD4+ T 
cell responses and thus preventing these individuals from developing primary CNS 
lymphoma. However, more studies are needed to confirm this finding. 
 
In another study by Sebelin-Wulf et al (2007) on post-transplant lymphoproliferative 
(PTLD) patients, they found by FACs analysis that PTLD patients had lower CD4+ T cell 
count when compared with patients with primary EBV infection or healthy EBV carriers. 
Whereas, CD8+ T cell count was similar to that of healthy EBV carriers. The author also 
measure the number of EBV-specific CD8+ T cells using HLA I tetramers for EBV-
antigens and IFN-γ staining, and analysed by FACs, where double positively stained cells 
represent EBV-specific CD8+ T cells. They showed that in PTLD patients >30% of the 
EBV-specific CD8+ T cells were also IFN-γ stained, suggesting majority of the EBV-
specific CD8+ T cells were not functional. Real time PCR assay also showed high EBV 
DNA load in the blood samples of PTLD patients, this was also true for patients with 
primary EBV infection. While EBV DNA load in healthy EBV-carriers were not 
detectable. Interestingly, the EBV DNA load in PTLD patients was inversely proportional 
to the total CD4+ T cell count (Sebelin-Wulf et al, 2007). When these patients were given a 
reduced immunosuppressive regimen, the frequency of EBV-specific CD8+ T cells 
remained constant during therapy and follow-up 6-12 months after therapy. Whereas, the 
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CD4+ T cell count remained stable during therapy and follow-up, however, EBNA1-
specific CD4+ T cell count was undetected and this was proportional to the drop in EBV 
load. EBNA1-specific CD4+ T cells were detected by stimulation with recombinant 
EBNA1 protein followed by IFN-γ secretion assay. These data suggested that CD4+ T cells 
are required, possible, for the maintenance of EBV-specific CD8+ T cells. The author was 
unable to conclude why there was a decline in EBNA1-specific CD4+ T cells with decrease 
in viral load, since other studies suggested the importance of EBNA1-specific CD4+ T cells 
in the protection against EBV diseases in HIV patients (Piriou et al, 2005). However, Voo 
et al (2005) showed that EBNA1-specific CD4+ T cell clones selected on the basis of IFN-
γ secretion in response to epitope peptide expressed phenotypic markers of T regulatory 
(Treg) cells (CD25+GITR+Foxp3+). More importantly, these Treg cells inhibited the 
proliferation of third party T cells. Thus the EBNA1-specific CD4+ T cells that were 
observed by Sebelin-Wulf et al (2007) could possibly be Treg cells and may possibly 
account for the inhibition of EBV-specific CD8+ T cell function. Therefore, in addition to 
having a protective role, CD4+ T cells could also promote EBV infection in vitro. 
 
Based on work in Caucasians, CD4+ T cell responses to the latent antigens show a 
completely different pattern of immunodominance seen with CD8+ T cell responses. 
EBNA1 and EBNA3C specific CD4+ T cell responses are readily detectable in healthy 
Caucasian EBV carriers by IFNγ ELISpot (Leen et al, 2001). Responses could be as 
frequent as 70% of healthy Caucasian donors tested would have EBNA1 or EBNA3C 
response. In this study, Leen et al (2001) describe finding 15 EBNA1 epitopes and 10 
EBNA3C epitopes. However, LMP1 and LMP2 responses are poorly recognized (Leen et 
al., 2001) with frequency of responders to LMP1 and LMP2 between 10-15% of total 
donors tested. More importantly, only a few epitopes have been identified; 3 epitopes in 
LMP1 and 4 epitopes in LMP2. 
 
Phenotype studies showed that majority of EBV specific CD4+ T cells are biased towards 
secreting Th1 cytokines, especially IFNγ and are of the memory phenotype expressing 
surface markers CD45Ro+CD27+CD28+ (Amyes et al., 2003). Bickham et al (2001) showed 
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that there are two populations of EBNA1 specific CD4+ T cells, Th1 measuring IFNγ 
release and Th2 measuring IL-4 release, but the response is skewed towards Th1 
population. This skewing of CD4+ responses to Th1 has been demonstrated to be an effect 
of IL12 producing DCs (Cella et al., 1996; Koch et al., 1996) and is reflected in vivo with 
the skewing of IgG1 anti-body directed against EBNA1 (Bickham et al., 2001), since Th1 
cytokines has been observed to bias IgG1 production (Hussain et al., 1999). In addition to 
the IFNγ anti-viral response, these Th1 polarised EBV specific CD4+ T cells were 
demonstrated to inhibit the outgrowth of LCLs (Wilson et al., 2001) and this inhibition is 
not due to the effect of cytokine release but cell-cell interaction. Th2 polarised CD4+ T 
cells, however, were unable to kill EBNA1 expressing target cells (Bickham et al., 2001).  
 
These studies show that EBV-specific CD8+ and CD4+ T cell responses are frequently 
detected in healthy EBV carrier and patients with EBV diseases. More importantly, both 
CD8+ and CD4+ T cells are as important in the protection of EBV infection. These studies 
pointed to the importance in search for CD4+ T cell responses to EBV antigens. 
 
 
 
 
 
 
 
 
 
 
 
 
Section 1.6 
EBV tumours 
43 
 
1.6 EBV tumours 
This section of the thesis will review some of the evidence which associate EBV to human 
tumours. More importantly, also look at the EBV gene expression pattern in these tumours. 
This will set a scene for the coming sections reviewing immunotherapeutic strategies that 
are studied. 
 
1.6.1 B-Cell tumours 
B cells act as the reservoir for EBV to persist, therefore B cell tumours account for the 
majority of the EBV tumours. This section will review how EBV infection contributes to 
the development of Burkitt Lymphoma (BL), Hodgkin Disease (HD) and Post-Transplant 
Lymphoproliferative Disorder (PTLD).  
 
1.6.1.1 Burkitt Lymphoma  
Burkitt lymphoma (BL) was first described in children in equatorial Africa by Denis 
Burkitt. BL is predominantly a disease of children and young adults, and rarely occurs after 
the age of 45 (Parkin, 2006). Evidence of the association of African BL with EBV came 
from sero-epidemiological studies conducted in Uganda (de-Thé et al, 1978). The authors 
showed that the level of antibodies to EBV, which could be detected months or years before 
the onset of disease, was considerably higher in children who subsequently developed BL 
than in normal control. In addition, EBV DNA could be detected in over 95% of BL 
tumours from sub-Saharan Africa (Parkin, 2006). 
 
There are 3 variants of BL; endemic, sporadic and immunodeficiency related. BL described 
in equatorial Africa are endemic BL where EBV has been detected in almost all cases of 
endemic variant. Sporadic BL are found in North America and Europe, these cases of BL 
are much rarer than endemic BL and accounts for 20-30% of childhood non-Hodgkin 
Lymphoma (nHL) with a different clinical presentation. BL cases that occur in North 
Africa resembles that of sporadic BL clinical presentation, however, 85% of sporadic BL 
cases in North Africa have detectable EBV DNA (Parkin, 2006). Lymphomas arising in 
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immunodeficient individuals are relatively rare with the exception of AIDS cases. EBV 
DNA have been detected in 30-40% of immunodeficiency-related cases (Young and 
Rickinson, 2004).  
 
A characteristic of BL is the translocation of chromosome 8 and either the immunoglobulin 
loci on chromosome 14 or 2 and 22 near the location of the c-myc oncogene resulting in 
altered regulation of c-myc expression (Pagano et al, 2004). This chromosomal 
translocation may be triggered during gene rearrangement or class switching, since BL cells 
display cell-surface markers that represent germinal centre B cells. 
 
The endemic pattern of BL suggests that both genetic and environmental factors are likely 
to contribute to the development of the tumour. Malarial infection is a factor that has been 
linked to BL since in areas of endemic BL there is also a high incidence of malarial 
infection. More importantly, chronic malarial infection would lead to an expanded germinal 
centre and BL cells express markers of germinal centre B cells (Pagano et al, 2004). 
 
Most EBV-positive endemic BL cases show a latency type I EBV gene expression pattern. 
However, in some cases, in addition to EBNA1 and EBERs, expression of EBNAs 3A, 3B, 
3C and LP could also be detected but not EBNA2 and LMPs (Kelly et al, 2002). 
 
1.6.1.2 Hodgkin’s Disease 
Hodgkin’s disease (HD) is a distinct disorder in which the characteristic malignant cells, 
known as the Hodgkin (large mono-nucleated) and Reed-Sternberg (multinucleated) cells 
(HRS), make up only 1-2% of the total tumour mass. HD has been categorised by the 
World Health Organisation (WHO) into two classifications; nodular lymphocyte-
predominant, which represents 5% of all HD cases and is not typically EBV-associated, and 
classical HD (Gandhi et al, 2004). Classical HD is also further divided into four subtypes; 
nodular sclerosis which accounts for the majority of classical HD cases, mixed cellularity, 
lymphocyte-rich, and lymphocyte-depleted.  Lymphocyte-rich and lymphocyte-depleted 
HD subtypes together account for less than 5% of classical HD cases, thus most studies of 
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EBV-associated HD came from the study of nodular sclerosis HD and mixed cellularity 
HD.  
 
The association of EBV with HD appears to depend on age (Parkin, 2006), with the highest 
rate occurring in young adults in developed countries and in childhood in developing 
countries. EBV-positive HD seems to predominate in males. Mixed cellularity HD appears 
to affect older adult age group (45+ years of age). Whereas, nodular sclerosis HD is more 
frequent in young Caucasian adults (Gandhi et al, 2004; Parkin, 2006). Sero-
epidemiological studies showed that IgA and IgG antibodies against EBNA1, VCA and 
EA-D are elevated in the serum of HD patients that were taken years prior diagnosis of the 
disease when compared to EBV-positive healthy controls (Mueller et al, 1989). In addition, 
elevated EBV DNA load could also be detected in the serum of HD patients years before 
the diagnosis of the disease when compared to EBV-negative HD patient or to healthy 
controls (Gandhi et al, 2004). Furthermore, EBV DNA could be detected in EBV-positive 
HD HRS cells. 
 
Molecular analysis of Hodgkin/Reed-Sternberg cells showed that these cells are derived 
from preapoptotic postgerminal centre B cells (Kanzler et al, 1996). These cells were 
shown to have undergone crippling mutation, which under normal circumstances, would be 
eliminated by apoptosis. However, in the case of HD, these cells survive probably rescued 
by certain transforming events. The Hodgkin/Reed-Sternberg cells display a latency type II 
EBV gene expression program which indicates an important role for EBV in the rescue of 
these preapoptotic cells. This is because LMP1 and LMP2A may mimic and replace 
survival signals induced by activated CD40 and B-cell receptor.  
 
1.6.1.3 Post-transplant lymphoproliferative disease 
Post-transplant lymphoproliferative disease (PTLD) is a major graft and life threatening 
complication of solid organ transplant. This condition is described as an uncontrolled 
proliferation of lymphocytes due to the effect of post-transplant immunosuppression. 
Sometimes this condition is reversible by reduction of immunosuppression (Dharnidharka 
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et al, 2007). The highest risk to developing PTLD is in cases where the recipient is EBV-
seronegative receiving an allograft from and EBV-positive organ donor. Such patients 
acquire primary infection under the influence of immunosuppression during early post-
transplant period and these patients do not have EBV-specific T cells (Mathur et al, 2004). 
 
1.6.2 T/NK cell tumours 
EBV can infect CD4+, CD8+ T cells as well as NK cells in a minority of IM patients and 
even fewer cases in transplant patients (PTLD). Thus T/NK cell lymphomas are rarely 
observed (Tsao et al, 2004). Most EBV-associated T-cell lymphomas show a cytotoxic 
phenotype which suggests that these tumours may have arisen as a result of proliferating 
cytotoxic T cells trying to kill the EBV-infected cells (Young et al, 2004). Most EBV-
associated T-cell lymphoma arises after chronic active EBV infection. T and NK cell 
lymphomas typically show a latency type II EBV gene expression pattern (Yang et al, 
2004; Tsao et al, 2004).  
 
1.6.3 Carcinomas 
Epithelial cells are relatively resistant to EBV infection, but they have been associated with 
many carcinomas with intense lymphoid infiltrate (lymphoepithelioma), such as carcinomas 
in organs (salivary gland, thymus and lung) (Takada, 2000). This part of the thesis will 
review two very important EBV associated carcinomas, gastric carcinoma and 
nasopharyngeal carcinoma.  
 
1.6.3.1 Gastric Carcinoma 
The first evidence for EBV-association with gastric carcinoma came from the detection of 
the EBV genome in a case of undifferentiated lymphoepithelioma-like gastric carcinoma 
using polymerase chain reaction (Burke et al, 1990). Shortly after the first report of 
undifferentiated EBV presence in lymphoepithelioma-like gastric carcinoma, more cases of 
EBV genome was also found present in lymphoepithelioma-like gastric carcinoma (Min et 
al, 1991; Shibata et al, 1991; Pittaluga et al, 1992). The presence of the EBV genome in 
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lymphoepithelioma-like gastric carcinoma ranges between 75-100% of cases (Osato and 
Imai, 1996). 
 
In addition to finding EBV DNA in these rare lymphoepithelioma-like gastric carcinoma 
cases, EBV DNA could also be detected in 2-16% of cases of the more common gastric 
adenocarcinoma (Osato and Imai, 1996). In a study of 970 cases of gastric carcinoma, 
Tokunaga et al (1993) detected using EBER1 in-situ hybridization, 67 cases (7%) were 
EBV-positive, of which, 8/9 (89%) cases were lymphoepithelioma-like carcinoma and 
59/961 (6%) were poor or moderately differentiated adenocarcinomas. In another study by 
Imai et al (1994) analysis 1000 cases of gastric carcinoma using PCR and EBER1 in-situ 
hybridization showed that 70 (7%) of cases were EBV-positive. Of these 70 EBV-positive 
samples, 8/9 (90%) were EBV-positive undifferentiated lymphoepithelioma-like 
carcinoma, 27/476 (6%) were poorly differentiated adenocarinoma, and 35/515 (7%) were 
moderately to well-differentiated adenocarinomas. It became clear that EBV-association to 
gastric carcinoma is very similar to that of EBV-associated nasopharyngeal carcinoma, in 
that, EBV could almost always be detected in undifferentiated epithelial cells. 
 
Epidemiological studies showed that EBV associated cases of gastric carcinoma in many 
countries is around 10%, with higher EBV-positive cases in the United Sates (16%), this 
may possibly be due to environmental and cultural factors (Qiu et al, 1997). EBV-
association seems to correlate with age since EBV-association is higher in older patients 
(60+ years of age) compared to younger patients. EBV-association is also more common in 
male than in female by 3:1 (M:F) (Tokunaga  et al, 1993). 
 
In-situ hybridization showed that, in EBV-associated gastric carcinoma, EBERs, EBNA1, 
LMP2A, BARF0 and occasionally in small number of cells also the LMP1 transcripts are 
present (Osato and Imai, 1996). Western blotting confirms that the EBNA1 protein is 
present but failed to detect LMP1 or EBNA2. In a small number of cells in some tumors, 
the BZLF1 and BHLF1 proteins were also detected indicating that switching from latent to 
lytic infection occasionally occurs in gastric carcinoma. 
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1.6.3.2 Nasopharyngeal Carcinoma 
Nasopharyngeal carcinoma (NPC) is observed in all parts of the world but vary in incidence 
and histologic subtypes among population groups (Parkin, 2006). However, 
undifferentiated NPC is frequently observed in Southeastern Asian populations, especially 
among Southeastern Chinese people, with incidence rate up to 100/105/year in some 
regions. The tumor is also frequently observed in Inuit populations and Mediterranean 
Africa. On the other hand, NPC incidence in Western populations is relatively low. Two 
other factors have been linked to NPC which may explain the high incidence in these areas. 
Firstly, it has been observed that individuals whose parents have NPC are at increased risk 
to developing NPC, therefore, there is genetic susceptibility among Southern Chinese, 
South East Asian and Inuit people. Secondly, the local diet, the consumption of chemical 
carcinogens in preserved food (preserved meat and salted-fish), influences the risk. 
 
NPC is an epithelial tumor that has been categoried by the WHO into three categories; (1) 
WHO I tumors are highly differentiated with characteristics of epithelial growth patterns 
and keratin filaments; (2) WHO II tumors are poorly differentiated and non-keratinized but 
yet they have retained epithelial cell shape and growth patterns; and (3) WHO III tumors 
are undifferentiated and non-keratinized that lack distinctive epithelial cell growth patterns. 
 
Association of EBV to NPC tumors first came from seroepidemiologic studies showing 
elevated antibody titers in the serum of NPC patients with WHO II and III tumours that are 
directed at EBV capsid antigens (VCA) and early lytic antigens (EA). More importantly, in 
addition to elevated IgG antibodies there were also elevated IgA antibodies directed against 
VCA and EA. It is still debatable as to whether WHO I NPC patients is associated with 
EBV since some studies suggests that these patients have serological profiles similar to the 
control population (Pearson et al., 1983) while other studies suggest that elevated IgA titres 
against VCA could be detected in these individuals (Sam et al., 1989).  
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In situ hybridization assays also confirms the detection of EBV DNA in WHO II and III 
tumors (Desgranges et al., 1975a; Desgranges et al., 1975b), however, the detection of 
EBV DNA in WHO I tumors is less consistent. The lack of clarity in the association with 
EBV and WHO I tumors is mainly because WHO I tumors are relatively uncommon and 
therefore very few samples could be studied. However, in WHO I tumor that had detected 
EBV DNA, LMP1 and EBER expression was relatively lower than that of undifferentiated 
tumors (Pathmanathan et al., 1995) which, may explain the inconsistency of EBV DNA 
detection in differentiated tumors. 
 
EBV gene expression in undifferentiated NPC tumors is limited to the transcription of 
EBERs, EBNA1, LMP1, LMP2, Bam H1A transcripts (Busson et al., 1992; Gilligan et al., 
1990; Gilligan et al., 1991) and BARF1 (Seto et al., 2005). At the protein level, EBNA1 is 
consistently expressed and LMP1 and LMP2 have been detected in approximately 50% of 
tumor samples studied (Heussinger., 2004; Young et al., 1988). Whereas there is still no 
substantial evidence which shows that any of the Bam H1A transcripts and BARF1 is 
expressed in the protein level. At least, in a immunotherapeutic point of view, EBNA1, 
LMP1, LMP2, the predicted Bam H1A polypeptides and BARF1 are potential antigens 
which could be targeted by T lymphocytes. 
 
Elevated EBV VCA- and EA-specific IgA levels could be readily detected in NPC patients 
(Henle and Henle, 1976) and correlates with tumour burden and recurrence. More 
importantly, IgA antibodies to EBV could also be detected at an elevated level in NPC 
patients years before the diagnosis of the disease. Therefore, measuring IgA titres has been 
an important diagnostic tool to determine tumour burden. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Section 1.7 
Immunotherapeutic strategies targeting EBV-positive 
tumours 
50 
1.7 Immunotherapeutic strategies against EBV-positive tumours 
The study of immune-therapy as a treatment for EBV-associated disease started around the 
late 1970’s, in terms of developing prophylactic vaccines and therapeutic vaccines. This 
section of the thesis will review the progress of some of these studies and more 
importantly, to address the importance of EBV-specific CD4+ T cells in immune-therapy. 
 
1.7.1 Prophylactic vaccination 
The work with generating a vaccine as a prevention of EBV infection started around the 
late 1970s with the recognition of EBV associated cancers, endemic BL and 
undifferentiated NPC, aimed at reducing the tumor incidence amongst risk groups (Epstein, 
1976). The glycoprotein gp340 was chosen as the candidate (Randle et al., 1985) for a 
prophylactive vaccine because of its ability to induce virus neutralizing antibodies in 
humans (Pearson et al., 1971). This vaccine was tested in an animal model, cottontop 
tamarins (Saguinus Oedipus Oedipus), because EBV infection of this species causes 
malignant lymphomas (Cleary et al., 1985). Several studies have shown that most gp340 
vaccinated cottontop tamarins produce neutralizing antibody response (Randle et al., 1985; 
Morgan et al., 1988; Finerty et al., 1992). More importantly, when these immunized 
cottontop tamarins were challenged with B95.8 strain EBV, they did not develop lesions 
whereas, control animals did. A similar result was also observed using other animal 
models, marmoset (Callithrix Jacchus), where the authors observed an increase in gp340 
specific antibodies and decrease in viral load in immunized animals when challenged with 
the M81 strain of EBV (Mackett et al., 1996; Cox et al., 1998). In the cottontop tamarin 
model, the authors demonstrated that gp340 vaccination could successfully prevent clinical 
disease. However, the vaccine was unable to prevent persistent infection of the viruses in 
both animal models discussed. Other studies using the gp340 vaccine showed that in 
addition to neutralizing antibody responses, there was also CD4+ T cell responses directed 
against gp340 which could be detected from blood samples taken from healthy human EBV 
carriers (Ulaeto et al., 1988; Wallace et al., 1991). The gp340 vaccine can induce both 
humoral and cell-mediated responses. Furthermore, CD4+ T cell responses to gp340 may 
be important in the control of EBV infection and possibly a role in prevention.  
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A gp340-based vaccine has been tested in humans in China with promising results, where 
vaccinated children all developed antibodies against gp340 (and in most cases also 
neutralizing antibody response) with indication of protection against EBV infection (Gu et 
al, 1995). In a more recent report by Moutschen et al (2007) looking at phase I and II trials 
of a gp350-based vaccine in Belgium, they reported that the vaccine was immunogenic and 
can induce gp350-specific antibody response (including neutralizing antibody response) 
and cell-mediated response. Initial results with the gp340-based and gp350-based 
prophylactic vaccines show protection of naïve healthy host against EBV infection 
 
1.7.2 Adoptive T cell therapy 
Much of the work with adoptive T cell therapy was focused on treating transplant patients 
who are at a high risk of developing PTLD due to the use of immunosuppressive agents. 
The objective of adoptive T cell therapy in PTLD is to provide these patients with EBV-
immunity. The first study of adoptive T cell transfer was conducted by Papadopoulos et al 
(1994) where 5 EBV-positive PTLD individuals were treated with unselected populations 
of donor-derived lymphocytes. In all cases regression of the tumour occured however, they 
also developed graft-versus-host disease. Rooney et al (1995 and 1998) further developed 
the method by enriching EBV-specific T cells in vitro by LCL stimulation. These T cells 
were then transferred into transplant recipients who were at high risk of developing PTLD. 
In all 39 cases, the recipients did not develop PTLD compared to 7/61 of the control group 
who developed PTLD. These data clearly suggest, at least for the treatment of PTLD, that 
adoptive transfer of EBV-specific T cells could prevent development of PTLD in high risk 
patients and possibly other EBV-associated diseases. 
 
Adoptive T cell therapy has also been studied in the treatment of other EBV-associated 
diseases such as HD. Lucas et al (2004) described in their phase I clinical study the 
adoptive transfer of allogeneic EBV-specific T cells. The reason for using allogeneic T 
cells instead of autologous T cells is because other studies suggest that T cells from HD 
patients expand at a slower rate and have reduced expression of T cell receptor ζ chain 
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(Roskrow et al, 1998). This study suggests adoptive transfer of allogeneic EBV-specific T 
cells in the treatment of EBV disease is safe, since these T cells specifically recognise EBV 
antigens restricted through HLA I molecules and does not induce graft-versus-host disease 
(Lucas et al, 2004). More importantly, one patient out of six was disease free 22 months 
after infusion. However, 5/6 patients later showed progression of the disease. This study 
demonstrates adoptive transfer of EBV-specific T cells to treat EBV diseases is possible. 
However, further studies are required to improve the effectiveness of the treatment.  
 
The study of CD8+ T cell responses to EBV antigens in Chinese healthy EBV carriers and 
in NPC patients suggest immunotherapy may be possible (Lee et al, 2000). In this study the 
authors detected, in the blood of NPC patients using cytotoxicity assay, CD8+ T cell 
responses against NPC-associated EBV protein LMP2 and EBNA1 but not to LMP1 or 
BARF0. Interestingly, the authors also detected EBNA1-specific CD8+ T cell responses 
from tumour infiltrating lymphocytes (TIL) but did not detect any responses against the 
other NPC-associated EBV proteins. More importantly, Lee et al (2000) demonstrated 
using an HLA-A11 north African-derived NPC cell line (C15) that the HLA I processing 
pathway is intact. In this experiment, the authors infected the C15 cell line with a vaccine 
vector expressing EBNA3B and were then presented to HLA-A11 restricted EBNA3B-
specific CD8+ T cells. The EBNA3B vaccina infected C15 cells were recognised and killed 
by the HLA-A11 restricted EBNA3B-specific CD8+ T cells. These data show that NPC 
cells do have the capability to process and present antigens via the HLA I pathway and 
NPC patients have CTL responses against NPC-associated EBV proteins EBNA1 and 
LMP2. It was argued at the time of publication that the EBNA1 protein does not get 
processed and presented via the HLA I pathway, therefore EBNA1 would not have any 
therapeutic benefit. But recent research show strong evidence that EBNA1 is processed and 
presented by the HLA I pathway, thus EBNA1 and LMP2 are potential targets for immune 
therapy (Blake et al, 1997). 
 
The adoptive transfer of LMP2-specific CD8+ T cells in NPC has been studied by Straathof 
et al (2005). In this study of 10 NPC patients, comprised of 4 patients who were in 
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remission but are at high risk of relapse and 6 patients were unresponsive to chemotherapy 
and radiation, autologous LMP2-specific CD8+ T cells administration was demonstrated to 
be safe with no immediate or long-term effects. Nine of ten patients had detectable EBV 
DNA in the PBMCs prior to T cell transfer and EBV load fell within 6 weeks after infusion 
in 6 patients (Straathof et al, 2005). The LMP2-specific T cell population was accessed in 8 
patients after T cell infusion using IFN-γ ELISpot assays. In 4 of 8 patients, the number of 
LMP2-specific T cells increased by 2-fold, but this increase in LMP2-immunity was only 
transient and returned back to baseline level 6 weeks after infusion in 3 of the 4 patients. 
Clinical responses were evaluated from computed tomography and magnetic resonance 
imaging. Of the 6 patients, who were unresponsive to chemotherapy and radiation, 1 patient 
had stable disease for more than 14 months without additional therapy, 1 patient had partial 
response sustained for 12 months, 2 patients had no response and 2 patients had complete 
remission. All 4 patients who were in remission at the time of T cell therapy remained 
disease free after 19-27 months (Straathof et al, 2005). The outcome of this study show a 
promising future for T cell based therapy in the treatment of EBV diseases. However, 
further studies are needed to improve the tumour response rate, possibly by maintaining the 
number of EBV-specific T cells, since in 2 patients who had tumour response sustained 
LMP2-immunity for 3 months. This may be an implication that CD4+ T cells are needed in 
maintaining an effective CD8+ response. 
 
The following conclusions could be made from adoptive T cell transfer studies; (1) EBV-
specific T cells could be safely administered into patients with EBV diseases, (2) in most 
cases, tumour-specific responses are observed and in some cases would lead to remission, 
(3) adoptive T cell transfer studies in patients with increased risk of relapse or EBV-
diseases show almost 100% prevention, and (4) as a direct treatment of EBV tumours, 
tumour response rate is poor because EBV-specific immunity could not be sustained. These 
points do strongly support that CD8+ T cells are important in the treatment of EBV 
diseases but also indicate CD4+ T cells are required. 
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1.7.3 Vaccine therapy 
Studies on vaccine-based therapy have also showed promising results in vitro and in vivo, 
such as using polyepitope vaccine and EBV chimeric antigen MVA constructs. The 
objective of these vaccine therapies are to induce a broad EBV-specific response in vivo, 
possibly both CD8+ and CD4+ responses. 
 
The polyepitope technology allows the expression of epitopes in a string-of-beads without 
the flanking sequence. This would limit or remove the oncogenic effect of certain proteins, 
such as LMP1. In a study by Smith et al (2006), the authors generated a polyepitope 
vaccine containing CD8+-specific epitopes from EBNA1, LMP1 and LMP2 (E1-LMPpoly). 
In this study, PBMCs from 14 human volunteers (4 healthy EBV carriers and 10 HD 
patients) were infected with adenovirus expressing E1-LMPpoly (AdE1-LMPpoly). The 
authors report that their polyepitope vaccine was capable of inducing CD8+ responses 
against the EBV epitopes from EBNA1, LMP1 and LMP2 in healthy EBV carriers. But 
more importantly, they also showed that the polyepitope vaccine could restore EBV-
specific CD8+ T cell function in PBMC samples taken from HD patients, with a significant 
proportion of the cells expression CD62L which is required for entry into the lymph node 
and access the tumour site. However, in this study, Smith et al (2006) did not incorporate 
CD4+ T cell epitopes into their construct.  
 
In another study, Taylor et al (2004) generated an EBNA1-LMP2 (EL) chimer MVA 
construct, by joining the C-terminal half of EBNA1 (EBNA1 363-641) with full length 
LMP2 (mutated at positions 74 and 112), and tested the ability of the construct to induce 
EBNA1 and LMP2 –specific CD4+ and CD8+ responses in vitro. In this study, the authors 
demonstrated that the EBNA1 and LMP2 in the construct did not retain biological function. 
More importantly, when the construct was infected into DC, these MVA-EL infected DCs 
were killed by EBNA1 and LMP2-specific CD8+ T cell clones and induced CD4+ T cells 
recognition. 
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1.8 Project aims 
The aim of this thesis was to determine potential NPC-associated EBV protein targets that 
could induce EBV-antigen-specific T cell responses which could be useful in the treatment 
of EBV-associated NPC. 
 
The first objective of this thesis will explore the potential usefulness of BART products 
and/or BARF1 as T cell targets, both CD4+ and CD8+ responses. This section of the thesis 
was initiated from the study by Kienzle et al (1998) where they report the finding of CD8+ 
T cell response against an HLA-A2 restricted BARF0 epitope. The study by Kienzle et al 
(1998) is the first piece of evidence which indicated that these BART products and BARF1 
protein may possibly be expressed and could be potential targets for T cell recognition. In 
the context of NPC, BART and BARF1 transcripts are expressed by NPC cells, and if T 
cell responses to these predicted BART products and BARF1 protein are detected, it would 
be a good indication that these polypeptides are expressed in NPC cells. More importantly, 
they are potential targets for immunotherapy. 
 
The second objective of this thesis will focus on determining CD4+ T cell responses to the 
Chinese EBNA1 protein using PBMC samples from healthy S.E. Chinese EBV carriers 
(Hong Kong). CD4+ T cell responses to EBNA1 have been described in healthy Caucasian 
EBV carriers (Leen et al, 2001), however, HLA polymorphism between the two 
populations and EBNA1 polymorphism between the Chinese and Caucasian EBV strains 
may contribute to differences in antigen presentation to T cells. Therefore, it was important 
to revisit CD4+ T cell responses, using PBMCs from healthy Chinese EBV carriers, to 
Chinese EBNA1.  
 
The third and final objective of this thesis was to generate Chinese EBNA1-specific CD4+ 
T cell lines and clone for use to accurately define epitopes identified within the Chinese 
EBNA1 protein. This section of work will provide vital information about the features of 
Chinese EBNA1-specific CD4+ T cells and their potential usefulness in T cell based 
immunotherapy for the treatment of NPC. 
 
 
 
 
 
 
 
 
 
 
 
 
 
Section 2 
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2.0 Methods and Materials 
 
2.1 Tissue culture media, supplements and reagents 
 
2.1.1 RPMI 1640 
RPMI 1640 supplemented with L-glutamine (0.2M) purchased from GIBCO was used for 
culture of all lymphocyte cell lines 
 
2.1.2 Foetal calf serum (FCS) 
FCS had been pre-membrane filtered, virus and mycoplasma screened, was purchased from 
GIBCO or Imperial Labs and stored at -20˚C in 20ml aliquoted until use. 
 
2.1.3 Human Serum (HS) 
Sterile male HS of type AB purchased from HD supplies (UK) had been screened for virus 
and mycoplasma was stored in -20˚C in 25ml aliquots until use. 
 
2.1.4 Penicillin-Streptomycin 
A combined solution of Penicillin (104 units/ml) and Streptomycin (10mg/ml) in 0.9% 
NaCl was purchased from SIGMA and stored at -20˚C in 5ml aliquots until use. 
 
2.1.5 MLA 
The Gibbon cell line MLA-144 spontaneously release IL-2 into the supernatant which was 
used as a source of growth stimulus to supplement T cell media. These cells were sub-
cultured for 2 weeks in RPMI 1640 with 10% FCS without further feeding, of which, 
supernatant was harvested by centrifugation at 1600rpm for 10 mins and filtered through a 
146mm 0.2μm membrane (PALL). MLA supernatant was stored in 60ml aliquots at -20˚C 
until use at 30% of T cell media. 
 
2.1.6 IL-2 
Lypophilised powder (Totem (Peprotech)) was reconstituted at 105 IU/ml, filtered through a 
0.2μm membrane and stored at -20˚C in 500μl aliquots until use. 
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2.1.7 Phytohaemagglutinin (PHA) 
PHA was purchased from ICN. 
 
2.1.8 Complete media 
Complete media was prepared by combining 500ml of RPMI 1640, 50ml of FCS, and 1ml 
of Penicillin-Streptomycin. Lymphoblastoid cell lines were all cultured in complete media. 
 
2.1.9 T cell line and clone media 
T cell line and clone media was prepared by mixing 500ml RPMI 1640, 50ml FCS, 10ml 
HS, 1ml Penicillin-Streptomycin, 150ml MLA and IL2 (25IU/ml). T cell lines and clones 
were all cultured using this media. 
 
2.1.10 Tissue culture plates 
Tissue culture plates, 24-well plates and 96 U-bottom, V-bottom and flat-bottom plates 
were all purchased from IWAKI or NUNC. Falcon 50ml and 15ml test tubes were 
purchased from BioRad or Starstedt. 
 
2.1.11 Blood donors 
Blood was donated for the BamH1A and BARF1 work by healthy laboratory donors and 
buffy coats obtained from the Birmingham Blood Transfusion Service (Vincent Drive, 
Edgbaston, Birmingham). While for the EBNA1 work, peripheral blood mononuclear cells 
(PBMCS) samples came from Prince of Wales Hospital (Shatin, Hong Kong) 
 
2.1.12 Preparation of PBMCs 
PBMCs were obtained from peripheral blood collected by venepuncture into heparinised 
syringes or from buffy coats. Blood donations were diluted 1:1 in RPMI 1640 and layered 
onto 50ml Falcon test tubes containing 10ml lymphoprep (Axis-Shield diagnostics) and 
separated by density grade centrifugation at 1900rpm for 30mins. PBMCs were harvested 
from the interface of the lymphoprep and plasma and were washed several times at 
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decreasing rpm. PBMC samples were then either used fresh or kept in liquid nitrogen until 
needed. 
 
2.1.13 EBV virus stock 
EBV virus stock was generated from the B95.8 cell line cultured in RPMI 1640, 10% FCS 
and 2mM/ml L-glutamine. The cell line was maintained by feeding twice a week. The 
B95.8 virus stock was prepared by collecting the supernatant from B95.8 cell line and 
centrifuged at 1400rpm for 5 mins. The supernatant was then passed through a 0.45 μm 
filter and finally stored at 4ºC until use (but not stored for more than 3months). 
 
2.1.14 Cyclosporin A (CSA) 
CSA (Sanimmun, Sandoz) was reconstituted in RPMI 1640 to a stock concentration of 
10μg/ml. 
 
2.1.15 Generation of lymphoblastoid cell lines (LCL) 
LCLs were generated by in vitro transformation of B cells from PBMC samples of HK 
Control donors for the EBNA1 work. 5x106 PBMCs were pelleted by centrifuge at 
1600rpm and all supernatant was removed. Cell pellet was resuspended in 500μl aliquot of 
B95.8 virus from the Marmoset B95.8 cell line and incubated for 1 hour in a 37˚C 
incubator with 5% CO2 flicking every 15mins. After incubation, cells were washed and 
cultured in 24 well plates with RPMI 1640 with L-glutamine containing 10% FCS, 
penicillin/streptomycin and 0.1 μg/ml cyclosporin A for the first 2 weeks to suppress T cell 
activity. LCL cultures were subsequently split and re-fed with fresh medium twice weekly. 
 
2.1.16 Treatment of PBMC with PHA 
PBMCs (106 cells/ml ) were cultured for one hour with complete media containing 1μg/ml 
of PHA. After one hour, PBMCs were washed. 
 
2.1.17 γ-irradition of PBMC and LCLs 
PBMCs were irradiated at 4000rads and LCLs at 6000rads using a γ-irradition source. 
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2.1.18 Cryopreservation reagents  
Dimethyl sulphoxide (DMSO- tissue culture grade) and Isopropanol (Propan-2-ol) were 
purchased from sigma. 1ml sterile plastic cryovials were from NUNC and Mr Frosty 
containers were from Nalgene.  
 
2.1.19 Freezing media 
100ml of freezing media was prepared by mixing 40ml RPMI 1640, 50ml FCS and 10ml 
DMSO. 
 
2.1.20 Cryopreservation and recovery of cryopreserved cells 
Cells to be cryopreserved were centrifuged at 1600rpm for 10mins and resuspended in 
freezing media and aliquoted in 1ml sterile plastic cryovials (Nunc). The aliquots were 
placed in -70˚C freezer overnight in a Mr Frosty (Nalgene) containing isopropanol and then 
transferred the following day in a freezer containing liquid nitrogen for long term storage.  
 
Cells were recovered from liquid nitrogen by fast thawing in a 37˚C waterbath and 
transferred to a 15ml tube to which 5ml of RPMI 1640 containing 10% FCS was added 
drop-wise. Cells were allowed to rest for 1 min before pelleted by centrifuge at 1600rpm. 
The cells were further washed 2 times in RPMI 1640 containing 10% FCS before 
resuspended in their appropriate growth medium for culture. 
 
2.1.21 Human IFNγ 
Human IFNγ was purchased from R&D systems 
 
2.1.22 Phosphate buffered saline (PBS) 
10 tablets (OXOID) were dissolved per litre of sterile water 
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2.1.23 Peptides 
Synthetic 20mer peptides were generated using 9-fluorenylmethoxycarbonyl chemistry 
(Alta Biosciences, University of Birmingham) and dissolved in dimethylsulfoxide (DMSO, 
Fischer Scientific). Synthetic peptides used for this study were a series of 20-mer peptides, 
overlapping by 15 amino acids, covering 126aa, 174aa and 103aa unique sequences of the 
B95.8 BamH1A polypeptide products A73, BARF0 and RPMS1 respectively and 220aa 
BARF1 and 641aa unique sequence of the CKL EBNA1. The peptide concentrations were 
determined by Biuret assay (Doumas, 1975) 
 
2.1.24 Bovine serum albumin (BSA) 
BSA (5mg) was purchased from Fermentas Life Sciences 
 
2.1.25 Biuret reagent 
Biuret reagent was prepared by dissolving 4.6g sodium tartrate and 2.5g potassium iodide 
in 250ml 0.6% copper sulphate solution. To this 50ml of sodium hydroxide, 300ml of 
distilled water was added. 
 
2.1.26 Biuret assay 
The Biuret assay was performed in a 96-well v-bottom plate.100μl of Biuret reagent was 
aliquoted to each well to which 20μl of the peptide solution was added followed by a 
further 100μl of Biuret reagent. The plate was left to incubate at room temperature for 
10mins, to allow the colour to develop, and then centrifuged at 2000rpm for 3mins to 
remove precipitants. 150μl of supernatant from each well was transferred into a 96-well 
flat-bottomed plate and the absorbance read using an automated plate-reader (Bio-Tek) at 
540nm. The peptide concentration was calculated from a standard curve (2.5mg-40mg/ml) 
of bovine serum albumin (BSA) prepared during the same assay. 
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2.1.27 Mycoplasma test 
Cell cultures were tested weekly for mycoplasma infection using Immuno-Mark 
immunofluorescence mycoplasma testing kit (ICN) in accordance to the manufacture 
instructions. 
 
2.1.28 Antibodies 
Antibodies used in the depletion of CD8+ T cell population (magnetic bead coated Anti-
CD8 monoclonal antibody) was purchased from Dynal UK Ltd.  
 
Rabbit anti-human IgM CD16 antibodies used in the depletion of CD16+ NK cells were 
purchased from Serotec.  
 
Antibodies used in flow cytometry were purchased from BD Biosciences (FITC-conjugated 
anti-CD8, FITC-conjugated anti-CD4, FITC-conjugated anti-CD16. 
 
Antibodies used in the identification of epitope HLA-restriction were purchased from 
Serotec (anti-HLA-DQ, SPVL3), established in this laboratory (anti-HLA-DR, produced by 
the L243 ATCC clone), and provided by Dr. A.M de Jong from the University of Leiden, 
the Netherlands (anti-HLA-DP B7.21). 
 
Antibody used in the detection of Epstein-Barr Virus capsid antigens (VCA staining), the 
FITC-conjugated goat anti-human IgG, was purchased from BD Biosciences. 
 
Antibodies used in the ELISpot assay were purchased from Mabtech (Stockholm, Sweden). 
 
Antibodies used in the ELISA assay were purchased from Pierce Endogen. 
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2.1.29 Rabbit complement 
Rabbit complement was purchased from serotec. 
 
2.1.30 CD16+ NK cell depletion of PBMC 
For ELISpots with high background, PBMC samples were depleted of CD16+ NK cell 
population using CD16 IgM-induced complement killing. PBMCs were incubated in the 
dark with rabbit antihuman CD16 IgM antibodies for 30 minutes. During this time, the 
rabbit complement (Serotec) was reconstituted in ice cold distilled water and kept on ice 
until use. After the incubation, the rabbit complement was added to the CD16 IgM labeled 
PBMCs, incubate for 1 hour at 37˚C and then washed 3 times with RPMI 1640 containing 
10% FCS. 
 
2.1.31 CD8+ T cell depletion of PBMCs 
For the EBNA1 work, PBMC samples were depleted of CD8+ T cell population using 
Dynabead depletion (Dynal, UK Ltd). PBMCs were incubated with magnetic beads pre-
conjugated to anti-CD8+ antibodies in a 4˚C cold room for 30 mins on a cell roller. 4 beads 
were used per target cell, assuming that the CD8+ populations make up one third of the total 
PBMC count. After incubation, a magnet was used to retain the CD8+ T cells and the 
enriched CD4+ T cell population in the supernatant was removed. 
 
2.2 Generation of T cell lines and clones 
 
2.2.1 ELISpot assay plate 
ELISpot assay plates, 96 well Millipore plates, were purchased from Bedford MA 
 
2.2.2 Identification of EBNA1-specific CD4+ T cell responses by ELISpot assay 
96 well Millipore plates with a 0.45μm hydrophobic high protein-binding immobilon-P 
polyvinylidene difluoride membrane were coated with 15μg/ml of anti-IFN-γ mAbs, 1-DIK 
(Mabtech, Stockholm, Sweden) overnight at 4˚C. The wells were washed 6 times in the 
following morning with RPMI 1640 and then blocked for 1 hour with RPMI 1640 with 
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10% FCS. 5x105 CD8-depleted or whole PBMCs were added to single wells to which 
individual peptides were added to make a final concentration of each peptide of 2μM. The 
plates were incubated overnight at 37˚ and 5% CO2. In the following day, cells were 
removed from the plate by washing 6 times with PBS containing 0.05% Tween (wash 
buffer), and 1μg/ml solution of biotinylated anti-IFN-γ mAb, 7-B6-1 (Mabtech), was added 
to each well and left to incubate for 2-4 hours at room temperature. The wells were washed 
again 6 times with wash buffer and PBS streptavidin-conjugated alkaline phosphatase 
(Mabtech) was added for 2 hours. The wells were given a final wash and an alkaline 
phosphatase-conjugated substrate kit containing 5-bromo-4-chloro-3-indolyl phosphate 
(Bio-Rad, Richmond, CA) was added to the wells for 15-20mins. The plate was developed 
by running under cold water to which spots representing individual IFN-γ producing cells 
could be visualized. Spots in each well were counted under a dissection microscope by eye 
3 times and an average taken as the result. 
 
2.2.3 Isolation of EBNA1-specific CD4+ T cell lines 
HK control donor PBMCs were thawed from liquid nitrogen and depleted of CD8+ T cell 
population. 5x106 CD8-depleted PBMCs per reactivation were pelleted by centrifugation, 
resuspended in 1ml of RPMI 1640 containing 5μg/ml peptide and incubated for 1 hour at 
37˚C with flicking every 15mins. After 1 hour incubation, each reactivation was washed 3 
times with RPMI 1640 and resuspended in 2ml of RPMI 1640 with L-glutamine and 
penicillin/streptomycin in a 24 well plate (IWAKI) and in cubated for 7 days at 37˚C. On 
day 7, the culture were tested for peptide specificity by IFN-γ ELISpot. 
 
2.2.4 Preparation of peptide-loaded LCLs 
LCLs (106 cells/ml) were incubated for 1 hour with 5μg/ml of relevant peptides at 37˚C. 
After 1 hour, the LCLs were washed 3 times in complete media. 
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2.2.5 Cloning media 
Cloning media was prepared by mixing 500ml RPMI 1640 with 10ml HS, 1ml penicillin-
streptomycin, 106 cells/ml of γ-irradiated PHA-treated PBMC and 104 cells/ml of γ-
irradiated peptide-loaded LCLs. 
 
2.2.6 Generation of EBNA1-specific CD4+ T cell clones 
Epitope-specific CD4+ T cell clones were isolated by limiting dilution cloning from 
polyclonal PBMC cultures. T cells from the reactivations were seeded, in 100μl RPMI 
1640 with L-glutamine and 10% human serum, at between 0.3 and 30 cells per well in 96-
well U-bottom plates (Nunc or IWAKI) with 104 cells per well of γ-irradiated autologous 
LCLs (6000 rads) preloaded with 5μM of the relevant peptide and 105 cells per well of 
allogeneic γ-irradiated phytohaemagglutinin (PHA)-treated PBMCs (4000 rads) as feeders. 
Feeder cells were separated from a pool of 3 fresh buffy coats obtained from the 
Birmingham National Blood Transfusion Service, and activated with 10μg/ml PHA for 1 
hour before washing with RPMI 1640 and γ-irradiated. On day 3, the wells were fed with 
100μl RPMI 1640 with L-glutamine, 10% human serum, 60% MLA and 20 IU/ml IL-2. 
 
2.2.7 Identification of epitope-specific CD4+ T cell clones 
After 4-6 weeks depending on the growth of the microcultures, proliferating wells were 
tested for peptide specificity by IFNγ Enzyme linked immunosorbant assay (ELISA). Cells 
were prepared by taking 50μl of each growing clone into a 96-well v-bottom plate, 
centrifuged, washed 3 times in RPMI 1640 and resuspended in 250μl medium. 100μl of 
each clone was incubated overnight with LCL alone or LCL pre-exposed to 5μM epitope 
peptide and, on the following day, the supernatants were tested by IFNγ ELISA to identify 
the epitope-specific clone, as those giving increased IFNγ release in response to LCL pre-
exposed to epitope peptide than LCL alone.  
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2.2.8 IFN-γ ELISA assay 
A known number of T cells (200-5000) were incubated in U- or V-bottom microtest plate 
wells with standard numbers of autologous, HLA-matched or HLA-mismatched LCLs that 
were either unmanipulated, pre-loaded for 1 hour with 5μM peptide (or an equivalent 
concentration of DMSO solvent as a control) and then washed, or pre-infected with MVA 
expressing gly-ala deleted EBNA1 (E1ΔGA) or LAMP-targeted E1ΔGA (or MVA-pSC11) 
at an moi. of 10 and then washed. In blocking assays, LCLs were pre-incubated (either as 
LCLs alone or pre-loaded with epitope peptide) with MAbs specific for HLA-DR (L243, 
ATCC clone HB-55), HLA-DQ (SPV-L3, Serotec) and HLA-DP (B7.21 provided by DR 
A.M. de Jong, Leiden University, The Netherlands) for 1 hour before T cells were added to 
the assay. The supernatant was harvested 18 hours later and was assayed for IFNγ by 
ELISA (Endogen) following the manufacturer’s protocol. 96-well Maxisorp plates (Nunc) 
were coated with 50μl of a 0.75μg/ml solution of a mouse IgG1K anti-human IFNγ MAb 
(Pierce, Endogen) overnight at 4°C and, on the following morning, the antibody was 
flicked out of the wells and then blocked at room temperature for 1 hour with 1% BSA, 
0.05% Tween 20 in PBS. The plates were then washed 4 times in wash buffer (0.05% 
Tween 20 in PBS) and 50μl of neat or diluted supernatant from the T cell assay was added 
to each well and left at room temperature for 2-4 hours. After incubation, the supernatant 
was discarded, washed 6 times in wash buffer and biotinylated mouse IgG1K anti-human 
IFNγ MAb (Pierce, Endogen) was added at 0.375μg/ml and left at room temperature for 1-2 
hours, followed by further washing and addition of Extravidin peroxidase conjugate 
(SIGMA) for a further 30 minutes. After a final 8 washes of the plates in wash buffer, 
100μl of developing solution TMB (3,5’,5’,5’-tetramethyl benzidine, Tebu-Bio 
laboratories) was added and left at room temperature for 20 minutes to allow the colour to 
develop. 100μl of 1M HCL was added to each well to stop the reaction and the 
absorbencies were measured at 450nm using an automated spectrophotometer (Wallace 
Victor2 1420 multilabel Counter). All results presented were the mean of triplicate wells. 
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2.2.9 Flow Cytometry 
Flow cytometry was performed to confirm the percentage of CD8+, CD4+ and/or CD16+ 
cells within whole PBMC, CD8+ depleted PBMC, CD16+ depleted PBMC and T cell 
clones. 1x106 cells were pelleted by centrifugation at 13,000 rpm for 1 minute in a 15 ml 
Falcon tube pre-coated with FCS to prevent cells adhering to the tube. The cells were 
washed in PBS and resuspended in 500μl 1% BSA in PBS and aliquoted into four 10ml 
Falcon tubes, to which, either 2μl of a FITC-conjugated anti-CD8+ MAb (BD Biosciences), 
2μl of a FITC-conjugated anti-CD4+ MAb (BD Biosciences), 2μl FITC-conjugated anti-
CD16 MAb (BD Biosciences) or 10μl of an IgG control MAb were added. Cells were 
incubated for 30 minutes at room temperature before washing in 1% BSA in PBS three 
times to remove excess antibody and resuspended in 500μl 1% paraformaldehyde in PBS. 
The samples were kept at 4˚C until analysis on a Becton Dickinson 440 flow cytometer. 
 
2.2.10 MVA 
The different MVA constructs were prepared and provided by Dr. Graham Taylor at the 
University of Birmingham 
 
2.2.11 51 Chromium 
51 Chromium was purchased from Amersham Biosciences. 
 
2.2.12 Cytotoxic T lymphocyte (CTL) assay 
CD4+ T cell clones were tested for cytotoxicity against target cells by chromium release 
assays. 1x106 target LCL cells were pelleted by centrifugation at 1600 rpm, supernatant 
media was removed by pipetteing and the cells were resuspended in 15μl (75μCi) of 51Cr-
sodium chromate (Amersham Biosciences). Target cells were then incubated at 37°C, 5% 
CO2 for 90 minutes to allow uptake of the radioisotope. To appropriate targets, 5μM 
epitope peptides (or an equivalent volume of DMSO solvent as a control) were added for 
the final hour of incubation. During this time, the T cell clones were counted and diluted in 
RPMI 1640 containing 10% FCS and aliquoted in 100μl into 96-well V-bottom plates 
providing the required number of cells for various effector:target ratios. Following 
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incubation with the radioisotope, the target cells were washed twice with RPMI 1640 
containing 10% FCS, counted and diluted to allow 2500 target cells to be added to the T 
cells per 100μl aliquot. For each target, the radioactivity spontaneously released from the 
labeled targets when incubated with 100μl of the medium alone and the maximum 
radioactivity released when incubated with 100μl 1% SDS solution served as controls. The 
plates were centrifuged at 1200rpm for 3 minutes and incubated for 5 hours or 18 hours at 
37°C, 5% CO2. After this time, 100μl was harvested from each well into LP2 tubes 
(Luckman) and the radioactivities were counted on a gamma-counter (Cobra Auto-Gamma 
counting system, Hewlett Packard). Results for the CTL assays are expressed as a 
percentage specific lysis where; 
 
% specific lysis = (release from target with T cells – spontaneous release) x 100 
     Maximum release 
 
And all results are expressed as the means from triplicate wells. 
 
2.2.13 VCA staining 
The EBV status of the blood donors participating in this study was tested by 
immunofluorescent staining for antibodies against the viral capsid antigen (VCA). Cells 
from a B95.8 LCL and a control EBV-negative cell line, BJAB, were washed in PBS and 
resuspended at a concentration of 107 cells/ml. The cell suspension were transferred onto 
the holes of SM-011 slides (Hendley-Essex) in 10μl aliquots, air dried and fixed in acetone 
for 5 minutes at -20°C. Once fixed, the slides were air dried at room temperature and either 
used immediately for the detection of VCA antibodies or stored at -20°C for later use. 
Plasma collected from blood donors, during the preparation of PBMCs, was diluted 1:10 – 
1:5120. 20μl of donor plasma, at each dilution, was added onto a hole of B95.8 LCL-fixed 
slide and a BJAB LCL-fixed slide. The slides were incubated for 1 hour at 37°C in a moist 
chamber to prevent drying out. Following washing in PBS twice for 10 minutes, the areas 
of the slide around the spots of cells were dried with a cotton bud to prevent transfer of 
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antibodies between the different cells. 10μl of 1:50 dilution of a FITC-conjugated anti-
human IgG MAb was added to each spot of cells and incubated for 1 hour at 37°C in the 
humidified box. The washing and drying procedures were repeated and DABCO was dotted 
on the slides and covered with coverslips (22x70x1, Surgipath). The slides were examined 
under a UV microscope and donors who were positive for anti-VCA antibodies detected 
against B95.8 LCL but not BJAB LCL were designated EBV-positive. And donors without 
detectable fluorescence to either cell lines were designated EBV-negative. 
 
2.2.14 Human Leukocyte Antigen (HLA) typing 
47 donors from the EBNA1 work were HLA typed at the class II A, B and C loci and at the 
class II DR and DQ loci at the Birmingham Blood Transfusion Service and class II DP 
typed at the National Blood Authority (Tissue Typing Laboratory, Churchill Hospital, 
Oxford, United Kingdom) by PCR-based DNA typing. 
 
2.2.15 DNA extraction for HLA typing and the sequencing of BARF1 and EBNA1 
DNA was extracted from spontaneous LCL samples generated from Healthy Chinese 
donors. 5x105 cells was washed once with PBS, transferred to a 1.5ml Eppendorf tube and 
kept cold on ice for 10 minutes. The cells were then centrifuged at 13,000 rpm for 10 
minutes with a desk-top microcentrifuge to get a pellet of cells and the excess PBS was 
removed with a pipette, to which, 400μl of 50mM Tris at pH8 and 500μl of warm phenol 
was added, vortex for 30 seconds and centrifuged at 13,000 rpm for 10 minutes. The 
aqueous layer was extracted with a pipette into a fresh 1.5ml Eppendorf tube, 500μl of 
warm phenol was added, vortex for 30 seconds and centrifuged for 2 minutes at 13,000 
rpm. The aqueous layer was extracted to a fresh 1.5ml Eppendorf tube and 500μl of 
chloroform was added, vortex for 30 seconds and centrifuged for 2 minutes at 13,000 rpm, 
and this procedure was repeated once. The aqueous layer was extracted to a fresh 1.5ml 
Eppendorf tube, 100μl of 3M sodium acetate at pH 5.2 and 200μl of 100% ethanol was 
added and vortex for 30 seconds. The mixture was stored overnight in a -70˚C. 
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2.3 Sequencing of BARF1 and EBNA1 
 
2.3.1 Sodium Acetate 
3M sodium acetate was prepared by dissolving 24.6g of sodium acetate (Sigma) into 100ml 
of distilled water 
 
2.3.2 Tris/acetate buffered EDTA (TAE) 
500mls of a concentrated stock of TAE (50x) was prepared by addition of 121g Tris base, 
28.6ml glacial acetic acid and 5ml 0.5M EDTA to sterile water. 
 
2.3.3 Ethidium Bromide 
(10mg/ml) Ethidium Bromide was purchased from Sigma (UK) 
 
2.3.4 PCR and Sequencing primers 
The sequencing primers were generated by Sigma-Genosys Ltd (UK). The primers used in 
the PCR reaction and sequencing for BARF1 and EBNA1 are listed in table 2.1 
 
2.3.5 PCR reagents 
Taq polymerase was purchased from Roche 
 
2.3.6 Polymerase Chain Reaction (PCR) 
DNA extracts generated from Healthy Chinese donor spontaneous LCL samples were used 
in the amplification of the BARF1 and EBNA1 gene. A master mix for one reaction was 
prepared in a 50μl PCR thermal eppendorf tube by mixing 2.5μl of 10x PCR in Mg2+ 
buffer, 0.5μl 10mM dNTP, 1.25μl 10mM primer 1, 1.25μl primer 2, 17.5μl de-ionised 
water and 0.2μl Taq polymerase. To this, 2μl of DNA preparations (or B95.8 DNA extract 
was used as positive control and de-ionised water was used as negative control) was added 
to the master mix. The solution was overlaid with 50μl of mineral oil and subjected to 40 
cycles at 94˚C for 30 seconds and 72˚C for 30 seconds. 
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 Coordinate of the primers in 
relation to the EBV genome 
Primer Sequence 
BARF1 
PCR primer 1 
 
165383-165403 
 
5’-TGTAGACTTGGCTGGCCTCAT-3’ 
PCR primer 2 166324-166305 5’-AGCAGCTGTGACAATCTTCA-3’ 
Seq-primer 1* 166118-166099 5’-ATTTTTCCCAACGCAGGTCA-3’ 
Seq-primer 2 165890-165873 5’-GACAGACAGCGTTAGAGG-3’ 
Seq-primer 3 
EBNA1 
PCR primer 1 
PCR primer 2 
Seq-primer 1 
Seq-primer 2 
Seq-primer 3 
Seq-primer 4 
Seq-primer 5 
Seq-primer 6 
Seq-primer 7 
165618-165635 
 
107659-107704 
110149-110130 
107830-107849 
107967-107947 
109083-109102 
109115-109095 
109323-109342 
109869-109850 
109904-109885 
5’-AGCCTCGGTCCAGACATT-3’ 
 
5’-AATTTGAGGCCTGGCTTGAG-3’ 
5’-TAAGGGGGCCAGGCTAAAGC-3’ 
5’-ACAGCGACCATGAAGGGGAT-3’ 
5’-TGGCCCCTCGTCAGACATGAT-3’ 
5’-AAAGAGGCCCAGGAGTCCCA-3’ 
5’-GATGACTGACTACTGGGACTC-3’ 
5’-CGCAAAAAAGGAGGGTGGTT-3’ 
5’-CTGCCCTTCCTCACCCTCAT-3’ 
5’-TAAGGGGGCCAGGCTAAAGC-3’ 
 
Table 2.1: Primers used in the sequencing of the BARF1 and EBNA1 gene 
* Sequencing primer 
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2.3.7 Agarose gel powder for the separation of PCR products 
Agarose gel powder was purchased from Sigma. 
 
2.3.8 Preparation of electrophoresis 
PCR products were purified using gel electrophoresis. 1.5g of agarose gel powder was 
dissolved in 100ml of distilled water and 2ml of 50x TAE and 5μl of (10mg/ml) ethidium 
bromide was added to the mixture. The gel was allowed to set in a rectangular container 
with a comb placed at one end of the gel. The set gel was loaded onto an electrophoresis 
tank containing running buffer (1x TAE and ethidium bromide). 10μl of PCR product with 
2μ of dye contain 5x TAE was loaded into the wells of the gel and 4μ of DNA ladder was 
loaded at the end wells. The gel was allowed to run at 180V for 45 minutes. The gel was 
taken into the dark room and observed under a UV light.  
 
2.3.9 Extraction of PCR products from the agarose gel 
DNA extraction from the agarose gel was conducted using QIAquick kit (Qiagen) 
following the instruction manual provided. 
 
2.3.10 Sequencing reaction reagents 
Reagents used in the sequencing reaction were purchased from ADI Prism 
 
2.3.11 Sequencing reaction using BIGDYE terminator (v2) 
20μl of sequencing mix was prepared by mixing 4μ of BIGDYE reagent (ADI Prism), 4μl 
of 2.5x buffer (ADI Prism), 5-20ng of PCR product, distilled water and 1μl of 3mM 
sequence primers in a thermal eppendorf. The sequencing mix was subjected to 10 seconds 
at 96˚C and 25 cycles; 96˚C for 10 seconds, 50˚C for 5 seconds and 60˚C for 4 minutes. 
 
2.3.12 Ethanol Precipitation of sequencing products 
Sequencing products were purified by ethanol precipitation by mixing 20μl of sequencing 
products with 2μl 3M sodium acetate and 50μl 100% ethanol and vortex thoroughly in a 1.5 
ml microfuge tube. The mixture was left on ice for 10-15 minutes, and centrifuged for 10-
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20 minutes in a desktop micro-centrifuge. The supernatant was carefully removed without 
disturbing the DNA pellet using a pipette. The pellet was rinsed with 250μl of 70% ethanol, 
centrifuged for 5 minutes and supernatant discarded. The DNA pellet was dried at 90-
100˚C for 5-10 minutes, 10μl of Hi-Di solution (Roche) was added to the pellet and left at 
90-100˚C for 1 minute. The sequencing samples were then analysed. 
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3.1.0 Screening Caucasian donors for T-cell memory to BART products and to 
BARF1 
 
3.1.1 Introduction 
NPC biopsies and an NPC-derived cell line (C15) have been demonstrated to express a set 
of Bam HIA rightward transcripts (BARTs) polyadenylated RNAs and BARF1 RNA. 
However, the expression of BARTs at the protein level is still unclear, but they have the 
potential to encode at least three predicted polypeptide products A73, RPMS1 and BARF0. 
Figure 3.1.1 shows the location of the BARTs and BARF1 on a map of the EBV genome 
and, in addition, the 13kbp region that is deleted from the B95.8 strain. The BARTs are 
heavily spliced: the introns are represented by a line; boxes represent the exons; and the 
arrow shows the direction of transcription. The BARF1 gene is approximately 5kbp 
downstream from the BART genes (Figure 3.1.1). 
 
This phase of the thesis work was initiated because the postulated BART-encoded 
polypeptides and BARF1 protein represent potential sources of T cell epitopes that might 
be exploited as therapeutic targets in the context of NPC.  This section of work was setup to 
find other T-cells responses (CD4+ or CD8+) against the three predicted BART-encoded 
polypeptides or against the BARF1 protein. The long term aim of such work is to find the 
full spectrum of immunogenic viral epitopes potentially presented by NPC cells. 
 
At the time this work began, we still did not have access to blood samples from healthy 
Chinese donors and so the screening work in this Chapter had to be carried out using 
healthy Caucasian donors. The results of these initial screening experiments are presented 
in full at this point of the thesis. However, the long-term direction of the work switched 
back towards what appears to be a potentially more useful target, EBNA1. 
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Figure 3.1.1: Location of the BART and BARF1 gene within the EBV genome 
This Figure was adapted from Smith et al (2000) showing the location of the BARTs and 
BARF1 on a map of the linear EBV genome and, in addition, the 13kbp region that is 
deleted from the B95.8 strain. The BARTs are heavily spliced: the introns are represented 
by a line; the exons are shown with the numbers directly above it; and the arrow shows the 
direction of transcription. The BARF1 gene is approximately 5kbp downstream from the 
BART genes. 
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3.1.2 Predicted BamH1A and BARF1 peptide panels. 
Since this study was carried out on healthy Caucasian donors, the Caucasian EBV strain 
B95.8 sequence was used to infer the primary sequence of the predicted BARF0 (Baer et al, 
1984), RMPS1 (Smith et al., 2000) and A73 (Smith et al., 2000) polypeptides and the  
BARF1 protein (de Turenne-Tessier et al., 1999). Figure 3.1.2 shows these primary 
sequences. RPMS1, BARF0 and A73 are predicted to be 103, 174 and 126 amino acids in 
length respectively and BARF1 is a 220 amino acid protein. Panels of 20-mer peptides 
(overlapping by 15 amino acids) were constructed for each of the sequences by 
Altabiosciences (The University of Birmingham). These four peptide panels are shown in 
Tables A3.1.1 - A.3.1.4 of the Appendix: there were 22 overlapping peptides covering A73 
(Table A3.1.1); 32 overlapping peptides covering BARF0 plus the previously published 9-
mer epitope LLWAARPRL (Kienzle et al, 1998) (Table A3.1.2); 18 overlapping peptides 
covering RPMS1 (Table A3.1.3); and 42 overlapping peptides covering BARF1 (Table 
A3.1.4). 
 
3.1.3 Preliminary assays 
Since in the long-term, our aim was to examine Chinese donor PBMC samples 
cryopreserved in Hong Kong, preliminary experiments were conducted to test if the 
ELISpot assay could detect IFN-γ release from samples that had been cryopreserved over a 
period of 6 months. Prior to conducting BART and BARF1 work, a mini-project was 
conducted to look for CD4+ T cell responses against a panel of 58 EBNA3A peptide pools. 
Firstly, this has never been done before and, secondly, to optimize the ELISpot protocol. In 
total, 15 donors were screened of which one donor, UK-SL, tested positive against one of 
the EBNA3A peptide pools, pool 41. From this experiment, the following optimization is 
described. A freshly prepared PBMC sample from a laboratory donor in Birmingham, UK-
SL, was divided into two samples. One was cryopreserved immediately (frozen PBMC), 
while the other was rested overnight in complete culture media at 37˚C before being tested 
the next day. The frozen PBMC sample was thawed after 6 months in cryopreservation, and 
again rested overnight in complete media at 37˚C before testing. This resting stage was 
found to give lower background than cells tested immediately after thawing. Figure 3.1.3 
RPMS1 
1MAGARRRARC10 11PASAGCAYSA20 21RPPPLSTRGR30 31RISAGSGQPR40 
41WWPWGSPPPP50 51DTRYRRPGPG60 61RRARSCLHAG70 71PRGRPPHSRT80 
81RARRTSPGAG90 91GGGWRGGSCT100 101SQR103 
 
RK-BARFO 
1MAATLPLPRC10 11TDSMAARVPI20 21EELRELRHLR30 31GHCREDVVGV40 
41QRSGRPLCLR50 51PPRARDRALL60 61WAARPRLLLS70 71LQQVPEPRLA80 
81DFILKQSRDR90 91LRIHRHRQVV100 101TGDVGPLCRG110 111RVAVVGQNHQ120 
121LAHTAPAGHR130 131GDVEARVWDG140 141TYAPKAAQQI150 161QGPFQALQPH170 
171GVRHAIKHAI180 181DSLH184 
 
A73 
1MSMPPKGFLK10 11KEMKPETRLL20 21NKPPTVLTRP30 31AMFCAWKLYS40 
41RKMPSRSKTL50 51EARCSSRPPC60 61DSPACQTRDT70 71GCPRRSGTGR80 
81RGWRARRLGK90 91ESWFADAWRM100 101ARYWGCAVKA110 111AAQSAFSAST120 
121ASPEEL126 
 
BARF1 
1MARFIAQLLL10 11LASCVAAGQA20 21VTAFLGEERV30 31TLTSYWRRVS40 
41LGPEIVSWFK50 51LGPGEEQVLI60 61GRMHHDVIFI70 71EWPFRGFFDI80 
81HRSANTFFLV90 91VTAANISHDG100 101NYLCRMKLGE110 111TEVTKQEHLS120 
121VVKPLTLSVH130 131SERSQFPDFS140 141VLTVTCTVNA150 151FPHPHVQWLM160 
161PEGVEPAPTA170 171ANGGVMKEKD180 181GSLSVAVDLS190 191LPKPWHLPVT200 
201CVGKNDKEEA210 211HGVYVSGYLS220 221Q 
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Figure 3.1.2: The amino acid sequence of the predicted BART products and BARF1 
This Figure shows the amino acid sequences of the three predicted polypeptide products 
(RPMS1, RK-BARF0 and A73) and BARF1. The superscripted numbers shows the 
coordinate of the amino acids relative to the polypeptide. The amino acid sequences were 
taken from Smith et al (2000) and the RK-BARF0 and BARF1 sequences were taken from 
the nucleotide database at http://www.ncbi.nlm.nih.gov/. 
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Figure 3.1.3: IFN-γ ELISPOT assay of ‘fresh’ and ‘frozen’ PBMC samples 
Results of IFN-γ ELISPOT assays using (A) ‘fresh’ and (B) ‘frozen’ CD8-depleted PBMCs 
from UKL-SL exposed to a panel of 58 B95.8 strain EBNA3A peptide pools or assayed in 
the presence of known EBV antigen pool or PHA. Results are shown as numbers of spot-
forming cells per 106 CD8-depleted PBMCs tested. The dotted line represents the average 
background reading of the assay. Note that responses occasionally mapped to a single 
peptide pool, pool 41.  
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shows the ELISpot data of UK-SL fresh (Figure 3.1.3A) and frozen (Figure 3.1.3B) 
samples screening against 58 EBNA3A pools; each peptide pool contains five adjacent 
overlapping peptides (20-mer peptides overlapping by 15 amino aicds). For positive 
controls we included in Table A3.1.5 a list of peptides pulled together as a peptide pool 
control. The peptide pool contains eight known CD4+ and four known CD8+ EBV epitope 
peptides. This selection of known CD4+ EBV epitope peptide pool is to detect response in 
the majority, if not all, EBV positive carriers that are screened in these experiments. And, 
(2) a polyclonal stimulus, PHA. As a negative control, we included wells without peptide 
but with an equivalent concentration of DMSO solvent alone (not shown in the figure). 
Both fresh and cryopreserved samples responded by IFN-γ detection against EBNA3A 
peptide pool 41 and against the known EBV epitope peptide pool with similar intensity (50 
SFC per million cells). This assay, and similar experiments on other laboratory donor 
samples, demonstrated that cryopreservation of PBMC samples does not affect the ability 
of T-cells to respond (by IFN-γ release) against EBV-specific peptides. 
 
Although not applicable in work with donor UK-SL, we found that high backgrounds is one 
of the biggest problems in an ELISpot assay as such background responses will tend to 
mask weak or borderline responses. Because NK cells are potential sources of non-specific 
IFN-γ production from PBMC samples, experiments were conducted to compare whole 
PBMC and NK-depleted PBMC preparations as responders in ELISpot assay. NK cells 
were removed by exposure to anti-CD16 IgM antibody followed by rabbit complement to 
lyse CD16-positive cells. The quality of the depletion was assessed by staining with FITC-
labelled IgG MAbs to CD16, CD4 and CD8 or with an irrelevant FITC-labelled isotype-
matched (IgG1) MAb. As can be seen from the FACS profiles in Figure 3.1.4, after CD16 
depletion, CD4+ and CD8+ populations are still present whereas the CD16+ population is 
completely removed. An ELISpot was conducted on CD16-depleted and undepleted 
PBMCs from a buffy coat sample which in earlier assays had given high background 
responses. Figure 3.1.5 shows a representation of such a result where the background 
response is significantly reduced while the positive control EBV peptide pool and PHA 
control response was unaffected. This protocol was therefore used for re-testing samples 
Before CD16 depletion After CD16 depletion
No Antibodies
IgG1 FITC
CD4 FITC
CD8 FITC
CD16 FITC
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Figure 3.1.4: CD16-depletion of whole PBMC 
The result shows the FACs analysis of whole PBMCs from UKL-SL before and after 
CD16-depletion. Before CD16-depletion (Left column, reading from top to bottom) shows 
the individual PBMC subpopulation staining using FITC conjugated antibodies for the 
respective cellular markers for CD4+, CD8+ and CD16+ cells. After CD16-depletion (Right 
column), the CD4+ and CD8+ subpopulations of PBMC are unaffected and the CD16+ 
subpopulation of cells were removed from the PBMC.  
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Figure 3.1.5: INF-γ ELISpot assay before and after CD16-depletion 
Results of IFN-γ ELISpot assays before CD16-depletion (A) and after CD16-depletion (B) 
of PBMCs from UKL-SL exposed to a panel of the first 18 of 58 B95.8 EBV strain peptide 
pools. Results are shown as numbers of spot-forming cells (SFC) per 106 CD8-depleted 
PBMCs tested. Note the average background reading (dotted line) before CD16-depletion 
(A) is approximately 40 SFC per 106 CD8-depleted cells, and after CD16-depletion (B), the 
background reading is lowered to approximately 0-5 SFC per 106 CD8-depleted cells. 
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that gave high backgrounds in the initial screening assays. Majority of the samples that 
were screened using BART and BARF1 peptides gave high background responses and 
therefore, they were NK cell depleted, unless otherwise indicated.  
 
3.1.4 Screening assays 
The EBV serological status of 25 healthy Caucasian donor serum samples, whom were 
used in the ELISpot screening for BARTs and BARF1 responses, was determined using 
anti-IgG monoclonal antibodies (MAbs). The results are summarised in Table 3.1.1, where 
24 of 25 donor serum samples were tested positive and UKL25 serum sample was negative 
for IgG antibodies. 
 
ELISpot screening of BART and BARF1 peptides was conducted using PBMC samples 
taken from these same 25 healthy Caucasian donors either using 60-100ml bleeds of 
laboratory donors (denoted UKL) or from buffy coat donations (denoted UKB). PBMC 
preparations from laboratory donors were usually tested immediately on the day of bleed 
while PBMC preparations from buffy coats were usually cryopreserved until testing at a 
later date. Buffy coats gave high enough PBMC yields for multiple freezings (6-8 vials of 
50x106 PBMC/vial of freezing), ideal for a rescreen if initial screening gave positive 
results. In every assay, whole PBMC preparations (containing both CD4+ and CD8+ T-cell 
populations) were tested against the peptide panels and therefore could in theory detect 
either CD4+ or CD8+ memory against the BART encoded polypeptides or BARF1 protein.  
 
The 20-mer peptides were used individually rather than in pools of 3 adjacent peptides as 
used in EBNA1 screening work described by Leen et al (2001). This was possible because 
each peptide panel contained fewer peptides (42 peptides at most) compared to the EBNA1 
work (80+ peptides) done earlier by Leen et al (2001). The same controls were used as 
described earlier in the preliminary assays.  
 
The ELISpot plates were all counted by eye under a dissection microscope because at this 
stage of work an ELISpot reader for automated reading was unavailable. Note that all 25  
82 
UK donor VCA test 
*UKL1 †+ 
UKL2 + 
UKL3 + 
UKL4 + 
UKL5 + 
UKL6 + 
UKL7 + 
UKL8 + 
††UKB9 + 
UKB10 + 
UKB11 + 
UKB12 + 
UKB13 + 
UKB14 + 
UKB15 + 
UKB16 + 
UKB17 + 
UKB18 + 
UKB19 + 
UKB20 + 
UKL21 + 
UKL22 + 
UKB23 + 
UKB24 + 
UKL25 ‡― 
 
Table 3.1.1: VCA staining of 25 UK donors 
*UK Laboratory donors 
†† UK Blood transfusion  
    donors 
†Positive staining for IgG  
   antibodies against EBV  
‡Negative staining for IgG  
    antibodies against EBV 
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donors gave strong positive response against the PHA control wells reflected by the wells, 
turning completely dark purple (this is represented as >1000 SFC per million cells in the 
assay Figures but the exact value is not known). A value 500 SFC per million cells is given 
to greater than half the donors tested (17/27), where the known EBV peptide pools induced 
very strong T cell responses such that the spots on the ELISpot plate were difficult to count. 
The DMSO control wells were used to set the background base line. 
 
3.1.5 Screening from predicted BART-encoded polypeptides (RPMS1, A73 and 
BARF0) 
Figure 3.1.6 A, B and C show three representative results from the screening of the BARF0 
peptide panel. Responses to individual peptides are shown as histograms and are expressed 
as the number of spots forming cells (SFC) per 106 PBMC. Clear positive responses above 
background values (mean SFC count ±3 standard deviation from negative control wells; see 
dotted line) were observed in the positive control wells containing the pool of known EBV 
peptides. Scanning the graph immediately shows that none of the donors responded against 
any of the BARF0 peptides above background (dotted line). Seropositive donors UK6 
(Figure 3.1.6A) and UKB18 (Figure 3.1.6B) showed responses to the EBV epitope peptide 
pool control wells and also the PHA control whereas seronegative donor UKL 25 (Figure 
3.1.6C) did not show any responses towards the EBV epitope peptide pool control wells but 
did respond against the PHA control. Of the 24 healthy seropositive Caucasian donors 
screened in this manner, the majority of the donors gave strong responses against the EBV 
peptide pool control. Data from the BARF0 peptide panel assays are summarised in Table 
3.1.2. Most donors did not show any responses against any of the BARF0 peptides. The 
only responders are UKL 8 (to peptides RK3 and RK5) and UKB 17 (to peptide RK17). 
However, both donors were re-tested on two subsequent occasions against these and the 
adjacent peptides and, on each occasions, no responses was seen. Note that the background 
response in the re-test is significantly reduced in donor UKL8 because of NK cell depletion 
from whole PBMC, yet even in the optimal circumstances there was no hint of response to 
peptides RK3 and RK5. Note that peptide RK13 is the reported HLA-A*0201 restricted 
epitope LLWAARPRL (Kienzle et al, 1998); no donors responded against this peptide. 
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Figure 3.1.6: Screening for T cell responses to BARF0 20-mer peptides 
Result show three typical IFN-γ ELISpot assays using whole PBMCs from donors UKL-6 
(A), UKL-8 (B) and UKL-25 (C) exposed to a panel of 32 B95.8 EBV strain predicted 
BARF0 20-mer peptides. Results are shown as SFC per 106 cells. Peptide RK13 (*) is the 
reported HLA-A*0201 restricted epitope LLWAARPRL (Kienzle et al, 1998). Both EBV-
seropositive donors, UKL-6 and UKL-8, responded to the EBV peptide pool control, 
whereas, EBV-seronegative donor (UKL-25) did not. All three donors responded against 
PHA. Note that there are no significant T cell responses to any of the BARF0 peptides 
above the background (dotted line) level from any of the three donors tested. Also note, no 
response was detected against the reported HLA-A*0201 restricted epitope.  
BARF0 Peptide panel
Donor Background RK1 RK2 RK3 RK4 RK5 RK6 RK7 RK8 RK9 RK10 RK11 RK12 RK13* RK14 RK15 RK16 RK17 RK18 RK19 RK20 RK21 RK22 RK23 RK24 RK25 RK26 RK27 RK28 RK29 RK30 RK31 RK32 EBV peptide pool PHA Control
UKL 1 0-6 2 0 2 0 0 0 2 6 4 2 4 0 4 0 0 2 2 0 0 2 0 0 0 2 6 2 6 4 2 2 2 2 500(+) 1000(-)
UKL 2 22-40 22 38 22 30 32 22 38 24 40 40 32 34 38 22 26 32 32 38 28 38 34 36 34 26 28 22 34 34 36 32 38 40 174 1000
UKL 3 4-16 4 4 14 6 6 18 16 12 16 12 6 18 8 12 8 10 8 16 2 4 6 8 16 12 4 8 4 10 8 12 16 10 500 1000
UKL 4 14-38 14 20 38 20 30 34 34 28 30 34 18 30 16 28 22 38 38 38 32 34 14 18 22 26 24 14 34 16 26 34 30 24 500 1000
UKL 5 4-16 8 4 10 12 6 2 10 14 6 10 8 4 10 6 16 4 8 6 10 8 2 0 6 8 6 6 10 10 4 8 6 6 126 1000
UKL 6 0-10 4 4 0 2 2 4 6 4 4 2 8 10 4 6 8 4 0 2 8 6 8 2 6 4 4 6 8 4 4 0 2 6 500 1000
UKL 7 2-14 8 6 6 6 12 12 2 12 12 6 2 12 4 4 4 4 12 10 12 8 8 8 10 2 6 2 4 10 12 14 8 8 340 1000
UKL 8 48-76 48 46 **112 66 114 64 56 30 64 22 60 38 62 50 60 66 50 52 68 62 70 76 50 40 56 58 48 64 56 48 38 60 500 1000
2-6 0 4 0 2 0 250 1000
UKL 8 retest 2 2-6 2 6 0 0 0 250 1000
UKB 9 6-24 14 6 20 10 24 22 18 10 12 16 24 18 22 22 24 24 24 20 16 12 22 16 10 14 12 10 18 16 8 24 14 24 500 1000
UKB 10 2-12 2 10 2 6 6 0 12 0 2 2 2 2 0 6 4 4 2 6 2 6 12 6 8 10 0 6 0 4 8 10 0 2 310 1000
UKB 11 16-36 26 26 18 16 26 30 6 16 22 30 34 20 30 18 34 22 22 36 36 32 30 18 16 26 22 24 30 18 12 16 30 32 500 1000
UKB 12 24-36 24 36 36 30 32 30 24 30 34 30 36 34 34 32 30 26 30 24 34 32 30 34 32 26 28 30 28 30 36 34 32 30 500 1000
UKB 13 24-38 28 26 24 24 34 38 30 34 36 32 34 34 30 34 38 38 36 24 28 28 36 34 36 34 30 34 26 30 32 24 26 24 500 1000
UKL 14 4-18 6 8 16 6 18 10 18 10 6 4 8 18 8 6 6 4 18 4 6 0 6 18 8 10 6 4 14 8 14 12 18 10 400 1000
UKL 15 0-14 10 4 12 6 8 8 8 4 8 8 10 10 12 10 10 12 6 12 6 12 16 22 14 6 6 8 8 4 0 6 14 12 246 1000
UKB 16 30-52 36 30 34 48 30 30 38 32 40 44 40 48 40 36 40 42 48 38 36 42 46 42 36 40 48 44 40 40 36 46 42 42 500 1000
UKB 17 0-14 8 2 0 2 4 10 4 12 6 8 10 2 6 8 4 14 68 0 4 2 6 8 2 0 4 4 2 4 4 2 0 4 350 1000
UKB 17 retest 1 2-12 4 10 2 300 1000
UKB 17 retest 2 2-12 8 12 6 332 1000
UKB 18 22-40 38 30 32 34 30 24 28 38 40 36 32 38 40 38 36 28 24 22 28 22 24 30 40 38 30 40 36 38 36 32 34 34 500 1000
UKB 19 34-56 34 36 50 44 50 56 36 50 50 52 42 46 48 52 56 48 52 54 54 42 52 52 46 56 38 56 52 44 48 56 52 48 500 1000
UKB 20 6-20 14 8 12 18 16 18 16 18 16 18 12 20 12 18 10 16 16 10 20 14 16 18 12 12 18 20 20 10 20 18 16 6 500 1000
UKL 21 2-14 2 10 10 10 8 6 10 4 12 6 4 2 10 8 8 2 6 6 6 14 12 0 6 8 8 12 6 6 4 2 12 14 500 1000
UKL 22 0-12 8 0 4 2 10 0 2 6 12 6 6 2 6 0 4 8 2 4 6 2 8 12 0 6 2 6 4 6 6 4 4 8 500 1000
UKB 23 0-14 2 6 4 4 6 14 12 2 2 4 6 6 2 4 10 10 0 0 0 2 0 8 0 0 8 6 6 8 4 6 0 2 500 1000
UKB 24 0-10 0 0 10 0 8 2 8 8 6 6 8 4 4 4 10 10 4 8 0 2 0 0 8 0 8 2 0 2 2 2 6 4 500 1000
UKL 25 2-14 8 6 14 8 8 12 12 10 4 8 2 12 12 6 8 8 10 12 14 4 12 2 10 6 4 10 10 12 14 8 6 8 16 1000
Table 3.1.2: SUMMARY OF BARF0 PEPTIDE SCREENING
UKL - Laboratory Donors
UKB - Buffy Coat Samples
#All positive results are retested twice
(+) Wells that exceed countable by eye are given a value of 500 SFC per million cells
UKL 8 retest 1#
**Positive ELISpot results are bolded
* Peptide LLWAARPRL as tested by Kienzle et al (1998)
(-) ELISpot wells containing PHA show up as a dark purple well and are given the value of 1000 SFC per million cells
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Figure 3.1.7: Screening for T cell responses to A73 20-mer peptides 
Result show three typical IFN-γ ELISpot assays using whole PBMCs from donors UKB-9 
(A), UKL-22 (B) and UKL-25 (C) exposed to a panel of 22 B95.8 EBV strain predicted 
A73 20-mer peptides. Results are shown as SFC per 106 cells. Both EBV-seropositive 
donors, UKB-9 and UKL-22, responded to the EBV peptide pool control, whereas, EBV-
seronegative donor (UKL-25) did not. All three donors responded against PHA. Note that 
there are no significant T cell responses to any of the A73 peptides above the background 
(dotted line) level from any of the three donors tested.  
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Figures 3.1.7 A, B and C show data from two representative donors UKL19 and UKB22 
and seronegative donor UKL25 screened against the panel of 22 A73 20-mer peptides; no  
responses were observed. Table 3.1.3 summarises the overall results. Again, there were two 
potential responses from the initial screening; UKL8 (peptides A4 and A5) and UKB17 
(peptides A6, A10 and A1, but none of these were observed in the two subsequent repeat 
assays. 
 
Likewise Figure 3.1.8 A, B and C show negative data from two seropositive donors UKB13 
and UKB23 and the seronegative donor UKL25 screened against 18 RPMS1 peptides. 
Table 3.1.4 summarises the overall results and again 2 donors gave possible responses in 
the initial assays; UKL4 (peptides R6, R13 and R14) and UKL6 (R3, R5, R6 and R8), but 
these responses were not repeatable in the two retest assays that could be performed. 
 
3.1.6 Screening of BARF1 peptide panel 
Figure 3.1.9 A, B and C show the corresponding data from two seropositive donors UKL6 
and UKB19 and the seronegative donor UKL25 screened against the 42 BARF1 peptide 
panel. The Figures show that none of the donors responded against any of the peptides. 
Again, both UKL6 and UKB19 responded to the known EBV epitope peptide pool and to 
PHA whereas, UKL25 only responded to PHA. The 25 donors screened against the BARF1 
peptide panel are summarised in Table 3.1.5. Scanning the Table show that one donor 
responded against several BARF1 peptides, UKL5 (peptides B10, B11, B15, B16, B17 and 
B20), however re-test assays again show that these responses did not repeat. 
 
3.1.7 Discussion 
Looking overall at the results of these experiments, there was never a reproducible response 
to any of the peptides tested in the 24 EBV-immune donors examined. How might such 
negative results be interpreted? To date, there is still no unequivocal evidence showing that 
the postulated BART-encoded polypeptides are expressed. Evidence which may suggest the 
expression of the postulated BART-encoded products came from studies showing the 
potential functions of these predicted proteins (Smith et al, 2000; Thornburg et al, 2004).  
A73 peptide panel
Donor Background A1 A2 A3 A4 A5 A6 A7 A8 A9 A10 A11 A12 A13 A14 A15 A16 A17 A18 A19 A20 A21 A22 EBV peptide pool PHA Control
UKL 1 0-8 8 2 2 0 8 0 0 0 2 0 2 0 4 2 4 0 2 0 2 4 2 0 500(+) 1000(-)
UKL 2 0-20 20 8 18 14 12 20 16 20 16 2 12 0 4 14 18 12 12 8 8 12 8 4 174 1000
UKL 3 0-18 18 8 8 6 2 10 0 6 16 12 2 6 8 8 14 6 8 18 4 12 0 8 500 1000
UKL 4 12-42 32 30 34 24 20 12 14 12 22 24 20 12 60 14 22 38 42 8 30 42 22 12 500 1000
UKL 5 4-14 8 4 10 8 6 8 6 8 12 8 6 4 4 14 10 6 4 4 6 8 8 6 126 1000
UKL 6 0-12 6 4 12 4 0 0 6 0 6 2 2 2 4 4 6 6 6 8 6 4 2 6 500 1000
UKL 7 2-14 8 2 12 10 8 6 10 4 6 2 6 6 4 6 8 8 14 10 8 8 8 8 340 1000
UKL 8 78-90 90 62 78 **172 138 48 52 46 38 72 30 60 80 66 64 54 52 38 36 38 42 60 500 1000
2-4 0 2 0 0 250 1000
UKL 8 retest 2 2-4 0 0 0 0 250 1000
UKB 9 6-24 24 20 24 18 24 18 22 22 16 20 12 12 22 20 22 18 24 14 10 6 12 12 500 1000
UKB 10 2-10 8 4 4 2 2 10 8 8 8 10 2 8 2 0 2 4 0 10 4 2 6 2 310 1000
UKB 11 30-46 44 34 54 30 30 38 34 36 34 34 38 30 44 34 38 36 34 34 36 32 30 36 500 1000
UKB 12 32-48 32 36 36 40 34 34 44 36 46 38 48 48 36 34 44 38 44 44 42 34 36 34 500 1000
UKB 13 28-38 28 30 38 30 38 38 30 36 36 32 34 34 36 30 28 32 30 36 34 30 36 38 500 1000
UKL 14 4-22 6 6 10 14 12 6 4 8 10 14 4 4 12 14 14 12 12 8 4 4 4 22 400 1000
UKL 15 6-12 4 10 10 8 0 4 14 12 10 10 0 8 14 12 6 2 12 14 8 10 8 8 246 1000
UKB 16 36-48 34 36 38 42 46 26 46 42 40 38 36 36 46 46 32 30 36 28 36 38 38 36 500 1000
UKB 17 8-12 4 6 6 12 12 24 4 4 8 20 6 6 10 2 20 6 8 6 0 6 8 4 350 1000
UKB 17 retest 1 10-12 10 12 12 8 8 6 8 10 10 300 1000
UKB 17 retest 2 10-12 8 14 12 8 10 8 6 6 8 332 1000
UKB 18 20-38 30 32 28 28 24 28 26 34 36 24 20 28 24 22 26 34 38 38 36 36 30 32 500 1000
UKB 19 30-44 42 36 36 34 30 32 32 30 38 40 38 42 38 44 34 34 34 36 36 30 44 42 500 1000
UKB 20 18-36 18 36 20 26 16 22 16 20 6 14 20 10 14 20 36 36 32 12 12 8 16 24 500 1000
UKL 21 0-16 0 16 14 4 10 14 16 6 2 4 0 6 4 10 6 6 16 0 10 2 2 2 500 1000
UKL 22 0-6 4 4 2 0 4 6 6 6 2 10 2 2 2 2 2 4 2 4 4 2 2 6 500 1000
UKB 23 2-14 4 6 6 10 10 14 6 0 4 2 10 2 6 8 6 2 14 4 8 8 14 6 500 1000
UKB 24 0-12 12 8 10 6 8 4 6 2 14 0 6 4 10 8 4 6 10 12 4 0 10 6 500 1000
UKL 25 2-16 12 10 12 6 12 16 14 14 16 10 10 4 16 16 4 8 14 2 8 8 8 6 16 1000
Table 3.1.3: SUMMARY OF A73 PEPTIDE SCREENING
UKL - Laboratory Donors
UKB - Buffy Coat Samples
#All positive results are retested twice
(+) Wells that exceed countable by eye are given a value of 500 SFC per million cells
UKL 8 retest 1#
**Positive ELISpot results are bolded
(-) ELISpot wells containing PHA show up as a dark purple well and are given the value of 1000 SFC per million cells
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Figure 3.1.8: Screening for T cell responses to RPMS1 20-mer peptides 
Result show three typical IFN-γ ELISpot assays using whole PBMCs from donors UKB-13 
(A), UKB-23 (B) and UKL-25 (C) exposed to a panel of 18 B95.8 EBV strain predicted 
RPMS1 20-mer peptides. Results are shown as SFC per 106 cells. Both EBV-seropositive 
donors, UKB-13 and UKB-23, responded to the EBV peptide pool control, whereas, EBV-
seronegative donor (UKL-25) did not. All three donors responded against PHA. Note that 
there are no significant T cell responses to any of the RPMS1 peptides above the 
background (dotted line) level from any of the three donors tested.  
RPMS1 peptide panel
Donor Background R1 R2 R3 R4 R5 R6 R7 R8 R9 R10 R11 R12 R13 R14 R15 R16 R17 R18 EBV peptide pool PHA Control
UKL 1 38-46 34 46 44 38 42 46 44 40 40 46 38 46 46 38 44 40 38 42 500(+) 1000(-)
UKL 2 28-42 34 32 28 24 42 30 40 38 36 36 30 36 38 34 26 32 36 38 292 1000
UKL 3 20-30 20 26 22 30 26 30 20 22 30 24 28 28 24 26 24 20 22 30 500 1000
UKL 4 22-40 30 54 32 26 38 **68 26 40 22 32 40 24 58 64 32 34 36 28 500 1000
0-4 2 2 0 0 0 2 0 2 2 2 0 2 0 2 0 2 0 4 500 1000
UKL 5 4-24 12 16 16 12 14 24 14 14 6 12 4 18 12 18 22 18 24 18 266 1000
UKL 6 2-12 4 4 12 4 16 14 6 12 8 2 4 4 8 4 2 8 6 8 500 1000
UKL 6 retest 0-16 0 8 6 0 4 8 8 0 6 0 2 8 4 0 0 8 2 16 500 1000
UKL 7 0-12 6 0 0 12 12 2 10 12 8 6 10 2 4 8 6 6 12 10 214 1000
UKL 8 10-24 4 12 6 2 6 6 12 10 10 8 6 12 20 2 8 18 24 8 500 1000
UKB 9 2-16 8 6 2 10 6 14 14 12 10 16 10 16 8 16 10 6 4 10 500 1000
UKB 10 0-10 0 0 2 2 2 2 4 2 6 4 10 0 0 0 0 0 2 2 340 1000
UKB 11 20-38 28 30 28 28 32 32 34 20 22 34 20 38 32 38 28 36 34 22 500 1000
UKB 12 14-30 25 28 26 30 28 26 20 30 24 24 28 22 18 14 18 16 16 14 500 1000
UKB 13 14-34 34 34 32 34 22 24 30 18 26 24 20 22 22 24 30 34 24 14 500 1000
UKL 14 16-34 14 24 34 12 30 26 20 30 24 22 26 32 18 32 34 24 30 34 400 1000
UKL 15 20-38 28 28 22 22 20 30 26 34 20 24 22 34 30 28 38 24 22 22 318 1000
UKB 16 22-48 22 36 48 42 28 36 36 46 30 36 22 20 30 44 34 34 42 36 500 1000
UKB 17 28-48 40 44 24 40 44 48 40 46 42 40 30 46 34 28 30 38 48 40 400 1000
UKB 18 20-32 24 22 20 20 30 28 20 24 30 26 22 20 24 22 32 24 30 24 500 1000
UKB 19 16-34 22 20 26 22 24 16 24 22 30 34 22 22 34 22 30 24 34 22 500 1000
UKB 20 16-34 34 24 20 28 34 18 18 22 18 28 20 16 30 32 24 20 24 30 500 1000
UKL 21 20-38 34 34 22 20 30 24 38 20 30 32 22 38 30 32 30 26 28 22 500 1000
UKL 22 20-38 30 26 32 32 38 20 30 22 38 38 32 22 26 36 38 22 30 30 500 1000
UKB 23 4-22 4 4 14 10 8 8 12 10 14 14 10 6 8 20 6 22 12 14 500 1000
UKB 24 10-28 12 18 12 22 28 24 20 10 12 14 12 28 26 10 24 18 28 12 500 1000
UKL 25 34-42 20 32 28 34 42 42 30 20 24 26 24 28 32 32 42 34 28 30 40 1000
Table 3.1.4: SUMMARY OF RPMS1 PEPTIDE SCREENING
UKL - Laboratory Donors
UKB - Buffy Coat Samples
#All positive results are retested once
(+) Wells that exceed countable by eye are given a value of 500 SFC per million cells
UKL 4 retest#
**Positive ELISpot results are bolded
(-) ELISpot wells containing PHA show up as a dark purple well and are given the value of 1000 SFC per million cells
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Figure 3.1.9: Screening for T cell responses to BARF1 20-mer peptides 
Result show three typical IFN-γ ELISpot assays using whole PBMCs from donors UKL-6 
(A), UKB-19 (B) and UKL-25 (C) exposed to a panel of 42 B95.8 EBV strain BARF1 20-
mer peptides. Results are shown as SFC per 106 cells. Both EBV-seropositive donors, 
UKL-6 and UKB-19, responded to the EBV peptide pool control, whereas, EBV-
seronegative donor (UKL-25) did not. All three donors responded against PHA. Note that 
there are no significant T cell responses to any of the BARF1 peptides above the 
background (dotted line) level from any of the three donors tested.  
 
BARF1 peptide panel
Donor Background B1 B2 B3 B4 B5 B6 B7 B8 B9 B10 B11 B12 B13 B14 B15 B16 B17 B18 B19 B20 B21 B22 B23 B24 B25 B26 B27 B28 B29 B30 B31 B32 B33 B34 B35 B36 B37 B38 B39 B40 B41 EBV peptide pool PHA Control
UKL 1 4-24 18 20 18 8 24 4 30 16 8 16 16 14 24 18 16 20 14 22 12 8 16 14 8 6 24 8 20 20 8 20 18 6 14 24 8 14 18 16 12 14 16 500(+) 1000(-)
UKL 2 10-36 14 26 14 32 38 34 36 36 32 32 34 36 24 28 36 26 28 30 32 34 28 24 10 36 20 32 34 34 36 22 36 32 32 34 28 34 18 18 22 36 36 106 1000
UKL 3 10-40 10 24 26 30 28 40 30 24 24 38 40 38 20 40 40 30 34 34 32 40 40 38 32 42 10 30 40 40 40 40 34 42 22 40 10 18 22 28 40 30 26 500 1000
UKL 4 10-36 14 26 14 32 36 34 36 36 32 32 34 36 24 28 36 26 28 30 32 34 28 24 10 36 20 32 34 34 42 22 36 32 32 34 28 34 18 18 22 36 66 500 1000
UKL 5 32-36 20 46 38 22 34 36 24 26 38 **70 72 48 38 36 72 64 68 42 48 72 34 46 50 22 56 46 52 40 32 34 26 36 48 48 52 52 38 30 28 28 64 138 1000
UKL 5 retest 1# 34-38 36 34 38 36 36 38 34 34 38 34 34 36 32 30 122 1000
UKL 5 retest 2 38-64 34 34 36 34 34 34 34 34 34 34 36 38 36 36 120 1000
UKL 6 10-34 10 14 12 8 8 12 12 14 22 16 10 8 6 12 10 20 4 14 18 34 20 24 16 14 24 14 14 10 16 12 20 26 10 18 20 16 12 12 8 12 22 500 1000
UKL 7 0-10 0 2 0 4 4 0 6 4 6 8 8 0 2 4 4 2 2 4 6 2 12 0 10 2 2 4 2 0 2 4 2 6 0 0 4 0 4 8 2 2 2 110 1000
UKL 8 2-28 2 10 14 0 16 8 26 8 10 8 4 2 12 18 14 18 12 14 12 12 10 18 8 2 2 14 22 20 22 24 22 20 12 10 6 10 14 2 10 28 18 500 1000
UKB 9 2-20 12 8 14 10 8 6 20 6 12 6 14 8 14 2 20 6 14 10 8 8 4 10 6 4 6 10 8 12 4 4 8 4 8 6 10 6 6 6 4 6 6 500 1000
UKB 10 2-16 4 4 10 8 6 12 10 8 2 6 10 24 10 8 12 12 10 6 8 2 8 10 0 6 4 8 6 8 8 6 8 6 14 10 6 4 10 14 10 14 10 166 1000
UKB 11 0-12 0 0 4 10 8 10 6 2 12 0 0 10 0 2 0 2 2 2 6 4 0 0 12 6 0 4 2 0 0 6 6 0 4 6 2 8 4 4 6 0 4 500 1000
UKB 12 0-10 2 4 2 0 2 10 4 8 0 4 2 2 6 6 6 8 0 4 6 8 8 6 2 6 2 2 6 8 8 2 4 4 10 6 8 2 10 2 4 8 2 500 1000
UKB 13 14-40 18 20 32 18 30 36 34 26 14 40 38 40 40 36 26 40 24 36 20 32 26 30 32 14 22 20 28 32 32 34 24 34 14 38 22 24 38 16 40 20 26 500 1000
UKL 14 22-32 32 26 22 24 22 28 32 24 24 30 30 22 22 22 30 30 28 26 24 30 30 32 30 28 32 30 30 30 30 32 28 28 32 32 32 28 28 24 28 28 32 220 1000
UKL 15 4-28 16 8 24 8 10 14 10 16 8 10 16 10 18 6 22 12 4 6 18 16 12 10 14 10 12 8 14 12 6 6 16 10 12 6 10 22 28 16 6 8 10 148 1000
UKB 16 14-32 20 18 28 14 18 32 32 32 22 32 24 24 12 26 26 22 26 16 30 32 6 18 20 20 18 24 28 32 32 26 18 30 14 16 28 12 10 22 22 30 16 500 1000
UKB 17 20-40 28 20 24 34 34 30 36 36 20 34 30 34 34 36 34 36 38 26 36 38 26 40 24 38 40 28 32 40 40 38 36 24 22 32 24 40 40 36 40 20 20 192 1000
UKB 18 10-32 16 18 32 24 24 32 26 16 14 24 22 12 20 24 30 30 32 20 30 32 32 26 32 10 16 18 24 28 32 30 24 20 32 32 28 20 12 16 32 18 14 500 1000
UKB 19 20-44 36 44 28 38 28 28 28 30 34 20 22 22 22 24 32 26 42 24 26 28 38 28 20 16 34 28 16 36 38 38 44 40 44 22 20 20 12 16 24 38 38 500 1000
UKB 20 8-28 8 16 22 22 20 14 28 28 20 12 28 18 30 28 24 24 28 26 28 28 28 28 24 22 28 22 18 20 16 26 26 22 28 24 24 22 12 16 22 16 18 500 1000
UKL 21 8-20 8 8 20 12 10 6 8 10 6 8 12 18 10 20 14 12 10 12 18 14 20 10 12 20 16 26 20 12 14 8 14 12 18 8 12 16 20 14 18 18 12 500 1000
UKL 22 6-24 12 8 10 12 14 18 12 24 10 14 8 10 12 24 20 6 10 8 20 10 18 24 16 20 20 12 10 24 20 8 18 14 16 6 16 12 16 18 10 24 24 500 1000
UKB 23 12-26 26 22 28 24 20 26 26 26 18 20 20 14 24 20 18 14 18 24 26 20 18 26 16 24 16 16 18 12 12 22 18 20 24 20 22 16 12 22 26 24 18 500 1000
UKB 24 4-24 22 16 24 22 18 24 20 16 12 4 10 8 18 10 24 12 10 18 22 24 16 20 24 10 18 12 20 20 18 14 22 20 22 10 16 12 16 22 22 14 14 500 1000
UKL 25 8-26 10 14 8 20 14 16 24 16 12 22 14 8 10 18 8 14 22 14 16 16 12 12 24 12 12 14 10 10 12 14 18 10 26 26 12 10 28 4 26 16 10 28 1000
Table 3.1.5: SUMMARY OF BARF1 PEPTIDE SCREENING
UKL - Laboratory Donors
UKB - Buffy Coat Samples
#All positive results are retested twice
(+) Wells that exceed countable by eye are given a value of 500 SFC per million cells
**Positive ELISpot results are bolded
(-) ELISpot wells containing PHA show up as a dark purple well and are given the value of 1000 SFC per million cells
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Indeed perhaps the strongest evidence to date for their existence is the finding in a single 
healthy Caucasian donor of a response to one of the predicted BARF0-derived peptides, an 
HLA-A*0201 restricted epitope LLWAARPRL (Kienzle et al, 1998). In that work, this 
response was observed in vitro as a CD8+ cytotoxic T cell clone which recognised cells 
transfected with a BARF0 expression construct (Keinzle et al, 1998). More importantly, the 
authors showed that such response could be detected in other EBV-seropositive carriers but 
not in EBV-seronegative individuals. This particular 9-mer epitope (RK13) was therefore 
incorporated in the ELISpot screening along with the panel of 20-mer peptides. 
Interestingly, by chance, we were able to include in this present work the very donor whom 
the clone response was cloned by Kienzle et al. No response was seen in this donor by 
ELISpot (UKL25) and more importantly we found that this donor is EBV sero-negative. 
This suggests that the findings by Kienzle et al (1998 and 1999) do not reflect a specific 
EBV-induced response to the BARF0 peptide but the existence within UKL25 T cell 
repertoire of rare cells fortuitously cross-reactive with the peptide.  
 
One of the major differences between the study by Kienzle et al (1998) and the work 
presented in this thesis is in the methods used in the detection for T cell responses. In the 
study by Kienzle et al (1998), the authors were using an epitope prediction program to 
determine possible HLA-restricted epitopes within the amino acid sequence of BARF0. At 
the time of this study, these epitope prediction softwares are limited only to the prediction 
of well defined HLA molecules. More importantly, these softwares do occasionally miss-
out well defined HLA-restricted epitopes and often give high scores to epitopes that do not 
induce T cell responses in in vitro studies (Kotturi et al, 2007). To further demonstrate this 
point, the A73 amino acid sequence was analysed by a well-developed epitope prediction 
software for HLA-A*0201-restricted epitope, SYFPEITHI (http://www.syfpeithi.de). The 
SYFPEITHI software predicts an HLA-A*0201 epitope RLLNKPPTV with a score of 26 
out of a possible maximum score of 36. Note that the maximum score for a well defined 
HLA-A*0201 epitope GILGFVFTL from the influenza matrix protein is 30/36. This 
RLLNKPPTV sequence (see Figure 3.1.7) lies in the A2 15-mer peptide and no CD8+ T 
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cell responses were ever detected, above background IFN-γ release, from any of the 25 
donors using IFN-γ ELISpot assay.  
 
A second important difference between this work and work reported by Kienzle et al 
(1998) is the method of reading T cell response. In the study by Kienzle et al (1998), the 
authors measured cytotoxicity by 52Cr release of BARF0-specific T cell clones, while in 
this study, IFN-γ production was measure by ELISpot assay of whole PBMC. There are 
two points discussed here; (1) the study clones versus whole PBMC and (2) measuring 
cytotoxicity versus IFN-γ production. Firstly, the study of responses in whole PBMC 
reflects more closely to responses seen in vivo as a whole. Studies to date strongly suggest 
that the number of virus-specific T cells play an important role in the control of infection 
and closely reflects antigen expression. For example, EBV lytic antigen-specific CD8+ T 
cell responses are high in IM patients which accounts for 25% of the total CD8+ T cell 
population (Callan et al, 1998). This is because during primary infection, lytic cycle 
antigens are expressed therefore there is a high number of circulating EBV lytic antigen-
specific CD8+ T cells. If responses could only be detected by cloning and not by IFN-γ 
ELISpot assay, this may reflect that these BART products and BARF1 protein are not 
expressed or are expressed only at very low levels, and more importantly, responses are 
very weak. 
 
Secondly, the ELISpot assay is a sensitive method in detecting IFN-γ secretion by a single 
cell, since theoretically, each spot that are present on a ELISpot well represents IFN-γ 
secretion by a single cell. The reason why IFN-γ ELISpot assay was chosen for the studies 
in this thesis is because CD4+ T cells of Th1 phenotype secrete IFN-γ in response to 
antigen stimulation and have been demonstrated to have cytotoxic functions (Wilson et al, 
2001). More importantly, IFN-γ ELISpot assay was demonstrated to be an effective method 
of detecting EBNA1-sepcific CD8+ T cell responses to viral antigens where cytotoxicity 
assays have failed to do so(Blake et al, 1997), and these IFN-γ producing EBNA1-specific 
CD8+ T cells when cloned have also been shown to inhibit outgrowth of LCLs. While 
other studies have shown that IFN-γ ELISpot assay is good for detecting T cell specificity 
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to epitopes and the number of T cells that make response, it often does not correlate to anti-
viral activity (Loffredo et al, 2007; Yang, 2003). Keeping in mind the objective of this 
section of work, the IFN-γ ELISpot assay is ideal for screening, in large scale studies, for 
antigen-specific T cell responses in initial studies. Functional studies will ultimately require 
cloning of antigen-specific T cells. 
 
The consistently negative results seen in the present work cannot prove that there are no T-
cell responses against the BART and BARF1 peptides. However, they do suggest that, if 
such responses do exist, they are present at very low frequency. The central objective to 
this study was to determine, using the BART and BARF1 peptides, the potential usefulness 
of BART products and/or BARF1 as T cell targets. Clearly, if T cell responses are rare, 
these proteins (if expressed) will have little or no therapeutic value. The ELISpot assay has 
its limitations, not least because such responses need to be seen over the background that 
frequently complicates the assay. We have set our criteria that a significant response must 
be +3SD reproducibly above the background. However, we could improve the sensitivity of 
the assay screening separately for CD4 and CD8 T cell responses, i.e. by depleting whole 
PBMC of CD16 and CD4 populations to enhance detection for CD8 T cell responses and 
depleting whole PBMC of CD16 and CD8 populations to enhance detection CD4 T cell 
responses. However, such a procedure demands large blood samples from laboratory 
donors and is very time consuming.  
 
This work has been dealing with these predicted BART polypeptides as potential targets for 
T cell responses. The fact that such responses were never observed does not necessarily 
mean that these polypeptides are never expressed. It must be stressed that the predicted 
BART polypeptides are all relatively small, with BARF0 being the largest of the three at 
174 amino acids long. It may be possible that these polypeptides induce responses only 
very rarely because they are so small and therefore provide a very limited repertoire of 
potential T cell epitopes; a parallel example could be the rarity of CD8+ and CD4+ T cell 
responses among Caucasians to the smallest EBNAs, EBNA-LP, which has 111 amino 
acids of unique sequences. 
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Unlike the predicted BART polypeptides, BARF1 is a known early lytic protein that is 
repeatedly expressed in NPC and gastric carcinoma in the absence of other lytic proteins 
(Seto et al, 2005). But, more interestingly, BARF1 shared 18% amino acid sequence 
homology with human CD80. This is shown in Figure 3.1.10 highlighted in red with the 
BARF1 sequence at the top aligned with the human CD80 sequence at the bottom and the 
numbering represents the coordinates in relation to the BARF1 amino acids sequence. 
 
CD8+ T cell responses against the BARF1 protein had been looked at before in the context 
of acute viral infection in IM patients. Pudney et al (2005) reported CD8+ T cell responses 
in IM patients to the two immediate early proteins, against seven early lytic proteins and 
three late lytic proteins. However no BARF1-specific CD8+ responses were found testing 
on vaccinia BARF1-expressing target cells. The present findings extend this by showing 
that virus carriers have no detectable CD4+ and CD8+ T cell memory to BARF1 by ex vivo 
ELISpot analysis on peptide panels. This lack of responses to BARF1 could be partly 
explained by its limited homology to a cellular protein (CD80), by its immune-evasive 
properties or by the fact that the protein is again reasonably small and may only rarely 
provide immunogenic T cell epitopes. 
 
Taken at face value, the present results imply that BART polypeptides (if they exist) and 
BARF1 have little or no immunotherapeutic value in the context of NPC. However, this 
work has been conducted using Caucasian donors while our main interest is directed at the 
Chinese population where NPC occurrence is high. Extrapolations from one to the other 
population need to be made with care since there is (1) geographic polymorphisms in EBV 
latent gene sequences that may well extend to BARTs and to BARF1 (Midgley et al, 2003), 
and (2) differences in HLA allele distribution (Chang and Hawkins, 1997) between 
Caucasians and Chinese populations. Both could affect the immunogenecity of these 
potential target antigens.  
  
               1        10          20         30 
               .        .           .          .                         
BARF1 ..............MARFIAQLLLLAS..CVAAGQA.VTAFLGERVTLTS.YWRRVS 
CD80 MGHTRRQGTSPSKCPYLNFFQLLVLAGLSHFCSGVIHVTKEVKEVATLSCGHNVSVE 
 
 40        50        60        70        80        90       
 .         .         .         .         .         .  
BARF1 LGPEIEVSWFKLGPGEEQVLIGRMHHDVIFIEWPFRGFFDIHRSANTFFLVVTAANI 
CD80 ELAQTRIYWQKEKKMVLTMMSGDMN...IWPEYKNRTIFDIT...NNLSIVILALRP 
 
    100       110       120       130           140   
    .         .         .         .             .  
BARF1 SHDGNYLCRMKLGETEVTKQEHLSVVKPLTLSVHSERSQ....FPDFSVLTVTCTVN 
CD80 SDEGTYECVVLKYEKDAFKREHLAEVTLSVKADFPTPSISDFEIPTSNIRRIICSTS 
 
  150       160       170       180       190       200 
  .         .         .         .         .         .        
BARF1 .AFPHPHVQWLMPEGVEPAPTAANGGVMKEKDGSLSVAVDLSLPKPWHLPVTCVGKN 
CD80 GGFPEPHLSWLENGEELNAINTTVSQDPETELYAVSSKLDFNMTT..NHSFMCLIKY 
  
     210       220 
     .         .  
BARF1 DKEEAHGVYVSGYLSQ.................... 
CD80 GHLRVNQTFNWNTSFAPRCRERRRNERLRRESVRPV 
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Figure 3.1.10: Amino acid sequence of BARF1 aligned with human CD80 
This Figure shows the amino acid sequence alignment of BARF1 alongside human CD80. 
The numbers located at the top of the figure are the amino acid coordinates in relation to 
the BARF1 sequence. Highlighted in red are the amino acids that are shared between 
BARF1 and human CD80. The (.) represents empty gaps so that the two sequences can 
form the best homology match. There are 47 amino acids that are shared (highlighted red) 
between BARF1 and human CD80 out of a total of 256 amino acids (the total number of 
amino acids from human CD80), making BARF1 approximately 18% homologous to 
human CD80. 
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As a preliminary step to assess ‘geographic’ sequence polymorphisms in EBV, the BARF1 
gene was PCR amplified and sequenced from EBV DNA extracted from the Caucasian type 
I virus B95.8, the African type II virus Ag876 and two representative Chinese isolate CKL 
(Type I Chinese EBV isolate from Chinese NPC patient) and C5 (type I EBV isolate from a 
healthy Chinese donor as reported by Midgley et al (2003)). Figure A3.1.1 shows the 
results. Underlined is the B95.8 BARF1 sequence (used as a reference point) starting at 
B95.8 nucleotide 165504 and ending at B95.8 nucleotide 166164. The B95.8 and Ag876 
virus strains were found to have identical BARF1 nucleotide sequences. Both Chinese 
isolates, CKL and C5, showed one nucleotide change (T to C) marked in red at position. 
This does not lead to a coding change and therefore the BARF1 amino acid sequence is 
fully conserved between the different virus strains tested. Work on geographic 
polymorphism in BART sequences is still ongoing; the BARTs are heavily spliced across 
many distantly arranged exons making them more difficult to sequence and analyse. 
 
A second factor, HLA allele distributions are different in Chinese compared to Caucasians 
(Chang and Hawkins, 1997) and so epitope choice may be radically different. There is 
therefore really no alternative other than to re-do the ELISpot screening in Chinese donors 
using appropriate peptide panels. However, a judgment had to be made and it was felt that 
the present finding of non-responsiveness to these polypeptides in the UK population made 
it unlikely that the same polypeptides would be highly immunogenic in another population. 
For these reasons, it was decided that the project would return to studying T cell responses 
to EBNA1, the only EBV latent protein definitely known to be expressed in all NPC 
tumours and one which is known to elicit T cell responses, in particular CD4+ T cell 
responses, in Caucasian populations. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Section 3.2 
 
Screening Chinese donors for CD4+ T cell  
memory to EBNA1 
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3.2.0 Screening Chinese Donors for CD4+ T cell Memory to EBNA1 
 
3.2.1 Introduction 
In this section of work, I describe the ELISpot screening of CD4+ T cell response to 
Chinese sequence EBNA1 peptides. This was felt to be potentially more important than 
CD8+ responses. Note that, although, CD8+ T cell responses against EBNA1, as described 
in the Introduction, had been identified (Blake et al., 1997; Blake et al., 2000), the 
biological effectiveness, such as the inhibition of LCL outgrowth, of such responses has 
only recently been demonstrated (Tellam et al, 2001; Voo et al, 2004; Lee et al, 2004; 
Tellam et al, 2004). More importantly, such EBNA1-specific CD8+ T cell responses remain 
relatively rare and linked to a small subset of HLA class I alleles. If EBNA1 were to be as 
immunogenic to CD4+ T cells in Chinese donors as it was seen to be in Caucasians, the 
long term aim of exploiting EBNA1-specific responses in targeting of NPC tumours is 
therefore likely to be heavily reliant on such CD4+ T cells. 
 
3.2.2 EBNA 1 peptide panel 
Since earlier literature reported that Chinese EBV strains carried a slightly different 
EBNA1 allelic sequence (the I allele) to both of the alleles (the V and T allele) present in 
Caucasian viruses, a first step was to sequence the EBNA 1 gene from a representative 
Chinese virus isolate. The virus strain selected was CKL, an isolate originally made from 
the blood of a Chinese NPC patient that earlier studies in this laboratory had shown to carry 
typical Chinese virus sequences at the EBNA 2, 3A, 3B and 3C loci (Midgley et al, 2000). 
The EBNA 1 gene of CKL was PCR amplified using sets of primers flanking the entire 
EBNA1 gene. Figure 3.2.1 shows the amino acid sequence, relative to the B95.8 prototype 
sequence that was determined in parallel in the present work. There were 14 substitutions in 
all, 3 in N-terminus upstream of the Gly/ala repeat domain and 11 amino acid changes in 
the downstream C-terminal half. To ensure that ELISpot screening was conducted using 
appropriate peptides, 36 new 20-mer peptides were made accommodating all the changes 
unique to the CKL sequence and these were used 
MSDEGPGTGP GNGLGEKGDT SGPEGSGGSG PQRRGGDNHG RGRGRGRGRG GGRPGAPGGS GSGPRHRDGV RRPQKRPSCI GCKGTHGGTG  
MSDEGPGTGP GNGLGQKEDS SGPEGSGGSG PQRRGGDNHG RGRGRGRGRG GGRPGAPGGS GSGPRHRDGV RRPQKRPSCI GCKGTHGGTG 
 
                   ER ARGRSRERAR GRGRGRGEKR PRSPSSQSSS SGSPPRRPPP GRRPFFHPVG EADYFEYHQE GGPDGEPDVP  
                   ER ARGRSRERAR GRGRGRGEKR PRSPSSQSSS SGSPPRRPPP GRRPFFHPVG DADYFEYLQE GGPDGEPDVP  
 
PGAIEQGPAD DPGEGPSTGP RGQGDGGRRK KGGWFGKHRG QGGSNPKFEN IAEGLRALLA RSHVERTTDE GTWVAGVFVY GGSKTSLYNL  
PGAIEQGPTD DPGEGPSTGP RGQGDGGRRK KGGWFGKHRG QGGSNPKFEN IAEGLRVLLA RSHVERTTEE GNWVAGVFVY GGSKTSLYNL  
 
RRGTALAIPQ CRLTPLSRLP FGMAPGPGPQ PGPLRESIVC YFMVFLQTHI FAEVLKDAIK DLVMTKPAPT CNIRVTVCSF DDGVDLPPWF  
RRGIALAVPQ CRITPLSRLP FGMAPGPGPQ PGPLRESIVC YFMVFLQTHI FAEVLKDAIK DLVMTKPAPT CNIKVTVCSF DDGVDLPPWF  
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Figure 3.2.1: EBNA1 amino acid sequence from B95.8 and Chinese virus strains 
The Figure shows the EBNA1 amino acid sequence from both the B95.8 and CKL EBV 
strains. The numbers located at the top of the sequences are the amino acid coordinates of 
the protein relative to the B95.8 EBNA1 sequence. In blue is the glycine-alanine repeat 
domain. In bold is the amino acid sequence which differs between the B95.8 and CKL EBV 
strains. There were 14 substitutions in all, 3 in N-terminus upstream of the Gly/ala repeat 
domain and 11 amino acid changes in the downstream C-terminal half. 
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alongside the remaining 45 EBNA 1 20-mer peptides from the existing B95.8 panel which 
represented sequences in common with the CKL allele. This is shown in appendix Table 
A3.2.1. 
 
3.2.3 ELISpot screening with full EBNA 1 peptide panel 
PBMC samples from healthy Chinese donors were either tested immediately on the day of 
bleeding or were cryopreserved as PBMCs until testing at a later date. Immediate assays 
were conducted at The Chinese University of Hong Kong by Lin Xiaorong using protocols 
developed at the University of Birmingham as part of the present thesis work; assays on 
cryopreserved samples were conducted at The University of Birmingham using the same 
panel of peptides and the same experimental protocol. In every assay, PBMCs were first 
depleted of CD8+ T-cells by CD8 magnetic Dynabeads. This step serves both to enrich the 
tested population for CD4+ T cells and to remove any possible contamination from EBNA 
1-specific CD8+ T cell memory. The quality of the depletion was assessed by staining with 
FITC-labelled IgG monoclonal antibody CD8 and as controls, with similarly labelled IgG1 
antibodies to CD4 and an irrelevant antibody antigen. The FACS profiles of the assay are 
shown in Figure 3.2.2; after CD8-depletion, the CD4+ T cell population is still present 
whereas the CD8+ population is completely removed.  
 
Assays were then conducted on CD8-depleted PBMCs using each of the 81 individual 
EBNA 1 20-mer peptides separately, rather than in pools of 3 adjacent peptides as 
described in earlier work by Leen et al (2001). This was possible because the present assays 
were conducted on large blood samples obtained from buffy coat donations rather than 
from the usual 60ml bleeds donated by laboratory volunteers. Figure 3.2.3 and 3.2.4 present 
the data obtained from fresh cells isolated from four representative donors, HK control 201, 
215, 228, and 233. The donors are represented as HK controls (healthy EBV carriers) and 
would serve in later studies for comparison with data from NPC patients. Responses to 
individual peptides are shown as histograms and are expressed as the number of spot 
forming cells (SFC) per 106 CD8-depleted PBMCs. Clear positive responses above 
background values (mean SFC count ± 3 standard deviation from control wells; see dotted 
Before CD8 depletion After CD8 depletion
No Antibodies
IgG1 FITC
CD4 FITC
CD8 FITC
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Figure 3.2.2: FACS analysis of CD8-depletion 
Result show the FACS analysis before (left column) and after (right column) CD8-
depletion. Before CD8-depletion (left column), both CD4+ and CD8+ T cell subpopulation 
could be clearly seen in FACS chart. After CD8+-depletion (right column), the CD4+ 
subpopulation is unaffected by the depletion assay and the CD8+ subpopulation is 
completely removed. 
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Figure 3.2.3: IFN-γ ELISpot screening for EBNA1 response 
Result shows two typical IFN-γ ELISpot assays of two Hong Kong donor PBMC samples 
(HK Control 201 and 215) exposed to 81 individual EBNA1 20-mer peptides derived from 
the CKL EBV strain (this wok was conducted in Hong Kong by Lin Xiaorong). The results 
are expressed as the number of spot forming cells (SFC) per 106 CD8-depleted PBMCs. 
HK Control 201 (top) show responses to multiple EBNA1 20-mer peptides (peptides 14, 
38, 41, 42, 50, 51, 54-62, 64, 66 and 67) above the back ground reading (dotted line). HK 
Control 215 (bottom) also shows responses to multiple EBNA1 20-mer peptides (peptides 
48, 49, 65-67, 71 and 72). Both donors gave strong responses to PHA control with the 
entire ELISpot well covered (data not shown). Note that the two donors show a completely 
different pattern of response against the EBNA1 peptide panel. HK Control 201 has a very 
broad response spanning throughout the entire EBNA1 protein, whereas, HK 215 responds 
only to a few peptides. The HLA typing of these two donors were not available at the time 
of this work discussed in this section and will be discussed later in the next section. 
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Figure 3.2.4: More IFN-γ ELISpot screening of EBNA1 response 
Result shows two more typical IFN-γ ELISpot assays of two Hong Kong donor PBMC 
samples (HK Control 228 and 233) exposed to 81 individual EBNA1 20-mer peptides 
derived from the CKL EBV strain (this work was conducted by Lin Xiaorong in Hong 
Kong). The results are expressed as the number of spot forming cells (SFC) per 106 CD8-
depleted PBMCs. HK Control 228 (top) show responses to multiple EBNA1 20-mer 
peptides (peptides 42, 51, 54-58, 66-68) above the back ground reading (dotted line). HK 
Control 233 (bottom) also shows responses to multiple EBNA1 20-mer peptides (peptides 
48, 49, 54-59). Both responders gave strong responses to PHA control (data not shown). 
Note that the two donors also show a completely different pattern of response against the 
EBNA1 peptide panel. But, there is also a pattern of response that is commonly observed in 
both donors, peptides 54-58. Also note that both donors have a high back ground reading, 
approximately 40-50 SFC per million cells. 
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line) were observed in all four donors, and had strong responses to PHA (data not shown). 
It is important to note that the level of background on ex vivo fresh samples varied 
significantly between individual donors such that the mean background could be as low as 
20 SFC/106 and as high as 70 SFC/106. Any assays giving backgrounds over 100 SFC/106 
in the initial screening were discarded because, at that time, the NK cell depletion assay 
(described in section 3.1) was not set up in Hong Kong. 
 
From the initial results illustrated in Figure 3.2.3 and 3.2.4 it can be seen that responses 
varied in size up to a maximum of 300 SFC/106 above background. All samples were then 
checked by re-screening on cryopreserved samples from the same bleeds. Re-screening 
assays were carried out focusing either on all peptides which gave positive responses in the 
initial assay or, where cryopreserved cell numbers were limiting, only on peptides that had 
produced weak positive or borderline responses. To illustrate results obtained in such re-
screening, Table 3.2.1 shows the original data alongside the re-test results. The latter are 
expressed again as SFC/106 cells and responses significantly above background (i.e. > 
mean background +3 SD) are identified by yellow shading. Note that Table 3.2.1 only 
includes the EBNA1 peptides against which one or more donors showed a response in the 
initial assay. Generally, these repeat assays confirmed the original findings even though the 
absolute size of the response could vary by a factor of (at most) three fold between the two 
assays. However, there were occasional examples where a response identified in the 
original ex vivo screen did not repeat in either of the duplicate re-test wells, such as HK 
control 201 to peptides 14 and 38. Such non-reproducible responses were omitted in the 
overall compilation of the data. Table 3.2.1 nevertheless does show the reproducibility of 
the assay in most cases, for example HK control 201 responses to peptides 41/42, 50/51, 
54-60, 64, and 66/67. 
 
In total, 47 healthy Chinese donors were screened on the full panel of EBNA 1 peptides 
and, where appropriate, re-screened for positive peptide responses. Four of the 47 donors 
were discarded because background IFNγ response levels were unacceptably high in the 
initial screening. The data were therefore compiled from 43 informative donors, and the 
EBNA 1 Peptide Number
Donor Background 1 2 3 14 38 41 42 47 48 49 50 51 52 53 54 55 56 57 58 59 60 62 63 64 65 66 67 68 69 70 72 73
HK Control 201 initial 2-16 68 152 130 198 198 168 188 114 244 276 212 98 62 134 92 82
HK Control 201 retest 1 2-10 4 2 130 198 118 118 188 114 162 244 212 98 36 134 92 82
HK Control 201 retest 2 2-10 4 6 114 206 124 118 180 88 172 280 190 88 46 118 96 64
HK Control 202 initial 2-8 34 52 34 40 34
HK Control 202 retest 2 48 52 56 80 58 60 62 62 68 74
HK Control 212 initial 4-16 40 30 44
HK Control 212 retest 16 4 14 28 36 34
HK Control 215 initial 4-16 64 60 182 242 236 54 86
HK Control 215 retest 1 6-10 48 52 178 180 102 54 70
HK Control 215 retest 2 6-10 60 50 184 190 86 66 82
HK Control 221 initial 4-16 124
HK Control 221 retest 46 50 48 62
HK Control 222 initial 6-26 50 52 36 34 36 82 90 42
HK Control 222 retest 0 8 18 22 18 28 8 6 2 12 46 18 10
HK Control 224 initial 10-22 104 96 40 46 50 44 46
HK Control 224 retest 0 14 22 22 6 10 24 28 4
HK Control 228 initial 28-66 138 158 104 108 168 160 134 120 172 108
HK Control 228 retest 1 2-24 64 102 102 64 90 98 100 74 98 48
HK Control 228 retest 2 2-24 60 116 98 80 74 88 104 76 114 72
HK Control 229 initial 14-28 48
HK Control 229 retest 24 4 18 14 30 18
HK Control 230 initial 0-10 *56 32 52 42 64 92 74
HK Control 230 retest 4 **12 44 50 36 70 90 26 20 14 90 166 106 64
HK Control 232 initial 40-78 120 136
HK Control 232 retest 4 2 12 18 18 4
HK Control 233 initial 2-54 84 144 100 92 86 120 108 88
HK Control 233 retest 1 0-4 64 50 48 32 84 44 76 28
HK Control 233 retest 2 0-4 58 64 46 44 80 58 64 30
HK Control 234 initial 34-54 120 96 112
HK Control 234 retest 176 152 172 238 190 210 164 162
HK Control 240 initial 14-36 48 56 76 62
HK Control 240 retest 4 18 42 44 16 44 28 56 68 22
HK Control 241 initial 34-64 300 132 100 108 90
HK Control 241 retest 10 32 120 98 46 36 38 40 22 14
HK Control 242 initial 26-32 46 46
HK Control 242 retest 1 4 18 26 14 20
HK Control 244 initial 68-80 120 122 260 162
HK Control 244 retest 92 52 160 144 76 104 88 136 176 134 174 162 110
HK Control 247 initial 0 110 124 20 62
HK Control 247 retest 82 130 214 214 236 128 48 102 128 216
HK Control 248 initial 2-10 98 70 38 32 38
HK Control 248 retest 2 4 28 20 14 6 4 8 20 16
HK Control 249 initial 10-16 34 106 90 38
HK Control 249 retest 98 74 182 180 172 118 176
Table 3.2.1: SUMMARY OF EBNA1 PEPTIDE RE-TEST FROM FIRST COHORT STUDY
* highlighted yellow is the peptide response that needs retesting
** neighboring peptide that were included in the rest along side the retest peptide
EBNA 1 Peptide Number
Donor Background 2 14 38 41 42 48 49 50 51 54 55 56 57 58 59 60 63 64 65 66 67 68 69 72 73
HK Control 201 2-16 *68 152 130 198 198 168 188 114 244 276 212 98 62 134 92 82
HK Control 202 2-8 34 52 34 40 34
HK Control 203 28-40 80 70 64 82 66
HK Control 204  12-24 44 30 34 42
HK Control 205 0-4
HK Control 206 4-12
HK Control 207 0-8
HK Control 208 14-30 44 58
HK Control 209 4-16 30 48 26
HK Control 210 42-60
HK Control 211 4-20 40 72 56 28
HK Control 212 4-18 40 30 44
HK Control 213 4-24
HK Control 215 4-16 64 60 182 242 236 54 86
HK Control 218 54-80
HK Control 219 4-32 112 130 60 42
HK Control 220 12-46
HK Control 221 4-16 124
HK Control 222 6-26 50 52 36 34 36 82 90 42
HK Control 223 6-16 44 46 34
HK Control 224 10-22 104 96 40 46 50 44 46
HK Control 225 62-84
HK Control 226 12-56
HK Control 227 30-50
HK Control 228 28-66 138 158 104 108 168 160 134 120 172 108
HK Control 229 14-28 48
HK Control 230  0-10 56 32 52 42 64 92 74
HK Control 231  38-74 100 108
HK Control 232 40-78 120 136
HK Control 233 2-54 84 144 100 92 86 120 108 88
HK Control 234 34-58 120 96 112
HK Control 236 8-30 62
HK Control 237 26-44
HK Control 240 14-36 48 56 76 62
HK Control 241 34-64 300 132 100 108 90
HK Control 242 26-32 58 52 46 46
HK Control 243 50-56
HK Control 244 68-80 120 122 260 162
HK Control 245 62-90
HK Control 247 0 110 124 20 62
HK Control 248 2-10 98 70 38 32 38
HK Control 249 10-16 34 106 90 38
HK Control 250 0-2
Table 3.2.2: SUMMARY OF FULL-PANEL EBNA 1 PEPTIDE SCREENING
Note: only positive data are shown in the table
* results are expressed as spot forming cells (SFC) per million cells
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overall results are shown in Table 3.2.2; again only those peptides against which one or 
more donors made a response are included in the Table. Of the 43 informative donors, 29 
gave a positive response to one or more EBNA 1 peptides, whereas 14 donors did not 
respond to any peptides. Scanning the Table immediately shows that some peptides (e.g. in 
the region 66-68) were seen by several different individuals, whereas other peptides (e.g. 
41/42 and 72/73) were seen by one or two responders only. Levels of response ranged from 
30 SFC/106 (i.e. the minimum considered significant in such assays) to a maximum of 300 
SFC/106 above background. Further comments on the data are made later after presenting 
the results from more limited screening on a second cohort of donors. 
 
A second cohort of 43 healthy Chinese donors was screened on a mini-panel of 18 EBNA1 
peptides that were observed to be most frequently recognised in the initial cohort assay. 
Table 3.2.3 shows the 18 peptides in the mini-panel screening.  Some 8 donors gave 
unacceptably high backgrounds in this assay and so informative results were obtained from 
35 individuals. Representative results from four informative donors are shown as 
histograms in Figure 3.2.5 (for HK controls 263 and 280) and Figure 3.2.6 (for HK controls 
285 and 291). Again clear IFN-γ responses could be observed to particular sets of 
overlapping peptides. Responses to some of these donors were re-tested and the data are 
shown in Table 3.2.4 and again non-reproducible responses were omitted in the overall 
compilation of the data. Overall results from screening on the EBNA 1 mini-panel are 
summarised in Table 3.2.5. Of the 35 informative donors, 25 gave a positive response to 
one or more peptides and 10 were uniformly negative. Responses ranged in size from 30 
SFC/106 to, in this case, a maximum of 380 SFC/106 cells. 
 
3.2.4 Provisional identification of epitope regions 
Table 3.2.6 summarises the results of both the full-panel and mini-panel screening. 
Identifying individual epitopes from ELISpot data of this kind is problematic because of the 
nature of the assay. Responding cells are exposed to a high peptide concentration and 
therefore might be able to respond to adjacent pairs or even adjacent triplets of 20-mer 
peptides (i.e. shared sequences 15 or even 10 amino acids in length) even though the  
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 Peptide sequence Coordinates Virus type Peptide no. 
EBNA1 WFGKHRGQGGSNPKFENIAE 464-483 B95-8 47 
EBNA1 *RGQGGSNPKFENIAEGLRVL 469-488 **Chinese 48 
EBNA1 SNPKFENIAEGLRVLLARSH 474-493 Chinese 49 
EBNA1 ENIAEGLRVLLARSHVERTT 479-498 Chinese 50 
EBNA1 VERTTEEGNWVAGVFVYGGS 494-513 Chinese 53 
EBNA1 EEGNWVAGVFVYGGSKTSLY 499-518 Chinese 54 
EBNA1 VAGVFVYGGSKTSLYNLRRG 504-523 B95-8 55 
EBNA1 VYGGSKTSLYNLRRGIALAV 509-528 Chinese 56 
EBNA1 KTSLYNLRRGIALAVPQCRI 514-533 Chinese 57 
EBNA1 NLRRGIALAVPQCRITPLSR 519-538 Chinese 58 
EBNA1 IALAVPQCRITPLSRLPFGM 524-543 Chinese 59 
EBNA1 PQCRITPLSRLPFGMAPGPG 529-548 Chinese 60 
EBNA1 PQPGPLRESIVCYFMVFLQT 549-568 B95-8 64 
EBNA1 LRESIVCYFMVFLQTHIFAE 554-573 B95-8 65 
EBNA1 VCYFMVFLQTHIFAEVLKDA 559-578 B95-8 66 
EBNA1 VFLQTHIFAEVLKDAIKDLV 564-583 B95-8 67 
EBNA1 HIFAEVLKDAIKDLVMTKPA 569-588 B95-8 68 
EBNA1 VLKDAIKDLVMTKPAPTCNI 574-593 B95-8 69 
 
Table 3.2.3: Mini-panel EBNA1 peptides 
 
* In bold is the amino acid substitution that is found in the CKL sequence 
** Unique to the Chinese CKL EBV strain 
5 10 15 20 25 35 40 45 50 55 60 65 70 75 8030
 48  49  50  51  53  54  55  57  58  65  66  67  68 56  59
 48  49  50  51  53  54  55  57  58  65  66  67  68 56  59
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Figure 3.2.5: IFN-γ ELISpot screening of mini-panel EBNA1 peptide 
Result shows two typical IFN-γ ELISpot assays of two Hong Kong donor PBMC samples 
(HK Control 263 and 280) exposed to 18 individual mini-panel EBNA1 20-mer peptides 
derived from the CKL EBV strain. The results are expressed as the number of spot forming 
cells (SFC) per 106 CD8-depleted PBMCs. HK Control 263 (top) show responses to 
multiple mini-panel EBNA1 20-mer peptides (peptides 55-58 and 66-68) above the back 
ground reading (dotted line). HK Control 280 (bottom) also shows responses to multiple 
EBNA1 20-mer peptides (peptides 55-58 and 65-66). Note that the two donors have a 
common response to peptides 55-58. 
 
15 20 25 30
5 10 15 20 25 30 35 40
5 10
 48  49  50  51  53  54  55  57  58  65  66  67  68 56  59
 48  49  50  51  53  54  55  57  58  65  66  67  68 56  59
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Figure 3.2.6: IFN-γ ELISpot screening of mini-panel EBNA1 peptide continued 
Result shows two typical IFN-γ ELISpot assays of two Hong Kong donor PBMC samples 
(HK Control 285 and 291) exposed to 18 individual mini-panel EBNA1 20-mer peptides 
derived from the CKL EBV strain. The results are expressed as the number of spot forming 
cells (SFC) per 106 CD8-depleted PBMCs. HK Control 285 (top) show responses to 
multiple mini-panel EBNA1 20-mer peptides (peptides 48, 49, 53, and 55-58) above the 
back ground reading (dotted line). HK Control 291 (bottom) also shows responses to 
multiple EBNA1 20-mer peptides (peptides 48, 49 and 66-68). Note that the two donors 
have a common response to peptides 48 and 49. 
EBNA 1 Peptide Number
Donor Background 1 2 3 14 38 41 42 47 48 49 50 51 52 53 54 55 56 57 58 59 60 62 63 64 65 66 67 68 69 70 72 73
HK Control 252 initial 1-10 158 162 148 88 42
HK Control 252 retest 40 188 156 266 292 258 166 370 168
HK Control 256 initial 4-22 96 98 96 46
HK Control 256 retest 188 180 190 164 122 226 150
HK Control 257 initial 1-12 *96 92 82
HK Control 257 retest 24 **20 40 60 106
HK Control 262 initial 2-12 74 68 90 68 70
HK Control 262 retest 30 40 62 70 44 40 54 74 86 58
HK Control 263 initial 32-52 162 198 278 380 240 300 298
HK Control 263 retest 80 122 198 170 282
HK Control 266 initial 16-38 94 86 96 80 68
HK Control 266 retest 20 46 108 90
HK Control 268 initial 4-14 112 100 70
HK Control 268 retest 114 130 106 126 102
HK Control 276 initial 2-12 26 124 144 96
HK Control 276 retest 18 42 80 94 80 40
HK Control 280 initial 6-24 156 126 104 44 166 128
HK Control 280 retest 58 48 104 124 54 38 58 40 72 122 48 56
HK Control 282 initial 2-10 58 50
HK Control 282 retest 150 72 72 88 202 224
HK Control 285 initial 12-28 110 124 150 240 180 218 80
HK Control 285 retest 40 60 114 124 120 108 108 28 136 132 76 62 50
Table 3.2.4: SUMMARY OF EBNA1 PEPTIDE RE-TEST FROM SECOND COHORT STUDY
* highlighted yellow is the peptide response that needs retesting
** neighboring peptide that were included in the rest along side the retest peptide
n.d n.d n.d n.d n.d n.d n.d n.d n.d n.d n.d n.d n.d n.d
n.d n.d n.d n.d n.d n.d n.d n.d n.d n.d n.d n.d n.d n.d
n.d n.d n.d n.d n.d n.d n.d n.d n.d n.d n.d n.d n.d n.d
n.d n.d n.d n.d n.d n.d n.d n.d n.d n.d n.d n.d n.d n.d
n.d n.d n.d n.d n.d n.d n.d n.d n.d n.d n.d n.d n.d n.d
n.d n.d n.d n.d n.d n.d n.d n.d n.d n.d n.d n.d n.d n.d
n.d n.d n.d n.d n.d n.d n.d n.d n.d n.d n.d n.d n.d n.d
n.d n.d n.d n.d n.d n.d n.d n.d n.d n.d n.d n.d n.d n.d
n.d n.d n.d n.d n.d n.d n.d n.d n.d n.d n.d n.d n.d n.d
n.d n.d n.d n.d n.d n.d n.d n.d n.d n.d n.d n.d n.d n.d
n.d n.d n.d n.d n.d n.d n.d n.d n.d n.d n.d n.d n.d n.d
n.d n.d n.d n.d n.d n.d n.d n.d n.d n.d n.d n.d n.d n.d
n.d n.d n.d n.d n.d n.d n.d n.d n.d n.d n.d n.d n.d n.d
n.d n.d n.d n.d n.d n.d n.d n.d n.d n.d n.d n.d n.d n.d
n.d n.d n.d n.d n.d n.d n.d n.d n.d n.d n.d n.d n.d n.d
n.d n.d n.d n.d n.d n.d n.d n.d n.d n.d n.d n.d n.d n.d
n.d n.d n.d n.d n.d n.d n.d n.d n.d n.d n.d n.d n.d n.d
n.d n.d n.d n.d n.d n.d n.d n.d n.d n.d n.d n.d n.d n.d
n.d n.d n.d n.d n.d n.d n.d n.d n.d n.d n.d n.d n.d n.d
n.d n.d n.d n.d n.d n.d n.d n.d n.d n.d n.d n.d n.d n.d
n.d n.d n.d n.d n.d n.d n.d n.d n.d n.d n.d n.d n.d n.d
n.d n.d n.d n.d n.d n.d n.d n.d n.d n.d n.d n.d n.d n.d
n.d - not determined
EBNA 1 Peptide Number
Donor Background 2 14 38 41 42 48 49 50 51 54 55 56 57 58 59 60 63 64 65 66 67 68 69 72 73
HK Control 251 4±2 *116 118 40 30 38 130 74
HK Control 252 3±1 158 162 148 88 42
HK Control 253 4±2 56 48 64 24 56 50
HK Control 254 4±2
HK Control 255 3±2
HK Control 256 6±3 96 98 96 46
HK Control 257 4±3 96 92 82
HK Control 258 7±3 136 196 172
HK Control 259 3±2
HK Control 260 2±2 20 128 158 138 66
HK Control 261 5±2
HK Control 262 4±2 74 68 90 68 70
HK Control 263 22±4 162 198 278 380 240 300 298
HK Control 264 12±3
HK Control 266 9±3 94 86 96 80 68
HK Control 267 8±2 86 114 80
HK Control 268 4±1 112 100 70
HK Control 269 4±1
HK Control 276 3±2 26 124 144 96
HK Control 277 4±2 42 82 40 78 302 352 320
HK Control 278 3±2 74 58 40 90 68
HK Control 279 8±2 86 90 116 86
HK Control 280 6±2 156 126 104 44 166 128
HK Control 281 4±1 64 50
HK Control 282 4±1 58 50
HK Control 283 5±3 40 60 40
HK Control 284 4±2 80 54 38 52 32 32
HK Control 285 9±3 110 124 150 240 180 218 80
HK Control 286 14±3 122 106 88 86 60
HK Control 287 9±1 68 104 96
HK Control 288 8±3 74 124 108
HK Control 289 3±2 46 32
HK Control 290 2±1
HK Control 291 6±2 88 74 44 114 96
HK Control 293 7±1
Table 3.2.5: SUMMARY OF MIN-PANEL EBNA 1 PEPTIDE SCREENING
n.d n.d n.d n.d n.d n.d n.d n.d n.d n.d n.d n.d n.d
n.d n.d n.d n.d n.d n.d n.d n.d n.d n.d n.d n.d n.d
n.d n.d n.d n.d n.d n.d n.d n.d n.d n.d n.d n.d n.d
n.d n.d n.d n.d n.d n.d n.d n.d n.d n.d n.d n.d n.d
n.d n.d n.d n.d n.d n.d n.d n.d n.d n.d n.d n.d n.d
n.d n.d n.d n.d n.d n.d n.d n.d n.d n.d n.d n.d n.d
n.d n.d n.d n.d n.d n.d n.d n.d n.d n.d n.d n.d n.d
n.d n.d n.d n.d n.d n.d n.d n.d n.d n.d n.d n.d n.d
n.d n.d n.d n.d n.d n.d n.d n.d n.d n.d n.d n.d n.d
n.d n.d n.d n.d n.d n.d n.d n.d n.d n.d n.d n.d n.d
n.d n.d n.d n.d n.d n.d n.d n.d n.d n.d n.d n.d n.d
n.d n.d n.d n.d n.d n.d n.d n.d n.d n.d n.d n.d n.d
n.d n.d n.d n.d n.d n.d n.d n.d n.d n.d n.d n.d n.d
n.d n.d n.d n.d n.d n.d n.d n.d n.d n.d n.d n.d n.d
n.d n.d n.d n.d n.d n.d n.d n.d n.d n.d n.d n.d n.d
n.d n.d n.d n.d n.d n.d n.d n.d n.d n.d n.d n.d n.d
n.d n.d n.d n.d n.d n.d n.d n.d n.d n.d n.d n.d n.d
n.d n.d n.d n.d n.d n.d n.d n.d n.d n.d n.d n.d n.d
n.d n.d n.d n.d n.d n.d n.d n.d n.d n.d n.d n.d n.d
n.d n.d n.d n.d n.d n.d n.d n.d n.d n.d n.d n.d n.d
n.d n.d n.d n.d n.d n.d n.d n.d n.d n.d n.d n.d n.d
n.d n.d n.d n.d n.d n.d n.d n.d n.d n.d n.d n.d n.d
n.d n.d n.d n.d n.d n.d n.d n.d n.d n.d n.d n.d n.d
n.d n.d n.d n.d n.d n.d n.d n.d n.d n.d n.d n.d n.d
n.d n.d n.d n.d n.d n.d n.d n.d n.d n.d n.d n.d n.d
n.d n.d n.d n.d n.d n.d n.d n.d n.d n.d n.d n.d n.d
n.d n.d n.d n.d n.d n.d n.d n.d n.d n.d n.d n.d n.d
n.d n.d n.d n.d n.d n.d n.d n.d n.d n.d n.d n.d n.d
n.d n.d n.d n.d n.d n.d n.d n.d n.d n.d n.d n.d n.d
n.d n.d n.d n.d n.d n.d n.d n.d n.d n.d n.d n.d n.d
n.d n.d n.d n.d n.d n.d n.d n.d n.d n.d n.d n.d n.d
n.d n.d n.d n.d n.d n.d n.d n.d n.d n.d n.d n.d n.d
n.d n.d n.d n.d n.d n.d n.d n.d n.d n.d n.d n.d n.d
n.d n.d n.d n.d n.d n.d n.d n.d n.d n.d n.d n.d n.d
n.d n.d n.d n.d n.d n.d n.d n.d n.d n.d n.d n.d n.d
n.d - not determined
* results are shown as spot forming cells (SFC) per million cells
EBNA 1 Peptide Number
Donor Background 2 14 38 41 42 48 49 50 51 54 55 56 57 58 59 60 63 64 65 66 67 68 69 72 73
*HK Control 201 4±2 68 152 (+)130 198 198 168 188 114 244 276 212 98 62 134 92 82
HK Control 202 2±1 34 52 34 40 34
HK Control 203 16±2 80 70 64 82 66
HK Control 204 9±2 44 30 34 42
**HK Control 205 1±1
HK Control 206 4±1
HK Control 207 2±1
HK Control 208 10±3 44 58
HK Control 209 4±2 30 48 26
HK Control 210 27±3
HK Control 211 4±2 40 72 56 28
HK Control 212 5±2 40 30 44
HK Control 213 7±3
HK Control 215 5±2 64 60 182 242 236 54 86
HK Control 218 33±4
HK Control 219 6±4 112 130 60 42
HK Control 220 13±5
HK Control 221 4±2 124
HK Control 222 7±3 50 52 36 34 36 82 90 42
HK Control 223 6±2 44 46 34
HK Control 224 7±2 104 96 40 46 50 44 46
HK Control 225 33±9
HK Control 226 13±6
HK Control 227 18±4
HK Control 228 23±7 138 158 104 108 168 160 134 120 172 108
HK Control 229 10±2 48
HK Control 230 1±1 56 32 52 42 64 92 74
HK Control 231 28±6 100 108
HK Control 232 28±6 120 136
HK Control 233 16±11 84 144 100 92 86 120 108 88
HK Control 234 22±5 120 96 112
HK Control 236 10±3 62
HK Control 237 17±3
HK Control 240 13±4 48 56 76 62
HK Control 241 24±4 300 132 100 108 90
HK Control 242 16±5 58 52 46 46
HK Control 243 31±4
HK Control 244 44±10 120 122 260 162
HK Control 245 35±9
HK Control 247 1±2 110 124 20 62
HK Control 248 4±4 98 70 38 32 38
HK Control 249 7±4 34 106 90 38
HK Control 250 2±2
HK Control 251 4±2 116 118 40 30 38 130 74
HK Control 252 3±1 158 162 148 88 42
HK Control 253 4±2 56 48 64 24 56 50
HK Control 254 4±2
HK Control 255 3±2
HK Control 256 6±3 96 98 96 46
n.d n.d n.d n.d n.d n.d n.d n.d n.d n.d n.d n.d n.d
n.d n.d n.d n.d n.d n.d n.d n.d n.d n.d n.d n.d n.d
n.d n.d n.d n.d n.d n.d n.d n.d n.d n.d n.d n.d n.d
n.d n.d n.d n.d n.d n.d n.d n.d n.d n.d n.d n.d n.d
n.d n.d n.d n.d n.d n.d n.d n.d n.d n.d n.d n.d n.d
n.d n.d n.d n.d n.d n.d n.d n.d n.d n.d n.d n.d n.d
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optimal epitope peptide may be fully contained within just one of the 20-mer sequences. 
We looked for examples of such adjacent peptide pairs or triplets. Instances where 
responses were found to more than three adjacent peptides were deemed to reflect the 
existence of more than one epitope in this region, since full 20-mer peptides n and n+3  
could only share 5 amino acids in common and would be very unlikely to detect the same 
epitope response. Based on these criteria, we provisionally identified the following epitope 
regions; peptides 41/42 are seen by two responders to one or both peptides (HK control 201 
and 228); peptides 48/49 are seen by multiple donors all but one of whom responded to 
both peptides; peptides 50/51 are seen by four donors responding to one or both peptides; 
peptides 54/55 are seen by two donors responding to one or both peptides (HK control 201 
and 285); peptides 56/57 are seen by multiple donors responding to one or both peptides at 
levels higher than seen against adjacent peptides 55 and 58; peptides 58/59 are seen by 
multiple donors responding to one or both peptides at levels higher than seen against 
adjacent peptides 57 and 60; peptide 64 is seen by a single donor HK control 201; peptides 
65-67 are seen by multiple donors responding to one, two, or three peptides at levels higher 
than seen against peptides 64 and 68; peptides 66-68 are seen by multiple donors 
responding to one, two, or three peptides at levels higher than seen against adjacent 
peptides 65 and 69; and peptides 72/73 are seen by a single donor HK control 215. 
 
Based on this interpretation, Table 3.2.7 identifies the ten provisional epitope regions with 
their coordinates, the primary EBNA 1 sequence and with adjacent 20-mer peptides aligned 
so as to display their 15-mer sequence of overlap. The donors who responded to these 
epitope regions are summarised in Table 3.2.8. From Tables 3.2.6 and 3.2.7, the frequency 
of response and response sizes was calculated to yield Table 3.2.9 A, B and C respectively. 
Table 3.2.9A shows the number of donors tested and the number who responded to any of 
the EBNA1 peptides in the two cohorts. Overall, the screening indicated that almost 70% 
donors screened have detectable CD4+ T cell memory to one or more EBNA1 peptide. The 
actual frequency of positive responders may have been even higher if the mini-panel cohort 
of donors had been screened on the full panel of EBNA1 peptides. 
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Peptide no.    Coordinate Chinese epitope sequence  
41 
42 
434-453 
439-458 
IEQGPTDDPGEGPSTGPRGQ      
           TDDPGEGPSTGPRGQGDGGR 
48 
49 
469-488 
474-493 
RGQGGSNPKFENIAEGLRVL 
              SNPKFENIAEGLRVLLARSH 
50 
51 
479-498 
484-503 
ENIAEGLRVLLARSHVERTT 
           GLRVLLARSHVERTTEEGNW 
54 
55 
499-518 
504-523 
EEGNWVAGVFVYGGSKTSLY 
              VAGVFVYGGSKTSLYNLRRG 
56 
57 
509-528 
514-533 
VYGGSKTSLYNLRRGIALAV 
             KTSLYNLRRGIALAVPQCRI 
58 
59 
519-538 
524-543 
NLRRGIALAVPQCRITPLSR 
            IALAVPQCRITPLSRLPFGM 
64 549-568 PQPGPLRESIVCYFMVFLQT 
65 
66 
554-573 
559-578 
LRESIVCYFMVFLQTHIFAE 
           VCYFMVFLQTHIFAEVLKDA 
67 
68 
  564-583 
  569-588 
VFLQTHIFAEVLKDAIKDLV 
            HIFAEVLKDAIKDLVMTKPA 
72 
73 
589-608 
594-613 
PTCNIKVTVCSFDDGVDLPP 
           KVTVCSFDDGVDLPPWFPPM 
 
Table 3.2.7: 10 provisional epitope regions 
 
Responders
(HK Control) 41/42 48/49 50/51 54/55 56/57 58/59 64 65/66 67/68 72/73
201 √ √ √ √ √ √ √
202 √
203 √ √ √
204 √ √
208 √
209 √
211 √
215 √ √ √
219 √ √
222 √
223 √
224 √ √ √
228 √ √ √ √ √
230 √ √ √
231 √
233 √ √ √ √
234 √
236 √
240 √ √
241 √ √
242 √
244 √ √ √
247 √ √
248 √ √
249 √
251 √ √ √
252 √ √
253 √ √ √
257 √
258 √
260 √ √ √
262 √ √ √
263 √ √ √
266 √ √ √
267 √
268 √
276 √ √
277 √ √ √
278 √ √
279 √
280 √ √
281 √
283 √
284 √ √ √
285 √ √ √ √
286 √ √
287 √
288 √
291 √ √
Responders 2 16 4 4 11 16 1 14 34 1
Total Tested 43 78 43 78 78 78 43 78 78 43
Frequency (%) 5 21 9 5 14 21 2 18 44 2
Epitope regions
Table 3.2.8: Summary of epitope region analysis
√ - there is a response to this epitope region 
25%
50%
25%
50%
1 641
GA repeat 
domain
93
 434
469
479 499 509  519
 549
 554
 559
 589
325
The frequency of response to the 10 EBNA1 epitope regions
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Figure 3.2.7: The frequency of response to the 10 EBNA1 epitope regions 
The Figure shows the location of the ten epitope regions on the EBNA 1 molecule and, for 
each region, indicates the frequency of positive responders in the form of a histogram. The 
red histogram represent that the responses are novel epitopes (unique to the Chinese study), 
and black histogram represent that the responses found in this study and the Caucasian 
study. Looking at the figure immediately shows that the epitope regions 48/49 (469), 
56/57(509), 58/59 (519), and 65-67 (554) were each recognised by 15-20% of individuals 
whereas epitope 66-68 (559) was recognised by a remarkable 44% of all individuals. 
Cohort 1 Cohort 2 Total
No. of donors tested 43 35 78
No. of responders 25 24 49
Frequency of response (%) 58 69 63
Table 3.2.9A: Frequency of responses in the two studied cohort
peptide number 41/42 48/49 50/51 54/55 56/57 58/59 64 65-67 66-68 72/73
No. of responders 2 16 4 4 11 16 1 14 34 1
No. donors tested 43 78 43 78 78 78 43 78 78 43
Frequency of response (%) 5 21 9 5 14 21 2 18 44 2
peptide number 41/42 48/49 50/51 54/55 56/57 58/59 64 65-67 66-68 72/73
Range of response 138-198 44-144 56-198 40-120 46-300 20-380 134 40-166 38-352 86
mean of response 168 92 134 87 133 110 134 96 111 86
Table 3.2.9B: Frequency of responses to the individual epitope regions
Table 3.2.9C: The response size to the individual epitope regions
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Figure 3.2.7 shows the location of these ten epitope regions on the EBNA 1 molecule and, 
for each region, indicates the frequency of positive responders. Using the values from  
summary Table 3.2.9B, while some epitope regions only showed occasional responses, it 
was clear that other regions were frequently recognised. The epitopes 48/49 (469), 56/57 
(509), 58/59 (519), and 65-67 (554) were each recognised by 15-20% of individuals 
whereas epitope 66-68 (559) was recognised by a remarkable 44% of all individuals. Figure 
3.2.7 also emphasises the concentration of the epitope regions within the C-terminal half of 
EBNA 1. 
 
Table 3.2.9C shows the mean size and overall range of the response observed and all 
individual responses for each epitope are plotted in Figure 3.2.8 above the map of the 
EBNA 1 molecule showing epitope location. The average mean response size ranges from 
86-168 SFC per 10^6 cells however the individual response size range from 20-380 SFC 
per 10^6 cells. Looking at Figure 3.2.8, the majority of the SFC per 10^6 cells lies within a 
range of approximately 50-150 SFC per 10^6 cells with occasionally very weak and very 
strong responses also observed. There is no one epitope that consistently elicits very strong 
or very weak responses as measured in the ELISpot assay. 
  
3.2.5 Discussion 
 
3.2.5.1 Limitations of ELISPOT screening  
ELISPOT screening for epitope detection is an imprecise science and there are a few areas 
of concern when interpreting ELISPOT data. One concern is the use of a high peptide 
concentration does not represent antigen expression under physiological condition and may 
explain why CD4+ T cell responses are detected to adjacent peptides, and precise epitope 
mapping is made difficult. Arguably this reduces the chances of missing weak epitope-
specific responses but, because adjacent peptides share significant overlapping sequences, 
the assay can only identify ‘epitope regions’ rather than precise epitope location. Where 
responses to 4-5 adjacent peptides are seen (such as seen in responses to peptides 54-60 in  
1 641
200
400
SF
C
 p
er
 1
06
 c
el
ls300
100
 434 469 479 499 509
 519
 549
 554
 559  589
200
400
300
100
400
SF
C
 p
er
 1
06
 c
el
ls
The response size to the 10 EBNA1 epitope regions
121 
 
 
 
 
 
 
Figure 3.2.8: The response size to the 10 EBNA1 epitope regions 
The Figure shows the location of the ten epitope regions on the EBNA 1 molecule and, for 
each region, the individual size of the response are represented by a blue dot. The scales 
located on both sides of the Figure are expressed as spot forming cells (SFC) per million 
cells. The black line represents the mean response size for that particular epitope region. 
Note that the range of response size may vary from as few as 20 SFC per million cells to as 
high as 380 SFC per million cells. However, the mean response size does not vary as much 
(86-168 SFC per million cells).  
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HK control 201), it raises a question as to how many epitopes are represented in this region 
of response? Defining ‘epitope regions’this way is more likely to underestimate the true 
number of independent epitopes because an epitope restricted through an HLA II molecule 
is limited to a 15-mer peptide whereas 4-5 adjacent peptides covers 70-80 amino acids. 
Therefore, comparisons of response patterns in large numbers of different donors can give a 
clearer picture by identifying individuals that respond only to ‘one end’ of 4-5 peptide 
region and others responding to the other end. That is why we screened 79 donors in the 
present study. Hudgens et al (2004) recently introduced an ELISpot assay protocol 
allowing statistical analysis of results in order to establish ‘unified’ criteria for identifying a 
positive and a negative result. The aim is to allow the collation of results between 
laboratories, studies and populations. One of the most important requirements is to perform 
experiments with multiple repeats so that a statistical analysis could be performed. For 
example to study responses against one peptide, the experiment would need to be done in 
triplicate wells and repeated several times on different days. In practice, however, this is 
not feasible in the context of large scale screening on peptide panels, not least because of 
the volumes of blood required from each donor and the manpower required to screen a 
large range of individuals. Our approach was a compromise solution, using buffy coat 
samples that allowed an initial screen on the whole peptide panel and repeat assays to 
validate potential positive responses. 
 
At the time when this work was initiated, the NK cell depletion assay (as described in the 
previous chapter) was not set up in Hong Kong. As a result, some donors were totally non-
informative because of high background in the ELISpot assay and were omitted from the 
compilation of the results. We established a criteria in which a positive response is defined 
as +3SD over the mean background value. However, using these criteria underestimates the 
true frequency of responses since weak responses become undetectable especially when 
background values are high.  
 
These assays used an ELISpot counter to read the spots on the ELISpot plates. This 
machine works by making a scan of the ELISpot plate and is assisted by software to 
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analyse and count the spots. Spots are counted according to criteria set by the user, for 
example the minimum size and intensity that defines a spot. The problem with counting the 
ELISpot using a machine is that dust particles can form spots that may match the user 
criteria and get counted as a spot; conversely true spots which do not match the criteria are 
missed. Therefore ELISpots that were counted by machine were routinely double-checked 
by eye to ensure the validity of results.   
 
Even using our protocol rather than that by Hudgens et al (2004), the ELISpot assay has a 
high demand on cell numbers. Depleting the CD8+ population from PBMC itself loses 
around 50% of the T-cells (those include around 25% due to loss of the CD8+ population 
and further 25% non-specific losses in washing). However, CD8+ depletion was deemed a 
necessary step. There must also be a balance between using too many cells (i.e. risking high 
background) and using too few cells (i.e. risking missing out responses) in the assay. The 
most appropriate cell numbers to use in the assay is between 200,000-500,000 cells/assay 
wells. Ideally, using 500,000 cells/assay wells is just enough cells to coat the bottom of the 
wells which reduces chance of missing out weak responses while preventing cells from 
overlapping each other. This kind of approach is suitable for initial screening on large 
peptide panels using buffy coats but not for screening on small patient samples. However, 
the matrix approach (Lauer et al, 2004) could solve the problem with large peptide panel 
screening using small patient samples. The matrix approach uses a system where peptide 
pools (containing no more than 10 peptides) are prepared in a matrix array such that each 
individual peptide could be found in two pools. A positive response in two peptide pools 
containing the same peptide would result in a true response against that peptide. This 
approach would use fewer cell numbers since the screening is done in peptide pools and it 
requires a response to be seen in two separate pools; therefore the chances of false response 
are rare. However there may be difficulties in screening the EBNA1 peptide panel in this 
way, since often a donor will respond to multiple epitopes and this opens up the possibility 
of competition between peptides in a large peptide pool. 
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3.2.5.2 EBNA1 responses in Chinese versus Caucasian 
Leen et al (2001) described ELISpot screening on peptide pools using two peptide panels; 
81 20-mer B95.8 EBNA1 peptides and 22 20-mer Q/T variant peptides. In total, 26 
seropositive donors were screened against the B95.8 EBNA1 peptide panel of which 19 
donors responded against a total of 15 epitope regions. These 7 non-responsive donors were 
subjected to screening using the 22 Q/T variant peptides in 3/7 responded to one or more of 
3 Q/T-specific epitope regions; EBNA1 424-443, 514-533 and 589-608. More interestingly, 
the original 19 B95.8 EBNA1 peptide responders were also rescreened using the 22 Q/T 
variant peptides and in every case they showed cross-reactivity with the relevant epitope 
variant. It seems that, under the conditions of the ELISpot assay, differences of one or two 
amino acids in epitope sequences do not affect responsiveness. There were no additional 
responses that were specifically directed at the Q/T variant peptides. More recently 
(unpublished work) this laboratory has found two new B95.8 epitopes (EBNA1 56* and 
379*) in a study of ELISpot responses in 10 more Caucasian donors; 1 in 10 donors 
screened responded to these two new epitopes.  
  
In the present study, 43 donors were subjected to a complete screening and 35 donors to 
mini-panel screening using the CKL Chinese prototype virus peptide sequence. This 
detected responses in 53/78 donors and located 10 epitopes. The question is whether 
focusing on this one allelic sequence of EBNA 1 was justified. In this context, Midgley et 
al (2000) found that the non-CKL EBNA 1 sequences are found in only a very small 
percentage of Chinese virus strains. Interestingly, Midgley et al (2000) identified, by 
comparing DNA sequences of EBNA2 and the EBNA3s, two major viral strains designated 
the Li and Wu family isolates. In addition, Wu/Li recombinant viruses were identified such 
that the viruses show Wu-like EBNA2 and EBNA3A, recombinant EBNA3B and Li-like 
EBNA3C. In the context of EBNA1, all the Li family isolates follow the V-allele consensus 
(as described by Gutierrez et al., 1997) whereas, 3/7 Wu family virus isolates show a single 
codon change at position 585 from a Thr->Ile. Therefore, studying the CKL EBNA 1 
sequence as representative of most Chinese strains is justified.  
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It is significant that in the present study of Chinese individuals, fewer EBNA1 epitope 
regions were found than in the earlier work on Caucasians, yet more donors were screened. 
It is of course possible that we have underestimated the true number of epitope regions 
using our current method because the epitopes lay close to or overlap each other, especially 
in the region EBNA1 494-548. This clustering of responses to the C-terminal half of the 
protein is also observed in the Caucasian study, thus it is likely that some of these epitope 
regions contain more than one epitope. Likewise we may be missing weak responses due to 
masking on to high backgrounds. However, there is no reason to believe that this is a 
problem unique to the present study. Likewise we may be missing rare responses, perhaps 
restricted through rare HLA II alleles in the Chinese population but, since we screened 
many more donors than Leen et al (2001), there is again no reason to believe that this is a 
problem that has affected our study only. 
 
Figure 3.2.9 compares the epitope regions identified in this study and by Leen et al (2001) 
and re-emphasises the concentration of responses in the C-terminal half of the EBNA1-
protein in both studies. This may reflect the possibility that the C-terminal half of the 
EBNA1 protein is highly immunogenic. However, further studies are required to determine 
the actual number of epitope in this region. There is clearly no global effect of gly-ala 
repeat domain on EBNA1 processing via the MHC class II pathway since there are so many 
epitopes in the C-terminal region, but could this suggest that the gly-ala repeat domain is 
inhibiting the processing of the N-terminal half of the protein from presentation to CD4+ T 
cells? Significantly, the recent work on Caucasians has detected CD4+ T cell responses to 
two epitopes located in the N-terminal half of the protein. The prediction is that some 
Chinese donors will also see N-terminal epitopes, although clearly if they do exist, such 
responses are quite rare.  
 
As a corollary to the reduced number of epitopes detected from the study of Chinese 
donors, there were a correspondingly larger proportion of Chinese donors responding to 
particular regions. This is shown in Figure 3.2.10 comparing the two sets of results. The 
frequency is expressed as a percentage of the total number of responding donors tested 
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Figure 3.2.9: CD4+ T cell responses to EBNA1 in Caucasian and Chinese donors 
The Figure shows the location of CD4+ T cell epitope/epitope regions in the EBNA1 
molecule; the grey molecule represents the B95.8 EBV strain EBNA1 molecule, the 
molecule in red represents the CKL EBV strain EBNA1 molecule, the numbers located at 
the bottom of the molecule are the coordinate of the glycine-alanine repeat region within 
the molecule and the actual size of the EBNA1 molecule, and the number allocated to the 
bolded bars represent the epitope/epitope regions. There are a total of 17 CD4+ epitopes 
identified in the Caucasian study, where two epitope (*) were recently found and are 
unpublished data. In our study, we have found 10 epitope regions of which 6 epitope 
regions (in red) are novel epitopes and 4 epitope regions are located in the same coordinate 
within the EBNA1 molecule as the ones described in the Caucasian work. 
Frequency of EBNA1 responses in the Caucasian population 
Frequency of EBNA1 responses in the Chinese population 
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Figure 3.2.10: Frequency of EBNA1 responses in Chinese vs. Caucasian 
This F igure shows the frequency of EBNA1 response in the Chinese population (top) and 
comparing the frequency of EBNA1 response in the Caucasian population (below). The 
frequency is expressed as a percentage of the total number of responding donors tested 
against that particular peptide(s). The Figure shows that there is a tendency towards higher 
frequencies in Chinese epitope regions and with one very frequent (EBNA1 559) response 
that is higher than anything in Caucasians. 
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HK Control Background 41 42 50 51 54 55 
201 2-20 
*102 
**(130) 
236 
(198) 
206 
(198) 
188 
(168) 
174 
(188) 
96 
(114) 
228 2-26 n.d 
126 
(138) 
n.d 
116 
(158) 
76 
(104) 
94 
(108) 
233 0-19 n.d n.d n.d n.d 
90 
(100) 
138 
(92) 
 
Table 3.2.10: CD4+ T cell responses to B95.8 equivalent EBNA1 peptides 
 
*CD4+ T cell response to B95.8 equivalent of the EBNA1 peptide 
** CD4+ T cell response to the CKL EBNA1 peptide 
n.d – not determined 
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against that particular peptide(s). The Figure shows that there is a tendency towards higher 
frequencies in Chinese epitope regions and with one very frequent (EBNA1 559) response 
that is higher than anything in Caucasians. However where such frequent responses are 
obtained, we do not yet know whether this is (i) HLA alleles being less polymorphic in the 
Chinese population or (ii) a larger proportion of promiscuous epitopes? 
 
As shown in Figure 3.2.9, of the 10 epitope regions seen by Chinese donors, 6 are unique to 
the Chinese population. Three of the 6 Chinese-specific responses (i.e. EBNA 1 434, 479 
and 499) are unique Chinese sequences and three were identical to the B95.8 sequences 
(i.e. EBNA 1 549, 559 and 589). The B95.8 equivalent of EBNA 1 434, 479 and 499 20-  
mer peptides were also tested on HK control 201 and 228 and EBNA 1 499 20-mer was 
tested on HK control 233 to see whether there is cross-reactivity of response. Table 3.2.10 
shows the ELISpot data of the experiment, in red are the responses to the B95.8 equivalent 
of the epitope region along side (in black) are the responses to the Chinese peptides and the 
data are expressed as SFC/106 CD8-depleted PBMCs. The Table clearly shows that there 
are no significant differences between CD4+ T cell responses against the Chinese or the 
B95.8 equivalent of the epitope regions. Therefore suggesting that EBNA 1 polymorphism, 
at least against these three epitope regions, is not the contributing factor as to why CD4+ T 
cell responses are seen in Chinese but not in the Caucasian population. The existence of 
new epitopes is therefore likely to reflect differences in HLA polymorphism between the 
two populations. However, further studies are required to determine the factors that may 
influence the responses between Chinese and Caucasian donors. 
 
The criteria that were used in mapping the number of epitope regions would have 
underestimated the number of true epitopes present, especially in the region EBNA 1 499-
543. Eliciting a number of responses when mapping epitope regions, several factors were 
taken into account; (1) the pattern of response to individual peptides within the region, (2) 
the number of examples of this pattern within our studied population and (3) the size of the 
response to each individual peptide (designating weaker neighboring responses as overlap 
from the epitope response). There were some instances, such as that seen with HK control 
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240 response to peptide 56 but not 57 and HK control 242 response to peptide 57 but not 
56, where both were categorized as a 56/57 epitope region response. However, such 
responses could represent rare responses to quite separate epitopes. 
 
3.2.5.3 Immunodominance among EBNA 1 epitopes 
There are several ways of defining immunodominance and consequently the term is used 
rather loosely in the literature. It may be used to refer (i) to epitopes that are commonly 
seen in assays on a population group; in this case immunodominance can be dramatically 
affected by the frequency of the restricting allele in the population or, for a promiscuous 
epitope, by the combined frequency of restricting alleles. Alternatively, it may be used to 
describe (ii) epitopes that in individuals with the relevant alleles, consistently induce strong 
responses i.e. responses that are larger than competing epitope responses seen through the 
same or different alleles in the individual responding donor. 
 
According to definition (i), Figure 3.2.7 shows that; EBNA 1 559 is the most 
immunodominant epitope region because it is seen by 44% of the population studied 
followed by EBNA 1 469, EBNA 1 (509, 519 and 554), EBNA 1 479, EBNA 1 434, and 
EBNA 1 (499, 549 and 589). Where there are more than one epitope regions with the same 
frequency such as EBNA 1 (509, 519 and 554) and EBNA 1 (499, 549 and 589). However, 
according to definition (ii), from Figure 3.2.8 there is no clear hierarchy of 
immunodominance among the different epitopes according to response size. The mean 
response size for almost all response lies in a narrow range between 90 and 160 SFC per 
million cells. We will re-visit immunodominance after presenting the work to chapter 3.3.0. 
 
3.2.6 Conclusion 
Now that the work had identified 10 CD4+ epitope regions in EBNA1, the next step was to 
characterise these epitope regions by cloning out the responding cells. This would allow 
definition of: (1) the optimal epitope sequence and (2) the restriction element(s) before re-
visiting the question of immunodominance. Access to epitope specific clones would also 
allow us to address the possible therapeutic value of such responses, asking whether 
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EBNA1-specific CD4+ T cells against particular epitopes are capable of recognising 
EBNA1-expressing latently-infected target cells. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Section 3.3 
 
Generating and characterising  
EBNA1-specific T-cell clones 
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3.3.0 Generating and characterising EBNA1 specific CD4+ T-cell clones 
 
3.3.1 Introduction 
This section of work describes experiments designed to generate CD4+ T cell clones from 
positive responders to EBNA1 (identified in section 3.2) using the epitope region peptides 
in an in vitro reactivation protocol. The objective was to determine whether the ELISpot 
findings reflect true EBNA1-specific memory responses and, if so, to study the restriction 
and functional capacity of such responses. 
 
3.3.2 Optimisation of protocol 
Preliminary experiments were conducted to determine the optimal conditions required for 
cloning from cryopreserved PBMC samples. In this case PBMCs from the EBV-
seropositive donor UKSL (known to respond to a CD4+ epitope region EBNA3A 649-666: 
see section 3.1) that had been cryopreserved for 6 months before thawing were compared 
with PBMCs freshly prepared from the same donor. Both thawed and fresh PBMCs were 
rested overnight before CD8+ T cell depletion on day 2; this step was found to be optimal 
for cell number recovery post-depletion. CD8-depleted PBMC of both samples were then 
rested for a second night, and on day 3, both PBMC samples were stimulated with the two 
relevant EBNA3A peptides, EBNA3A 649-662 and 653-666, and cultured for seven days 
in serum free media to generate parallel polyclonal cell cultures (from frozen and fresh 
cells). In previous experiments (data not shown) PBMCs were reactivated in media 
containing different serum concentrations to generate polyclonal cell cultures. It was found 
that reactivation using serum free media generated polyclonal cell cultures that were 
antigen-specific whereas, polyclonal cultures generated from serum-containing media gave 
unspecific responses in IFN-γ ELISA assays.  
 
Figure 3.3.1 summarises the culture protocol. From 7 post-stimulation (i.e. day 10 since the 
cells were thawed), the polyclonal cell cultures were maintained in culture media 
containing 10% pooled human serum. Also on day 7, both polyclonal cell cultures were 
EBNA 3A 649-666 cloning from UK-SL
Fresh Blood Sample Frozen Blood Sample
CD8-depleted CD8-depleted
7 Days
Test
Polyclonal 
for Specificity                          √                                                       √  
Cloned at 
0.3 cells/well
Clones generated 
from 960 wells cloning          315                  Specificity          289
Screened                                 
2-6 weeks
Clones
Specificity 31                                   29
Expanded peptide
specific clones
2-6 weeks
Clones
Grew                                        11                                                     5
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Figure 3.3.1: Quality of UKSL cloning stages using frozen and fresh PBMCs 
This Figure summarises the cloning process of UK-SL, using fresh and frozen PBMC 
samples, to generate EBNA 3A 649-666-specific CD4+ T cell clones. Fresh blood samples 
were taken on day 0, CD8+ T cell depleted on day 2, before stimulation on day 3 with 2 
relevant peptides EBNA 3A 649-662 and 653-666. Frozen PBMCs were kept in liquid 
nitrogen for 6 months before they were thawed on day 0 of the experiment, CD8+ T cell 
depleted on day 2 and stimulated on day 3 with the same peptides. Both PBMC cultures 
were allowed to grow in culture for 7 days after stimulation. Both polyclonal cultures were 
then tested on day 7 by IFN-γ ELISA assay for peptide-specificity, and were (√) peptide-
specific. The polyclonal cultures were also cloned on day 7 at 0.3 cells/well. The clones 
were left to expand in culture for 2-6 weeks before they were tested for peptide-specificity. 
315/960 and 289/960 clones generated from fresh and frozen PBMCs respectively were 
tested peptide-specific. The peptide-specific clones were then transferred to 2ml culture 
wells for further expansion. After a further 2-6 weeks, the clones were re-rested for peptide-
specificity to which only 31/315 (fresh PBMC) and 29/289 clones (frozen PBMCs) were 
peptide-specific. The peptide-specific clones were allowed a further 2-6 weeks to expand in 
culture before being retested for peptide-specificity. 11/31 (fresh) and 5/29 (frozen) clones 
were tested peptide-specific.
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Figure 3.3.2: IFN-γ ELISA assay to determine epitope-specificity of UKSL polyclonal 
cultures  
In this assay, 5000 polyclonal cells/well was cultured overnight with 50,000 autologous 
LCL/well pre-loaded with a range of concentrations (10-fold dilution) of the individual 
EBNA3A peptides from 10-5M to 10-10M or to DMSO alone (neg). Recognition was 
detected by IFN-γ released into the supernatant and assayed by ELISA. The results are 
shown as IFN-γ release expressed as pg/ml. Both fresh (A) and frozen (B) PBMC samples 
gave polyclonal cell cultures that specifically responded to the EBNA3A 649-662 and 653-
666 peptides in a dose-dependent fashion, and gave very similar titration curves.
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tested for reactivity to the two peptides and the data are shown in Figure 3.3.2. In this 
assay, 5000 polyclonal cells/well was cultured overnight with 50,000 autologous LCL/well 
pre-loaded with a range of concentrations (10-fold dilution) of the individual EBNA3A 
peptides from 10-5M to 10-10M or to DMSO alone (no peptide control) or an irrelevant 
peptide LMP2 340-349 at 10-5M. Recognition was detected by IFN-γ released into the 
supernatant and assayed by ELISA. Figure 3.3.2 shows the results as IFN-γ release 
expressed as pg/ml. Both frozen and fresh PBMC samples gave polyclonal cell cultures that 
specifically responded to the EBNA3A 649-662 and 653-666 peptides in a dose-dependent 
fashion, and gave very similar titration curves. For both polyclonal cultures, the peptide 
concentration that could induce half maximum response (C1/2) was 10-7M for EBNA3A 
649-662 and 10-7.5M for EBNA3A 653-666, suggesting that EBNA3A 653-666 is the 
optimal peptide. 
 
As shown in Figure 3.3.1, on day 7 of culture both polyclonal cultures were seeded at 30, 3 
and 0.3 cells/well in 10 x 96 well u-bottom tissue culture plates with a “clone mix” 
containing 50,000 γ-irradiated autologous LCL/ml (pre-loaded with the epitope region 
peptides) and 1 million γ-irradiated pooled PBMCs/ml (pre-treated with PHA). On day 13, 
the wells were fed with clone media (containing 60% MLA, 40U IL2 and 5% human 
serum) and re-fed every 2 weeks. After 2-6 weeks, all wells seeded at 30 and 3 cells/well 
had grown. Cloning at 0.3 cells/well had growth in 315 (fresh PBMC samples) and 289 
(frozen PBMC samples) wells from 960 wells of cloning (see Figure 3.3.1). Because 
cloning from the polyclonal cell culture was setup at 0.3 cells/well and if all cells were to 
grow, it is expected that approximately 1/3 of 960 wells (320 wells) would have growth. 
Therefore, using the current protocol of cloning ~100% of positive wells had grown.  
 
All clones were screened for epitope specificity in a simplified screening assay. In this 
assay, 50μl of resuspended cells from each growing well was cultured overnight with 
50,000 autologous LCL/well pre-loaded with epitope region peptides or DMSO. 
Supernatant was tested for IFN-γ release by ELISA, identifying 31/315 and 29/289 clones 
as epitope region-specific from fresh and frozen PBMC samples respectively. These 
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epitope region-specific clones were transferred into 2ml tissue culture plates containing 
clone media, 50,000 γ-irradiated autologous LCL/ml (pre-loaded with epitope region 
peptides) and 1 million γ-irradiated pooled PBMCs/ml (pre-treated with PHA). After 2-3 
weeks, 16 and 18 clones that had expanded well were re-tested for epitope region 
specificity. Of these, 11 and 5 clones from fresh and frozen PBMC samples respectively 
were still epitope region-specific. 
 
The quality of the clones generated from fresh and frozen PBMC samples were assessed 
and representative data from one clone from fresh PBMCs (clone 8) and one clone from 
frozen PBMCs (clone 2) are shown in Figure 3.3.3. In this assay, 500 T cells/well were 
cultured overnight with 50,000 autologous LCL/well pre-loaded with diluting 
concentrations (10-fold) of epitope region peptides or with DMSO or LMP2 340-349 
peptide controls as mentioned above. The Figure shows that clones generated from fresh 
and frozen PBMC samples responds similarly with the same C1/2 values as observed in the 
polyclonal cell culture experiments, 10-7.5M for EBNA1 663-666. These results show that 
the polyclonal culture data could be reproduced using clones. Note that IFN-γ release 
(pg/ml) values are much lower in these assays than in those conducted using polyclonal cell 
cultures; this in part reflects the fact that fewer cells (10-fold) were used in the clonal 
assays.  
 
These preliminary experiments showed that this cloning protocol could yield epitope 
region-specific polyclonal cell cultures and clones with roughly similar efficiency from 
fresh and frozen PBMC preparations. This protocol was therefore employed in the 
following experiments conducted on frozen PBMC samples from HK control donors. 
 
3.3.3 HLA typing of HK controls 
Additional PBMC samples were available from 47 of the HK donors screened by ELIspot, 
of which 33 gave a response to one or more EBNA1 peptides. ELIspot responses from 
these 47 donors are summarised in Table 3.3.1; all 47 donors were HLA-DR and –DQ 
typed. 
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Figure 3.3.3 IFN-γ ELISA assay to determine epitope-specificity of UKSL clones  
In this assay, 500 T cells/well were cultured overnight with 50,000 autologous LCL/well 
pre-loaded with diluting concentrations (10-fold) of epitope region peptides or with DMSO 
(neg). Recognition was detected by IFN-γ released into the supernatant and assayed by 
ELISA. The results are shown as IFN-γ release expressed as pg/ml. Both fresh (A) and 
frozen (B) PBMC samples generated clones that specifically responded to the EBNA3A 
649-662 and 653-666 peptides in a dose-dependent fashion, also giving very similar 
titration curves.
Responders HLA Types
(HK Control) 41/42 48/49 50/51 54/55 56/57 58/59 64 65/66 67/68 72/73 DR DR DR DR DQ DQ DP DP
201 √ √ √ √ √ √ √ 11 13 52b 52b 7 7 2 13
202 √ 8 12 52c 52c 7 6
203 √ √ √ 4 12 52c 53 7 7
204 √ √ 15 16 51 51 5 6
208 √
209 √
211 √ 4 9 53 53 8 9
215 √ √ √ 9 16 53 51 9 5 5 5
219 √ √ 9 15 53 51 6 9
222 √ 8 12 52b 52b 7 6
223 √
224 √ √ √ 15 16 51 51 5 6
228 √ √ √ √ √ 17 11 52a 52b 2 7 2 5
230 √ √ √ 11 14 52b 52b 7 5
231 √
233 √ √ √ √ 11 15 52b 51 7 6 3 13
234 √
236 √ 16 12 52a 51 5 7
240 √ √ 9 11 52b 53 7 9
241 √ √ 11 14 52b 52b 5 7
242 √ 8 16 51 51 4 5
244 √ √ √ 17 12 52a 52b 2 7
247 √ √ 12 15 52a 51 6 7
248 √ √ 9 11 52b 53 7 9
249 √
251 √ √ √ 15 16 51 51 5 6
252 √ √ 15 12 52c 51 6 7
253 √ √ √ 7 15 53 51 2 6
257 √ 14 14 52b 52b 5 5
258 √
260 √ √ √
262 √ √ √
263 √ √ √ 11 14 52b 52b 7 5
266 √ √ √
267 √
268 √ 15 15 51 51 6 6
276 √ √
277 √ √ √ 12 15 52a 51 6 7
278 √ √ 15 15 51 51 6 6
279 √
280 √ √ 11 12 52b 52b 7 7
281 √ 15 13 52b 51 6 7
283 √
284 √ √ √ 12 15 51 51 7 6
285 √ √ √ √ 11 15 52b 51 7 6
286 √ √ 10 15 51 51 5 5
287 √
288 √
291 √ √ 8 16 51 51 5 6
Epitope regions
Table 3.3.1: Summary of epitope-specific responses to EBNA1 peptides and HLA Class II typing of 47 healthy HK donors
√ - response was made to the epitope region
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3.3.4 Selecting and cloning from HK Control donors 
Based on Table 3.3.1, HK control 201, 215, 228 and 233 were chosen for cloning because 
they showed a wide range of epitope-region responses. In vitro reactivation and limiting 
dilution cultures were set up from thawed PBMCs using the protocol shown in Figure 3.3.1.  
 
Figure 3.3.4 summarises a typical set of data, in this case from HK control 215, to illustrate 
the fact that the yield of amplifiable epitope-region-specific clones was always low from 
the HK samples. This donor responded to three epitope regions EBNA1 469-493, 564-588 
and 589-613 in the ELISpot assay. Figure 3.3.5 shows the screening of epitope specificity 
on polyclonal cell cultures generated from the different peptide stimulations. Epitope-
specific responses were detectable for two of the three peptide pairs tested. Interestingly, 
the polyclonal cell culture generated with the EBNA1 469-488 and 474-493 peptides only 
recognised peptide EBNA1 474-493 at a C1/2 value of 10-7.5M and did not recognise 
EBNA1 469-488 (Figure 3.3.5A). The polyclonal cell culture generated using the EBNA1 
564-583 and 569-582 peptides recognised both peptides 564-583 and 569-588 with C1/2 
values 10-8M and 10-6.5M respectively (Figure 3.3.5B). By contrast, stimulation with 
peptides 589-608 and 594-613 reproducibly produced cultures with a high spontaneous 
level of IFN-γ production that prevented any detection of epitope specificity (Figure 
3.3.5C). 
 
As in the established protocol, cloning was done on day 7 post-stimulation but in this case 
was also carried out from the polyclonal culture every week for six weeks. Typically, 
cultures seeded at 30 and 3 cells/well showed growth in all the wells and cultures seeded at 
0.3 cells/well had growth in approximately 1/3 of all the wells. Clones from 0.3 cells/well 
were tested for peptide specificity, of which 28/318, 57/421 and 0/294 clones tested peptide 
specific to EBNA1 469-493, 564-588 and 589-613 respectively; the absence of EBNA1 
589-613-specific clones was not surprising in view of the data already obtained from the 
polyclonal culture. However, most of those clones specific for the other two peptides did 
not expand and were lost at this stage. Overall only 10/28 and 8/57 clones generated against 
EBNA1 469-493 and 564-588 respectively expanded  
EBNA 1 469-493 564-588 589-613
7 Days
Polyclonal
Specificity      √      √     X
Cloned at 
0.3 cells/well
Clones generated
from 960 wells               318     421    294 Specificity
cloning Screened 
2-6 weeks
Clones
Specificity     28     57     0 (~10-15%)
Expanded peptide
specific clones
2-6 weeks
Specific
Clones
Grew      1     3      0
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Figure 3.3.4: Quality of HK Control 215 cloning stages 
This Figure summarises the cloning process of HK control 215, using frozen PBMC 
samples. Frozen PBMCs were thawed on day 0 of the experiment, CD8+ T cell depleted on 
day 2 and stimulated on day 3 with the peptide pools EBNA1 469-493, 564-588, and 589-
613. The PBMC cultures were allowed to grow in culture for 7 days after stimulation, and 
then tested on day 7 by IFN-γ ELISA assay for peptide-specificity. Polyclonal cultures 
generated from peptide pools EBNA1 469-493 and 564-588 were (√) peptide-specific, and 
polyclonal culture generated from peptide pool EBNA1 589-613 was (X) not peptide 
specific. The polyclonal cultures were also cloned on day 7 at 0.3 cells/well. The clones 
were left to expand in culture for 2-6 weeks before they were tested for peptide-specificity. 
318/960, 421/960 and 294/960 clones generated from EBNA1 469-493, 564-588, and 589-
613 peptide pool stimulation respectively were tested peptide-specific. The peptide-specific 
clones were then transferred to 2ml culture wells for further expansion. After a further 2-6 
weeks, the clones were rerested for peptide-specificity to which 28/318 (EBNA1 469-493), 
57/421 (EBNA1 564-588) and 0/294 clones (EBNA1 and 589-613) were peptide-specific. 
The peptide-specific clones were allowed a further 2-6 weeks to expand in culture before 
again being retested for peptide-specificity. 1/28 (EBNA1 469-493) and 3/57 (EBNA1 564-
588) clones were tested peptide-specific.
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Figure 3.3.5: IFN-γ ELISA assay to determine epitope-specificity of HK#215 
polyclonal cultures  
In this assay, 5000 polyclonal cells/well was cultured overnight with 50,000 autologous 
LCL/well pre-loaded with a range of concentrations (10-fold dilution) of the individual 
EBNA1 peptides from 10-5M to 10-10M or to DMSO alone (neg). Recognition was detected 
by IFN-γ released into the supernatant and assayed by ELISA. The results are shown as 
IFN-γ release expressed as pg/ml. Interestingly, the polyclonal cell culture generated with 
the EBNA1 469-488 and 474-493 peptides only recognised peptide EBNA1 474-493 and 
did not recognise EBNA1 469-488 (A). The polyclonal cell culture generated using the 
EBNA1 564-583 and 569-582 peptides recognised both peptides 564-583 and 569-588 (B). 
By contrast, stimulation with peptides 589-608 and 594-613 reproducibly produced cultures 
with a high spontaneous level of IFN-γ production that prevented any detection of epitope 
specificity (C). 
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further and were available to be re-tested for epitope peptide-specificity. As summarised in 
Figure 3.3.4, 1 of these 10 and 3 of these 8 clones respectively had retained epitope 
specificity. Figure 3.3.6 shows examples of one epitope-specific clone of each type. Figure 
3.3.6A shows that clone HK215c1 (EBNA1 469-493) responds to both EBNA1 peptides 
469-488 and 474-493 in a dose-dependent manner, unlike the polyclonal cultures which it 
was derived from only responds to EBNA1 474-493. Whereas clone HK215c50 (EBNA1 
564-588) responds to both EBNA1 peptides, 564-583 and 569-588, also in a dose-
dependent manner similar to the polyclonal culture which it was derived from (Figure 
3.3.6B). This possibly suggests that the epitope is contained between the overlap of the two 
20-mer peptides. However, further tests are needed to confirm the exact epitope location.  
Figure 3.3.6C shows a typical response of clones generated from EBNA1 589-613 
polyclonal cultures. The clone did not respond to any of the two EBNA1 peptides, 589-608 
and 594-613. Note that the EBNA1 589-613 polyclonal cell line (Figure 3.3.5C) showed 
high spontaneous level of IFN-γ production. Initially it was believed that the polyclonal cell 
line was infected, so a new polyclonal cell line was made, but the same high spontaneous 
IFN- γ production was also observed. A possible explanation to this observation is that the 
polyclonal cell line was still producing IFN-γ as a result of peptide stimulation from day 0. 
This may explain why EBNA1 589-613 -specific clones, generated from the EBNA1 589-
613  polyclonal cell line, loose their epitope-specificity over time, possible due to over 
stimulation. Note that responses from clones (pg/ml of IFN-γ release) are much lower than 
response seen in the polyclonal culture assays. This is because fewer cell numbers are used 
in the clone assay (500 clonal T cells) compared to the polyclonal assay (5000 polyclonal 
cells). 
 
Table 3.3.2A summarises which epitope region-specific polyclonal cell culture and clones 
were successfully generated from the four donors tested, HK Control 201, 215, 228 and 
233, and Table 3.3.2B shows the number of epitope region-specific clones obtained. Where 
there are multiple clones generated against one epitope region, these clones were 
cryopreserved for later testing while one clone was selected for immediate tests.  
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Figure 3.3.6: IFN-γ ELISA assay to determine epitope-specificity of HK#215 clones  
In this assay, 500 T cells/well were cultured overnight with 50,000 autologous LCL/well 
pre-loaded with diluting concentrations (10-fold) of epitope region peptides or with DMSO 
(neg). Recognition was detected by IFN-γ released into the supernatant and assayed by 
ELISA. The results are shown as IFN-γ release expressed as pg/ml. Interestingly, clone 
HK215c1 generated with the EBNA1 469-488 and 474-493 peptides recognised both 
peptides in a dose-dependent manner (A). Clone HK215c50 generated using the EBNA1 
564-583 and 569-582 peptides also recognised both peptides 564-583 and 569-588 in a 
dose-dependent manner (B). By contrast, stimulation with peptides 589-608 and 594-613 
reproducibly produced clones which had lost peptide-specificity (C). 
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Figure 3.3.7: Characterisation of EBNA1 469-493 using clone HK215c5 and 
polyclonal cell lines generated from HK#215 and 233 
In the assay shown in (A), 500 T cells/well (clones) or 5000 cells/well (polyclonal cells) 
were cultured overnight with 50,000 autologous LCL/well pre-loaded with diluting 
concentrations (10-fold) of epitope region peptides or with DMSO (neg). In the blocking 
assay (B), autologous LCLs (50,000 LCL cells/well) were pre-loaded with 10-7 M peptide 
(EBNA1 474-493) and then treated with anti-DP, -DQ, –DR, or culture media with no 
antibodies for one hour before the cells were cultured with 5000 polyclonal cells/well in an 
overnight assay. Recognition was detected by IFN-γ released into the supernatant and 
assayed by ELISA. The results are shown as IFN-γ release expressed as pg/ml. Figure 
3.3.7A shows a peptide titration curve of clone HK Control 215c5 and polyclonal culture 
HK Control 233 against peptides EBNA1 469-488 and 474-493. Clone HK Control 215c5 
recognises peptide EBNA1 474-493 but not peptide EBNA1 469-488 while polyclonal 
culture HK Control 233 recognises peptide EBNA1 474-493 better than EBNA1 469-488. 
Figure 3.3.7B shows the blocking data from the two polyclonal cultures, HK215 and 233. 
There was no blocking of IFN-γ release when using anti-DQ and anti-DP monoclonal 
antibodies with IFN-γ release values whereas peptide recognition was completely blocked 
by anti-DR monoclonal antibody in both polyclonal cultures. 
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3.3.5 Analysis of responses to epitope region EBNA1 469-493 
The following section describe assays conducted using the above clones and polyclonal cell 
cultures. The results are reported with respect to individual epitope regions, taking all the 
available data for each region from the four donors tested. One clone was generated from 
HK control 215 and two polyclonal cell cultures from HK control 215 and 233 that were 
specific for epitope region EBNA1 469-493. Figure 3.3.7A shows a peptide titration curve 
of clone HK Control 215c5 and polyclonal culture HK Control 233 against peptides 
EBNA1 469-488 and 474-493. This assay was conducted in the same manner as described 
above.  
 
Clone HK Control 215c5 recognises peptide EBNA1 474-493 but not peptide EBNA1 469-
488 while polyclonal culture HK Control 233 recognises peptide EBNA1 474-493 better 
than EBNA1 469-488. Note that in the initial ELISpot assay, HK control 215 responded to 
both overlapping peptides. However the clone only recognises one peptide, namely EBNA1 
474-493. This suggest that there may be two possible epitopes within the two overlapping 
peptides, one epitope that is recognised by HK control 215c5 (EBNA1 474-493) and 
another epitope that is yet to be determined. It is unusual to see a response by a clone, in 
this case HK control 215c5, to one peptide and not to the overlapping peptide since 
adjacent peptides overlap by 15 amino acids. A possible explanation is that the key amino 
acids which form the epitope peptide-HLA II complex lies completely within the 20-mer 
peptide (EBNA1 474-493), and adjacent peptides do not have these correct interactions. 
Both the clone and polyclonal culture recognise EBNA1 469-488 with a C1/2 value of 10-
7.5M. Ideally, a titration should include neighbouring peptides EBNA1 464-483 and 479-
498 because these peptides share 15 amino acid sequences in common with this epitope 
region, but this was not possible in this case due to limited cell numbers. However, 
ELISpot data for both donors show that they did not respond to the EBNA1 479-498 
peptide, therefore it is very likely that the optimal epitope is indeed EBNA1 474-493. We 
could not generate additional data using this clone because the clone would not expand 
further in culture.  
 
AHLA Types
Donors DR DR DR DR DQ DQ
HK Control 204 15 16 51 51 5 6
HK Control 215 9 16 53 51 9 5
HK Control 219 9 15 53 51 6 9
HK Control 224 15 16 51 51 5 6
HK Control 233 11 15 52b 51 7 6
HK Control 242 8 16 51 51 4 5
HK Control 247 12 15 52a 51 6 7
HK Control 251 15 16 51 51 5 6
HK Control 253 7 15 53 51 2 6
HK Control 268 15 15 51 51 6 6
HK Control 277 12 15 52a 51 6 7
HK Control 278 15 15 51 51 6 6
HK Control 281 15 13 52b 51 6 7
HK Control 284 12 15 51 51 7 6
HK Control 285 11 15 52b 51 7 6
HK Control 291 8 16 51 51 5 6
B Frequency of responders with the following HLA types C Frequency of non-responders with the following HLA types
HLA type No. Respondents Total number of respondents Frequency (%) HLA type No. Non-responders Total No. of non-responders
DR7 1 16 6 DR7 0 17
DR8 2 16 13 DR8 2 17
DR9 2 16 13 DR9 3 17
DR15 13 16 81 DR15 2 17
DR11 2 16 13 DR11 8 17
DR12 3 16 19 DR12 7 17
DR13 1 16 6 DR13 1 17
DR16 6 16 38 DR16 1 17
DR51 16 16 100 DR51 3 17
DR52a 2 16 13 DR52a 3 17
DR52b 3 16 19 DR52b 11 17
DR53 3 16 19 DR53 4 17
DQ2 1 16 6 DQ2 2 17
DQ4 1 16 6 DQ4 0 17
DQ5 6 16 38 DQ5 6 17
DQ6 14 16 88 DQ6 3 17
DQ7 6 16 38 DQ7 14 17
DQ9 2 16 13 DQ9 3 17
HLA types of respondents against peptide EBNA1 474-498 (peptides 48/49)
Table 3.3.3: HLA restriction of EBNA1 474-498 (peptides 48/49) using HLA typing
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Polyclonal cultures from HK Control 215 and 233 were used in determining the HLA class 
II restriction element for EBNA1 474-493. Autologous LCLs were pre-loaded with 10^-7M 
epitope peptide for 1 hour and excess peptides were washed off. Monoclonal antibodies 
HLA -DR, -DQ and –DP and culture media (as no antibody control) were then added at 
1μg/ml (2 μg/ml for anti-DR was used) to the individual tests for one hour before adding 
5x105 cells. Figure 3.3.7B shows the blocking data from the two polyclonal cultures, the 
axis shows the IFN-γ release expressed as pg/ml and the y-axis shows the different 
antibodies used and the no antibody control. There was no blocking of IFN-γ release when 
using anti-DQ and anti-DP monoclonal antibodies with IFN-γ release values whereas 
peptide recognition was completely blocked by anti-DR monoclonal antibody in both 
polyclonal cultures. Thereafter, these particular polyclonal cultures were lost due to 
bacterial infection and so the restricting allele could not be further examined using 
allogeneic LCLs as presenting cells. However it was clear that the epitope was likely to be 
presented by a DR allele shared between HK control 215 (DR 9, 16, 53, 51) and HK control 
233 (DR 11, 15, 52b, 51); the only shared allele was DR51. 
 
To examine this question of restriction another way, we re-visited the HLA typing data for 
the 16/33 HLA typed HK donors who responded to this epitope region in ELISpot assay. 
Table 3.3.3A records the HLA class II type of the 16 responders against epitope region 
EBNA1 474-498. Table 3.3.3B shows the frequency with which each individual allele is 
present among the 16 responders, and Table 3.3.3C shows the frequency with which each 
individual allele is present among the 17/33 HLA typed donors who did not respond to this 
epitope. From Table 3.3.3B, three HLA alleles are relatively common among the 16 
responders, HLA DR15 (81%), DR51 (100%) and DQ6 (88%). It is therefore again likely 
that this epitope region is restricted through HLA DR51. It is important to note from Table 
3.3.3C, however, that there were other DR51+ individuals who did not make a response 
against epitope region EBNA1 474-498. All of these actually made responses to other 
EBNA1 peptides of unknown restriction (Table 3.3.1).  
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Figure 3.3.8: Characterisation of EBNA1 479-503 using clone HK228c81 
In this assay, 500 T cells/well were cultured overnight with 50,000 autologous LCL/well 
pre-loaded with; (A) diluting concentrations (10-fold) of epitope region peptides or with 
DMSO (neg), (B) at 10-7M peptide EBNA1 484-503 and then treated with anti-DP, -DQ, -
DR or culture media as no antibodies, or (C) 50,000 autologous LCL/well or allogeneic 
LCL/well pre-loaded with 10-7M peptide EBNA1 484-503. Recognition was detected by 
IFN-γ released into the supernatant and assayed by ELISA. The results are shown as IFN-γ 
release expressed as pg/ml. Figure 3.3.8A shows a peptide titration curve of this clones 
response to peptides EBNA1 474-493, 479-498, and 484-503; dose-dependant recognition 
was observed against all three peptides at C1/2 values 10-6.5M (EBNA1 474-493), 10-7.5M 
(EBNA1 479-498) and 10-5.5M (EBNA1 484-503). Figure 3.3.8B show that this response 
was blocked using monoclonal antibody against HLA class II DQ and no blocking was 
observed with anti-DP and –DR antibodies. This epitope is restricted through the DQ7 
allele (C) and not other HLA-DQ alleles (DQ2 and 6).  
AHLA Types
Donors DR DR DR DR DQ DQ
HK Control 201 11 13 52b 52b 7 7
HK Control 228 17 11 52a 52b 2 7
HK Control 230 11 14 52b 52b 7 5
HK Control 244 17 12 52a 52b 2 7
B Frequency of responders with the following HLA types C Frequency of non-responders with the following HLA types
HLA type No. Respondents Total number of respondents Frequency (%) HLA type No. Responders Total number of responders
DR11 3 4 75 DR11 7 29
DR13 1 4 25 DR13 1 29
DR14 1 4 25 DR14 3 29
DR17 1 4 25 DR17 1 29
DR52a 2 4 50 DR52a 3 29
DR52b 4 4 100 DR52b 10 29
DQ2 2 4 50 DQ2 1 29
DQ5 1 4 25 DQ5 11 29
DQ7 4 4 100 DQ7 16 29
HLA types of respondents against peptide EBNA1 479-503 (peptides 50/51)
Table 3.3.4: HLA restriction of EBNA1 479-503 (peptides 50/51) using HLA typing
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In summary, the minimal epitope for epitope region EBNA1 469-493 is EBNA1 474-493, 
and is likely restricted through the HLA class II DR51 allele; certainly all responding 
donors were DR51+, although there was a minority of DR51+ individuals in whom EBNA1 
474-493 had not induced a memory response.  
 
3.3.6 Analysis of responses to epitope region EBNA1 479-503 
As described earlier, polyclonal cultures that were generated from HK control 201 and 228 
using the epitope region peptides EBNA1 479-503 were non-specific, and therefore we 
could only analyse this epitope region at the clonal level. 12 clones were generated from 
HK Control 228, of which one (c81) was used in the initial characterisation of the epitope 
region. Figure 3.3.8A shows a peptide titration curve of this clones response to peptides 
EBNA1 474-493, 479-498, and 484-503; dose-dependant recognition was observed against 
all three peptides at C1/2 values 10-6.5M (EBNA1 474-493), 10-7.5M (EBNA1 479-498) and 
10-5.5M (EBNA1 484-503). The optimal peptide therefore is EBNA1 479-498. As shown in 
Figure 3.3.8B this response was blocked using monoclonal antibody against HLA class II 
DQ and no blocking was observed with anti-DP and –DR antibodies. 
 
The HLA class II element was determined using antigen presenting cells from four 
different allogeneic LCLs with one or other of the relevant DQ alleles of HK control 228 
(DQ2 or DQ7). These LCLs were pre-loaded with the optimal peptide, washed and 
incubated overnight with 500 T cells/well and supernatant harvested for detection of IFN-γ 
release by ELISA assay. Figure 3.3.8C shows an example of the result; DQ7-positive LCLs 
present the epitope peptide to the clone whereas a DQ2-positive LCL does not. This was 
consistant with HLA typing data. Table 3.3.4A shows the HLA class II types of the four 
donors who responded against this epitope region and Table 3.3.4B shows that two alleles 
(DR52b and DQ7) were shared by all four responders. However, note from Table 3.3.4B 
that the donor panel include 21 DQ7-positive donors who did not respond to this epitope 
region; of these 21 non-responders to EBNA1 479-498, 16 made one or more response 
against other epitope regions (Table 3.3.1). These findings suggest that EBNA1 epitope 
479-498 is HLA DQ7-restricted but that the epitope is only immunogenic in a minority of  
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Figure 3.3.9: Characterisation of EBNA1 509-533 using clone HK233c27 
In this assay, 500 T cells/well were cultured overnight with 50,000 autologous LCL/well 
pre-loaded with; (A) diluting concentrations (10-fold) of epitope region peptides or with 
DMSO (neg) and (B) at 10-7M peptide EBNA1 514-533 and then treated with anti-DP, -
DQ, -DR or culture media as no antibodies. Recognition was detected by IFN-γ released 
into the supernatant and assayed by ELISA. The results are shown as IFN-γ release 
expressed as pg/ml. Figure 3.3.9A shows the peptide titration result of peptides EBNA1 
504-523, 509-528 and 514-533 against the clone. This clone responded well to two of these 
peptides, with a C1/2 of 10-7.5M for EBNA1 509-528 and of 10-6.5M for EBNA1 514-533. 
The third peptide, EBNA1 504-523 was recognised but only at a very high concentration of 
10-5M. Therefore, EBNA1 509-528 appears to be the optimal epitope. As shown in Figure 
3.3.9B, recognition was blocked using monoclonal antibody against HLA class II DR 
alleles but was unaffected by anti-DP and anti-DQ antibodies.  
 
AHLA Types
Donors DR DR DR DR DQ DQ
HK Control 201 11 13 52b 52b 7 7
HK Control 228 17 11 52a 52b 2 7
HK Control 230 11 14 52b 52b 7 5
HK Control 233 11 15 52b 51 7 6
HK Control 240 9 11 52b 53 7 9
HK Control 241 11 14 52b 52b 5 7
HK Control 248 9 11 52b 53 7 9
HK Control 263 11 14 52b 52b 7 5
HK Control 280 11 12 52b 52b 7 7
HK Control 285 11 15 52b 51 7 6
HK Control 286 10 15 51 51 5 5
B Frequency of responders with the following HLA types C Frequency of non-responders with the following HLA types
HLA type No. Respondents Total number of respondents Frequency (%) HLA type No. Responders Total number of responders
DR9 2 11 18 DR9 3 22
DR10 1 11 9 DR10 0 22
DR11 10 11 91 DR11 0 22
DR12 1 11 9 DR12 9 22
DR13 1 11 9 DR13 1 22
DR14 2 11 18 DR14 2 22
DR15 3 11 27 DR15 12 22
DR16 1 11 9 DR16 6 22
DR17 1 11 9 DR17 1 22
DR51 4 11 36 DR51 15 22
DR52a 1 11 9 DR52a 4 22
DR52b 8 11 73 DR52b 6 22
DR52c 1 11 9 DR52c 2 22
DR53 1 11 9 DR53 6 22
DQ2 1 11 9 DQ2 2 22
DQ5 4 11 36 DQ5 8 22
DQ6 2 11 18 DQ6 15 22
DQ7 10 11 91 DQ7 10 22
DQ9 2 11 18 DQ9 3 22
HLA types of respondents against peptide EBNA1 509-533 (peptides 56/57)
Table 3.3.5: HLA restriction of EBNA1 509-533 (peptides 56/57) using HLA typing
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DQ7+ donors. The strength of this conclusion would have been improved by data from 
additional clones, but unfortunately the remaining HK control 228 clones initially identified 
as epitope-specific failed to grow from cryostorage. 
 
3.3.7 Analysis of responses to epitope region EBNA1 509-533 
Polyclonal cultures generated from HK controls 201, 228 and 233 using epitope region 
peptides EBNA1 509-533 were non-specific and therefore this epitope region was again 
characterised using just one clone, HK control 233c27. Figure 3.3.9A shows the peptide 
titration result of peptides EBNA1 504-523, 509-528 and 514-533 against the clone. This 
clone responded well to two of these peptides, with a C1/2 of 10-7.5M for EBNA1 509-528 
and of 10-6.5M for EBNA1 514-533. The third peptide, EBNA1 504-523 was recognised but 
only at a very high concentration of 10-5M. Therefore, EBNA1 509-528 appears to be the 
optimal epitope. As shown in Figure 3.3.9B, recognition was blocked using monoclonal 
antibody against HLA class II DR alleles but was unaffected by anti-DP and anti-DQ 
antibodies.  
 
When the HLA class II types of the 11 EBNA1 509-533 responders as shown in Table 
3.3.5A were analysed as in Table 3.3.5B to show the frequency of HLA class II alleles 
among the responding donors, there are two important points to note: there are two 
relatively common alleles, DR11+ (91%) and DQ7+ (91%), among responders (Table  
3.3.5B) but the epitope region is restricted through a DR allele in clone HK233c27. 
Combining the data from the HLA class II-restriction experiments, the clone is restricted  
through HLA DR11. However, 10/11 responders are DR11 positive but one responder, HK 
control 286, is DR11 negative. It is thus likely that epitope EBNA1 509-529 is also 
restricted through a different HLA class II allele for HK control 286.In summary, the 
minimal epitope for epitope region EBNA1 509-533 is 509-528 and is possibly restricted 
through HLA DR11 and another HLA class II allele yet to be identified. 
 
 
 
5000
4000
3000
2000
1000
0
In
te
rfe
ro
n-
γ 
re
le
as
e
(p
g/
m
l)
 5  6  7  8  9  10 neg
-log10 [peptide] M
EBNA 1 564-588 HK#215c79
     VCYFMVFLQTHIFAEVLKDA
     VFLQTHIFAEVLKDAIKDLV
         HIFAEVKLDAIKDLVMTKPA
A
6000
         MVFLQTHIFAEVLKD
     VFLQTHIFAEVLKDAIKDLV
 IVCYFMVFLQTHIFA
        THIFAEVKLDAIKDL
PLRESIVCYFMVFLQ
             EVKLDAIKDLVMTKP
5000
4000
3000
2000
1000
0
In
te
rf
er
on
-γ
 re
le
as
e
(p
g/
m
l)
 5  6  7  8  9  10 neg
-log10 [peptide] M
A
6000
EBNA 1 564-588 HK#228C28 
A
B
155 
 
 
 
 
 
 
Figure 3.3.10: Characterisation of EBNA1 564-588 using clones HK215c79 and 
HK228c28 
In this assay, 500 T cells/well were cultured overnight with 50,000 autologous LCL/well 
pre-loaded with diluting concentrations (10-fold) of epitope region peptides (20-mers and 
15-mers) or with DMSO (neg). Recognition was detected by IFN-γ released into the 
supernatant and assayed by ELISA. The results are shown as IFN-γ release expressed as 
pg/ml. Figure 3.3.10A shows the titrations of EBNA1 peptides 559-578, 564-583 and 569-
588 using representative clone HK control 215c79. This clone responded against the three 
peptides with C1/2 values 10-6M (EBNA1 559-578) and 10-8M (EBNA1 564-583) and >10-
5.5M (EBNA1 569-588). Figure 3.3.10B shows that this clone responded to two of five 15-
mer peptides (EBNA1 563-577 and 568-582) and the 20-mer peptide. However, both 15-
mer peptides have a C1/2 value at 10-6M compared to 10-8M for the 20-mer EBNA1 564-
583. 
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3.3.8 Analysis of responses to epitope region EBNA1 564-588 
Polyclonal cultures were generated from HK control 215 and 228 using epitope region 
EBNA1 564-588 peptides. Of these, HK control 228 polyclonal culture was not specific 
and was therefore not used in the characterisation of the epitope region. In addition the 
polyclonal culture from HK control 215 was lost to bacterial infection. Therefore analysis 
of this epitope relies on data from clones. In total, 3 HK control 215 and 23 HK control 228 
clones were generated from reactivation using epitope regions peptides EBNA1 564-583 
and 569-588. Figure 3.3.10A shows the titrations of EBNA1 peptides 559-578, 564-583 
and 569-588 using representative clone HK control 215c79. This clone responded against 
the three peptides with C1/2 values 10-6M (EBNA1 559-578) and 10-8M (EBNA1 564-583) 
and >10-5.5M (EBNA1 569-588). Clearly the optimal peptide is EBNA1 564-583.  
 
Because this epitope appeared to induce CD4+ T cell memory in 44% of the donors 
screened, it was of great interest to characterise it more carefully, and further work was 
carried out with an epitope-specific clone from the other donor HK control 228c28.  Five 
15-mer overlapping peptides (EBNA1 553-567, 558-572, 563-577, 568-582 and 573-587) 
covering the whole stretch of the three peptides from EBNA1 554-588 were made 
(Altabiosciences, University of Birmingham) and used in peptide titrations alongside the 
20-mer EBNA1 564-583 using this clone. Figure 3.3.10B shows that this clone responded 
to two of five 15-mer peptides (EBNA1 563-577 and 568-582) and the 20-mer peptide. 
However, both 15-mer peptides have a C1/2 value at 10-6M compared to 10-8M for the 20-
mer EBNA1 564-583. Thus the optimal peptide remained as the 20-mer EBNA1 564-583. 
The HLA restriction element for both clones HK control 215c79 and HKcontrol 228c28 
was determined using monoclonal antibody blocking assay (Figure 3.3.11A). In both cases, 
while no effect was observed using anti-DR and anti-DQ antibodies, there was complete 
blocking of IFN-γ release by anti-DP antibodies. At this point of the work, HLA DP typing 
was not available but subsequently four HK donor PBMC samples were HLA DP typed by 
the National Blood Authority (Tissue Typing Laboratory, Churchill Hospital, Oxford, 
United Kingdom), see Figure 3.3.11B. When these results were analysed in light of these 
HLA types, it became clear that presentation of this EBNA1 epitope was limited to cells  
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Figure 3.3.11 Determining EBNA1 564-588 restriction elements using clones 
HK215c79 and HK228c28 
In this assay, 500 T cells/well were cultured overnight with 50,000 autologous LCL/well 
pre-loaded with (A) peptide EBNA1 564-583 at 10-7M and then treated with anti-DP, -DQ, 
-DR or culture media as no antibodies or (B) 50,000 autologous LCL/well or allogeneic 
LCL/well pre-loaded with 10-7M peptide EBNA1 564-583. Recognition was detected by 
IFN-γ released into the supernatant and assayed by ELISA. The results are shown as IFN-γ 
release expressed as pg/ml. The HLA restriction element for both clones HK215c79 and 
HK228c28 was determined using monoclonal antibody blocking assay (Figure 3.3.11A). In 
both cases, while no effect was observed using anti-DR and anti-DQ antibodies, there was 
complete blocking of IFN-γ release by anti-DP antibodies. Figure 3.3.11B shows that 
presentation of this EBNA1 epitope was limited to cells with the DP5 allele. Both donors, 
HK control 215c79 and HK control 228c28, were DP5-positive, and in fact HK control 215 
was homozygous for this allele 
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Figure 3.3.12: Western blot of MVA protein expression  
This Figure (kindly provided by Dr. Taylor at the University of Birmingham) shows a 
western blot of EBNA1 expression in LCLs infected with the different viral constructs 
using an EBNA1 MAb for detection. Note that all LCLs show a very faint band of naturally 
expressed EBNA1 protein (approximately 75Kd). Cells infected with the different vaccinia 
viruses express the relevant EBNA1 product size; E1ΔGA (approximately 50Kd) and 
LAMP-E1ΔGA (approximately 55Kd). Also note cells infected with vaccinia EBNA1 
(vaccinia expressing a reverse orientated construct of fully length EBNA1) shows EBNA1 
of the expected size plus a range of breakdown products. 
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with the DP5 allele. Both donors, HK control 215c79 and HK control 228c28, were DP5-
positive, and in fact HK control 215 was homozygous for this allele. 
 
Attempts were made to test more clones cryopreserved from donors HK control 215 and 
288 but unfortunately these cells again did not expand from cryostorage. Therefore in 
summary, the minimal epitope for the epitope region EBNA1 559-583 is 564-583 and, on 
the basis of clones from two independent sources, is restricted through the DP5 allele. 
 
3.3.9 Functional Studies 
Having determined the epitope and likely restriction element for four EBNA1 epitope 
regions, the next objective was to study the functional aspects of clones recognising these 
epitopes. At this stage only three clones HK233c27, HK228c28 and HK215c79 had 
maintained in culture long enough for such study. There are two questions that were of 
immediate interest; (i) are the clones specific to the EBNA1 antigen? and (ii) could the 
clones recognise naturally infected target cells?  
 
3.3.9.1 Clonal specificity for EBNA1 antigen 
In this experiment, two modified vaccinia virus Ankara (MVA) recombinants, MVA-
E1ΔGA and MVA-LAMP-E1ΔGA were used. The MVA-E1ΔGA expresses EBNA 1 with 
the gly-ala repeat domain removed because full-length EBNA1 vaccinia is difficult to make 
(Murray et al, 1992). The MVA-LAMP-E1ΔGA expresses gly-ala repeat domain deleted 
EBNA1 with a class II pathway targeting sequence (LAMP) as reported by Taylor et al 
(2004). These viruses were constructed and tested for their ability to infect LCLs as 
reported by Taylor et al (2004). Figure 3.3.12 shows a western blot of EBNA1 expression 
in LCLs infected with the different viral constructs using an EBNA1 MAb for detection. 
Note that all LCLs show a very faint band of naturally expressed EBNA1 protein 
(approximately 75Kd). Cells infected with the different vaccinia viruses express the 
relevant EBNA1 product size; E1ΔGA (approximately 50Kd) and LAMP-E1ΔGA 
(approximately 55Kd). Also note cells infected with vaccinia EBNA1 (vaccinia expressing 
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a reverse orientated construct of fully length EBNA1) shows the expression of EBNA1 of 
the expected size plus a range of breakdown products. 
 
Once protein expression from these viruses was confirmed, they were used to infect 
selected HLA-class II matched LCLs or mis-matched LCLs for clones HK 215c79 and 
228c28 to see whether the epitope EBNA1 564-583 is endogenously processed for 
presentation. A negative control (LCLs infected with control MVA pSC11) and a positive 
control (matched LCLs pre-loaded with epitope peptide) were used. The test LCLs were 
infected with the different viruses or loaded with epitope peptide or culture media for 1 
hour. The LCLs were then washed and 500 clonal T cells were added (each assay well 
containing 50,000 LCLs and 500 clonal T-cells) and left to incubate overnight and assay 
with ELISA for IFN-γ release. Each experiment was done in triplicate wells. The results are 
shown in Figure 3.3.13; both clones showed recognition of LCLs infected with MVA-
LAMP-E1dGA and peptide loaded LCLs but no recognition was observed against LCLs 
infected with MVA- E1dGA or LCL alone. It is important to note that matched LCLs 
infected with MVA-LAMP-E1dGA gives a lower recognition (10-20 fold difference) 
compared to matched LCLs preloaded with epitope peptide, this is because the epitope 
peptides (used at high concentrations) are fully loaded on the LCL’s surface MHC class II 
molecules. Note that the background IFN-γ secretion is below 1000 pg/ml, therefore the 
response to MVA-LAMP-E1dGA infected cells are around 15-fold higher than the 
background. 
 
The central point from this work is that both clones are able to detect LCLs infected with 
MVA-LAMP- E1dGA but not MVA- E1dGA. This clearly shows that these clones are 
capable of recognizing the EBNA1 antigen (if appropriately targeted into the HLA class II 
processing pathway) and that they are not just peptide-specific. 
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Figure 3.3.13: EBNA1 564-583 endogenous processing and presentation  
In this assay, 500 T cells/well were cultured overnight with 50,000 autologous LCL/well 
pre-infected with the different MVA viruses or pre-loaded with EBNA1 564-583 peptide at 
10-7M, and HLA-mismatched LCL. Recognition was detected by IFN-γ released into the 
supernatant and assayed by ELISA. The results are shown as IFN-γ release expressed as 
pg/ml. Both clones, HK215c79 (top) and HK228c28 (bottom), showed recognition of LCLs 
infected with MVA-LAMP-E1dGA and peptide loaded LCLs but no recognition was 
observed against LCLs infected with MVA- E1dGA or LCL alone. It is important to note 
that matched LCLs infected with MVA-LAMP-E1dGA gives a lower recognition compared 
to matched LCLs preloaded with epitope peptide, this is because the epitope peptides (used 
at high concentrations) are fully loaded on the LCL’s surface MHC class II molecules. 
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3.3.9.2 Recognition of naturally infected target cells through endogenous antigen 
expression 
In further experiments, clones HK control 233c27 (specific for EBNA1 509-528) and 
215c79 and 228c28 (specific for EBNA1 564-583) were tested for direct recognition of un-
manipulated autologous LCL or allogenic mis-matched LCL. In this case, LCLs (50,000 
LCL cells/well) were loaded with the epitope peptide as a positive control. And LCLs 
(untreated) were used at 50,000 LCL cells/well (done in triplicate wells) tested on 
increasing number of clonal T-cells (starting at 500, 1000, 2500 and 5000 clonal T-cells). 
The level of un-manipulated LCL recognition, read from a 5000 T cell input, was expressed 
as a percentage of that seen in the same assay against peptide-loaded LCL cells. 
 
Figure 3.3.14A shows the data for clone HK control 215c79 against epitope EBNA1 564-
583. With peptide-loaded targets, there is an increase in IFN-γ release as the number of 
clonal T-cells increase. There is no IFN-γ release against mis-matched LCL loaded with 
peptide. The same was observed with un-manipulated LCLs (Figure 3.3.14B) where an 
increase in T cell numbers increases recognition of matched LCLs and there is no 
recognition to mis-matched LCLs. This recognition of un-manipulated autologous LCL 
could be blocked using anti-DP blocking antibodies. Note the scales (interferon-γ (pg/ml)) 
between the experiment conducted with peptide and without peptide. T cell responses 
against LCLs loaded with peptide produces a bigger response than LCLs without peptide.  
 
An experiment was setup to determine whether the LCL growth conditions would influence 
direct recognition of these LCLs by the clone HK control 215c79. Three growth densities 
were maintained by adjusting (where necessary) the number of cells in the culture every 3-4 
days at the time of regular replacement of half the medium; condition A is maintaining 
LCL growth at 0.75 million cells/ml, condition B is at 1.5 million cells/ml and condition C 
is at 2 million cells/ml in culture for a period of 1 month prior to test. 5000 clonal T cells 
were use as an input since in the previous experiment described above suggests that it gives 
the biggest response. In the experiment, 5000 clonal T cells/well were tested on 50,000 
LCL cells/well from the different growth conditions. The three  
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Figure 3.3.14: Recognition of naturally infected target cells by EBNA1 564-583-
specific clone HK215c79 
In this assay, increasing number of clonal T-cells (starting at 500, 1000, 2500 and 5000 
clonal T-cells) were cultured overnight with 50,000 autologous LCL/well pre-loaded with 
EBNA1 564-583 peptide at 10-7M (A) or no peptide (B-top), or (B-bottom) 5000 clonal T 
cells/well were cultured overnight with 50,000 autologous LCLs treated with anti-DP, -DQ, 
-DR or culture media as no antibodies. Recognition was detected by IFN-γ released into the 
supernatant and assayed by ELISA. The results are shown as IFN-γ release expressed as 
pg/ml. Figure 3.3.14A shows the data for clone HK control 215c79 against epitope EBNA1 
564-583. With peptide-loaded targets, there is an increase in IFN-γ release as the number of 
clonal T-cells increase. There is no IFN-γ release against mis-matched LCL loaded with 
peptide. The same was observed with un-manipulated LCLs (Figure 3.3.14B) where an 
increase in T cell numbers increases recognition of matched LCLs and there is no 
recognition to mis-matched LCLs. This recognition of un-manipulated autologous LCL 
could be blocked using anti-DP blocking antibodies. Note the scales (interferon-γ (pg/ml)) 
between the experiment conducted with peptide and without peptide, peptide coated LCLs 
always give a 10-fold greater response than natural targets. 
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Figure 3.3.15: Recognition of naturally infected target cells, maintained at different 
cell density, by EBNA1 564-583-specific clone HK215c79 
In this assay, increasing number of clonal T-cells (starting at 500, 1000, 2500 and 5000 
clonal T-cells) were cultured overnight with 50,000 autologous LCL/well, grown under 
three cell densities; (A) 0.75 million cells/ml (B) 1.5 million cells/ml and (C) 2 million 
cells/ml. These LCLs were either pre-loaded with EBNA1 564-583 peptide at 10-7M (top) 
or no peptide (bottom). Recognition was detected by IFN-γ released into the supernatant 
and assayed by ELISA. The results are shown as IFN-γ release expressed as pg/ml. Using 
clone HK control 215c79, condition A shows the lowest % LCL recognition (0.1%), with 
condition B at 0.9% and condition C shows the highest % LCL recognition (8.9%). 
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LCLs were used as targets simultaneously on the same day. Figure 3.3.15 shows the result 
of such experiment. Using clone HK control 215c79, condition A shows the lowest % LCL 
recognition (0.1%), with condition B at 0.9% and condition C shows the highest % LCL 
recognition (8.9%). This experiment suggests that dense LCL growth condition can 
increase the magnitude of LCL recognition by the T cell clones. 
 
In the same experiment, the same target LCLs as described above, were also assayed for 
recognition by clone HK control 228c28. A similar pattern of results were observed. Figure 
3.3.16 shows the lowest LCL recognition with condition A at 0.1%, condition B has a 0.2% 
LCL recognition and the highest LCL recognition at 1.8% (condition C).  
 
Figure 3.3.17 shows the result for HK control 233c27 against epitope EBNA1 509-528. 
However, in this case, all three experiments were using LCL targets mentioned in condition 
C as described above. This is because clone HK control 233c27 was growing poorly in 
culture and at any one time there was insufficient T cell numbers to use multiple targets. 
The clone was therefore tested, on three separate occasions, using the condition that gave 
the highest LCL recognition. The results demonstrate that the percentage LCL recognition 
is repeatable, ranging from 7.9-8.6% of the optimal value seen against peptide-loaded LCL 
in the same assay. 
 
3.3.10 Discussion 
The primary objectives of this work were (i) to determine the minimal epitope within the 
epitope regions and its restriction element and (ii) to determine the capacity of these 
EBNA1-specific CD4+ T cell clones to see naturally infected target cells 
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Figure 3.3.16: Recognition of naturally infected target cells, maintained at different 
cell density, by EBNA1 564-583-specific clone HK228c28 
In this assay, increasing number of clonal T-cells (starting at 500, 1000, 2500 and 5000 
clonal T-cells) were cultured overnight with 50,000 autologous LCL/well, grown under 
three cell densities; (A) 0.75 million cells/ml (B) 1.5 million cells/ml and (C) 2 million 
cells/ml. These LCLs were either pre-loaded with EBNA1 564-583 peptide at 10-7M (top) 
or no peptide (bottom). Recognition was detected by IFN-γ released into the supernatant 
and assayed by ELISA. The results are shown as IFN-γ release expressed as pg/ml. Using 
clone HK control 228c28, shows the lowest LCL recognition with condition A at 0.1%, 
condition B has a 0.2% LCL recognition and the highest LCL recognition at 1.8% 
(condition C).
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Figure 3.3.17: Recognition of naturally infected target cells by EBNA1 509-528-
specific clone HK233c27 
In this assay, increasing number of clonal T-cells (starting at 500, 1000, 2500 and 5000 
clonal T-cells) were cultured overnight with 50,000 autologous LCL/well maintained in 
culture at 2 million cells/ml. These LCLs were either pre-loaded with EBNA1 564-583 
peptide at 10-7M (top) or no peptide (bottom). Recognition was detected by IFN-γ released 
into the supernatant and assayed by ELISA. The results are shown as IFN-γ release 
expressed as pg/ml. Using clone HK control 228c28, shows the lowest LCL recognition 
with condition A at 0.1%, condition B has a 0.2% LCL recognition and the highest LCL 
recognition at 1.8% (condition C).
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3.3.10.1 Problems with generating and maintaining clones 
One of the major obstacles with this section of work was in maintaining and generating 
epitope-specific polyclonal cultures and clones. In theory, using peptides derived from 
epitope-rich region of EBNA1 should generate polyconal cell cultures that are specific to at 
least one or more of the epitope regions. As described earlier in section 3.3.2, various 
medium conditions were tested and I found that using serum free media in the reactivation 
of PBMCs was the optimal condition to generate epitope-specific polyclonal cell cultures. 
This was therefore used in the main experiments.  
 
Of the 13 polyclonal cell cultures generated, only 3 were tested epitope-specific. It is 
important to note that epitope-specific clones could be generated from both epitope-specific 
and non-specific polyclonal cell culture. However, most of these epitope-specific clones 
were lost during the expansion process, after newly generated clones were transferred from 
their 300μl cloning wells to larger 2ml wells. This transfer of cells from a small volume 
environment (where cells were having sufficient cell-cell contact) to a larger volume 
environment (where cells may not be having sufficient cell-cell contact) may be the 
underlying reason why clones were lost. Possibly, if the clones were expanded in several 
300μl cloning wells to reach a bigger population before transferring to the 2ml wells would 
have been a better option so that sufficient cell-cell contact between the clones could be 
maintained. 
 
Secondly, during the expansion process, many of the clones that grew lost their peptide-
specificity. Clones were re-stimulated every 2-3 weeks with γ-irradiated autologous LCLs 
preloaded with epitope peptides until the clones grew to a population of 1 million cells/well 
in 10x2ml wells. This constant bombardment of epitope peptides may have desensitized the 
TCR for the epitope peptide possibly causing downregulation (Taams et al, 1999). 
 
Thirdly, clones that were frozen down for later experiments in cryostorage failed to recover 
and grow when thawed. Clones from cryostorage were thawed on day 0 and stimulated 
immediately with γ-irradiated autologous LCLs preloaded with epitope peptide. Maybe if 
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these cells were rested over a longer period of time to allow recovery before reactivation, 
then they would have expanded. And these cells should have been kept in 300μl wells 
during this period for optimal cell-cell contact before being transferred to 2ml wells so that 
an appropriate population could be reached to maintain the cell-cell contact needed.  
 
3.3.10.2 Restricting the minimal epitope and its restriction elements. 
Both polyclonal cell cultures and clones were used to determine the minimal epitope within 
an epitope region. Table 3.3.6 summarises the findings in this work. 4 epitope regions were 
minimized to individual 20-mer epitope peptide. In some cases where both polyclonal cell 
culture and clones were available, epitope peptide titration experiments using polyclonal 
cell cultures gave data consistent with data derived from clones. In other cases polyclonal 
cell culture and clone data could be different; for example, with the epitope region EBNA1 
469-493, polyclonal cell cultures could see both peptides within this region while the clone 
could only see peptide EBNA1 474-493. The polyclonal data suggests the possibility that 
there is multiple TCR usage in the recognition of this epitope region (EBNA1 469-493). 
Therefore it would be important to generate different clones against this epitope region and 
try to correlate different fine specificities against the two different peptides with their 
different TCR usage. 
 
Analyses showed that the EBNA1 epitope 519-543, seen by 44% of responders tested was 
restricted through the HLA DP5 allele. This allele is itself very common in Southern 
Chinese, seen in 48.1% of the population (Tsuji, Aizawa and Sasazuki, 1991), thereby 
explaining why this epitope region is frequently immunogenic. More clones need to be 
generated from other responding donors to determine whether it is because EBNA1 519-
543 is indeed restricted through one very common HLA allele or whether it can be 
immunogenic in the context of other MHC class II elements. It would also be interesting to 
determine whether TCR usage among the response to this epitope was broader than  
 
Epitope Likely restriction elements (T cell data) HLA typing data
434-453
439-458
n.t Possible DR11, DR52b and/or DQ7
474-493 DR Possible DR51 
479-498 DQ7 DQ7 
499-518
504-523
n.t Possible DR11, DR52b and/or DQ7
509-528 DR DR11 and possibly DR15 and/or other HLA alleles
519-538
524-543
n.t INCONCLUSIVE
549-568 n.t INCONCLUSIVE
554-573
559-578
n.t DQ7 and  possibly other HLA alleles
564-583 DP5 DP 5  
589-608
594-613
n.t INCONCLUSIVE
Table 3.3.6: Summary of epitope/epitope regions and their likely HLA restriction molecules
 n.t – not tested
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that seen among response to other less frequent immunogenic epitopes, e.g., the DQ7 
restricted epitope EBNA1 479-498. 
 
3.3.10.3 Frequency of responses to EBNA1 epitopes in Chinese individuals as an 
indication of immunodominance 
At this point immunodominance among CD4+ T cell responses is revisited. As defined in 
Section 3.2, two factors must be considered when looking for immunodominance; the 
frequency of response and the response size. Immunodominance among CD4+ T cell 
responses has to be looked at in terms of the frequency of response rather than in terms of 
the size of response. This is because CD4+ T cell responses exist within a restricted size 
range and do not show consistent differences in size when comparing between epitopes. In 
relation to frequency of response, the DP5-restricted epitope EBNA1 564-583 is the 
immunodominant EBNA1 epitope seen in 44% of the healthy Chinese control screened. 
This immunodominance, using frequency of response among the population at large could 
be summarized as follow: 
 
EBNA1 564-583>>474-493 and 519-543>554-578> 509-528>479-503>434-458 and 499-523>549-568 and 
589-613 
 
How is this different to what we see in the Caucasian study? CD4+ T cell responses against 
EBNA1 is only partially characterised in Caucasians, but with the current information, we 
are seeing a different response pattern. In the Caucasian study, Leen et al (2001) has 
identified more epitopes, a total of 17 epitopes, whereas in this study only 10 epitopes has 
been identified even though, a considerably larger population group has been screened. The 
Caucasian study has identified four immunodominant epitopes (EBNA1 475-489, 485-499, 
515-528, 529-543) with a frequency of response between 20-25% of the population 
screened. In the present study, one immunodominant DP5 restricted epitope EBNA1 564-
583 has been identified with a frequency of response of 44% of the population screened, 
plus three relatively frequently observed epitopes EBNA1 519-543, 474-493, and 554-578 
with frequency of responses matching that of the dominant epitopes identified in the 
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Caucasian study, of 18-22% of the population studied. Overall, fewer epitopes have been 
identified in this study, four epitopes (EBNA1 564-583, 519-543, 474-493, and 554-578) 
are seen by a larger proportion of the studied population than the epitopes identified in the 
Caucasian work. However, if more healthy Chinese controls were screened against the 
entire EBNA1 peptide panel, possibly rarer responses could be identified, such as responses 
to the N-terminal portion of the EBNA protein.  
 
However, in Leen et al (2001) work, they have also studied CD4+ T cell responses against 
EBNA3C, LMP1 and LMP2 and found that EBNA1 and EBNA3C is more frequently 
recognised than LMP1 and LMP2 (EBNA1, EBNA3C>>LMP1,LMP2). It would be 
interesting to carry our work further into screening for CD4+ T cell responses against LMP1 
and LMP2 synthetic peptides in healthy Chinese donors and to determine and compare that 
with the Caucasian study. 
 
3.3.10.4 Processing of Endogenous Expressed EBNA1 
The MVA experiments have demonstrated that over expression of EBNA1 endogenously in 
an overnight assay does not increase antigen presentation unless the EBNA1 is targeted 
(using a LAMP sequence) to the class II pathway, this has also been reported by Taylor et 
al (2004). This suggests that untargeted EBNA1 does not have direct intracellular access 
into the class II pathway of antigen presentation, but suggest that there may be a slower 
(possibly indirect) route of entry into this pathway. 
 
Some access to the HLA class II pathway by EBNA1 has been demonstrated in the LCL 
recognition experiments because clones HK control 215c79 and 228c28 (to EBNA1 564-
583) and 233c27 could recognise un-manipulated LCLs expressing endogenous EBNA1. 
LCL recognition by the clones increases when exposed to LCL cells that have been 
cultured at high density (2 million cells/ml) condition. 
 
It has been suggested that EBNA1 processing by the MHC class II pathway may possibly 
be through autophagocytosis (Nimmerjahn et al, 2003; Geuze, 1998; Théry et al, 1999) or 
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other routes since the biosynthetic pathway of MHC class II intersects that of the endocytic 
pathway (Wolf and Ploegh, 1995; Watts, 1995). However, autophagy may seem to be a 
very unlikely route for the processing of EBNA1 to MHC class II molecules since 
overexpression of native EBNA1 by MVA vector is unable to increase CD4+ T cell 
responses to LCLs, whereas only LAMP-target EBNA1 is able to increase CD4+ T cell 
responses against EBNA1 epitope. However, using the same experimental model but 
increasing the total timeframe of infection to 42hours (including the 18 hour T cell assay) 
Taylor et al (2004) observed a slight increase in CD4+ T cell responses to the LCLs above 
that of uninfected LCLs. This suggests that either that autophagy is taking place but it 
requires a longer time, or that there is another slower route of EBNA1 processing.  
 
In another experiment with CD4+ T cells specific for EBNA2 and EBNA3C epitopes, 
Taylor et al (2004) showed that co-culturing HLA matched recipient cells lacking the 
antigen with HLA-mismatched donor cells expressing the antigen would lead to detectable 
CD4+ T cell recognition that increases with increasing time of co-culture. This suggested 
that some form of antigen transfer from one cell to another is taking place.  
 
The present work demonstrated, at least in terms of LCL recognition, that naturally 
expressed EBNA1 antigen could gain access to the HLA class II pathway for processing 
and presentation. The conditioning of LCL growth influences the ability of the clones to 
recognize antigen expression, such that, LCL grown under thicker density would increase 
recognition by the clones. It is possible that LCL grown in high cell density are starved of 
nutrient thus triggering autophagy, or that there are more cells producing EBNA1 and 
secreting the protein into the surrounding medium for neighbouring cells to pick up and 
process. The mechanism of how EBNA1 could gain access to the HLA class II processing 
machinery was not studied. But, it would be of great interest to study the underlying 
mechanism, for example (1) using autophagy inhibitors to determine whether LCL 
recognition could be blocked, or (2) by conducting a co-culture experiment, as described by 
Taylor et al (2004), to see whether EBNA1 expressed in HLA mis-matched LCLs could be 
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transferred to HLA matched EBV-negative antigen presenting cells and induce recognition 
by the T cell clones. 
 
3.3.10.5 Effector function of EBNA1 clones 
It would be interesting to determine whether EBNA1 CD4+ T cell clones have cytotoxic 
capacity as well IFN-γ release, since such cells could have the potential to eliminate 
EBNA1-expressing tumours. In a preliminary experiment, the cytotoxic capacity of clones 
HK control 215c79 and 228c28 was looked at. Appendix Figure A3.3.1 shows the result of 
a one-off experiment which was conducted at the end of this work. Lysis of autologous 
LCLs pre-loaded with epitope peptide could be seen as high as 50% in the 18 hour assay 
and as low as 25% in the 12 hour assay. 
 
However, it would be important to properly conduct this experiment looking at IFN-γ 
release in parallel to cytotoxic capacity to determine whether killing is induced by IFN-γ 
release or other means. It would be interesting to conduct further experiments looking at the 
mechanism of killing using various inhibitors, such as cyclosporine A (CSA) inhibition of 
IFN-γ release, concanamycin A to block perforin-mediated killing and the blocking anti-
Fas antibody 2B4 to prevent Fas-mediated lysis.  Also, it would be important to determine 
whether these clones are capable of controlling the out-growth of LCL cells in longer term 
assays, since the activity may mimic tumour-control in vivo by the same effectors. In this 
type of assay, LCLs are incubated either alone or cocultured with clonal T cells (at different 
T cell to LCL ratios) to determine whether the clones could suppress the growth of LCLs. 
The mechanism of suppression, if any, could be determined using various inhibitors. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Section 4 
 
Concluding Discussion 
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4.0 Concluding Discussion 
In the studies presented by this thesis, it was concluded in section 3.1, that the predicted 
BART products and BARF1 protein are of little or no immunotherapeutic value in the 
treatment of NPC. This was concluded on the basis that no CD8+ and CD4+ T cell 
responses were detected by IFN-γ ELISpot assay. Detection of T cell responses using the 
ELISpot assay was best suited for this study because of its unique ability to detect T cell 
specificity and number (strength of the response) in PBMC samples. In the context of 
immunotherapy, failure to detect these responses, in healthy EBV carriers, would reflect the 
rarity of these responses in vivo, if they do exist. This may also reflect that such responses 
would also be rare in NPC patients. It could be argued, at least from data presented by 
Kienzle et al (1998), that BARF0-specific CD8+ T cell responses, even though are rare, 
could be cloned from EBV-seropositive individuals (not in EBV naïve individuals). More 
importantly, these clones also recognised and kill BARF0-expressing target cells. These 
data reflect that BARF0-specific CD8+ T cells are present in vivo and the BARF0 protein 
must also be expressed during EBV infection. There are two points that need looking into: 
(1) The EBV-seropositive donor in which Kienzle et al (1998) generated BARF0-specific 
CD8+ T cell clones from was also incorporated into this thesis work, UKL25. This 
individual, at the time of this thesis work, was EBV-seronegative as indicated from the 
VCA staining study. Furthermore, CD8+ T cell responses against the BARF0 peptides were 
not detectable by IFN-γ ELISpot assay, and the 9-mer HLA-A2 peptide was also 
incorporated into this study, but no response was detected against this peptide. A possible 
explanation is that Kienzle et al (1998) cloned a naïve CD8+ T cell by chance from the T 
cell repertoire. However, Kienzle et al (1998) also report that they found BARF0-specific 
CD8+ T cell response in another EBV-seropositive donor and this response could not be 
detected in 2 EBV seronegative donors.  Considering UKL25 is EBV seronegative, of the 
four donors tested, 3 were EBV-seronegative and 1 was EBV-seropositive. More 
importantly, as indicated by the study in this thesis, if responses to BARF0 or the other 
BART products and BARF1 exist, it could not be detected by IFN-γ assay. (2) There is still 
yet no substantial evidence which suggest the BART products and BARF1 protein are 
expressed at the protein level. 
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Failure to detect T cell responses against the predicted BART products and the BARF1 
protein resulted in a decision to shift the direction of this thesis work looking for CD4+ T 
cell responses to EBNA1, a protein that is uniformly expressed in NPC tumours. CD4+ T 
cell responses to EBNA1 have been studied in Caucasian people, however, little is known 
about the EBNA1-CD4+ T cell epitopes presented by the HLA alleles in Chinese people, 
the population in which NPC is very common. In this section of work, section 3.2, CD4+ T 
cell responses were detected in 78 healthy Chinese EBV carriers by IFN-γ ELISpot assay. 
Analysis of these CD4+ T cell responses lead to the mapping of 10 epitope regions, all of 
which clustered at the C-terminal half of the protein. One particular epitope region stood 
out from the rest, epitope region EBNA1 564-588, to which almost half of the donors tested 
had detectable CD4+ T cell response to this region. We speculated that this epitope region 
is presented through an HLA allele that is possibly common to Chinese people, but further 
tests are required to confirm this. Comparison of the Chinese work with the Caucasian 
study identified 6 epitope regions that are unique to Chinese responses and 4 epitope 
regions which overlap responses that have already been identified in the Caucasian study. 
This section of work demonstrated that HLA polymorphism between the Chinese and 
Caucasian population would contribute to the differences in the presentation of EBNA1 
epitopes to CD4+ T cells. This is because CD4+ T cell epitopes identified in the Chinese 
study are different, at least 6 of the epitopes are unique to Chinese, from those identified in 
the Caucasian study. It could be argued that the differences in the amino acid composition 
in Chinese EBNA1 and Caucasian EBNA1 may contribute to this factor. However, we also 
determined that Chinese CD4+ T cells could also recognise Caucasian EBNA1 peptides. 
This strongly suggested that the amino acid composition, in this case, does not contribute to 
the identification of 6 unique Chinese epitopes. More importantly, all CD4+ T cell 
responses are possibly of the Th1 phenotype since the ELISpot assay was set to measure 
IFN-γ secretion by responding CD4+ T cells. Other studies have shown that Th1 cells are 
important in the control of EBV infection and could recognise and suppress LCL growth. In 
this study, the phenotype of these EBNA1-specific CD4+  T cells were not determined and 
further studies are required to determine the phenotype of these IFN-γ secreting cells and 
their possible role in EBV infection. However, if these Chinese EBNA1-specific Th1 cells 
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do recognise and control LCL growth in vitro, then it would be a good indication that they 
could also recognise and control tumour cells in vivo. 
 
Therefore, in section 3.3 of this work, the EBNA1-specific CD4+ T cells were cloned to 
determine their function roles in EBV infection. Generating CD4+ T cell clones for the 
epitope region EBNA1 559-583 was of great interest because around 50% of Chinese 
donors tested gave a response to this region of peptides. Two clones, HK215c79 and 
HK228c28, from two separate responders, HK control 215 and 228, were generated. Both 
clones were specific to a 20-mer peptide presented through an HLA-DP5 allele, an allele 
which is common in Chinese, >50% of Chinese people were reported to carry this allele 
(Tsuji et al, 1993). The frequency of the HLA-DP5 allele was reflected in the ELISpot data, 
of which, around 50% of Chinese donors tested had a response to the epitope region. In 
addition to recognition of the peptide EBNA1 564-583, these clones were demonstrated to 
also recognise the EBNA1 protein and also recognition of naturally infected HLA-DP5+ 
target cells. More importantly, preliminary CTL data suggest both clones also kill naturally 
infected target cells. Furthermore, another clone was described, generated from HK control 
233, HK233c27, recognises an HLA-DR restricted epitope EBNA1 509-528 (the exact 
HLA-DR restriction element is yet to be determined). Preliminary data suggest this clone 
also recognises naturally infected autologous target cells. These data strongly suggest that 
CD4+ T cells generate from different EBNA1 epitopes could recognise EBV infected cells 
exist in the T cell repertoire in vivo, and they can kill EBV infected cells. In the context of 
immunotherapy to treat NPC, such data suggest adoptive T cell therapy of tumour 
recognising and tumour killing EBNA1-specific CD4+ T cells is a possible strategy 
towards treating the NPC. Or, the EBNA1 protein could be made into a vaccine, either as a 
polyepitope vaccine as in the experiments described by Duraiswamy et al (2004) to express 
only the epitopes which induce EBNA1-specific CD4+ T cells that recognise and kill 
tumour cells, or as an EBNA1-LMP1 chimeric vaccine to boost both CD4+ and CD8+ T 
cell responses against the tumour (Taylor et al, 2004). The HLA-DP5 restricted epitope is 
of great importance because of the high frequency of the HLA-DP 5 allele in the Chinese 
population would suggest >50% of NPC patients would also have this allele. However, 
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further studies looking at CD4+ T cell responses against EBNA1 in NPC patients are need 
to determine if this speculation is also true for patients with NPC. 
 
 The future direction of this work would be to generate more EBNA1-specific CD4+ T cell 
clones and characterise these clones for recognition and killing of naturally infected target 
cells. So far, much of the focus has been centred on CD4+ T cells as effectors, however, the 
role of CD4+ T cells as ‘helper cells’ to maintain an effective CD8+ T cell response to 
EBV infection is as important. Therefore, phenotype studies would be as important in the 
characterisation of EBNA1-specific CD4+ T cells, such as their cytokine secretion profile. 
In addition to studying the role of EBNA1-specific CD4+ T cells in the control of EBV 
infection, it would be important to study whether EBNA1 would induce Treg cells. Treg 
cells can suppress the activation and proliferation of CD4+ and CD8+ T cells and is 
important in controlling autoreactive T cells. In vitro studies have shown that EBNA1 can 
induce IFN-γ secreting CD4+ T cells with Treg phenotype CD25+Foxp3+GITR+ (Voo et 
al, 2005). More importantly, Lau et al (2005) demonstrated that there is an increase in Treg 
cells in the peripheral blood and TILs of NPC patients, however, in this study the authors 
did not determine whether these Treg cells were induced by EBNA1. Inducing Treg 
response would be a problem in immunotherapy since these cells would inhibit T cell 
control of EBV infection in vivo. This would not be a problem for adoptive T cell therapy 
since T cells that are used in adoptive T cell therapy are expanded ex vivo and selectively 
chosen for their antitumour function. However, when designing a therapeutic vaccine to 
boost T cell responses in vivo, it would be important not to incorporate epitopes that induce 
Treg cells. 
 
Furthermore, it would be interesting to study CD4+ T cell responses to LMP1 and LMP2 in 
healthy Chinese EBV carriers, since LMP1 and LMP2 are two other proteins that are 
expressed NPC tumours. Eventually, this work would extend further into determining 
CD4+ T cell responses against EBNA1, LMP1 and LMP2 in the peripheral blood and TILs 
of NPC patients. This would provide an overview of the EBV-immune status of NPC 
patients to help identify responses that are ‘missing’ so that ‘missing’ responses could be 
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put back into the patients. Or NPC patients may have ‘inappropriate responses’ such as 
Treg responses, in this case, Treg cells could be depleted and effector and ‘helper’ cells 
could be boosted. These are several of the scenarios that future work would be looking into.
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Appendix 
 
 
 
 
 
Derived 
sequence
Peptide 
coordinate
B95.8 Peptide sequence Denoted peptide 
reference to text
A73‡ 1-20† MSMPPKGFLKKEMKPETRLL‡‡ A1††
A73 6-25 KGFLKKEMKPETRLLNKPPT A2
A73 11-30 KEMKPETRLLNKPPTVLTRP A3
A73 16-35 ETRLLNKPPTVLTRPAMFCA A4
A73 21-40 NKPPTVLTRPAMFCAWKLYS A5
A73 26-45 VLTRPAMFCAWKLYSRKMPS A6
A73 31-50 AMFCAWKLYSRKMPSRSKTL A7
A73 36-55 WKLYSRKMPSRSKTLEARCS A8
A73 41-60 RKMPSRSKTLEARCSSRPPC A9
A73 46-65 RSKTLEARCSSRPPCDSPAC A10
A73 51-70 EARCSSRPPCDSPACQTRDT A11
A73 56-75 SRPPCDSPACQTRDTGCPRR A12
A73 61-80 DSPACQTRDTGCPRRSGTGR A13
A73 66-85 QTRDTGCPRRSGTGRRGWRA A14
A73 71-90 GCPRRSGTGRRGWRARRLGK A15
A73 76-95 SGTGRRGWRARRLGKESWFA A16
A73 81-100 RGWRARRLGKESWFADAWRM A17
A73 86-105 RRLGKESWFADAWRMARYWG A18
A73 91-110 ESWFADAWRMARYWGCAVKA A19
A73 96-115 DAWRMARYWGCAVKAAAQSA A20
A73 101-120 ARYWGCAVKAAAQSAFSAST A21
A73 106-126 CAVKAAAQSAFSASTASPEEL A22
Table A3.1.1: 22 overlapping peptides covering A73
‡The peptide sequence is derived from this predicted polypeptide product
†Peptide coordinate in relation to the full length product
‡‡The amino acid sequence of the 20-mer peptide
††The denotation used in the main text to refer to this 20-mer peptide
Derived 
sequence
Peptide 
coordinate
B95.8 Peptide sequence Denoted peptide 
reference to text
BARFO 1-20 MAATLPLPRCTDSMAARVPI RK1
BARFO 6-25 PLPRCTDSMAARVPIEELRE RK2
BARFO 11-30 TDSMAARVPIEELRELRHLR RK3
BARFO 16-35 ARVPIEELRELRHLRGHCRE RK4
BARFO 21-40 EELRELRHLRGHCREDVVGV RK5
BARFO 26-45 LRHLRGHCREDVVGVQRSGR RK6
BARFO 31-50 GHCREDVVGVQRSGRPLCLR RK7
BARFO 36-55 DVVGVQRSGRPLCLRPPRAR RK8
BARFO 41-60 QRSGRPLCLRPPRARDRALL RK9
BARFO 46-65 PLCLRPPRARDRALLWAARP RK10
BARFO 51-70 PPRARDRALLWAARPRLLLS RK11
BARFO 56-75 DRALLWAARPRLLLSLQQVP RK12
BARFO 59-67 LLWAARPRL* RK13
BARFO 66-85 RLLLSLQQVPEPRLADFILK RK14
BARFO 71-90 LQQVPEPRLADFILKQSRDR RK15
BARFO 76-95 EPRLADFILKQSRDRLRIHR RK16
BARFO 81-100 DFILKQSRDRLRIHRHRQVV RK17
BARFO 86-105 QSRDRLRIHRHRQVVTGDVG RK18
BARFO 91-110 LRIHRHRQVVTGDVGPLCRG RK19
BARFO 96-115 HRQVVTGDVGPLCRGRVAVV RK20
BARFO 101-120 TGDVGPLCRGRVAVVGQNHQ RK21
BARFO 106-125 PLCRGRVAVVGQNHQLAHTA RK22
BARFO 111-130 RVAVVGQNHQLAHTAPAGHR RK23
BARFO 116-135 GQNHQLAHTAPAGHRGDVEA RK24
BARFO 121-140 LAHTAPAGHRGDVEARVWDG RK25
BARFO 126-145 PAGHRGDVEARVWDGTYAPK RK26
BARFO 131-150 GDVEARVWDGTYAPKAAQQI RK27
BARFO 136-155 RVWDGTYAPKAAQQIQGPFQ RK28
BARFO 141-160 TYAPKAAQQIQGPFQALQPH RK29
BARFO 146-165 AAQQIQGPFQALQPHGVRHA RK30
BARFO 151-170 QGPFQALQPHGVRHAIKHAI RK31
BARFO 156-174 ALQPHGVRHAIKHAIDSLH RK32
Table A3.1.2: 32 overlapping peptides covering BARF0
*Previously published 9-mer epitope (Kienzle et al , 1998)
Derived 
sequence
Peptide 
coordinate
B95.8 Peptide sequence Denoted peptide 
reference to text
RPMS1 1-20 MAGARRRARCPASAGCAYSA R1
RPMS1 6-25 RRARCPASAGCAYSARPPPL R2
RPMS1 11-30 PASAGCAYSARPPPLSTRGR R3
RPMS1 16-35 CAYSARPPPLSTRGRRISAG R4
RPMS1 21-40 RPPPLSTRGRRISAGSGQPR R5
RPMS1 26-45 STRGRRISAGSGQPRWWPWG R6
RPMS1 31-50 RISAGSGQPRWWPWGSPPPP R7
RPMS1 36-55 SGQPRWWPWGSPPPPDTRYR R8
RPMS1 41-60 WWPWGSPPPPDTRYRRPGPG R9
RPMS1 46-65 SPPPPDTRYRRPGPGRRARS R10
RPMS1 51-70 DTRYRRPGPGRRARSCLHAG R11
RPMS1 56-75 RPGPGRRARSCLHAGPRGRP R12
RPMS1 61-80 RRARSCLHAGPRGRPPHSRT R13
RPMS1 66-85 CLHAGPRGRPPHSRTRARRT R14
RPMS1 71-90 PRGRPPHSRTRARRTSPGAG R15
RPMS1 76-95 PHSRTRARRTSPGAGGGGWR R16
RPMS1 81-100 RARRTSPGAGGGGWRGGSCT R17
RPMS1 86-103 SPGAGGGGWRGGSCTSQR R18
Table A3.1.3: 18 overlapping peptides covering RPMS1
Derived Peptide B95.8 Peptide sequence Denoted peptide
sequence coordinate  reference to text
BARF1 1-20 MARFIAQLLLLASCVAAGQA B1
BARF1 6-52 AQLLLLASCVAAGQAVTAFL B2
BARF1 11-30 LASCVAAGQAVTAFLGERVT B3
BARF1 16-35 AAGQAVTAFLGERVTLTSYW B4
BARF1 21-40 VTAFLGERVTLTSYWRRVSL B5
BARF1 26-45 GERVTLTSYWRRVSLGPEIV B6
BARF1 31-50 LTSYWRRVSLGPEIVSWFKL B7
BARF1 36-55 RRVSLGPEIVSWFKLGPGEE B8
BARF1 41-60 GPEIVSWFKLGPGEEQVLIG B9
BARF1 46-65 SWFKLGPGEEQVLIGRMHHD B10
BARF1 51-70 GPGEEQVLIGRMHHDVIFIE B11
BARF1 56-75 QVLIGRMHHDVIFIEWPFRG B12
BARF1 61-80 RMHHDVIFIEWPFRGFFDIH B13
BARF1 66-85 VIFIEWPFRGFFDIHRSANT B14
BARF1 71-90 WPFRGFFDIHRSANTFFLVV B15
BARF1 76-95 FFDIHRSANTFFLVVTAANI B16
BARF1 81-100 RSANTFFLVVTAANISHDGN B17
BARF1 86-105 FFLVVTAANISHDGNYLCRM B18
BARF1 91-110 TAANISHDGNYLCRMKLGET B19
BARF1 96-115 SHDGNYLCRMKLGETEVTKQ B20
BARF1 101-120 YLCRMKLGETEVTKQEHLSV B21
BARF1 106-126 KLGETEVTKQEHLSVVKPLT B22
BARF1 111-130 EVTKQEHLSVVKPLTLSVHS B23
BARF1 116-135 EHLSVVKPLTLSVHSERSQF B24
BARF1 121-140 VKPLTLSVHSERSQFPDFSV B25
BARF1 126-145 LSVHSERSQFPDFSVLTVTC B26
BARF1 131-150 ERSQFPDFSVLTVTCTVNAF B27
BARF1 136-155 PDFSVLTVTCTVNAFPHPHV B28
BARF1 141-160 LTVTCTVNAFPHPHVQWLMP B29
BARF1 146-165 TVNAFPHPHVQWLMPEGVEP B30
BARF1 151-170 PHPHVQWLMPEGVEPAPTAA B31
BARF1 156-175 QWLMPEGVEPAPTAANGGVM B32
BARF1 161-180 EGVEPAPTAANGGVMKEKDG B33
BARF1 166-185 APTAANGGVMKEKDGSLSVA B34
BARF1 171-190 NGGVMKEKDGSLSVAVDLSL B35
BARF1 176-195 KEKDGSLSVAVDLSLPKPWH B36
BARF1 181-200 SLSVAVDLSLPKPWHLPVTC B37
BARF1 186-205 VDLSLPKPWHLPVTCVGKND B38
BARF1 191-210 PKPWHLPVTCVGKNDKEEAH B39
BARF1 196-215 LPVTCVGKNDKEEAHGVYVS B40
BARF1 201-220 VGKNDKEEAHGVYVSGYLSQ B41
Table A3.1.4: 42 overlapping peptides covering BARF1
Known EBV Epitopes Peptide coordinate Epitope sequence CD4/CD8 HLA restriction molecule 
EBNA1  475-489 NPKFENIAEGLRALL CD4 †DR 11 
EBNA1  515-528 TSLYNLRRGTALAI CD4 †DR 1 
EBNA1 529-543 PQCRLTPLSRLPFGM CD4 *DR 13 *DQ 3, 5, 6 
EBNA1  563-577 MVFLQTHIFAEVLKD CD4 †DR 15 
EBNA 3C 386-400 SDDELPYIDPNMEPV CD4 *DR 1 
EBNA 3C 916-930 PSMPFASDYSQGAFT CD4 *DR 4 
EBNA 3C 961-986 AQEILSDNSEISVFPK CD4 *DR 4 *DQ 2, 3, 5 
LMP1 212-226 SGHESDSNSNEGRHH CD4 *DQ 2 
EBNA 3A  158-166 QAKWRLQTL CD8 †B8 
EBNA 3B 416-424 IVTDFSVIK CD8 †A1101 
LMP2  329-337 LLWTLVVLL CD8 †A0201 
LMP2  419-427 TYGPVFMCL CD8 †A2402 
 
Table A3.1.5: Known CD4+/CD8+ EBV epitopes within the control peptide pool 
 
†Known HLA class II restriction allele 
*Possible HLA class II restriction alleles  
165504 ATGGCCAGGT TCATCGCTCA GCTCCTCCTG TTGGCCTCCT GTGTGGCCGC CGGCCAGGCT GTCACCGCTT TCTTGGGTGA 165583 
165504 ATGGCCAGGT TCATCGCTCA GCTCCTCCTG TTGGCCTCCT GCGTGGCCGC CGGCCAGGCT GTCACCGCTT TCTTGGGTGA 165583 
165504 ATGGCCAGGT TCATCGCTCA GCTCCTCCTG TTGGCCTCCT GCGTGGCCGC CGGCCAGGCT GTCACCGCTT TCTTGGGTGA 165583   
165504 ATGGCCAGGT TCATCGCTCA GCTCCTCCTG TTGGCCTCCT GTGTGGCCGC CGGCCAGGCT GTCACCGCTT TCTTGGGTGA 165583   
 
165584 GCGAGTCACC CTGACCTCCT ACTGGAGGAG GGTGAGCCTC GGTCCAGAGA TTGAGGTCAG CTGGTTTAAA CTGGGCCCAG 165663  
165584 GCGAGTCACC CTGACCTCCT ACTGGAGGAG GGTGAGCCTC GGTCCAGAGA TTGAGGTCAG CTGGTTTAAA CTGGGCCCAG 165663 
165584 GCGAGTCACC CTGACCTCCT ACTGGAGGAG GGTGAGCCTC GGTCCAGAGA TTGAGGTCAG CTGGTTTAAA CTGGGCCCAG 165663 
165584 GCGAGTCACC CTGACCTCCT ACTGGAGGAG GGTGAGCCTC GGTCCAGAGA TTGAGGTCAG CTGGTTTAAA CTGGGCCCAG 165663  
 
165664 GAGAGGAGCA GGTGCTTATT GGGCGCATGC ACCACGATGT CATCTTTATA GAGTGGCCTT TCAGGGGCTT CTTTGATATC 165743  
165664 GAGAGGAGCA GGTGCTTATT GGGCGCATGC ACCACGATGT CATCTTTATA GAGTGGCCTT TCAGGGGCTT CTTTGATATC 165743 
165664 GAGAGGAGCA GGTGCTTATT GGGCGCATGC ACCACGATGT CATCTTTATA GAGTGGCCTT TCAGGGGCTT CTTTGATATC 165743 
165664 GAGAGGAGCA GGTGCTTATT GGGCGCATGC ACCACGATGT CATCTTTATA GAGTGGCCTT TCAGGGGCTT CTTTGATATC 165743  
 
165744 CACAGAAGTG CCAACACCTT CTTTTTAGTA GTCACCGCTG CCAACATCTC CCATGACGGC AACTACCTGT GCCGCATGAA 165823 
165744 CACAGAAGTG CCAACACCTT CTTTTTAGTA GTCACCGCTG CCAACATCTC CCATGACGGC AACTACCTGT GCCGCATGAA 165823  
165744 CACAGAAGTG CCAACACCTT CTTTTTAGTA GTCACCGCTG CCAACATCTC CCATGACGGC AACTACCTGT GCCGCATGAA 165823 
165744 CACAGAAGTG CCAACACCTT CTTTTTAGTA GTCACCGCTG CCAACATCTC CCATGACGGC AACTACCTGT GCCGCATGAA 165823  
165824 ACTGGGCGAG ACCGAGGTCA CCAAGCAGGA ACACCTGAGC GTGGTGAAGC CTCTAACGCT GTCTGTCCAC TCCGAAAGGT 165903 
165824 ACTGGGCGAG ACCGAGGTCA CCAAGCAGGA ACACCTGAGC GTGGTGAAGC CTCTAACGCT GTCTGTCCAC TCCGAAAGGT 165903 
165824 ACTGGGCGAG ACCGAGGTCA CCAAGCAGGA ACACCTGAGC GTGGTGAAGC CTCTAACGCT GTCTGTCCAC TCCGAAAGGT 165903 
165824 ACTGGGCGAG ACCGAGGTCA CCAAGCAGGA ACACCTGAGC GTGGTGAAGC CTCTAACGCT GTCTGTCCAC TCCGAAAGGT 165903 
 
165904 CTCAGTTCCC AGACTTCTCT GTCCTTACTG TGACATGCAC CGTGAATGCA TTTCCCCATC CCCACGTCCA GTGGCTCATG 165983 
165904 CTCAGTTCCC AGACTTCTCT GTCCTTACTG TGACATGCAC CGTGAATGCA TTTCCCCATC CCCACGTCCA GTGGCTCATG 165983 
165904 CTCAGTTCCC AGACTTCTCT GTCCTTACTG TGACATGCAC CGTGAATGCA TTTCCCCATC CCCACGTCCA GTGGCTCATG 165983 
165904 CTCAGTTCCC AGACTTCTCT GTCCTTACTG TGACATGCAC CGTGAATGCA TTTCCCCATC CCCACGTCCA GTGGCTCATG 165983 
 
165984 CCCGAGGGCG TGGAGCCCGC ACCAACTGCG GCAAATGGCG GTGTTATGAA GGAAAAGGAT GGGAGCCTCT CTGTTGCTGT 166063 
165984 CCCGAGGGCG TGGAGCCCGC ACCAACTGCG GCAAATGGCG GTGTTATGAA GGAAAAGGAT GGGAGCCTCT CTGTTGCTGT 166063 
165984 CCCGAGGGCG TGGAGCCCGC ACCAACTGCG GCAAATGGCG GTGTTATGAA GGAAAAGGAT GGGAGCCTCT CTGTTGCTGT 166063 
165984 CCCGAGGGCG TGGAGCCCGC ACCAACTGCG GCAAATGGCG GTGTTATGAA GGAAAAGGAT GGGAGCCTCT CTGTTGCTGT 166063 
 
166064 TGACCTGTCA CTTCCCAAGC CCTGGCACCT GCCAGTGACC TGCGTTGGGA AAAATGACAA GGAGGAAGCC CACGGGGTTT 166143  
166064 TGACCTGTCA CTTCCCAAGC CCTGGCACCT GCCAGTGACC TGCGTTGGGA AAAATGACAA GGAGGAAGCC CACGGGGTTT 166143  
166064 TGACCTGTCA CTTCCCAAGC CCTGGCACCT GCCAGTGACC TGCGTTGGGA AAAATGACAA GGAGGAAGCC CACGGGGTTT 166143 
166064 TGACCTGTCA CTTCCCAAGC CCTGGCACCT GCCAGTGACC TGCGTTGGGA AAAATGACAA GGAGGAAGCC CACGGGGTTT 166143  
166144 ATGTTTCTGG ATACTTGTCG 166164  
166144 ATGTTTCTGG ATACTTGTCG 166164  
166144 ATGTTTCTGG ATACTTGTCG 166164  
166144 ATGTTTCTGG ATACTTGTCG 166164  
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B95.8
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Figure A3.1.1: Nucleotide sequence of BARF1 from four EBV strains 
This Figure shows the nucleotide sequence alignment of BARF1 from four EBV strains; 
(reading from top to bottom) B95.8, CKL, C5 and Ag876. The B95.8 EBV strain is the 
Caucasian type I virus, CKL is the type I Chinese EBV isolate from Chinese NPC 
patient, C5 is the type I EBV isolate from a healthy Chinese donor as reported by 
Midgley et al (2003), and Ag876 is a African type II virus. The numbers situated to the 
sides of the nucleotide sequence are the nucleotide coordinates in relation to the entire 
EBV B95.8 strain genome. The B95.8 nucleotide sequence is underline, to which it 
would serve as a reference point for comparison with the other EBV strain sequence. The 
letters which appear in red represent a difference in the nucleotide when comparison with 
the B95.8 sequence. Note there is a single nucleotide difference, at position 165545, in 
the BARF1 sequence of CKL and C5 EBV strain. This change in nucleotide sequence 
does not affect the amino acid sequence of the protein. Therefore, the amino acid 
sequence of BARF1 is fully conserved in the four EBV strains studied. 
 
Peptide sequence Coordinates Virus type Peptide no.
EBNA1 *MSDEGPGTGPGNGLGQKEDS 1-20 #Chinese **1
EBNA1 6-25 Chinese 2
EBNA1 11-30 Chinese 3
EBNA1 16-35 Chinese 4
EBNA1 SGPEGSGGSGPQRRGGDNHG 21-40 B95-8 5
EBNA1 SGGSGPQRRGGDNHGRGRGR 26-45 B95-8 6
EBNA1 PQRRGGDNHGRGRGRGRGRG 31-50 B95-8 7
EBNA1 GDNHGRGRGRGRGRGGGRPG 36-55 B95-8 8
EBNA1 RGRGRGRGRGGGRPGAPGGS 41-60 B95-8 9
EBNA1 GRGRGGGRPGAPGGSGSGPR 46-65 B95-8 10
EBNA1 GGRPGAPGGSGSGPRHRDGV 51-70 B95-8 11
EBNA1 APGGSGSGPRHRDGVRRPQK 56-75 B95-8 12
EBNA1 GSGPRHRDGVRRPQKRPSCI 61-80 B95-8 13
EBNA1 HRDGVRRPQKRPSCIGCKGT 66-85 B95-8 14
EBNA1 RRPQKRPSCIGCKGTHGGTG 71-90 B95-8 15
EBNA1 RPSCIGCKGTHGGTGAGGGG 76-90/324-328 B95-8 16
EBNA1 GCKGTHGGTGAGGGGRGRGG 81-95/324-333 B95-8 17
EBNA1 HGGTGAGGGGRGRGGSGGRG 86-100/338 B95-8 18
EBNA1 AGGGGRGRGGSGGRGRGGSG 324-343 B95-8 19
EBNA1 RGRGGSGGRGRGGSGGRGRG 329-348 B95-8 20
EBNA1 SGGRGRGGSGGRGRGGSGGR 334-353 B95-8 21
EBNA1 RGGSGGRGRGGSGGRRGRGR 339-358 B95-8 22
EBNA1 ERARGGRGRGGSGGRRGRGR 344-363 B95-8 23
EBNA1 349-368 Chinese 24
EBNA1 354-373 Chinese 25
EBNA1 359-378 Chinese 26
EBNA1 364-383 Chinese 27
EBNA1 ARGRGRGRGEKRPRSPSSQS 359-388 B95-8 28
EBNA1 RGRGEKRPRSPSSQSSSSGS 374-393 B95-8 29
EBNA1 KRPRSPSSQSSSSGSPPRRP 379-398 B95-8 30
EBNA1 PSSQSSSSGSPPRRPPPGRR 384-403 B95-8 31
EBNA1 SSSGSPPRRPPPGRRPFFHP 389-408 B95-8 32
EBNA1 394-413 Chinese 33
EBNA1 399-418 Chinese 34
EBNA1 404-423 Chinese 35
EBNA1 409-428 Chinese 36
EBNA1 414-433 Chinese 37
EBNA1 QEGGPDGEPDVPPGAIEQGP 419-438 Chinese 38
EBNA1 424-443 Chinese 39
EBNA1 429-448 Chinese 40
EBNA1 434-453 Chinese 41
EBNA1 439-458 Chinese 42
EBNA1 EGPSTGPRGQGDGGRRKKGG 444-463 B95-8 43
EBNA1 GPRGQGDGGRRKKGGWFGKH 449-468 B95-8 44
EBNA1 GDGGRRKKGGWFGKHRGQGG 454-473 B95-8 45
EBNA1 RKKGGWFGKHRGQGGSNPKF 459-478 B95-8 46
EBNA1 WFGKHRGQGGSNPKFENIAE 464-483 B95-8 47
EBNA1 469-488 Chinese 48
EBNA1 474-493 Chinese 49
EBNA1 479-498 Chinese 50
EBNA1 484-503 Chinese 51
EBNA1 489-508 Chinese 52
EBNA1 494-513 Chinese 53
EBNA1 499-518 Chinese 54
EBNA1 VAGVFVYGGSKTSLYNLRRG 504-523 B95-8 55
EBNA1 509-528 Chinese 56
EBNA1 514-533 Chinese 57
EBNA1 519-538 Chinese 58
EBNA1 524-543 Chinese 59
EBNA1 529-548 Chinese 60
EBNA1 TPLSRLPFGMAPGPGPQPGP 534-553 B95-8 61
EBNA1 LPFGMAPGPGPQPGPLRESI 539-558 B95-8 62
EBNA1 APGPGPQPGPLRESIVCYFM 544-563 B95-8 63
EBNA1 PQPGPLRESIVCYFMVFLQT 549-568 B95-8 64
EBNA1 LRESIVCYFMVFLQTHIFAE 554-573 B95-8 65
EBNA1 VCYFMVFLQTHIFAEVLKDA 559-578 B95-8 66
EBNA1 VFLQTHIFAEVLKDAIKDLV 564-583 B95-8 67
EBNA1 HIFAEVLKDAIKDLVMTKPA 569-588 B95-8 68
EBNA1 VLKDAIKDLVMTKPAPTCNI 574-593 B95-8 69
EBNA1 579-598 Chinese 70
EBNA1 584-603 Chinese 71
EBNA1 589-608 Chinese 72
EBNA1 594-613 Chinese 73
EBNA1 SFDDGVDLPPWFPPMVEGAA 599-618 B95-8 74
EBNA1 VDLPPWFPPMVEGAAAEGDD 604-623 B95-8 75
EBNA1 WFPPMVEGAAAEGDDGDDGD 609-628 B95-8 76
EBNA1 VEGAAAEGDDGDDGDEGGDG 614-633 B95-8 77
EBNA1 AEGDDGDDGDEGGDGDEGEE 619-638 B95-8 78
EBNA1 GDDGDEGGDGDEGEEEGQE 624-641 B95-8 79
EBNA1 AGAGGGAGGAGAGGGAGGAG B95-8 80
EBNA1 GGGAGAGGAGGAGGAGAGGAGAGA B95-8 81
Table A3.2.1: EBNA1 20-mer peptide panel
# EBNA1 sequence unique to the Chinese CKL EBV strain 
* In bold are the amino acid substitution
** Peptide numbers that are being referred to then in main text
PGTGPGNGLGQKEDSSGPEG
GNGLGQKEDSSGPEGSGGSG
QKEDSSGPEGSGGSGPQRRG
GSGGRRGRGRERARGRSRER
RGRGRERARGRSRERARGRG
ERARGRSRERARGRGRGRGE
RSRERARGRGRGRGEKRPRS
PPRRPPPGRRPFFHPVGDAD
PPGRRPFFHPVGDADYFEYL
PFFHPVGDADYFEYLQEGGP
VGDADYFEYLQEGGPDGEPD
YFEYLQEGGPDGEPDVPPGA
DGEPDVPPGAIEQGPTDDPG
VPPGAIEQGPTDDPGEGPST
IEQGPTDDPGEGPSTGPRGQ
TDDPGEGPSTGPRGQGDGGR
RGQGGSNPKFENIAEGLRVL
SNPKFENIAEGLRVLLARSH
ENIAEGLRVLLARSHVERTT
GLRVLLARSHVERTTEEGNW
LARSHVERTTEEGNWVAGVF
VERTTEEGNWVAGVFVYGGS
EEGNWVAGVFVYGGSKTSLY
VYGGSKTSLYNLRRGIALAV
KTSLYNLRRGIALAVPQCRI
NLRRGIALAVPQCRITPLSR
IALAVPQCRITPLSRLPFGM
PQCRITPLSRLPFGMAPGPG
IKDLVMTKPAPTCNIKVTVC
MTKPAPTCNIKVTVCSFDDG
PTCNIKVTVCSFDDGVDLPP
KVTVCSFDDGVDLPPWFPPM
Gly/Ala repeat
Gly/Ala repeat 
0 50 100
% Lysis
20:1
10:1
5:1
0 50 100
% Lysis
A B
HK#215c79 HK#228c28
18hour assay
12hour assay
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Figure A3.3.1: Killing of peptide-loaded target cells by EBNA1 564-583-specific clones 
HK215c79 and HK228c28 
Autologous LCLs and HLA-mismatched LCLs were preloaded with EBNA1 564-583 
peptide at 10-7M and 51Cr. Clonal T cells from HK215c79 (A) and HK228c28 (B) were co-
cultured with these LCLs at different clonal T cell to LCL rations (20:1, 10:1 and 5:1), or 
LCLs cultured with SDS, or LCLs alone for 12 hours (bold bar) and 18 hours (striped bar). 
Lysis is represented as a (%) calculated using the equation shown in section 2.2.11 where; 
LCLs cultured in SDS is the maximum 51Cr release, LCLs in culture media is the 
spontaneous 51Cr release, and LCLs co-cultured with clonal T cells assess for cytotoxicity. 
In the 18 hour assay, both clones were calculated to have 40-50% lysis of autologous LCLs 
pre-loaded with epitope peptide at a 20:1 clonal T cell to LCL ratio, and lysis decreases 
with decreasing clonal T cell to LCL ratio. In the 12 hour assay, lysis of autologous LCLs 
were lower than seen in the 18 hour assay, at 25-30% lysis in the 20:1 clonal T cell to LCL 
ratio, and lysis also decreases with decreasing clonal T cell to LCL ratio. Note that no lysis 
was observed on HLA-mismatched LCLs (data not shown). 
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Epstein-Barr virus nuclear antigen EBNA1, the one viral protein uniformly expressed in nasopharyngeal
carcinoma (NPC), represents a prime target for T-cell-based immunotherapy. However, little is known about
the EBNA1 epitopes, particularly CD4 epitopes, presented by HLA alleles in Chinese people, the group at
highest risk for NPC. We analyzed the CD4 T-cell responses to EBNA1 in 78 healthy Chinese donors and
found marked focusing on a small number of epitopes in the EBNA1 C-terminal region, including a DP5-
restricted epitope that was recognized by almost half of the donors tested and elicited responses able to
recognize EBNA1-expressing, DP5-positive target cells.
Undifferentiated nasopharyngeal carcinoma (NPC), an un-
usually prevalent tumor in Southeast Asian and particularly
Chinese populations, is consistently Epstein-Barr virus (EBV)
positive and expresses a subset of EBV latent proteins. These
include the nuclear antigen EBNA1, the latent membrane pro-
tein LMP2 in most cases, and in some cases LMP1 (12). A
detailed knowledge of both CD4 and CD8 T-cell responses
to these antigens is needed if one is to exploit such responses
for immunotherapeutic use (1, 7, 15). While there has been
extensive work on CD8 T-cell responses in that regard (4),
CD4-based studies have focused almost exclusively on Cauca-
sian donors (3, 6, 8, 10, 11, 14, 20) and little is known about
responses restricted through the different array of HLA II
alleles found in the Chinese population. Here we focus on CD4
responses to EBNA1, the only viral protein known to be ex-
pressed in all NPC tumors and one which proves to be a rich
source of CD4 epitopes.
ELISPOT assay mapping of CD4 epitope regions. Eighty-
one peptides (20-mers overlapping by 15 residues) were syn-
thesized according to the EBNA1 sequence common to 27/31
Chinese EBV strains, of which the NPC 15 (CKL) virus strain
is the prototype (9). On the basis of published protocols (6),
these peptides were tested individually in enzyme-linked im-
munospot (ELISPOT) assays of gamma interferon (IFN-)
release with peripheral blood mononuclear cells (PBMCs,
CD8 T cell depleted) obtained with informed consent from
healthy, EBV-seropositive Chinese donors resident in Hong
Kong, an area with a high incidence of NPC. Figure 1 shows
representative results from four responsive donors, HK 201,
HK 215, HK 263, and HK 280, to illustrate the low back-
grounds (0 to 10 spots/well) usually seen and the clear focusing
of responses mostly on adjacent sets of two or three overlap-
ping peptides in specific regions of the molecule. Overall, 50/78
donors tested in repeat assays showed reproducible responses
to particular peptides.
On this basis, we identified 10 distinct epitope regions in the
Chinese EBNA1 sequence. These are located on a linear map
of the EBNA1 protein (Fig. 2, right) where the filled horizontal
bars represent the percentages of donors responding to each
epitope region. Alongside (Fig. 2, left) are shown the corre-
sponding data from 37 healthy seropositive Caucasian donors
tested against the standard B95.8 EBNA1 peptide panel (6;
unpublished data). In both cases, CD4 epitopes are concen-
trated within the C-terminal half of the molecule. However,
compared to those of Caucasians, the EBNA1 responses of
Chinese donors are focused on a smaller number of epitope
regions, with correspondingly higher percentages of donors
responding to individual regions. In particular, EBNA1 pep-
tides 67 and 68 were recognized by 47% (37/78) of the Chinese
donors tested, a far higher frequency than that seen for any
Caucasian donor response.
Epitope definition by CD4 T-cell cloning. Four epitope
regions, represented by Chinese EBNA1 peptides 48 and 49,
50 and 51, 56 and 57, and 67 and 68, were selected for detailed
analysis. On the basis of previously published protocols (8),
PBMCs from selected donors were stimulated in vitro with
relevant peptide pairs and cloned on day 7 at limiting dilution
(0.3 cell/well) on autologous CKL virus-transformed B-lym-
phoblastoid cell line (LCL) feeders, and clones reactive to the
stimulating peptide pair were identified by specific IFN- re-
lease in an enzyme-linked immunosorbent assay. Such clones
were assayed on the autologous LCL loaded with serial dilu-
tions of individual peptides from the epitope region in order to
identify the optimal 20-mer epitope. Representative results are
* Corresponding author. Mailing address: Cancer Research UK In-
stitute for Cancer Studies, University of Birmingham, Vincent Drive,
Birmingham, United Kingdom B15 2TT. Phone: 44-121-414-4492. Fax:
44-121-414-4486. E-mail: A.B.Rickinson@bham.ac.uk.
† C.W.T. and X.L. contributed equally to this work.
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shown in Fig. 3A. Clones from donor HK 215 against the
peptide 48 and 49 region recognized peptide 49 but, surpris-
ingly, not peptide 48 even though both peptides had elicited
equally strong responses in the original ELISPOT assays.
Clones against the other epitope regions showed recognition of
two or more adjacent peptides but consistently identified one
of those peptides most efficiently, i.e., peptide 50 for clones
from donor HK 228, peptide 56 for clones from donor HK 233,
and peptide 67 for clones from two donors, HK 215 and
HK 228 (data not shown). Note also that these EBNA1
epitope-specific clones all showed functional avidities (defined
as the minimum peptide concentration required for 50%
monoclonal IFN- release) within the 10- to 100-nM range,
similar to those seen for most EBNA1-specific reactivities iso-
lated from Caucasian donors (8). Moreover, they were also
confirmed as antigen specific since they recognized autologous
target cells expressing a class II-targeted EBNA1 protein ex-
pressed from a recombinant vaccinia virus vector (17; data not
shown).
HLA class II restriction of epitope-specific responses. Fig-
ure 3B shows the restriction data obtained from these clones in
two types of assay. As previously described (8), these used (i)
individual HLA-DP-, -DQ-, or -DR-specific monoclonal anti-
bodies (MAbs) to block the recognition of autologous peptide-
loaded cells and (ii) allogeneic target cells of known HLA type
as peptide-presenting cells. Both the peptide 49-specific and
peptide 56-specific clones proved to be HLA-DR restricted by
blocking, but the precise alleles could not be identified by using
the allogeneic targets available at that time. We therefore
HLA typed 47 donors from the original panel; this revealed
strong correlations between HLA-DR51 positivity and respon-
siveness to peptide 49 and between HLA-DR11 positivity and
responsiveness to peptide 56, suggesting that these were the
likely restricting alleles. With regard to peptide 50, the MAb
blocking and allogeneic LCL assays suggested that this was
HLA-DQ7 restricted and, indeed, all five donors showing this
response in ELISPOT assays were DQ7 positive; however,
another 15 DQ7-positive individuals showed no response, sug-
gesting that this is not a consistently immunodominant epitope.
Most importantly, the peptide 67 response proved to be HLA-
DP5 restricted. This immediately suggested why it was seen so
frequently in the ELISPOT assays, since HLA-DP5 is carried
by50% of Chinese people (19) and, indeed, all responders to
this allele who were HLA typed proved to be DP5 positive.
FIG. 1. Results of IFN- ELISPOT assays using CD8-depleted
PBMCs from healthy Chinese donors exposed to individual CKL strain
EBNA1 peptides (1 to 81) or assayed in the absence of peptide as a
control (c). Results from four different donors are shown as numbers
of spot-forming cells per 106 CD8-depleted PBMCs tested. Note that
responses occasionally mapped to a single peptide (e.g., HK 201,
peptide 64) but usually mapped to two or three adjacent peptides (e.g.,
HK 201, peptides 41 and 42 and peptides 50 and 51; HK 215, peptides
48 and 49 and peptides 66, 67, and 68). Where there was recognition
of four or five adjacent peptides, cloning frequently revealed coresi-
dent responses to two separate epitopes.
FIG. 2. Locations of CD4 epitope regions, identified by peptide
number, on a linear map of the EBNA1 protein (with the position of
the internal glycine-alanine repeat domain also shown). (Right) Sum-
mary of data from 78 healthy Chinese donors screened by using the
CKL strain EBNA1 peptide panel. (Left) Summary of data from 37
healthy Caucasian donors from the United Kingdom who were
screened by using the B95.8 strain EBNA1 peptide panel. In each case,
the filled bars indicate the percentages of donors tested who responded
to these particular epitope regions.
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FIG. 3. Functional analysis of CD4 T-cell clones established from selected healthy Chinese donors by stimulating PBMCs with CKL strain EBNA1
peptide pair 48 and 49, 49 and 50, 56 and 57, or 67 and 68. (A) Identifying the optimal 20-mer epitope. Clones were stimulated with the autologous LCL
preloaded with limiting concentrations of individual peptides from the epitope region; recognition was assayed as IFN- release by enzyme-linked
immunosorbent assay. neg, negative. (B) Identifying HLA class II restriction. (Top) Clones were stimulated with the autologous LCL preloaded with a
just-optimal concentration of the epitope peptide in the presence of MAbs to HLA-DP, -DQ, or -DR. (Bottom) Clones were stimulated with the
autologous LCL or with an HLA-typed allogeneic LCL preloaded with a concentration of peptide similar to that above; relevant HLA class II alleles
shared between the LCL and donor T cells are shown. Results are expressed as in panel A. (C) Recognizing unmanipulated LCL. Clones seeded at
different cell numbers were stimulated with a standard number of cells of an autologous LCL (Aut) or an allogeneic HLA-mismatched LCL (Mis), either
alone or after loading with an optimal concentration of epitope peptide, and recognition was assayed as above.
TABLE 1. Summary of EBNA1 epitope responses
EBNA1
peptide no.
Amino acid
coordinates Epitope sequence
a No. of
respondersb
Restriction
element
% LCL
recognitione
41/42 434–458 IEQGPTDDPGEGPSTGPRGQGDGGR 2/43 NDc ND
49 474–493 SNPKFENIAEGLRVLLARSH 16/78 DR51 0.2
50 479–498 ENIAEGLRVLLARSHVERTT 5/43 DQ7 0.2
54/55 499–523 EEGNWVAGVFVYGGSKTSLYNLRRG 4/78 ND ND
56 509–528 VYGGSKTSLYNLRRGIALAV 11/78 DR11d 2
58/59 519–543 NLRRGIALAVPQCRITPLSRLPFGM 16/78 ND ND
64 549–568 PQPGPLRESIVCYFMVFLQT 1/43 ND ND
65/66 554–578 LRESIVCYFMVFLQTHIFAEVLKDA 14/78 ND ND
67 564–583 VFLQTHIFAEVLKDAIKDL 34/78 DP5 1
72/73 589–613 PTCNIKVTVCSFDDGVDLPPWFPPM 1/43 ND ND
a Amino acid changes in CKL strain EBNA1 relative to B95.8 EBNA1 are underlined.
b Note that of the 78 donors used, 43 were tested on all 81 EBNA1 peptides and a further 35 were tested on a limited panel of peptides that did not include peptide
41, 42, 50, 64, 72, or 73.
c ND, not determined.
d DR-restricted responses where the restricting allele is inferred to be DR51 and DR11 from the HLA type of epitope-responsive donors.
e IFN- levels from CD4 T cells challenged with the autologous LCL are expressed as a percentage of the levels seen on challenge with the same LCL optimally
loaded with epitope peptide.
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CD4 T-cell recognition of latently infected cells. Interest in
CD4 T-cell responses to EBV latent proteins reflects not just
their likely importance in the maintenance of effective CD8
T-cell surveillance (2, 13, 16) but also their possible role as
direct effectors capable of recognizing latently infected cells
that, like NPC tumors (5, 18), express HLA class II molecules.
To investigate this latter point, we used published protocols (8)
to assay the EBNA1-specific clones for recognition of autolo-
gous LCL targets. Specific recognition could not be detected
with clones to peptide 49 or 50 (data not shown). However,
clones to peptides 56 and 67 clearly did recognize the autolo-
gous LCL, with recognition titrating against T-cell input; for
these clones, levels of IFN- produced in response to the
autologous LCL (Fig. 3C, open bars, LCL alone) were around
2% and 1%, respectively, of those produced in response to the
same target cells optimally loaded with epitope peptide (Fig.
3C, filled bars, LCL  peptide).
Table 1 summarizes the essential data from the present
study. We conclude that most healthy Chinese donors possess
a strong CD4 T-cell memory for EBNA1; that responses are
focused on a small number of C-terminal EBNA1 epitopes,
including a DP5-restricted epitope seen by almost 50% of the
donors tested; and that some of the above responses (including
that to the DP5 epitope) have the potential to directly recog-
nize a latently infected HLA II-positive LCL. These findings
will help in both the design and testing of immunotherapeutic
strategies targeting NPC, whether based on vaccines to stimu-
late the patient’s own responses (7, 17) or on the adoptive
transfer of in vitro-expanded T-cell populations (1, 15).
This work was supported by Cancer Research UK, by the Hong
Kong Cancer Fund, and by the Royal Society, London.
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There is considerable interest in the potential of Epstein-Barr virus (EBV) latent antigen-specific CD4 T
cells to act as direct effectors controlling EBV-induced B lymphoproliferations. Such activity would require
direct CD4 T-cell recognition of latently infected cells through epitopes derived from endogenously expressed
viral proteins and presented on the target cell surface in association with HLA class II molecules. It is therefore
important to know how often these conditions are met. Here we provide CD4 epitope maps for four EBV
nuclear antigens, EBNA1, -2, -3A, and -3C, and establish CD4 T-cell clones against 12 representative
epitopes. For each epitope we identify the relevant HLA class II restricting allele and determine the efficiency
with which epitope-specific effectors recognize the autologous EBV-transformed B-lymphoblastoid cell line
(LCL). The level of recognition measured by gamma interferon release was consistent among clones to the
same epitope but varied between epitopes, with values ranging from 0 to 35% of the maximum seen against the
epitope peptide-loaded LCL. These epitope-specific differences, also apparent in short-term cytotoxicity and
longer-term outgrowth assays on LCL targets, did not relate to the identity of the source antigen and could not
be explained by the different functional avidities of the CD4 clones; rather, they appeared to reflect different
levels of epitope display at the LCL surface. Thus, while CD4 T-cell responses are detectable against many
epitopes in EBV latent proteins, only a minority of these responses are likely to have therapeutic potential as
effectors directly recognizing latently infected target cells.
Epstein-Barr virus (EBV), a herpesvirus with B-cell growth
transforming ability and lymphomagenic potential, provides
one of the most instructive systems in which to study T-cell
responses to viral infection in humans (11, 25). Primary infec-
tion is usually asymptomatic but in some individuals can
present as infectious mononucleosis, a self-limiting lympho-
proliferative disease where the symptoms are coincident with
the appearance of a large reactive T-cell response. Following
primary infection, the virus is carried for life as a latent infec-
tion of the circulating memory B-cell pool (1), with low-level
reactivation from latency into virus productive (lytic) infection
at oropharyngeal sites. Immune T-cell responses clearly play
some role in the maintenance of this virus-host balance since
T-cell-immunocompromised individuals show increased virus
replication in the oropharynx (4) and an increased risk of
EBV-driven B-lymphoproliferative disease (22). One of the
outstanding issues to resolve in this respect is the relative
contribution made by CD4 and CD8 T-cell responses to this
host control.
The HLA class I-restricted CD8 response has attracted the
most attention, for two reasons. Firstly, primary T-cell re-
sponses seen in the blood of infectious mononucleosis patients
are largely of CD8 T-cell origin; indeed, many of these in
vivo-primed reactivities have been mapped to epitopes drawn
from EBV lytic- and latent-cycle antigens (28, 29). Secondly,
memory T-cell responses reactivated from immune donors by
in vitro stimulation with the virus-transformed B-lymphoblas-
toid cell line (LCL) are likewise dominated by CD8 effectors.
Many such effectors recognize epitopes drawn from the latent-
cycle proteins that are expressed in all LCLs, namely, nuclear
antigens EBNA1, -2, -3A, -3B, -3C, and -LP and latent mem-
brane proteins LMP1 and -2, with responses to EBNA3A-,
-3B-, and -3C-derived epitopes frequently in the majority (8,
18). Such CD8 responses to EBV latent antigens are of par-
ticular interest because of their ability to recognize and kill
virus-transformed B cells in vitro and their therapeutic poten-
tial against EBV-driven B-lymphoproliferative disease in vivo
(24).
The growing interest in HLA class II-restricted CD4 T-cell
responses to the virus reflects not only an appreciation of the
general role that CD4 T cells are thought to play in the
maintenance of effective CD8 immunity (7, 26, 30) but also the
fact that EBV infects target cells in which the HLA class II
pathway of antigen presentation is active (33). This raises the
possibility that virus-specific CD4 T cells are able to recog-
nize infected cells directly and, if they are, could act (like
CD8 T cells) as effectors in their own right. Certainly there
are examples where indicator antigens have been expressed
endogenously within LCLs and appear to have gained direct
intracellular entry into the HLA class II processing pathway (2,
20, 23, 34), in some way bypassing the usual means of HLA
class II presentation involving uptake as exogenously acquired
antigen (33). The first CD4 T-cell clones to EBV latent pro-
* Corresponding author. Mailing address: CR-UK Institute for Can-
cer Studies, The University of Birmingham, Vincent Dr., Edgbaston,
Birmingham B15 2TT, United Kingdom. Phone: 44 121 414 4492. Fax:
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teins, specific for an EBNA1-derived and an EBNA2-derived
epitope, respectively, were identified as rare components of
LCL-reactivated memory T-cell preparations (9, 10). Of these,
only the EBNA2-specific clone appeared to be capable of rec-
ognizing LCLs directly in cytotoxicity assays (10). Since that
time, CD4 recall responses to more latent-cycle epitopes
have been generated by a variety of protocols, many involving
in vitro stimulation with dendritic cells either overexpressing
antigen from vaccinia virus vectors or preloaded with exoge-
nous antigen or with epitope peptides (13, 17, 21, 27, 32).
Although these clones display specificity for antigen in protein
loading assays, there are differing reports of their ability to
recognize LCLs naturally expressing cognate antigen from the
resident EBV genome. It is not clear whether these divergent
results reflect technical differences in the way in which the
clones are generated in vitro or genuine differences in the way
in which either individual antigens or individual epitopes are
processed and presented. The present study (i) provides de-
tailed CD4 epitope maps for four EBV latent-cycle antigens,
EBNA1, -2, -3A, and -3C; (ii) establishes CD4 T-cell clones
to 12 selected epitopes from these antigens; and (iii) charac-
terizes these clones in terms of their HLA class II restriction,
their functional avidity in peptide titration assays, and their
ability to recognize autologous LCL targets in gamma inter-
feron (IFN-) release, cytotoxicity, and outgrowth assays.
MATERIALS AND METHODS
Cell preparations and cell lines. Peripheral blood mononuclear cells (PBMCs)
were separated from healthy, EBV-immune donors by Ficoll-Hypaque centrifu-
gation into RPMI 1640 medium (Invitrogen) supplemented with 2 mM glu-
tamine, 100 IU of penicillin per ml, 100 g of streptomycin per ml, and 5%
autologous serum. Where specified, PBMCs were depleted of CD8 T cells with
CD8 Dynabeads (Dynal) in accordance with the manufacturer’s recommended
protocol. Dendritic cells were prepared as previously described (13), by 6-day
culture of adherent PBMCs in the above medium supplemented with granulo-
cyte-macrophage colony-stimulating factor and interleukin-4, and then matured
for 24 h in 50 ng of tumor necrosis factor alpha per ml. EBV-transformed LCLs
were prepared with prototype 1 strain B95.8 or prototype 2 strain Ag876. All
LCLs were cultured in medium (as described above) containing 10% fetal calf
serum, and all assays involved B95.8 virus-transformed LCLs unless otherwise
stated.
Synthetic peptides and protein preparations. Epitope peptides were synthe-
sized by 9-fluorenylmethoxycarbonyl chemistry (Alta Bioscience, University of
Birmingham) and dissolved in dimethyl sulfoxide (DMSO), and their concentra-
tions were determined by biuret assay. The preparation and purification of
baculovirus-expressed EBNA1 protein have been described elsewhere (13).
EBNA2 protein and appropriate control preparations made in baculovirus ex-
pression systems were kindly provided by Friedrich Gra¨sser, Homburg-Saar,
Germany (6). EBNA3A and EBNA3C protein preparations and controls were
likewise made from appropriate baculovirus vectors by infection of insect cells
and purification of nuclear proteins.
ELISPOT assays. CD8-depleted PBMC preparations were tested in ELISPOT
assays of IFN- release as previously described (13), with pools of overlapping
peptides (three or four peptides per pool) from the antigen sequence of interest,
followed by assays on individual peptides within positive pools. The EBNA1 and
EBNA2 panels were 20-mer peptides (overlapping by 15 residues), and the
EBNA3A and -3C panels were 15-mer peptides (overlapping by 10 residues), all
based on the B95.8 EBV strain sequence.
In vitro reactivation protocols. CD4 T-cell clones were generated from
cultures of CD8-depleted PBMCs 7 days after in vitro stimulation either with 5
M epitope peptide directly loaded onto the cells for 1 h or with autologous
dendritic cells loaded either with peptide or with protein (13) or (as for CD8
T-cell activation) with gamma-irradiated autologous LCLs (18). On day 7, cells
were cloned by limiting dilution at 3 cells per well on autologous gamma-
irradiated LCLs (104/well) loaded with the relevant peptide at 5 M and allo-
geneic gamma-irradiated, phytohemagglutinin-treated PBMCs (105/well) in in-
terleukin-2-supplemented medium with 5% autologous serum as previously
described (12). Growing microcultures were screened for peptide reactivity by
IFN- enzyme-linked immunosorbent assay (ELISA), and selected clones were
expanded as described above with fetal calf serum-supplemented medium.
ELISAs of IFN- release and MAb blocking. Cloned T cells were incubated in
U-bottom or V-bottom microtest plate wells with standard numbers of autolo-
gous, HLA-matched, or HLA-mismatched LCLs that were either unmanipulated
or prepulsed for 1 h with 5 M peptide (or an equivalent concentration of
DMSO solvent as a control) or preexposed in serum-free medium for 2 h to
specific EBV antigen preparations (or to control antigen preparations) and then
washed. The supernatant medium harvested after 18 h was assayed for IFN- by
ELISA (Endogen) in accordance with the manufacturer’s recommended proto-
col. In blocking assays, LCLs were preincubated with monoclonal antibodies
(MAbs) specific for HLA-DR (L243; ATCC clone HB-55), HLA-DQ (SPV-L3;
Serotec), and HLA-DP (B7.21; kindly provided by A. M. de Jong, Leiden Uni-
versity, Leiden, The Netherlands) for 1 h before addition of T-cells to the assay.
Chromium release assays. CD4 T-cell clones were tested for killing of target
cells at known effector/target ratios in 5- and 18-h chromium release assays, and
results were expressed as percent specific lysis of the target line. Targets were
HLA-matched or HLA-mismatched LCLs preexposed for 1 h to 5 M epitope
peptide or to an equivalent concentration of DMSO solvent as a control.
Outgrowth assays. Target LCLs (HLA matched and HLA mismatched, either
unmanipulated or prepulsed with 5 M epitope peptide and then washed) were
serially diluted into replicate U-bottom microtest plate wells at 104 to 300 per
well, and T cells were added to half of the replicates at 104/well. Plates were
incubated at 37°C in 5% CO2 with weekly refeeding, and LCL outgrowth was
scored after 4 weeks. Results are expressed as the minimum seeding of LCLs
required for successful outgrowth.
RESULTS
CD4 epitope mapping of EBV latent-cycle antigens. In initial
epitope mapping experiments, we increased the number of
EBV-seropositive donors screened for CD4 T-cell reactivity
to EBNA1 and EBNA3C peptide panels (13) and extended the
analysis to new peptide panels covering the primary sequences
of EBNA2 and EBNA3A. The results of these assays are sum-
marized in Fig. 1, showing all of the individual peptides against
which CD4 T-cell memory was detected; numbers refer to the
coordinate of the first amino acid in the peptide sequence. For
each peptide, the histogram indicates the overall percentage of
seropositive donors who made a detectable response. These
results, based on the screening of 23 to 32 donors per peptide
panel, confirm that a 200-amino-acid stretch in the C-terminal
half of EBNA1 is a rich source of CD4 epitopes, with 75% of
the donor cells reactive to 1 or more of the 17 epitopes in this
area. In addition 70% of the donor cells also responded to 1 or
more of 11 epitopes in the much larger EBNA3C protein. Of
note are individual epitopes, for example, EBNA1 515 (TSL)
and EBNA3C 386 (SDD), that were recognized by about 30%
of the donors tested. Although almost as large as EBNA3C,
the 944-amino-acid EBNA3A protein proved to be much less
immunogenic to the CD4 T-cell response, with only three
epitope peptides detected and 25% of the donors reactive to
any one of these epitopes. Screening of EBNA2, a protein with
a unique sequence similar in size to that of EBNA1, revealed
only six epitopes; however, one of these (EBNA2 276, PRS)
was recognized by 40% of the donors tested, and this was
largely responsible for the overall frequency of EBNA2-reac-
tive donors reaching 65%.
Throughout these ELISPOT assays, we consistently found
that the size of CD4 epitope-specific memory populations in
peripheral blood lay between the detection threshold of 30
spot-forming cells (SFC) and a maximum value of 350 SFC per
106 CD8-depleted PBMCs. This range is 10-fold smaller than
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the equivalent range of EBV latent epitope-specific CD8
T-cell memory, which, for immunodominant CD8 epitopes,
can reach up to 3,000 SFC/106 PBMCs (5, 31). Furthermore,
the size of the CD4 response to any particular epitope peptide
varied between individual donors across the full range, again in
contrast to certain immunodominant CD8 epitopes, which in
donors with the appropriate HLA type consistently produce
large responses in the ELISPOT assay (5, 31; data not shown).
Antigen specificity of CD4 T-cell clones generated by
epitope-peptide stimulation. On the basis of the above assays,
we selected 12 epitopes (4 from EBNA1, 3 from EBNA2, 2
from EBNA3A, and 3 from EBNA3C) against which to gen-
erate CD4 T-cell clones. These epitopes included some that
were recognized by a large proportion of donors, for example,
EBNA1 515 (TSL), EBNA2 276 (PRS), and EBNA3C 386
(SDD), and others that represented relatively rare responses.
Using donors with detectable CD4 T-cell memory to the
individual peptides in ELISPOT assays, we generated CD4
T-cell clones by limiting-dilution cloning of PBMCs 7 days
after peptide stimulation in vitro. All proliferating cultures
were first screened for peptide reactivity in ELISAs of IFN-
release, and peptide-specific clones were checked for antigen
specificity by testing on autologous antigen-presenting cells
that had been loaded with an exogenous supply of the relevant
EBV protein preparation. Figure 2 shows representative re-
sults from these antigen specificity assays, with clones raised
against the EBNA1 515 (TSL), EBNA2 276 (PRS), EBNA3A
780 (GPW), and EBNA3C 386 (SDD) epitopes. In each case,
we were able to confirm that the clones recognized not only the
epitope peptide but also processed antigen, whereas there was
no significant response to control epitope or antigen prepara-
tions. Specific recognition of antigen-loaded cells clearly re-
quired processing and could not be ascribed to contamination
of the protein preparation with preformed peptide, since pre-
fixing the presenting cells eliminated the response to antigen
but not that to exogenously loaded peptide (data not shown).
Figure 2 also shows representative MAb blocking assays in
which peptide-loaded autologous cells were used as targets in
the presence of high concentrations of HLA-DP-, -DQ-, and
-DR-specific MAbs. The results show that the TSL-, PRS- and
GPW-specific clones were all restricted through an HLA-DR
allele and the SDD-specific clones were all restricted through
FIG. 1. Mapping of CD4 epitopes within the primary sequences of EBNA1, -2, -3A, and -3C. The position of each epitope is identified by a
number that refers to the coordinate of the first amino acid in the protein as encoded by EBV strain B95.8. The bar above each epitope position
indicates the percentage of all EBV-seropositive donors tested who responded to the relevant epitope peptide in ELISPOT assays. Epitopes against
which CD4 T-cell clones were later derived are also identified by a three-letter code corresponding to the first three amino acids of the epitope
sequence and by an asterisk above the bar. For each protein, the number of unique amino acids (aa) is shown; this excludes the 233-amino-acid
glycine-alanine repeat domain (residues 93 to 325) for EBNA1 and the 42-amino-acid polyproline repeat domain (residues 59 to 100) for EBNA2.
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an HLA-DQ allele. In each case, the relevant allele could be
determined by screening partially HLA-matched target cells
for the ability to present the peptide. This identified the re-
stricting alleles as HLA-DR103 for TSL, HLA-DR52 for PRS,
HLA-DR1 for GPW, and HLA-DQ5 for SDD (data not
shown). In this way, restriction was mapped to defined
HLA-DR or HLA-DQ alleles for 10 of the 12 epitopes being
studied and to HLA-DP alleles for the other 2 epitopes (see
Table 1).
LCL recognition by CD4 T-cell clones: IFN- release as-
says. For the 12 sets of clones reactive to individual epitopes,
we then conducted a series of IFN- release assays (i) to
determine each clone’s functional avidity, defined in peptide
titration assays as that peptide concentration mediating 50%
maximal recognition, and (ii) to determine the efficiency with
which each clone recognized the unmanipulated LCL, express-
ing this as a percentage of the maximal response seen on the
same targets loaded with an optimal concentration of epitope
peptide. All of the clones generated against the same epitope-
HLA allele combination were functionally similar to one an-
other, and so the data for individual epitopes are illustrated
with a representative clone in each case.
Figure 3 presents the results for three CD4 epitopes in
EBNA1, PQC (529) restricted through HLA-DR14, VFL
(564) restricted through an HLA-DP allele, and TSL (515)
restricted through HLA-DR103. Peptide titrations (top pan-
els) determined the functional avidities as 15 nM for PQC-
specific clones, 30 nM for VFL-specific clones, and 90 nM for
TSL-specific clones. The same clones were then assayed at a
range of T-cell inputs (500 to 5,000 per well) against the au-
tologous LCL and an HLA-mismatched LCL (seeded at 5 
104 per well) where the LCL targets had either been preex-
posed to the cognate peptide at a 5 M concentration and then
washed (middle panels) or left untreated (bottom panels). The
PQC-specific clone showed strong recognition of the peptide-
loaded autologous LCL, with levels of IFN- release increasing
with increased T-cell input, and not of peptide-loaded control
targets. However, this clone, and several other PQC-specific
clones, showed no detectable recognition of the autologous
LCL without added peptide. This was also true of clones di-
FIG. 2. Antigen (Ag) specificity of CD4 T-cell clones raised against the TSL (EBNA1 515), PRS (EBNA2 276), GPW (EBNA3A 780), and
SDD (EBNA3C 386) epitopes. (Top panels) Clones (500 T cells per well) were stimulated overnight with autologous LCLs that were either
unmanipulated, prepulsed for 1 h with 5 M epitope peptide (pep; or an equivalent concentration of control peptide), or preexposed in serum-free
medium for 2 h to specific EBV antigen preparations (or to a control antigen) and then washed before the assay. Responses are expressed as
percentages of the maximum IFN- induced by peptide-loaded target cells in each case. (Bottom panels) The results shown in the bottom panels
are from a separate experiment in which autologous LCLs were preexposed for 1 h to epitope peptide at a concentration mediating half-maximal
responses, washed, and then incubated for a further hour in the presence of MAb to HLA-DP, HLA-DQ, or HLA-DR or in medium as a control
(No MAb) before the addition of 500 T cells to the cell suspension. Results are expressed as described above. Note that assays conducted with
the PRS-specific clones were carried out with LCLs transformed with the type 2 Ag876 EBV strain, in which the PRS epitope sequence is mutated
(10), thereby reducing background LCL recognition to zero.
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rected against a different EBNA1 epitope, NPK (475) (data
not shown). By contrast, clones specific for the VFL epitope
again responded well to peptide-loaded autologous targets but
in this case also showed low-level IFN- release in response to
the autologous LCL itself. This recognition was reproducible,
titrated against the input T-cell number, and also was blocked
specifically by the same anti-HLA-DP MAb as had blocked the
recognition of exogenously loaded peptide in the earlier assays.
However, comparing the observed levels of release of IFN-
against peptide-loaded and unloaded targets in the same assay
gave an efficiency of recognition of the unmanipulated LCL of
only 0.2%. Other VFL-specific clones gave similarly low values.
Interestingly, CD4 clones to the third EBNA1 epitope, TSL,
were also capable of recognizing the untreated autologous
LCL, but in this case at higher levels representing around 3%
of that seen on peptide-loaded targets. Recognition again ti-
trated against the input T-cell number and was blocked with
the appropriate antibody, in this case the anti-DR MAb.
The latter result was of particular interest since different
groups have reported either no LCL recognition by TSL-spe-
cific CD4 T-cell clones (9) or recognition that appeared to be
strong, albeit never directly compared with that seen on pep-
tide-loaded cells (17). To determine whether such differences
might have arisen wholly or in part through the use of different
in vitro reactivation protocols, we established TSL-specific
CD4 T-cell clones by standard peptide stimulation and com-
pared these to clones generated from the same donor by stim-
ulation with EBNA1 protein-loaded dendritic cells. We found
that the two sets of clones were very similar in the above types
of assay (data not shown), and indeed their functional avidities
were similar to those reported by others for TSL-specific
clones reactivated by autologous LCL stimulation (9).
Figure 4 shows corresponding data for CD4 T-cell clones
raised against EBNA2 epitope PAQ (301), EBNA3A epitope
GPW (780), and EBNA3C epitope SDD (386). These showed
functional avidities of 100, 30, and 30 nM, respectively, a range
not dissimilar from that seen with the EBNA1 epitope-specific
clones. Again, all three epitope-specific reactivities in Fig. 4
showed strong recognition of peptide-loaded autologous (but
not HLA-mismatched) LCL targets and also recognized the
unmanipulated autologous LCL at levels representing 3% (for
PAQ), 1% (for GPW), and 7% (for SDD) of the optimal levels
seen on peptide-loaded targets. These values were reproduc-
ibly observed both on repeat testing of the particular clones
illustrated and on testing of other clones generated against the
same epitopes. In this case, we also compared SDD-specific
clones generated by standard peptide stimulation against
clones produced by autologous LCL stimulation and found
that the two sets were again functionally very similar (data not
shown).
Similar experiments were conducted on a further five
epitopes from the EBNA2, EBNA3A, and EBNA3C proteins,
and we again observed that each individual epitope was asso-
ciated with its own characteristic level of LCL recognition (for
a summary, see Table 1). Of particular interest was EBNA2
epitope PRS (276) because it had been recognized by 40% of
the seropositive donors tested in ELISPOT assays (Fig. 1) and
in an earlier study (21) appeared to be presented in several
different HLA class II contexts. On the basis of our ELISPOT
screening, we selected four PRS-responsive donors with dis-
parate HLA class II types and from each generated PRS-
specific clones that, when tested in MAb blocking assays, were
all found to be restricted through an HLA-DR allele. Since all
individuals possess two DRB1 alleles and, in some cases, also
one or two additional DR alleles (designated DR51, -52a, -52b,
-52c, and -53), we screened each set of clones on a large panel
of fully DR-typed target cells loaded with the PRS peptide.
Figure 5 shows data from a representative range of targets
sufficient to map the HLA restricting allele in each case. We
found that PRS-specific clones from the four different donors
used four different alleles, DR52a, DR52b, DR52c, and DR7.
The four different sets of clones were then tested for func-
tional avidity and for autologous LCL recognition. As shown in
Fig. 6, all clones restricted through DR52 alleles had unusually
high avidities in peptide titration assays, with 50% end points
at 6 nM (DR52a), 3 nM (DR52b), and 7 nM (DR52c), whereas
the value of 30 nM for DR7-restricted clones was in the range
seen earlier for clones restricted through other DRB1 alleles.
Interestingly, all four sets of clones showed detectable recog-
nition of the unmanipulated autologous LCL but at widely
different efficiencies. These ranged from 1% of that seen on
peptide-loaded targets for the DR52a- and DR52c-restricted
clones to 15% for the DR7-restricted clones and to as high as
35% for DR52b-restricted clones. To check the reproducibility
of the latter result, we generated PRS-specific clones from a
second DR52b-positive donor by standard peptide stimulation
and from the same donor by two other in vitro reactivation
protocols, namely, stimulation with peptide-loaded dendritic
TABLE 1. Summary of epitope-specific CD4 T-cell clones
Protein and
epitope
Epitope
coordinates
HLA
restriction
Functional
aviditya
(concn [nM])
% Recognition
of LCLb
EBNA1
PQC 529–543 DR14 15 0
NPK 475–494 DP 50 0
VFL 564–583 DP 30 0.2
TSL 515–529 DR103 90 3
EBNA2
PAQ 301–320 DR17 100 3
GQT 11–30 DR4 80 15
PRS 276–295 DR52a 6 1
PRS 276–295 DR52c 7 1
PRS 276–295 DR7 30 15
PRS 276–295 DR52b 3 35
EBNA3A
GPW 780–799 DR1 30 1
EDL 364–383 DR15 10 4
EBNA3C
ILC 141–155 DR13 50 0
PHD 100–119 DR16 100 3
SDD 386–400 DQ5 30 7
a Functional avidity is defined as the concentration of epitope peptide medi-
ating 50% maximal IFN- release in peptide titration assays. Values shown are
the means of results of assays on several epitope-specific clones (except for PHD
and DR52c PRS, where only one clone was available).
b Recognition of the unmanipulated autologous LCL, as measured by IFN-
release, is expressed as a percentage of the IFN- release seen in the same assay
against the same LCL optimally loaded with epitope peptide. The value for each
epitope is the mean from assays on several epitope-specific clones (except for
PHD and DR52c PRS, where only one clone was available).
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cells and stimulation with the LCL alone. All epitope-specific
DR52b-restricted clones, regardless of the stimulation proto-
col or individual donor, gave a similar pattern of results.
Table 1 summarizes the data obtained with CD4 T-cell
clones to all 12 of the epitopes studied, including the PRS
epitope in its four different HLA contexts. Epitopes are
grouped in accordance with their source antigen and, within
each group, ordered by the efficiency of LCL recognition
shown by epitope-specific clones; the functional avidity of
these clones is shown alongside.
LCL recognition by CD4 T-cell clones: cytotoxicity and
LCL outgrowth assays. The ability of EBV latent-epitope-
specific CD4 T cells to recognize naturally infected B-cell
targets implies that such T cells might have a direct effector
role in the control of EBV infection. For that reason, we
examined whether the CD4 T-cell recognition of LCLs ob-
served by IFN- release was also detectable with other func-
tional readouts, namely, short-term cytotoxicity and longer-
term LCL outgrowth assays. This work was conducted with
CD4 T-cell clones to five selected epitopes; these were (in
FIG. 3. Functional analysis of CD4 T-cell clones against the PQC (EBNA1 529), VFL (EBNA1 564), and TSL (EBNA1 515) epitopes. (Top
panels) Clones (100 T cells per well) were stimulated overnight with autologous LCLs (5  104 per well) either unmanipulated (neg) or loaded
with epitope peptide at 105 to 1010 M concentrations. Responses were assayed by IFN- release and expressed as a percentage of the maximum
peptide-induced response. (Middle panels) Clones (500 to 5,000 T cells per well) were stimulated as described above with the autologous LCLs
(match) or with HLA class II-mismatched LCLs (5  104 per well), both previously exposed to 5 M epitope peptide and then washed before the
assay. Responses are expressed as IFN- release in picograms per milliliter. (Bottom panels, upper section) Clones were tested at the same time
as above, on the same autologous and HLA class II-mismatched LCLs but with no exogenous peptide treatment. Responses are expressed as IFN-
release in picograms per milliliter. The efficiency with which each clone is able to recognize unmanipulated autologous LCL targets is expressed
as a percentage of the maximal response seen on the same targets loaded with peptide (box at upper right of each graph). (Bottom panels, lower
section) The results shown in the lower section of the bottom panels are from a separate experiment in which the responses of 500 T cells to the
autologous LCL (non-peptide loaded) were assayed either alone (no MAb) or in the presence of MAbs to HLA-DP, HLA-DQ, or HLA-DR as
described above.
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order of increasing efficiency of LCL recognition by IFN-
release) clones specific for EBNA1 epitopes PQC and TSL,
EBNA2 epitope PAQ, EBNA3C epitope SDD, and DR52b-
restricted EBNA2 epitope PRS.
Figure 7 presents chromium release assay data showing the
levels of killing observed against HLA class II-matched and
mismatched target LCLs, each tested with and without pre-
loading with the relevant epitope peptide. Because pilot ex-
periments had shown that killing was not always apparent
within the conventional 5-h assay period, we measured specific
lysis after both 5 and 18 h. All of the clones showed killing of
the HLA-matched peptide-loaded LCL, apparent within 5 h
and stronger by 18 h, and no killing of the mismatched peptide-
loaded target. However, the clones differed in the ability to kill
the unmanipulated HLA-matched LCL. The PQC (data not
shown)- and TSL-specific CD4 effectors did not lyse these
targets significantly, even within 18 h. The PAQ-specific clone
gave marginal killing after 18 h only, while the SDD-specific
and PRS-specific clones both gave a hint of killing within 5 h
and clearly detectable lysis at the later time.
We then set up outgrowth assays in which replicate cultures
of HLA-matched and mismatched LCLs, either untreated or
preloaded with the relevant epitope peptide, were seeded into
U-bottom microtest plate wells at doubling dilutions of 104 to
300 cells per well; to some wells at each seeding, a standard
number of CD4 T cells (104 cells per well) were then added
from the same clones as tested above. The cultures were main-
tained in standard cell culture medium for 3 to 4 weeks and
examined for successful LCL outgrowth. Although these ex-
periments could be accurately scored by microscopic inspec-
tion of the cultures, in several cases we confirmed by CD19
staining that successful outgrowth involved the LCL and not
FIG. 4. Functional analysis of CD4 T-cell clones against the PAQ (EBNA2, 301), GPW (EBNA3A, 780), and SDD (EBNA3C, 386) epitopes.
The experimental design and expression of results are the same as in Fig. 3, except that the range of T-cell numbers used in LCL stimulation
experiments extended from 100 to 2,500 per well.
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surviving T cells. Figure 8 expresses the results of these assays
as the minimum number of each LCL required for successful
outgrowth under the various conditions. The results are con-
sistent with the earlier experiments in that clear evidence of
LCL growth inhibition was limited to T-cell–LCL combina-
tions with the higher levels of LCL recognition as determined
by IFN- release. Thus, PQC (data not shown)-, TSL-, and
PAQ-specific CD4 T-cell clones, which had shown levels of
unmanipulated LCL recognition of 0 to 3% of that seen
against peptide-loaded targets, markedly inhibited outgrowth
of HLA-matched LCLs if they had been peptide loaded but
had no effect on the corresponding nonloaded cells; as a spec-
ificity control, these same clones had little if any effect on
HLA-mismatched LCLs with or without peptide loading. By
contrast, clones specific for the SDD and PRS epitopes, which
had shown stronger recognition of autologous LCL in IFN-
assays, clearly were able to inhibit the outgrowth of HLA-
matched (but not mismatched) LCLs even without peptide
loading.
DISCUSSION
The extent to which EBV latent-specific CD4 T cells are
able to recognize naturally infected LCL targets is an impor-
tant in vitro indicator of their likely potential as direct effectors
controlling EBV-driven lymphoproliferations in vivo. Most in
vitro studies to date have focused on CD4 T-cell responses to
just one of the available latent proteins, EBNA1 (9, 13, 17, 27,
32) and, even when studying responses to the same epitope (9,
17), have reported discordant results with respect to LCL rec-
ognition. To address this issue in a more systematic way, the
present work set out to identify CD4 epitopes in a broader
range of latent-cycle antigens, EBNA1, -2, -3A, and -3C, and
then to generate CD4 T-cell clones to a representative panel
of epitopes drawn from these four proteins.
Screening with peptide panels showed that three antigens,
EBNA1, -2, and -3C, are each recognized by a majority (65 to
75%) of EBV-seropositive donors, whereas only a small num-
ber (25%) respond to EBNA3A. Interestingly certain
epitopes, for example, TSL in EBNA1, PRS in EBNA2, and
SDD in EBNA3C, were recognized by 30 to 40% of the donors
tested. Such a high frequency is explained in the case of the
PRS epitope by its capacity to elicit responses in the context of
several different HLA alleles (Fig. 5) (21). The same also
appears to be true of the TSL epitope because, although we
established epitope-specific clones that were DR103-restricted,
not all responders to TSL in ELISPOT screening assays ex-
press this allele (13; data not shown). However, this was not
the case for the SDD epitope; this was restricted to HLA-DQ5,
a high-incidence allele in Caucasian populations (16), and all
responders to this epitope indeed proved to be HLA-DQ5
positive. It is important to note that, while a high percentage of
immune donors might respond to certain epitopes, these are
not necessarily immunodominant responses in terms of abso-
lute size. Thus, both here and in an earlier study (13), we found
that responses to all CD4 epitopes fell within a rather narrow
size range and the strongest responses did not consistently map
to a particular set of epitopes or to epitopes from a particular
antigen. This contrasts with the CD8 response to EBV latent-
cycle antigens, which is not only much larger than the CD4
response but also tends to focus preferentially on immuno-
dominant epitopes from the EBNA3A, -3B, and -3C proteins
(11, 25).
Having established CD4 T-cell clones to 12 representative
epitopes and confirmed their specificity for the relevant EBV
target antigen in protein loading assays, we determined their
functional avidity by peptide titration. There were two impor-
tant findings in this regard. Firstly, all clones produced by
peptide stimulation of PBMCs and specific for the same
FIG. 5. Analysis of HLA class II allele restriction of CD4 T-cell
clones specific for the PRS (EBNA2, 276) epitope. Clones were estab-
lished from four donors whose HLA-DR types are in each case iden-
tified (Auto). These clones were then tested as described in the legend
to Fig. 3 (middle panels) against peptide-loaded cells of the autologous
LCL and of allogeneic LCLs of known HLA-DR type (Allo LCL).
Alleles matched with the autologous cells are identified by shading.
Results are expressed as a percentage of the maximum IFN- release
observed in the assay.
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epitope-HLA allele combination, whether from the same do-
nor or different donors, gave similar peptide titration curves.
Secondly, in several cases we compared epitope-specific CD4
T-cell clones that had been generated from individual donors
either by conventional peptide stimulation, by peptide- or an-
tigen-loaded dendritic cells, or by LCL stimulation and, when-
ever we tested them, found no significant differences in func-
tional avidity. We infer that stimulation protocols are not
major sources of artifacts in these experiments and that the
CD4 T-cell clones being used are genuinely representative of
the epitope-specific memory populations present in our EBV-
immune donors.
We then turned to the question of LCL recognition. To
allow comparisons to be made between individual clones to a
single epitope and between clones specific for different
epitopes, in each case we expressed the level of recognition of
the unmanipulated LCL as a percentage of that seen in parallel
against the same LCL preloaded with an optimal concentra-
tion of epitope peptide. The overall findings, summarized in
Table 1, allow a number of conclusions to be drawn. Firstly, the
level of LCL recognition is consistent among clones with the
same epitope specificity but differs markedly, from 0 to 35% of
optimal peptide-loaded values, between clones with different
specificities. Secondly, these interepitope differences are not
obviously related to the antigenic source of the epitope. Thus,
levels of LCL recognition ranged from 0 to 3% of peptide-
loaded values for EBNA1 epitopes, from 1 to 35% for EBNA2
epitopes, from 1 to 4% for EBNA3A epitopes, and from 0 to
7% for EBNA3C epitopes. Thirdly, the differences in LCL
recognition cannot solely be explained by differences in the
functional avidities of the CD4 T-cell clones. For example,
clones to the PQC epitope in EBNA1 had an avidity of 15 nM
and showed no LCL recognition whereas clones to the TSL
epitope also in EBNA1 recognized the LCL at an efficiency of
3% yet required a sixfold higher peptide concentration (90
nM) for half-maximal IFN- release in peptide titration assays.
Likewise, among EBNA2-specific clones, those against the
GQT epitope showed a 15% efficiency of LCL recognition yet
were 10-fold less avid in peptide titration assays than DR52a-
restricted, PRS-specific clones, which show much less efficient
(1%) LCL recognition. We conclude that, as for CD8 T-cell
clones in this viral system (3, 14, 15), the observed level of LCL
FIG. 6. Functional analysis of CD4 T-cell clones specific for the PRS (EBNA2, 276) epitope derived from different EBV-seropositive donors
and restricted through HLA-DR52a, -DR52b, -DR52c, and -DR7, respectively. The experimental design and expression of results are the same
as in Fig. 4. Note that peptide titration assays involving the DR52b-restricted PRS clones were conducted with the Ag876 virus-transformed LCL
as in Fig. 2.
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recognition will be a function both of the inherent avidity of
the CD4 T-cell clones and of the degree of representation of
the epitope-HLA complex on the LCL surface.
The example of the PRS epitope is particularly interesting in
this regard. It was already clear from the literature that this
epitope can elicit responses in the context of several different
HLA class II alleles. Thus, Khanna et al. reported strong kill-
ing of the autologous LCL by a PRS-specific clone reactivated
by LCL stimulation and restricted through an HLA-DQ allele
(10). Subsequently, Omiya and colleagues generated PRS-spe-
cific clones by peptide stimulation from several different do-
nors and mapped their restriction to five different HLA alleles.
Interestingly, all clones recognized the autologous LCL by
IFN- release, although at levels that were never compared to
the maximal peptide-induced response, whereas only clones
restricted through an unidentified DR52 allele killed LCL tar-
gets in cytotoxicity assays (21). Our work extends this analysis
by accurately quantitating LCL recognition by PRS-specific
clones restricted through four different HLA class II alleles.
Recognition ranged from 1% efficiency for DR52a- and
DR52c-restricted clones through 15% efficiency for DR7-re-
stricted clones to 35% efficiency for DR52b-restricted clones.
Again, these differences cannot be explained by differences in
functional avidity but instead reflect how the level of represen-
tation of the PRS epitope on the LCL surface is critically
influenced by the identity of the restricting allele.
A similar phenomenon may underlie the apparent discrep-
ancy in the literature with respect to CD4 T-cell clones spe-
cific for the TSL epitope in EBNA1. Khanna et al. reported no
LCL recognition in cytotoxicity assays by a DR1-restricted TSL
clone (9). This is reminiscent of the DR103-restricted clones
described in the present work, which again did not kill the LCL
but showed low-level (3%) efficiency of recognition by IFN-
release. In contrast, the TSL-specific clones with strong LCL
killing described by Munz and colleagues (17) may be re-
stricted through a different HLA class II allele that mediates
more efficient epitope presentation at the LCL surface. With
FIG. 7. Killing of LCL targets by CD4 T-cell clones against the
TSL (EBNA1 515), PAQ (EBNA2 301), SDD (EBNA3C 386), and
PRS (EBNA2 276) epitopes. Five- and 18-h chromium release assays
were conducted with HLA class II-matched and mismatched LCL
targets either unmanipulated or previously exposed to 5 M epitope
peptide and then washed before the assay. Results are expressed as
percent specific chromium release from target cells at effector/target
ratios of 5:1 (■) and 2.5:1 ().
FIG. 8. Inhibition of LCL outgrowth by the epitope-specific CD4
T-cell clones used in Fig. 7. For each clone, two HLA class II-matched
LCLs and one mismatched LCL were seeded at doubling dilutions of
104 to 300 cells per well either alone or with the addition of 104 CD4
T cells. The LCLs were either unmanipulated or previously exposed to
5 M epitope peptide and then washed before seeding. Results are
expressed as the minimum LCL seeding required for successful out-
growth in each case. For each clone, the results from LCL–T-cell
cocultures are shown for the unmanipulated LCL (■) and in the
adjacent column for the peptide-loaded LCL (u). These values are in
each case compared with the corresponding results for outgrowth of
the unmanipulated LCL or of the peptide-loaded LCL cultured in the
absence of T cells (dotted lines).
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promiscuous epitopes such as PRS and TSL, one can begin to
look for correlations between the level of epitope presentation
on infected cells and immunogenicity of the epitope in vivo.
Clearly in the case of PRS, even low-level presentation in the
context of the HLA-DR52a or -52c allele can elicit a response;
however, we found that only a small number of individuals with
the DR52a or DR52c allele screened actually made a detect-
able response to the peptide in ELISPOT assays. By contrast,
most individuals positive for HLA-DR7 or -DR52b, an allele
that mediates more efficient presentation of the epitope, did
have detectable PRS-specific memory (data not shown). These
questions will be better addressed once the restricting alleles
for other apparently promiscuous EBV epitopes have been
identified.
One of our main motivations for this work was to address the
potential importance of EBV latent epitope-specific CD4 T
cells as direct effectors capable of recognizing and eliminating
EBV-driven lymphoproliferations in vivo. Our final series of
experiments, measuring both short-term cytotoxicity and long-
term inhibition of target cell outgrowth in vitro, show firstly
that all of the epitope-specific CD4 T-cell clones tested were
cytotoxic on epitope-loaded LCL targets and could inhibit
their outgrowth in cocultivation assays. However, parallel as-
says on unmanipulated LCL targets split the clones into two
groups. Clones with an efficiency of LCL recognition at or
below 3% in IFN- assays showed no detectable killing in 18-h
assays and no detectable inhibition of outgrowth against the
unmanipulated LCL, whereas clones with efficiencies of 7% or
greater were active in both situations. These results, and those
of other studies with CD4 T-cell clones against as yet unde-
fined targets on the LCL surface (5), are all consistent with the
view that inhibition of LCL outgrowth correlates strongly with
cytotoxic activity. The present work confirms that CD4 T cells
specific for some EBV latent-cycle epitopes can prevent LCL
outgrowth in vitro (17, 19, 21) and therefore, like their CD8
T-cell counterparts, could act directly against EBV-driven lym-
phoproliferative lesions in vivo (24). However, our data sug-
gest that this is only true of CD4 T cells against a minority of
epitopes, namely, those epitopes represented on the surface of
latently infected cells above a critical threshold. This is not to
imply that T cells specific for other latent-cycle epitopes do not
play an important role in vivo; for example, they may act to
help CD8 responses but such helper activity is more likely to
be induced by specific recognition of antigen exogenously ac-
quired and presented by dendritic cells rather than of antigen
endogenously expressed by infected cells themselves. From a
therapeutic standpoint, identifying the subset of epitope-HLA
combinations that can mediate direct T-cell recognition and
determining the route whereby these epitopes access the HLA
class II pathway in infected cells represent important priorities
for future work.
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Full-length sequences of the Epstein–Barr virus (EBV) gene for latent membrane protein
(LMP)-1 from 22 nasopharyngeal carcinoma (NPC) biopsy specimens and 18 non-neoplastic
counterparts (NPI) were determined. Relative to the B95-8 strain, the amino acid sequences of
the toxic-signal and transformation domains were changed variably in NPC and NPI specimens;
in contrast, no change was observed in the NF-kB (nuclear factor kB) activation domain. HLA
typing revealed that 47 % of NPC and 31 % of NPI specimens were HLA A2-positive. A major
A2-restricted epitope within LMP-1 (residues 125–133) was analysed. At residue 126, a change
of LRF was detected in 91 % (20/22) of NPC and 67 % (12/18) of NPI specimens. In addition,
a deletion at residue 126 was detected in one NPC sample from Taiwan. At residue 129, a
change of MRI was observed in all samples, regardless of whether they were NPC or NPI. The
changes in this peptide between NPC and NPI specimens, including mutation and deletion, are
statistically significant (P<0?05). A recent report indicated that this variant sequence is recognized
poorly by epitope-specific T cells. Genotyping results indicated that 96 % of NPC and 67 % of
NPI samples carried a type A virus. By scanning the entire sequence of LMP-1, eight distinct
patterns were identified. Detailed examination of these patterns revealed that type A strains are
more prevalent in NPC than in NPI specimens and are marked by the loss of an XhoI site, the
presence of a 30 bp deletion and the presence of a mutated, A2-restricted, T cell target
epitope sequence. These results suggest that an EBV strain carrying an HLA A2-restricted
‘epitope-loss variant’ of LMP-1 is prevalent in NPC in southern China and Taiwan.
INTRODUCTION
Nasopharyngeal carcinoma (NPC) has unusually variable
incidence rates around the world. High-risk areas are
restricted to southern China, Hong Kong and south-east
Asian countries, including Taiwan, Singapore, Malaysia,
Indonesia and Vietnam (de The´, 1982). Intermediate risk
areas are confined to Alaska and north Africa, including
Algeria, Morocco and Tunisia. However, the rest of the
world, including the United States and Europe, comprises a
low-risk area. Regardless of geographical origin, Epstein–
Barr virus (EBV) is detected in all cells of undifferentiated
NPC biopsy specimens. Apart from ethnic factors, which
may influence the prevalence of EBV-associated tumours in
different countries, EBV strain variation may also contribute
to this geographical distribution of disease.
Multiple factors, including genetic and environmental
factors and EBV infection, are believed to account for the
marked racial differences and geographical variations
in NPC (Raab-Traub, 1992). However, it is not known
whether EBV-associated tumours reflect a particular
sensitivity of affected patients or the existence of highly
tumorigenic viral strains. Analyses of strain variation,
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